id	sid	tid	token	lemma	pos
bptjm-48	1	1	glioblastoma	glioblastoma	NOUN
bptjm-48	1	2	body.docx	body.docx	PROPN
bptjm-48	1	3	berkeley	berkeley	PROPN
bptjm-48	1	4	pharma	pharma	PROPN
bptjm-48	1	5	tech	tech	NOUN
bptjm-48	1	6	journal	journal	NOUN
bptjm-48	1	7	of	of	ADP
bptjm-48	1	8	medicine	medicine	NOUN
bptjm-48	1	9	correspondence	correspondence	NOUN
bptjm-48	1	10	:	:	PUNCT
bptjm-48	1	11	daniyalatiq7@gmail.com	daniyalatiq7@gmail.com	X
bptjm-48	1	12	keywords	keyword	VERB
bptjm-48	1	13	:	:	PUNCT
bptjm-48	1	14	neoantigen	neoantigen	PROPN
bptjm-48	1	15	glioblastoma	glioblastoma	NOUN
bptjm-48	1	16	monoclonal	monoclonal	NOUN
bptjm-48	1	17	antibodies	antibodie	VERB
bptjm-48	1	18	immune	immune	ADJ
bptjm-48	1	19	checkpoint	checkpoint	NOUN
bptjm-48	1	20	inhibitors	inhibitor	NOUN
bptjm-48	1	21	personalized	personalize	VERB
bptjm-48	1	22	therapy	therapy	NOUN
bptjm-48	1	23	submitted	submit	VERB
bptjm-48	1	24	:	:	PUNCT
bptjm-48	1	25	may	may	AUX
bptjm-48	1	26	8	8	NUM
bptjm-48	1	27	,	,	PUNCT
bptjm-48	1	28	2023	2023	NUM
bptjm-48	1	29	accepted	accept	VERB
bptjm-48	1	30	:	:	PUNCT
bptjm-48	1	31	july	july	PROPN
bptjm-48	1	32	14	14	NUM
bptjm-48	1	33	,	,	PUNCT
bptjm-48	1	34	2023	2023	NUM
bptjm-48	1	35	published	publish	VERB
bptjm-48	1	36	:	:	PUNCT
bptjm-48	1	37	december	december	PROPN
bptjm-48	1	38	30	30	NUM
bptjm-48	1	39	,	,	PUNCT
bptjm-48	1	40	2023	2023	NUM
bptjm-48	1	41	full	full	ADJ
bptjm-48	1	42	open	open	ADJ
bptjm-48	1	43	access	access	NOUN
bptjm-48	1	44	creative	creative	ADJ
bptjm-48	1	45	commons	common	NOUN
bptjm-48	1	46	attribution	attribution	NOUN
bptjm-48	1	47	license	license	VERB
bptjm-48	1	48	4.0	4.0	NUM
bptjm-48	1	49	exploring	explore	VERB
bptjm-48	1	50	novel	novel	ADJ
bptjm-48	1	51	neoantigen	neoantigen	NOUN
bptjm-48	1	52	-	-	PUNCT
bptjm-48	1	53	based	base	VERB
bptjm-48	1	54	treatment	treatment	NOUN
bptjm-48	1	55	methods	method	NOUN
bptjm-48	1	56	for	for	ADP
bptjm-48	1	57	glioblastoma	glioblastoma	NOUN
bptjm-48	1	58	by	by	ADP
bptjm-48	1	59	:	:	PUNCT
bptjm-48	1	60	daniyal	daniyal	ADV
bptjm-48	1	61	atiq	atiq	ADJ
bptjm-48	1	62	,	,	PUNCT
bptjm-48	1	63	yacoub	yacoub	PROPN
bptjm-48	1	64	alokam	alokam	PROPN
bptjm-48	1	65	,	,	PUNCT
bptjm-48	1	66	and	and	CCONJ
bptjm-48	1	67	suraj	suraj	PROPN
bptjm-48	1	68	shah	shah	PROPN
bptjm-48	1	69	abstract	abstract	ADJ
bptjm-48	1	70	glioblastoma	glioblastoma	NOUN
bptjm-48	1	71	,	,	PUNCT
bptjm-48	1	72	constituting	constitute	VERB
bptjm-48	1	73	almost	almost	ADV
bptjm-48	1	74	half	half	NOUN
bptjm-48	1	75	of	of	ADP
bptjm-48	1	76	all	all	DET
bptjm-48	1	77	malignant	malignant	ADJ
bptjm-48	1	78	brain	brain	NOUN
bptjm-48	1	79	tumors	tumor	NOUN
bptjm-48	1	80	,	,	PUNCT
bptjm-48	1	81	presents	present	VERB
bptjm-48	1	82	a	a	DET
bptjm-48	1	83	formidable	formidable	ADJ
bptjm-48	1	84	challenge	challenge	NOUN
bptjm-48	1	85	in	in	ADP
bptjm-48	1	86	treatment	treatment	NOUN
bptjm-48	1	87	due	due	ADP
bptjm-48	1	88	to	to	ADP
bptjm-48	1	89	the	the	DET
bptjm-48	1	90	blood	blood	NOUN
bptjm-48	1	91	-	-	PUNCT
bptjm-48	1	92	brain	brain	NOUN
bptjm-48	1	93	barrier	barrier	NOUN
bptjm-48	1	94	's	's	PART
bptjm-48	1	95	protective	protective	ADJ
bptjm-48	1	96	role	role	NOUN
bptjm-48	1	97	against	against	ADP
bptjm-48	1	98	certain	certain	ADJ
bptjm-48	1	99	therapies	therapy	NOUN
bptjm-48	1	100	.	.	PUNCT
bptjm-48	2	1	these	these	DET
bptjm-48	2	2	tumors	tumor	NOUN
bptjm-48	2	3	,	,	PUNCT
bptjm-48	2	4	characterized	characterize	VERB
bptjm-48	2	5	by	by	ADP
bptjm-48	2	6	rapid	rapid	ADJ
bptjm-48	2	7	growth	growth	NOUN
bptjm-48	2	8	,	,	PUNCT
bptjm-48	2	9	tissue	tissue	NOUN
bptjm-48	2	10	invasion	invasion	NOUN
bptjm-48	2	11	,	,	PUNCT
bptjm-48	2	12	and	and	CCONJ
bptjm-48	2	13	diverse	diverse	ADJ
bptjm-48	2	14	evolving	evolving	NOUN
bptjm-48	2	15	cells	cell	NOUN
bptjm-48	2	16	,	,	PUNCT
bptjm-48	2	17	afflict	afflict	NOUN
bptjm-48	2	18	individuals	individual	NOUN
bptjm-48	2	19	of	of	ADP
bptjm-48	2	20	all	all	DET
bptjm-48	2	21	ages	age	NOUN
bptjm-48	2	22	and	and	CCONJ
bptjm-48	2	23	resist	resist	VERB
bptjm-48	2	24	conventional	conventional	ADJ
bptjm-48	2	25	cancer	cancer	NOUN
bptjm-48	2	26	treatments	treatment	NOUN
bptjm-48	2	27	despite	despite	SCONJ
bptjm-48	2	28	extensive	extensive	ADJ
bptjm-48	2	29	biomedical	biomedical	ADJ
bptjm-48	2	30	research	research	NOUN
bptjm-48	2	31	.	.	PUNCT
bptjm-48	3	1	an	an	DET
bptjm-48	3	2	innovative	innovative	ADJ
bptjm-48	3	3	approach	approach	NOUN
bptjm-48	3	4	to	to	ADP
bptjm-48	3	5	glioblastoma	glioblastoma	NOUN
bptjm-48	3	6	treatment	treatment	NOUN
bptjm-48	3	7	involves	involve	VERB
bptjm-48	3	8	leveraging	leverage	VERB
bptjm-48	3	9	neoantigens	neoantigen	NOUN
bptjm-48	3	10	,	,	PUNCT
bptjm-48	3	11	specific	specific	ADJ
bptjm-48	3	12	to	to	ADP
bptjm-48	3	13	cancer	cancer	NOUN
bptjm-48	3	14	cells	cell	NOUN
bptjm-48	3	15	and	and	CCONJ
bptjm-48	3	16	targetable	targetable	ADJ
bptjm-48	3	17	by	by	ADP
bptjm-48	3	18	the	the	DET
bptjm-48	3	19	immune	immune	ADJ
bptjm-48	3	20	system	system	NOUN
bptjm-48	3	21	.	.	PUNCT
bptjm-48	4	1	clinical	clinical	ADJ
bptjm-48	4	2	trials	trial	NOUN
bptjm-48	4	3	suggest	suggest	VERB
bptjm-48	4	4	that	that	SCONJ
bptjm-48	4	5	neoantigenbased	neoantigenbase	VERB
bptjm-48	4	6	treatments	treatment	NOUN
bptjm-48	4	7	hold	hold	VERB
bptjm-48	4	8	promise	promise	NOUN
bptjm-48	4	9	,	,	PUNCT
bptjm-48	4	10	offering	offer	VERB
bptjm-48	4	11	more	more	ADV
bptjm-48	4	12	effective	effective	ADJ
bptjm-48	4	13	and	and	CCONJ
bptjm-48	4	14	personalized	personalized	ADJ
bptjm-48	4	15	options	option	NOUN
bptjm-48	4	16	for	for	ADP
bptjm-48	4	17	patients	patient	NOUN
bptjm-48	4	18	.	.	PUNCT
bptjm-48	5	1	exploring	explore	VERB
bptjm-48	5	2	this	this	DET
bptjm-48	5	3	avenue	avenue	NOUN
bptjm-48	5	4	,	,	PUNCT
bptjm-48	5	5	including	include	VERB
bptjm-48	5	6	vaccines	vaccine	NOUN
bptjm-48	5	7	,	,	PUNCT
bptjm-48	5	8	immune	immune	ADJ
bptjm-48	5	9	checkpoint	checkpoint	NOUN
bptjm-48	5	10	blockers	blocker	NOUN
bptjm-48	5	11	,	,	PUNCT
bptjm-48	5	12	and	and	CCONJ
bptjm-48	5	13	adoptive	adoptive	ADJ
bptjm-48	5	14	cellular	cellular	ADJ
bptjm-48	5	15	therapies	therapy	NOUN
bptjm-48	5	16	,	,	PUNCT
bptjm-48	5	17	is	be	AUX
bptjm-48	5	18	crucial	crucial	ADJ
bptjm-48	5	19	for	for	ADP
bptjm-48	5	20	improving	improve	VERB
bptjm-48	5	21	outcomes	outcome	NOUN
bptjm-48	5	22	.	.	PUNCT
bptjm-48	6	1	this	this	DET
bptjm-48	6	2	paper	paper	NOUN
bptjm-48	6	3	reviews	review	NOUN
bptjm-48	6	4	novel	novel	VERB
bptjm-48	6	5	therapeutic	therapeutic	ADJ
bptjm-48	6	6	options	option	NOUN
bptjm-48	6	7	within	within	ADP
bptjm-48	6	8	neoantigen	neoantigen	NOUN
bptjm-48	6	9	-	-	PUNCT
bptjm-48	6	10	based	base	VERB
bptjm-48	6	11	treatments	treatment	NOUN
bptjm-48	6	12	,	,	PUNCT
bptjm-48	6	13	providing	provide	VERB
bptjm-48	6	14	insights	insight	NOUN
bptjm-48	6	15	into	into	ADP
bptjm-48	6	16	potential	potential	ADJ
bptjm-48	6	17	advancements	advancement	NOUN
bptjm-48	6	18	against	against	ADP
bptjm-48	6	19	glioblastoma	glioblastoma	NOUN
bptjm-48	6	20	.	.	PUNCT
bptjm-48	7	1	1	1	X
bptjm-48	7	2	.	.	X
bptjm-48	7	3	introduction	introduction	NOUN
bptjm-48	7	4	the	the	DET
bptjm-48	7	5	aim	aim	NOUN
bptjm-48	7	6	of	of	ADP
bptjm-48	7	7	this	this	DET
bptjm-48	7	8	paper	paper	NOUN
bptjm-48	7	9	is	be	AUX
bptjm-48	7	10	to	to	PART
bptjm-48	7	11	explore	explore	VERB
bptjm-48	7	12	and	and	CCONJ
bptjm-48	7	13	evaluate	evaluate	VERB
bptjm-48	7	14	the	the	DET
bptjm-48	7	15	e	e	PROPN
bptjm-48	7	16	�	�	PROPN
bptjm-48	7	17	cacy	cacy	NOUN
bptjm-48	7	18	of	of	ADP
bptjm-48	7	19	neoantigen	neoantigen	NOUN
bptjm-48	7	20	-	-	PUNCT
bptjm-48	7	21	based	base	VERB
bptjm-48	7	22	vaccines	vaccine	NOUN
bptjm-48	7	23	,	,	PUNCT
bptjm-48	7	24	immune	immune	ADJ
bptjm-48	7	25	checkpoint	checkpoint	NOUN
bptjm-48	7	26	blockers	blocker	NOUN
bptjm-48	7	27	,	,	PUNCT
bptjm-48	7	28	and	and	CCONJ
bptjm-48	7	29	adoptive	adoptive	ADJ
bptjm-48	7	30	cellular	cellular	ADJ
bptjm-48	7	31	therapies	therapy	NOUN
bptjm-48	7	32	as	as	ADP
bptjm-48	7	33	potential	potential	ADJ
bptjm-48	7	34	treatment	treatment	NOUN
bptjm-48	7	35	methods	method	NOUN
bptjm-48	7	36	for	for	ADP
bptjm-48	7	37	glioblastoma	glioblastoma	NOUN
bptjm-48	7	38	.	.	PUNCT
bptjm-48	8	1	by	by	ADP
bptjm-48	8	2	referencing	reference	VERB
bptjm-48	8	3	scienti	scienti	NOUN
bptjm-48	8	4	�	�	PROPN
bptjm-48	8	5	c	c	NOUN
bptjm-48	8	6	literature	literature	NOUN
bptjm-48	8	7	and	and	CCONJ
bptjm-48	8	8	clinical	clinical	ADJ
bptjm-48	8	9	trials	trial	NOUN
bptjm-48	8	10	,	,	PUNCT
bptjm-48	8	11	this	this	DET
bptjm-48	8	12	research	research	NOUN
bptjm-48	8	13	seeks	seek	VERB
bptjm-48	8	14	to	to	PART
bptjm-48	8	15	accomplish	accomplish	VERB
bptjm-48	8	16	the	the	DET
bptjm-48	8	17	following	following	ADJ
bptjm-48	8	18	objectives	objective	NOUN
bptjm-48	8	19	:	:	PUNCT
bptjm-48	8	20	1.1	1.1	NUM
bptjm-48	8	21	.	.	PUNCT
bptjm-48	8	22	reviewing	review	VERB
bptjm-48	8	23	the	the	DET
bptjm-48	8	24	history	history	NOUN
bptjm-48	8	25	and	and	CCONJ
bptjm-48	8	26	background	background	NOUN
bptjm-48	8	27	of	of	ADP
bptjm-48	8	28	glioblastoma	glioblastoma	NOUN
bptjm-48	8	29	treatment	treatment	NOUN
bptjm-48	8	30	:	:	PUNCT
bptjm-48	8	31	conduct	conduct	VERB
bptjm-48	8	32	a	a	DET
bptjm-48	8	33	comprehensive	comprehensive	ADJ
bptjm-48	8	34	analysis	analysis	NOUN
bptjm-48	8	35	of	of	ADP
bptjm-48	8	36	the	the	DET
bptjm-48	8	37	historical	historical	ADJ
bptjm-48	8	38	context	context	NOUN
bptjm-48	8	39	and	and	CCONJ
bptjm-48	8	40	background	background	NOUN
bptjm-48	8	41	of	of	ADP
bptjm-48	8	42	glioblastoma	glioblastoma	NOUN
bptjm-48	8	43	treatment	treatment	NOUN
bptjm-48	8	44	methods	method	NOUN
bptjm-48	8	45	utilizing	utilize	VERB
bptjm-48	8	46	scienti	scienti	NOUN
bptjm-48	8	47	�	�	NOUN
bptjm-48	8	48	c	c	NOUN
bptjm-48	8	49	databases	database	NOUN
bptjm-48	8	50	such	such	ADJ
bptjm-48	8	51	as	as	ADP
bptjm-48	8	52	pubmed	pubmed	PROPN
bptjm-48	8	53	,	,	PUNCT
bptjm-48	8	54	google	google	PROPN
bptjm-48	8	55	scholar	scholar	NOUN
bptjm-48	8	56	,	,	PUNCT
bptjm-48	8	57	cinahl	cinahl	NOUN
bptjm-48	8	58	,	,	PUNCT
bptjm-48	8	59	etcetera	etcetera	PROPN
bptjm-48	8	60	.	.	PUNCT
bptjm-48	9	1	highlight	highlight	VERB
bptjm-48	9	2	the	the	DET
bptjm-48	9	3	limitations	limitation	NOUN
bptjm-48	9	4	and	and	CCONJ
bptjm-48	9	5	challenges	challenge	NOUN
bptjm-48	9	6	associated	associate	VERB
bptjm-48	9	7	with	with	ADP
bptjm-48	9	8	conventional	conventional	ADJ
bptjm-48	9	9	treatment	treatment	NOUN
bptjm-48	9	10	approaches	approach	NOUN
bptjm-48	9	11	,	,	PUNCT
bptjm-48	9	12	such	such	ADJ
bptjm-48	9	13	as	as	ADP
bptjm-48	9	14	surgery	surgery	NOUN
bptjm-48	9	15	,	,	PUNCT
bptjm-48	9	16	radiation	radiation	NOUN
bptjm-48	9	17	therapy	therapy	NOUN
bptjm-48	9	18	,	,	PUNCT
bptjm-48	9	19	and	and	CCONJ
bptjm-48	9	20	chemotherapy	chemotherapy	NOUN
bptjm-48	9	21	.	.	PUNCT
bptjm-48	10	1	1.2	1.2	NUM
bptjm-48	10	2	.	.	PUNCT
bptjm-48	10	3	investigating	investigate	VERB
bptjm-48	10	4	neoantigens	neoantigen	NOUN
bptjm-48	10	5	as	as	ADP
bptjm-48	10	6	potential	potential	ADJ
bptjm-48	10	7	treatment	treatment	NOUN
bptjm-48	10	8	options	option	NOUN
bptjm-48	10	9	for	for	ADP
bptjm-48	10	10	glioblastoma	glioblastoma	NOUN
bptjm-48	10	11	:	:	PUNCT
bptjm-48	10	12	review	review	NOUN
bptjm-48	10	13	scienti	scienti	NOUN
bptjm-48	10	14	�	�	PROPN
bptjm-48	10	15	c	c	PROPN
bptjm-48	10	16	literature	literature	NOUN
bptjm-48	10	17	to	to	PART
bptjm-48	10	18	examine	examine	VERB
bptjm-48	10	19	the	the	DET
bptjm-48	10	20	role	role	NOUN
bptjm-48	10	21	of	of	ADP
bptjm-48	10	22	neoantigens	neoantigen	NOUN
bptjm-48	10	23	in	in	ADP
bptjm-48	10	24	glioblastoma	glioblastoma	NOUN
bptjm-48	10	25	immunotherapy	immunotherapy	NOUN
bptjm-48	10	26	.	.	PUNCT
bptjm-48	11	1	explore	explore	VERB
bptjm-48	11	2	the	the	DET
bptjm-48	11	3	mechanisms	mechanism	NOUN
bptjm-48	11	4	through	through	ADP
bptjm-48	11	5	which	which	PRON
bptjm-48	11	6	neoantigens	neoantigen	NOUN
bptjm-48	11	7	can	can	AUX
bptjm-48	11	8	elicit	elicit	VERB
bptjm-48	11	9	an	an	DET
bptjm-48	11	10	immune	immune	ADJ
bptjm-48	11	11	response	response	NOUN
bptjm-48	11	12	against	against	ADP
bptjm-48	11	13	glioblastoma	glioblastoma	NOUN
bptjm-48	11	14	tumor	tumor	NOUN
bptjm-48	11	15	cells	cell	NOUN
bptjm-48	11	16	.	.	PUNCT
bptjm-48	12	1	evaluate	evaluate	VERB
bptjm-48	12	2	the	the	DET
bptjm-48	12	3	e	e	PROPN
bptjm-48	12	4	�	�	NOUN
bptjm-48	12	5	cacy	cacy	NOUN
bptjm-48	12	6	and	and	CCONJ
bptjm-48	12	7	safety	safety	NOUN
bptjm-48	12	8	of	of	ADP
bptjm-48	12	9	neoantigen	neoantigen	NOUN
bptjm-48	12	10	-	-	PUNCT
bptjm-48	12	11	based	base	VERB
bptjm-48	12	12	vaccines	vaccine	NOUN
bptjm-48	12	13	in	in	ADP
bptjm-48	12	14	preclinical	preclinical	ADJ
bptjm-48	12	15	and	and	CCONJ
bptjm-48	12	16	clinical	clinical	ADJ
bptjm-48	12	17	settings	setting	NOUN
bptjm-48	12	18	.	.	PUNCT
bptjm-48	13	1	1.3	1.3	NUM
bptjm-48	13	2	.	.	PUNCT
bptjm-48	14	1	assessing	assess	VERB
bptjm-48	14	2	the	the	DET
bptjm-48	14	3	e	e	PROPN
bptjm-48	14	4	�	�	NOUN
bptjm-48	14	5	cacy	cacy	NOUN
bptjm-48	14	6	of	of	ADP
bptjm-48	14	7	immune	immune	ADJ
bptjm-48	14	8	checkpoint	checkpoint	NOUN
bptjm-48	14	9	blockers	blocker	NOUN
bptjm-48	14	10	in	in	ADP
bptjm-48	14	11	glioblastoma	glioblastoma	NOUN
bptjm-48	14	12	treatment	treatment	NOUN
bptjm-48	14	13	:	:	PUNCT
bptjm-48	14	14	examine	examine	VERB
bptjm-48	14	15	the	the	DET
bptjm-48	14	16	role	role	NOUN
bptjm-48	14	17	of	of	ADP
bptjm-48	14	18	immune	immune	ADJ
bptjm-48	14	19	checkpoint	checkpoint	NOUN
bptjm-48	14	20	blockers	blocker	NOUN
bptjm-48	14	21	,	,	PUNCT
bptjm-48	14	22	such	such	ADJ
bptjm-48	14	23	as	as	ADP
bptjm-48	14	24	pd-1	pd-1	ADP
bptjm-48	14	25	/	/	SYM
bptjm-48	14	26	pd	pd	ADJ
bptjm-48	14	27	-	-	PUNCT
bptjm-48	14	28	l1	l1	PROPN
bptjm-48	14	29	inhibitors	inhibitor	NOUN
bptjm-48	14	30	and	and	CCONJ
bptjm-48	14	31	ctla-4	ctla-4	NOUN
bptjm-48	14	32	inhibitors	inhibitor	NOUN
bptjm-48	14	33	,	,	PUNCT
bptjm-48	14	34	in	in	ADP
bptjm-48	14	35	modulating	modulate	VERB
bptjm-48	14	36	the	the	DET
bptjm-48	14	37	immune	immune	ADJ
bptjm-48	14	38	response	response	NOUN
bptjm-48	14	39	against	against	ADP
bptjm-48	14	40	glioblastoma	glioblastoma	NOUN
bptjm-48	14	41	.	.	PUNCT
bptjm-48	15	1	analyze	analyze	VERB
bptjm-48	15	2	the	the	DET
bptjm-48	15	3	outcomes	outcome	NOUN
bptjm-48	15	4	of	of	ADP
bptjm-48	15	5	clinical	clinical	ADJ
bptjm-48	15	6	trials	trial	NOUN
bptjm-48	15	7	and	and	CCONJ
bptjm-48	15	8	real	real	ADJ
bptjm-48	15	9	-	-	PUNCT
bptjm-48	15	10	world	world	NOUN
bptjm-48	15	11	evidence	evidence	NOUN
bptjm-48	15	12	regarding	regard	VERB
bptjm-48	15	13	the	the	DET
bptjm-48	15	14	use	use	NOUN
bptjm-48	15	15	of	of	ADP
bptjm-48	15	16	immune	immune	ADJ
bptjm-48	15	17	checkpoint	checkpoint	NOUN
bptjm-48	15	18	blockers	blocker	NOUN
bptjm-48	15	19	in	in	ADP
bptjm-48	15	20	glioblastoma	glioblastoma	NOUN
bptjm-48	15	21	patients	patient	NOUN
bptjm-48	15	22	.	.	PUNCT
bptjm-48	16	1	assess	assess	VERB
bptjm-48	16	2	the	the	DET
bptjm-48	16	3	potential	potential	NOUN
bptjm-48	16	4	of	of	ADP
bptjm-48	16	5	combination	combination	NOUN
bptjm-48	16	6	therapies	therapy	NOUN
bptjm-48	16	7	involving	involve	VERB
bptjm-48	16	8	immune	immune	ADJ
bptjm-48	16	9	checkpoint	checkpoint	NOUN
bptjm-48	16	10	blockers	blocker	NOUN
bptjm-48	16	11	and	and	CCONJ
bptjm-48	16	12	other	other	ADJ
bptjm-48	16	13	treatment	treatment	NOUN
bptjm-48	16	14	modalities	modality	NOUN
bptjm-48	16	15	.	.	PUNCT
bptjm-48	17	1	1.4	1.4	NUM
bptjm-48	17	2	.	.	PUNCT
bptjm-48	17	3	exploring	explore	VERB
bptjm-48	17	4	adoptive	adoptive	ADJ
bptjm-48	17	5	cellular	cellular	ADJ
bptjm-48	17	6	therapies	therapy	NOUN
bptjm-48	17	7	for	for	ADP
bptjm-48	17	8	glioblastoma	glioblastoma	NOUN
bptjm-48	17	9	:	:	PUNCT
bptjm-48	17	10	berkeley	berkeley	PROPN
bptjm-48	17	11	pharma	pharma	PROPN
bptjm-48	17	12	tech	tech	NOUN
bptjm-48	17	13	journal	journal	NOUN
bptjm-48	17	14	of	of	ADP
bptjm-48	17	15	medicine	medicine	NOUN
bptjm-48	17	16	|	|	ADV
bptjm-48	17	17	30	30	NUM
bptjm-48	17	18	investigate	investigate	VERB
bptjm-48	17	19	the	the	DET
bptjm-48	17	20	use	use	NOUN
bptjm-48	17	21	of	of	ADP
bptjm-48	17	22	adoptive	adoptive	ADJ
bptjm-48	17	23	cellular	cellular	ADJ
bptjm-48	17	24	therapies	therapy	NOUN
bptjm-48	17	25	,	,	PUNCT
bptjm-48	17	26	including	include	VERB
bptjm-48	17	27	chimeric	chimeric	ADJ
bptjm-48	17	28	antigen	antigen	ADJ
bptjm-48	17	29	receptor	receptor	NOUN
bptjm-48	17	30	(	(	PUNCT
bptjm-48	17	31	car	car	NOUN
bptjm-48	17	32	)	)	PUNCT
bptjm-48	17	33	t	t	NOUN
bptjm-48	17	34	-	-	PUNCT
bptjm-48	17	35	cell	cell	NOUN
bptjm-48	17	36	therapy	therapy	NOUN
bptjm-48	17	37	and	and	CCONJ
bptjm-48	17	38	tumor	tumor	NOUN
bptjm-48	17	39	-	-	PUNCT
bptjm-48	17	40	in	in	ADP
bptjm-48	17	41	�	�	NOUN
bptjm-48	17	42	ltrating	ltrate	VERB
bptjm-48	17	43	lymphocyte	lymphocyte	NOUN
bptjm-48	17	44	(	(	PUNCT
bptjm-48	17	45	til	til	ADJ
bptjm-48	17	46	)	)	PUNCT
bptjm-48	17	47	therapy	therapy	NOUN
bptjm-48	17	48	,	,	PUNCT
bptjm-48	17	49	in	in	ADP
bptjm-48	17	50	glioblastoma	glioblastoma	NOUN
bptjm-48	17	51	treatment	treatment	NOUN
bptjm-48	17	52	.	.	PUNCT
bptjm-48	18	1	analyze	analyze	VERB
bptjm-48	18	2	the	the	DET
bptjm-48	18	3	e	e	PROPN
bptjm-48	18	4	�	�	PROPN
bptjm-48	18	5	cacy	cacy	NOUN
bptjm-48	18	6	and	and	CCONJ
bptjm-48	18	7	safety	safety	NOUN
bptjm-48	18	8	pro	pro	X
bptjm-48	18	9	�	�	VERB
bptjm-48	18	10	les	le	NOUN
bptjm-48	18	11	of	of	ADP
bptjm-48	18	12	adoptive	adoptive	ADJ
bptjm-48	18	13	cellular	cellular	ADJ
bptjm-48	18	14	therapies	therapy	NOUN
bptjm-48	18	15	in	in	ADP
bptjm-48	18	16	glioblastoma	glioblastoma	NOUN
bptjm-48	18	17	patients	patient	NOUN
bptjm-48	18	18	.	.	PUNCT
bptjm-48	19	1	evaluate	evaluate	VERB
bptjm-48	19	2	the	the	DET
bptjm-48	19	3	potential	potential	NOUN
bptjm-48	19	4	of	of	ADP
bptjm-48	19	5	enhancing	enhance	VERB
bptjm-48	19	6	the	the	DET
bptjm-48	19	7	e	e	PROPN
bptjm-48	19	8	�	�	PROPN
bptjm-48	19	9	ectiveness	ectiveness	NOUN
bptjm-48	19	10	of	of	ADP
bptjm-48	19	11	adoptive	adoptive	ADJ
bptjm-48	19	12	cellular	cellular	ADJ
bptjm-48	19	13	therapies	therapy	NOUN
bptjm-48	19	14	through	through	ADP
bptjm-48	19	15	genetic	genetic	ADJ
bptjm-48	19	16	engineering	engineering	NOUN
bptjm-48	19	17	and	and	CCONJ
bptjm-48	19	18	personalized	personalized	ADJ
bptjm-48	19	19	medicine	medicine	NOUN
bptjm-48	19	20	approaches	approach	NOUN
bptjm-48	19	21	.	.	PUNCT
bptjm-48	20	1	by	by	ADP
bptjm-48	20	2	addressing	address	VERB
bptjm-48	20	3	these	these	DET
bptjm-48	20	4	objectives	objective	NOUN
bptjm-48	20	5	,	,	PUNCT
bptjm-48	20	6	this	this	DET
bptjm-48	20	7	article	article	NOUN
bptjm-48	20	8	aims	aim	VERB
bptjm-48	20	9	to	to	PART
bptjm-48	20	10	contribute	contribute	VERB
bptjm-48	20	11	to	to	ADP
bptjm-48	20	12	the	the	DET
bptjm-48	20	13	advancement	advancement	NOUN
bptjm-48	20	14	of	of	ADP
bptjm-48	20	15	glioblastoma	glioblastoma	NOUN
bptjm-48	20	16	treatment	treatment	NOUN
bptjm-48	20	17	by	by	ADP
bptjm-48	20	18	shedding	shed	VERB
bptjm-48	20	19	light	light	NOUN
bptjm-48	20	20	onto	onto	ADP
bptjm-48	20	21	the	the	DET
bptjm-48	20	22	potential	potential	NOUN
bptjm-48	20	23	of	of	ADP
bptjm-48	20	24	neoantigen	neoantigen	NOUN
bptjm-48	20	25	-	-	PUNCT
bptjm-48	20	26	based	base	VERB
bptjm-48	20	27	vaccines	vaccine	NOUN
bptjm-48	20	28	,	,	PUNCT
bptjm-48	20	29	immune	immune	ADJ
bptjm-48	20	30	checkpoint	checkpoint	NOUN
bptjm-48	20	31	blockers	blocker	NOUN
bptjm-48	20	32	,	,	PUNCT
bptjm-48	20	33	and	and	CCONJ
bptjm-48	20	34	adoptive	adoptive	ADJ
bptjm-48	20	35	cellular	cellular	ADJ
bptjm-48	20	36	therapies	therapy	NOUN
bptjm-48	20	37	as	as	ADP
bptjm-48	20	38	innovative	innovative	ADJ
bptjm-48	20	39	and	and	CCONJ
bptjm-48	20	40	promising	promise	VERB
bptjm-48	20	41	therapeutic	therapeutic	ADJ
bptjm-48	20	42	strategies	strategy	NOUN
bptjm-48	20	43	.	.	PUNCT
bptjm-48	21	1	2	2	X
bptjm-48	21	2	.	.	X
bptjm-48	21	3	glioblastoma	glioblastoma	NOUN
bptjm-48	21	4	background	background	NOUN
bptjm-48	21	5	every	every	DET
bptjm-48	21	6	year	year	NOUN
bptjm-48	21	7	,	,	PUNCT
bptjm-48	21	8	it	it	PRON
bptjm-48	21	9	’s	’s	AUX
bptjm-48	21	10	estimated	estimate	VERB
bptjm-48	21	11	that	that	SCONJ
bptjm-48	21	12	approximately	approximately	ADV
bptjm-48	21	13	10,000	10,000	NUM
bptjm-48	21	14	people	people	NOUN
bptjm-48	21	15	will	will	AUX
bptjm-48	21	16	be	be	AUX
bptjm-48	21	17	diagnosed	diagnose	VERB
bptjm-48	21	18	with	with	ADP
bptjm-48	21	19	glioblastoma	glioblastoma	NOUN
bptjm-48	21	20	,	,	PUNCT
bptjm-48	21	21	which	which	PRON
bptjm-48	21	22	yields	yield	VERB
bptjm-48	21	23	a	a	DET
bptjm-48	21	24	25	25	NUM
bptjm-48	21	25	%	%	NOUN
bptjm-48	21	26	one	one	NUM
bptjm-48	21	27	-	-	PUNCT
bptjm-48	21	28	year	year	NOUN
bptjm-48	21	29	survival	survival	NOUN
bptjm-48	21	30	rate	rate	NOUN
bptjm-48	21	31	as	as	ADV
bptjm-48	21	32	well	well	ADV
bptjm-48	21	33	as	as	ADP
bptjm-48	21	34	a	a	DET
bptjm-48	21	35	6.8	6.8	NUM
bptjm-48	21	36	%	%	NOUN
bptjm-48	21	37	5	5	NUM
bptjm-48	21	38	-	-	PUNCT
bptjm-48	21	39	year	year	NOUN
bptjm-48	21	40	survival	survival	NOUN
bptjm-48	21	41	rate.1	rate.1	PROPN
bptjm-48	21	42	on	on	ADP
bptjm-48	21	43	average	average	ADJ
bptjm-48	21	44	,	,	PUNCT
bptjm-48	21	45	patients	patient	NOUN
bptjm-48	21	46	survive	survive	VERB
bptjm-48	21	47	eight	eight	NUM
bptjm-48	21	48	months	month	NOUN
bptjm-48	21	49	before	before	ADP
bptjm-48	21	50	succumbing	succumb	VERB
bptjm-48	21	51	.	.	PUNCT
bptjm-48	22	1	glioblastoma	glioblastoma	NOUN
bptjm-48	22	2	is	be	AUX
bptjm-48	22	3	a	a	DET
bptjm-48	22	4	grade	grade	NOUN
bptjm-48	22	5	iv	iv	NUM
bptjm-48	22	6	brain	brain	NOUN
bptjm-48	22	7	tumor2	tumor2	NOUN
bptjm-48	22	8	—	—	PUNCT
bptjm-48	22	9	signifying	signify	VERB
bptjm-48	22	10	that	that	SCONJ
bptjm-48	22	11	the	the	DET
bptjm-48	22	12	cells	cell	NOUN
bptjm-48	22	13	are	be	AUX
bptjm-48	22	14	actively	actively	ADV
bptjm-48	22	15	dividing	divide	VERB
bptjm-48	22	16	,	,	PUNCT
bptjm-48	22	17	and	and	CCONJ
bptjm-48	22	18	the	the	DET
bptjm-48	22	19	tumor	tumor	NOUN
bptjm-48	22	20	has	have	VERB
bptjm-48	22	21	dead	dead	ADJ
bptjm-48	22	22	tissue	tissue	NOUN
bptjm-48	22	23	as	as	ADV
bptjm-48	22	24	well	well	ADV
bptjm-48	22	25	as	as	ADP
bptjm-48	22	26	abnormal	abnormal	ADJ
bptjm-48	22	27	blood	blood	NOUN
bptjm-48	22	28	vessel	vessel	NOUN
bptjm-48	22	29	growth	growth	NOUN
bptjm-48	22	30	—	—	PUNCT
bptjm-48	22	31	that	that	PRON
bptjm-48	22	32	stems	stem	VERB
bptjm-48	22	33	from	from	ADP
bptjm-48	22	34	malfunctioning	malfunction	VERB
bptjm-48	22	35	astrocytes	astrocyte	NOUN
bptjm-48	22	36	,	,	PUNCT
bptjm-48	22	37	glial	glial	ADJ
bptjm-48	22	38	cells	cell	NOUN
bptjm-48	22	39	that	that	PRON
bptjm-48	22	40	provide	provide	VERB
bptjm-48	22	41	structural	structural	ADJ
bptjm-48	22	42	support	support	NOUN
bptjm-48	22	43	to	to	ADP
bptjm-48	22	44	neurons	neuron	NOUN
bptjm-48	22	45	,	,	PUNCT
bptjm-48	22	46	modulate	modulate	VERB
bptjm-48	22	47	synaptic	synaptic	ADJ
bptjm-48	22	48	activity	activity	NOUN
bptjm-48	22	49	,	,	PUNCT
bptjm-48	22	50	and	and	CCONJ
bptjm-48	22	51	act	act	VERB
bptjm-48	22	52	as	as	ADP
bptjm-48	22	53	a	a	DET
bptjm-48	22	54	major	major	ADJ
bptjm-48	22	55	component	component	NOUN
bptjm-48	22	56	in	in	ADP
bptjm-48	22	57	the	the	DET
bptjm-48	22	58	blood	blood	NOUN
bptjm-48	22	59	-	-	PUNCT
bptjm-48	22	60	brain	brain	NOUN
bptjm-48	22	61	barrier.3	barrier.3	PUNCT
bptjm-48	22	62	figure	figure	VERB
bptjm-48	22	63	1	1	NUM
bptjm-48	22	64	.	.	PUNCT
bptjm-48	22	65	glioblastoma	glioblastoma	NOUN
bptjm-48	22	66	statistics	statistic	VERB
bptjm-48	22	67	the	the	DET
bptjm-48	22	68	age	age	NOUN
bptjm-48	22	69	-	-	PUNCT
bptjm-48	22	70	adjusted	adjust	VERB
bptjm-48	22	71	incidence	incidence	NOUN
bptjm-48	22	72	of	of	ADP
bptjm-48	22	73	glioblastoma	glioblastoma	NOUN
bptjm-48	22	74	has	have	VERB
bptjm-48	22	75	a	a	DET
bptjm-48	22	76	positive	positive	ADJ
bptjm-48	22	77	correlation	correlation	NOUN
bptjm-48	22	78	with	with	ADP
bptjm-48	22	79	age	age	NOUN
bptjm-48	22	80	,	,	PUNCT
bptjm-48	22	81	being	be	AUX
bptjm-48	22	82	0.15	0.15	NUM
bptjm-48	22	83	per	per	ADP
bptjm-48	22	84	100,000	100,000	NUM
bptjm-48	22	85	in	in	ADP
bptjm-48	22	86	children	child	NOUN
bptjm-48	22	87	to	to	ADP
bptjm-48	22	88	15.03	15.03	NUM
bptjm-48	22	89	per	per	ADP
bptjm-48	22	90	100,000	100,000	NUM
bptjm-48	22	91	in	in	ADP
bptjm-48	22	92	patients	patient	NOUN
bptjm-48	22	93	berkeley	berkeley	PROPN
bptjm-48	22	94	pharma	pharma	PROPN
bptjm-48	22	95	tech	tech	NOUN
bptjm-48	22	96	journal	journal	NOUN
bptjm-48	22	97	of	of	ADP
bptjm-48	22	98	medicine	medicine	NOUN
bptjm-48	22	99	|	|	ADV
bptjm-48	22	100	31	31	NUM
bptjm-48	22	101	between	between	ADP
bptjm-48	22	102	75	75	NUM
bptjm-48	22	103	and	and	CCONJ
bptjm-48	22	104	84	84	NUM
bptjm-48	22	105	years	year	NOUN
bptjm-48	22	106	of	of	ADP
bptjm-48	22	107	age.4	age.4	PROPN
bptjm-48	22	108	glioblastoma	glioblastoma	NOUN
bptjm-48	22	109	develops	develop	VERB
bptjm-48	22	110	most	most	ADV
bptjm-48	22	111	commonly	commonly	ADV
bptjm-48	22	112	in	in	ADP
bptjm-48	22	113	the	the	DET
bptjm-48	22	114	frontal	frontal	ADJ
bptjm-48	22	115	lobe	lobe	NOUN
bptjm-48	22	116	,	,	PUNCT
bptjm-48	22	117	but	but	CCONJ
bptjm-48	22	118	has	have	AUX
bptjm-48	22	119	appeared	appear	VERB
bptjm-48	22	120	in	in	ADP
bptjm-48	22	121	the	the	DET
bptjm-48	22	122	temporal	temporal	ADJ
bptjm-48	22	123	,	,	PUNCT
bptjm-48	22	124	parietal	parietal	ADJ
bptjm-48	22	125	,	,	PUNCT
bptjm-48	22	126	and	and	CCONJ
bptjm-48	22	127	occipital	occipital	NOUN
bptjm-48	22	128	lobes	lobe	NOUN
bptjm-48	22	129	,	,	PUNCT
bptjm-48	22	130	and	and	CCONJ
bptjm-48	22	131	could	could	AUX
bptjm-48	22	132	even	even	ADV
bptjm-48	22	133	grow	grow	VERB
bptjm-48	22	134	into	into	ADP
bptjm-48	22	135	surrounding	surround	VERB
bptjm-48	22	136	brain	brain	NOUN
bptjm-48	22	137	tissues.5	tissues.5	PRON
bptjm-48	22	138	common	common	ADJ
bptjm-48	22	139	symptoms	symptom	NOUN
bptjm-48	22	140	of	of	ADP
bptjm-48	22	141	glioblastoma	glioblastoma	NOUN
bptjm-48	22	142	include	include	VERB
bptjm-48	22	143	seizures	seizure	NOUN
bptjm-48	22	144	,	,	PUNCT
bptjm-48	22	145	coordination	coordination	NOUN
bptjm-48	22	146	issues	issue	NOUN
bptjm-48	22	147	,	,	PUNCT
bptjm-48	22	148	paralysis	paralysis	NOUN
bptjm-48	22	149	,	,	PUNCT
bptjm-48	22	150	fatigue	fatigue	NOUN
bptjm-48	22	151	,	,	PUNCT
bptjm-48	22	152	severe	severe	ADJ
bptjm-48	22	153	headaches	headache	NOUN
bptjm-48	22	154	,	,	PUNCT
bptjm-48	22	155	and	and	CCONJ
bptjm-48	22	156	cognitive	cognitive	ADJ
bptjm-48	22	157	impairment	impairment	NOUN
bptjm-48	22	158	.	.	PUNCT
bptjm-48	23	1	major	major	ADJ
bptjm-48	23	2	risk	risk	NOUN
bptjm-48	23	3	factors	factor	NOUN
bptjm-48	23	4	have	have	VERB
bptjm-48	23	5	yet	yet	ADV
bptjm-48	23	6	to	to	PART
bptjm-48	23	7	be	be	AUX
bptjm-48	23	8	identi	identi	NOUN
bptjm-48	23	9	�	�	NOUN
bptjm-48	23	10	ed	ed	NOUN
bptjm-48	23	11	;	;	PUNCT
bptjm-48	23	12	however	however	ADV
bptjm-48	23	13	,	,	PUNCT
bptjm-48	23	14	it	it	PRON
bptjm-48	23	15	was	be	AUX
bptjm-48	23	16	recently	recently	ADV
bptjm-48	23	17	discovered	discover	VERB
bptjm-48	23	18	that	that	SCONJ
bptjm-48	23	19	exposure	exposure	NOUN
bptjm-48	23	20	to	to	ADP
bptjm-48	23	21	high	high	ADJ
bptjm-48	23	22	ionizing	ionizing	NOUN
bptjm-48	23	23	radiation	radiation	NOUN
bptjm-48	23	24	is	be	AUX
bptjm-48	23	25	a	a	DET
bptjm-48	23	26	major	major	ADJ
bptjm-48	23	27	contributor	contributor	NOUN
bptjm-48	23	28	towards	towards	ADP
bptjm-48	23	29	glioblastoma	glioblastoma	NOUN
bptjm-48	23	30	development	development	NOUN
bptjm-48	23	31	.	.	PUNCT
bptjm-48	24	1	moreover	moreover	ADV
bptjm-48	24	2	,	,	PUNCT
bptjm-48	24	3	exposure	exposure	NOUN
bptjm-48	24	4	to	to	ADP
bptjm-48	24	5	vinyl	vinyl	NOUN
bptjm-48	24	6	chloride	chloride	NOUN
bptjm-48	24	7	,	,	PUNCT
bptjm-48	24	8	pesticides	pesticide	NOUN
bptjm-48	24	9	,	,	PUNCT
bptjm-48	24	10	smoking	smoking	NOUN
bptjm-48	24	11	,	,	PUNCT
bptjm-48	24	12	petroleum	petroleum	NOUN
bptjm-48	24	13	re	re	NOUN
bptjm-48	24	14	�	�	NOUN
bptjm-48	24	15	ning	ning	NOUN
bptjm-48	24	16	,	,	PUNCT
bptjm-48	24	17	and	and	CCONJ
bptjm-48	24	18	synthetic	synthetic	ADJ
bptjm-48	24	19	rubber	rubber	NOUN
bptjm-48	24	20	have	have	AUX
bptjm-48	24	21	shown	show	VERB
bptjm-48	24	22	occasional	occasional	ADJ
bptjm-48	24	23	positive	positive	ADJ
bptjm-48	24	24	association	association	NOUN
bptjm-48	24	25	with	with	ADP
bptjm-48	24	26	glioblastoma	glioblastoma	NOUN
bptjm-48	24	27	emergence.6	emergence.6	PROPN
bptjm-48	24	28	currently	currently	ADV
bptjm-48	24	29	,	,	PUNCT
bptjm-48	24	30	the	the	DET
bptjm-48	24	31	main	main	ADJ
bptjm-48	24	32	treatment	treatment	NOUN
bptjm-48	24	33	methods	method	NOUN
bptjm-48	24	34	used	use	VERB
bptjm-48	24	35	include	include	VERB
bptjm-48	24	36	surgical	surgical	ADJ
bptjm-48	24	37	resection	resection	NOUN
bptjm-48	24	38	,	,	PUNCT
bptjm-48	24	39	alkylating	alkylate	VERB
bptjm-48	24	40	chemotherapy	chemotherapy	NOUN
bptjm-48	24	41	,	,	PUNCT
bptjm-48	24	42	radiation	radiation	NOUN
bptjm-48	24	43	therapy	therapy	NOUN
bptjm-48	24	44	,	,	PUNCT
bptjm-48	24	45	and	and	CCONJ
bptjm-48	24	46	tumor	tumor	NOUN
bptjm-48	24	47	treating	treat	VERB
bptjm-48	24	48	fields.6	fields.6	VERB
bptjm-48	24	49	the	the	DET
bptjm-48	24	50	majority	majority	NOUN
bptjm-48	24	51	of	of	ADP
bptjm-48	24	52	gliomas	glioma	NOUN
bptjm-48	24	53	have	have	AUX
bptjm-48	24	54	been	be	AUX
bptjm-48	24	55	found	find	VERB
bptjm-48	24	56	to	to	PART
bptjm-48	24	57	contain	contain	VERB
bptjm-48	24	58	point	point	NOUN
bptjm-48	24	59	mutations	mutation	NOUN
bptjm-48	24	60	in	in	ADP
bptjm-48	24	61	isocitrate	isocitrate	ADJ
bptjm-48	24	62	dehydrogenase	dehydrogenase	NOUN
bptjm-48	24	63	1	1	NUM
bptjm-48	24	64	and	and	CCONJ
bptjm-48	24	65	2	2	NUM
bptjm-48	24	66	.	.	X
bptjm-48	25	1	in	in	ADP
bptjm-48	25	2	glioblastoma	glioblastoma	NOUN
bptjm-48	25	3	,	,	PUNCT
bptjm-48	25	4	molecular	molecular	ADJ
bptjm-48	25	5	alterations	alteration	NOUN
bptjm-48	25	6	that	that	PRON
bptjm-48	25	7	have	have	AUX
bptjm-48	25	8	been	be	AUX
bptjm-48	25	9	discovered	discover	VERB
bptjm-48	25	10	include	include	VERB
bptjm-48	25	11	mutations	mutation	NOUN
bptjm-48	25	12	in	in	ADP
bptjm-48	25	13	genes	gene	NOUN
bptjm-48	25	14	regulating	regulate	VERB
bptjm-48	25	15	receptor	receptor	NOUN
bptjm-48	25	16	tyrosine	tyrosine	PROPN
bptjm-48	25	17	kinase	kinase	PROPN
bptjm-48	25	18	(	(	PUNCT
bptjm-48	25	19	rtk	rtk	PROPN
bptjm-48	25	20	)	)	PUNCT
bptjm-48	25	21	,	,	PUNCT
bptjm-48	25	22	rat	rat	NOUN
bptjm-48	25	23	sarcoma	sarcoma	NOUN
bptjm-48	25	24	(	(	PUNCT
bptjm-48	25	25	ras	ras	NOUN
bptjm-48	25	26	)	)	PUNCT
bptjm-48	25	27	,	,	PUNCT
bptjm-48	25	28	phosphoinositide	phosphoinositide	NOUN
bptjm-48	25	29	3	3	NUM
bptjm-48	25	30	-	-	PUNCT
bptjm-48	25	31	kinase	kinase	NOUN
bptjm-48	25	32	(	(	PUNCT
bptjm-48	25	33	pi3k	pi3k	PROPN
bptjm-48	25	34	)	)	PUNCT
bptjm-48	25	35	,	,	PUNCT
bptjm-48	25	36	p53	p53	NOUN
bptjm-48	25	37	,	,	PUNCT
bptjm-48	25	38	and	and	CCONJ
bptjm-48	25	39	retinoblastoma	retinoblastoma	NOUN
bptjm-48	25	40	protein	protein	NOUN
bptjm-48	25	41	(	(	PUNCT
bptjm-48	25	42	rb	rb	NOUN
bptjm-48	25	43	)	)	PUNCT
bptjm-48	25	44	signaling.7	signaling.7	ADJ
bptjm-48	25	45	current	current	ADJ
bptjm-48	25	46	research	research	NOUN
bptjm-48	25	47	shows	show	VERB
bptjm-48	25	48	mutations	mutation	NOUN
bptjm-48	25	49	in	in	ADP
bptjm-48	25	50	egfr	egfr	NOUN
bptjm-48	25	51	(	(	PUNCT
bptjm-48	25	52	57	57	NUM
bptjm-48	25	53	%	%	NOUN
bptjm-48	25	54	of	of	ADP
bptjm-48	25	55	gbm	gbm	NOUN
bptjm-48	25	56	patients	patient	NOUN
bptjm-48	25	57	)	)	PUNCT
bptjm-48	25	58	,	,	PUNCT
bptjm-48	25	59	her2	her2	PROPN
bptjm-48	25	60	,	,	PUNCT
bptjm-48	25	61	pdgfra	pdgfra	NOUN
bptjm-48	25	62	(	(	PUNCT
bptjm-48	25	63	13	13	NUM
bptjm-48	25	64	%	%	NOUN
bptjm-48	25	65	)	)	PUNCT
bptjm-48	25	66	,	,	PUNCT
bptjm-48	25	67	c	c	X
bptjm-48	25	68	-	-	PUNCT
bptjm-48	25	69	met	meet	VERB
bptjm-48	25	70	(	(	PUNCT
bptjm-48	25	71	1.6	1.6	NUM
bptjm-48	25	72	%	%	NOUN
bptjm-48	25	73	)	)	PUNCT
bptjm-48	25	74	,	,	PUNCT
bptjm-48	25	75	fgfr	fgfr	ADJ
bptjm-48	25	76	(	(	PUNCT
bptjm-48	25	77	3.2	3.2	NUM
bptjm-48	25	78	%	%	NOUN
bptjm-48	25	79	)	)	PUNCT
bptjm-48	25	80	,	,	PUNCT
bptjm-48	25	81	pten	pten	VERB
bptjm-48	25	82	(	(	PUNCT
bptjm-48	25	83	41	41	NUM
bptjm-48	25	84	%	%	NOUN
bptjm-48	25	85	)	)	PUNCT
bptjm-48	25	86	,	,	PUNCT
bptjm-48	25	87	and	and	CCONJ
bptjm-48	25	88	vegfr	vegfr	ADJ
bptjm-48	25	89	genes	gene	NOUN
bptjm-48	25	90	are	be	AUX
bptjm-48	25	91	therapeutic	therapeutic	ADJ
bptjm-48	25	92	targets	target	NOUN
bptjm-48	25	93	due	due	ADJ
bptjm-48	25	94	to	to	ADP
bptjm-48	25	95	having	having	AUX
bptjm-48	25	96	shown	show	VERB
bptjm-48	25	97	ampli	ampli	NOUN
bptjm-48	25	98	�	�	NOUN
bptjm-48	25	99	cations	cation	NOUN
bptjm-48	25	100	or	or	CCONJ
bptjm-48	25	101	mutations	mutation	NOUN
bptjm-48	25	102	from	from	ADP
bptjm-48	25	103	dysregulated	dysregulated	ADJ
bptjm-48	25	104	cell	cell	NOUN
bptjm-48	25	105	signaling	signal	VERB
bptjm-48	25	106	cascades	cascade	NOUN
bptjm-48	25	107	in	in	ADP
bptjm-48	25	108	glioblastoma.7	glioblastoma.7	PROPN
bptjm-48	25	109	kinase	kinase	PROPN
bptjm-48	25	110	inhibitors	inhibitor	NOUN
bptjm-48	25	111	have	have	AUX
bptjm-48	25	112	n’t	not	PART
bptjm-48	25	113	proven	prove	VERB
bptjm-48	25	114	to	to	PART
bptjm-48	25	115	be	be	AUX
bptjm-48	25	116	e	e	NOUN
bptjm-48	25	117	�	�	NOUN
bptjm-48	25	118	ective	ective	ADJ
bptjm-48	25	119	in	in	ADP
bptjm-48	25	120	glioblastoma	glioblastoma	NOUN
bptjm-48	25	121	therapy	therapy	NOUN
bptjm-48	25	122	due	due	ADP
bptjm-48	25	123	to	to	ADP
bptjm-48	25	124	their	their	PRON
bptjm-48	25	125	low	low	ADJ
bptjm-48	25	126	e	e	NOUN
bptjm-48	25	127	�	�	NOUN
bptjm-48	25	128	cacy	cacy	NOUN
bptjm-48	25	129	in	in	ADP
bptjm-48	25	130	penetrating	penetrate	VERB
bptjm-48	25	131	the	the	DET
bptjm-48	25	132	blood	blood	NOUN
bptjm-48	25	133	-	-	PUNCT
bptjm-48	25	134	brain	brain	NOUN
bptjm-48	25	135	barrier	barrier	NOUN
bptjm-48	25	136	;	;	PUNCT
bptjm-48	25	137	however	however	ADV
bptjm-48	25	138	,	,	PUNCT
bptjm-48	25	139	a	a	DET
bptjm-48	25	140	multitude	multitude	NOUN
bptjm-48	25	141	of	of	ADP
bptjm-48	25	142	experimental	experimental	ADJ
bptjm-48	25	143	treatments	treatment	NOUN
bptjm-48	25	144	have	have	AUX
bptjm-48	25	145	emerged	emerge	VERB
bptjm-48	25	146	and	and	CCONJ
bptjm-48	25	147	shown	show	VERB
bptjm-48	25	148	consistent	consistent	ADJ
bptjm-48	25	149	progress	progress	NOUN
bptjm-48	25	150	.	.	PUNCT
bptjm-48	26	1	azd3579	azd3579	NOUN
bptjm-48	26	2	(	(	PUNCT
bptjm-48	26	3	egfr	egfr	ADJ
bptjm-48	26	4	inhibitor	inhibitor	NOUN
bptjm-48	26	5	)	)	PUNCT
bptjm-48	26	6	has	have	AUX
bptjm-48	26	7	shown	show	VERB
bptjm-48	26	8	e	e	NOUN
bptjm-48	26	9	�	�	NOUN
bptjm-48	26	10	ective	ective	ADJ
bptjm-48	26	11	blood	blood	NOUN
bptjm-48	26	12	-	-	PUNCT
bptjm-48	26	13	brain	brain	NOUN
bptjm-48	26	14	barrier	barrier	NOUN
bptjm-48	26	15	penetration	penetration	NOUN
bptjm-48	26	16	in	in	ADP
bptjm-48	26	17	vivo	vivo	NOUN
bptjm-48	26	18	in	in	ADP
bptjm-48	26	19	rats	rat	NOUN
bptjm-48	26	20	and	and	CCONJ
bptjm-48	26	21	monkeys	monkey	NOUN
bptjm-48	26	22	,	,	PUNCT
bptjm-48	26	23	however	however	ADV
bptjm-48	26	24	its	its	PRON
bptjm-48	26	25	safety	safety	NOUN
bptjm-48	26	26	and	and	CCONJ
bptjm-48	26	27	e	e	NOUN
bptjm-48	26	28	�	�	NOUN
bptjm-48	26	29	cacy	cacy	NOUN
bptjm-48	26	30	in	in	ADP
bptjm-48	26	31	humans	human	NOUN
bptjm-48	26	32	has	have	VERB
bptjm-48	26	33	yet	yet	ADV
bptjm-48	26	34	to	to	PART
bptjm-48	26	35	be	be	AUX
bptjm-48	26	36	tested	test	VERB
bptjm-48	26	37	.	.	PUNCT
bptjm-48	27	1	epitinib	epitinib	NOUN
bptjm-48	27	2	(	(	PUNCT
bptjm-48	27	3	egfr	egfr	ADJ
bptjm-48	27	4	inhibitor	inhibitor	NOUN
bptjm-48	27	5	)	)	PUNCT
bptjm-48	27	6	was	be	AUX
bptjm-48	27	7	reported	report	VERB
bptjm-48	27	8	to	to	PART
bptjm-48	27	9	have	have	VERB
bptjm-48	27	10	optimal	optimal	ADJ
bptjm-48	27	11	bbb	bbb	NOUN
bptjm-48	27	12	penetration	penetration	NOUN
bptjm-48	27	13	,	,	PUNCT
bptjm-48	27	14	is	be	AUX
bptjm-48	27	15	well	well	ADV
bptjm-48	27	16	-	-	PUNCT
bptjm-48	27	17	tolerated	tolerate	VERB
bptjm-48	27	18	in	in	ADP
bptjm-48	27	19	patients	patient	NOUN
bptjm-48	27	20	,	,	PUNCT
bptjm-48	27	21	and	and	CCONJ
bptjm-48	27	22	is	be	AUX
bptjm-48	27	23	e	e	NOUN
bptjm-48	27	24	�	�	NOUN
bptjm-48	27	25	ective	ective	ADJ
bptjm-48	27	26	in	in	ADP
bptjm-48	27	27	treating	treat	VERB
bptjm-48	27	28	brain	brain	NOUN
bptjm-48	27	29	metastases	metastasis	NOUN
bptjm-48	27	30	as	as	ADV
bptjm-48	27	31	well	well	ADV
bptjm-48	27	32	.	.	PUNCT
bptjm-48	28	1	wsd0922	wsd0922	PROPN
bptjm-48	28	2	(	(	PUNCT
bptjm-48	28	3	egfr	egfr	ADJ
bptjm-48	28	4	inhibitor	inhibitor	NOUN
bptjm-48	28	5	)	)	PUNCT
bptjm-48	28	6	is	be	AUX
bptjm-48	28	7	reported	report	VERB
bptjm-48	28	8	to	to	PART
bptjm-48	28	9	have	have	VERB
bptjm-48	28	10	high	high	ADJ
bptjm-48	28	11	bbb	bbb	NOUN
bptjm-48	28	12	penetration	penetration	NOUN
bptjm-48	28	13	,	,	PUNCT
bptjm-48	28	14	reasonable	reasonable	ADJ
bptjm-48	28	15	safety	safety	NOUN
bptjm-48	28	16	,	,	PUNCT
bptjm-48	28	17	and	and	CCONJ
bptjm-48	28	18	has	have	AUX
bptjm-48	28	19	shown	show	VERB
bptjm-48	28	20	antitumor	antitumor	PROPN
bptjm-48	28	21	properties	property	NOUN
bptjm-48	28	22	in	in	ADP
bptjm-48	28	23	glioblastoma	glioblastoma	NOUN
bptjm-48	28	24	pdx	pdx	PROPN
bptjm-48	28	25	models.7	models.7	PROPN
bptjm-48	28	26	tucatinib	tucatinib	NOUN
bptjm-48	28	27	(	(	PUNCT
bptjm-48	28	28	her2	her2	NOUN
bptjm-48	28	29	inhibitor	inhibitor	NOUN
bptjm-48	28	30	)	)	PUNCT
bptjm-48	28	31	can	can	AUX
bptjm-48	28	32	cross	cross	VERB
bptjm-48	28	33	the	the	DET
bptjm-48	28	34	blood	blood	NOUN
bptjm-48	28	35	-	-	PUNCT
bptjm-48	28	36	brain	brain	NOUN
bptjm-48	28	37	barrier	barrier	NOUN
bptjm-48	28	38	and	and	CCONJ
bptjm-48	28	39	create	create	VERB
bptjm-48	28	40	survival	survival	PROPN
bptjm-48	28	41	bene	bene	PROPN
bptjm-48	28	42	�	�	PROPN
bptjm-48	28	43	ts	ts	X
bptjm-48	28	44	in	in	ADP
bptjm-48	28	45	mice	mouse	NOUN
bptjm-48	28	46	.	.	PUNCT
bptjm-48	29	1	for	for	ADP
bptjm-48	29	2	patients	patient	NOUN
bptjm-48	29	3	with	with	ADP
bptjm-48	29	4	breast	breast	NOUN
bptjm-48	29	5	cancer	cancer	NOUN
bptjm-48	29	6	and	and	CCONJ
bptjm-48	29	7	brain	brain	NOUN
bptjm-48	29	8	berkeley	berkeley	PROPN
bptjm-48	29	9	pharma	pharma	PROPN
bptjm-48	29	10	tech	tech	NOUN
bptjm-48	29	11	journal	journal	NOUN
bptjm-48	29	12	of	of	ADP
bptjm-48	29	13	medicine	medicine	NOUN
bptjm-48	29	14	|	|	ADV
bptjm-48	29	15	32	32	NUM
bptjm-48	29	16	metastasis	metastasis	NOUN
bptjm-48	29	17	,	,	PUNCT
bptjm-48	29	18	tucatinib	tucatinib	NOUN
bptjm-48	29	19	produced	produce	VERB
bptjm-48	29	20	better	well	ADJ
bptjm-48	29	21	progression	progression	NOUN
bptjm-48	29	22	-	-	PUNCT
bptjm-48	29	23	free	free	ADJ
bptjm-48	29	24	survival	survival	NOUN
bptjm-48	29	25	and	and	CCONJ
bptjm-48	29	26	overall	overall	ADJ
bptjm-48	29	27	survival	survival	NOUN
bptjm-48	29	28	.	.	PUNCT
bptjm-48	30	1	neratinib	neratinib	NOUN
bptjm-48	30	2	(	(	PUNCT
bptjm-48	30	3	her2	her2	PROPN
bptjm-48	30	4	inhibitor)had	inhibitor)had	VERB
bptjm-48	30	5	limited	limited	ADJ
bptjm-48	30	6	bbb	bbb	NOUN
bptjm-48	30	7	penetration	penetration	NOUN
bptjm-48	30	8	in	in	ADP
bptjm-48	30	9	mice	mouse	NOUN
bptjm-48	30	10	and	and	CCONJ
bptjm-48	30	11	was	be	AUX
bptjm-48	30	12	not	not	PART
bptjm-48	30	13	successful	successful	ADJ
bptjm-48	30	14	in	in	ADP
bptjm-48	30	15	a	a	DET
bptjm-48	30	16	phase	phase	NOUN
bptjm-48	30	17	ii	ii	NOUN
bptjm-48	30	18	trial	trial	NOUN
bptjm-48	30	19	for	for	ADP
bptjm-48	30	20	patients	patient	NOUN
bptjm-48	30	21	that	that	PRON
bptjm-48	30	22	had	have	AUX
bptjm-48	30	23	her2	her2	VERB
bptjm-48	30	24	-	-	PUNCT
bptjm-48	30	25	positive	positive	ADJ
bptjm-48	30	26	brain	brain	NOUN
bptjm-48	30	27	metastases.7	metastases.7	NOUN
bptjm-48	30	28	additionally	additionally	ADV
bptjm-48	30	29	,	,	PUNCT
bptjm-48	30	30	for	for	ADP
bptjm-48	30	31	newly	newly	ADV
bptjm-48	30	32	diagnosed	diagnose	VERB
bptjm-48	30	33	glioblastoma	glioblastoma	NOUN
bptjm-48	30	34	cases	case	NOUN
bptjm-48	30	35	,	,	PUNCT
bptjm-48	30	36	clinical	clinical	ADJ
bptjm-48	30	37	trials	trial	NOUN
bptjm-48	30	38	involving	involve	VERB
bptjm-48	30	39	the	the	DET
bptjm-48	30	40	drug	drug	NOUN
bptjm-48	30	41	temozolomide	temozolomide	NOUN
bptjm-48	30	42	—	—	PUNCT
bptjm-48	30	43	a	a	DET
bptjm-48	30	44	monofunctional	monofunctional	ADJ
bptjm-48	30	45	dna	dna	NOUN
bptjm-48	30	46	alkylating	alkylate	VERB
bptjm-48	30	47	agent	agent	NOUN
bptjm-48	30	48	—	—	PUNCT
bptjm-48	30	49	have	have	AUX
bptjm-48	30	50	shown	show	VERB
bptjm-48	30	51	signi	signi	PROPN
bptjm-48	30	52	�	�	NOUN
bptjm-48	30	53	cant	cant	NOUN
bptjm-48	30	54	progress	progress	NOUN
bptjm-48	30	55	.	.	PUNCT
bptjm-48	31	1	adding	add	VERB
bptjm-48	31	2	the	the	DET
bptjm-48	31	3	temozolomide	temozolomide	NOUN
bptjm-48	31	4	regimen	regiman	NOUN
bptjm-48	31	5	improved	improve	VERB
bptjm-48	31	6	the	the	DET
bptjm-48	31	7	overall	overall	ADJ
bptjm-48	31	8	survival	survival	NOUN
bptjm-48	31	9	and	and	CCONJ
bptjm-48	31	10	progression	progression	NOUN
bptjm-48	31	11	free	free	ADJ
bptjm-48	31	12	survival	survival	NOUN
bptjm-48	31	13	in	in	ADP
bptjm-48	31	14	patients	patient	NOUN
bptjm-48	31	15	with	with	ADP
bptjm-48	31	16	gbm	gbm	PROPN
bptjm-48	31	17	compared	compare	VERB
bptjm-48	31	18	with	with	ADP
bptjm-48	31	19	radiotherapy	radiotherapy	NOUN
bptjm-48	31	20	alone	alone	ADV
bptjm-48	31	21	.	.	PUNCT
bptjm-48	32	1	temozolomide	temozolomide	NOUN
bptjm-48	32	2	is	be	AUX
bptjm-48	32	3	a	a	DET
bptjm-48	32	4	lipophilic	lipophilic	ADJ
bptjm-48	32	5	molecule	molecule	NOUN
bptjm-48	32	6	that	that	PRON
bptjm-48	32	7	crosses	cross	VERB
bptjm-48	32	8	the	the	DET
bptjm-48	32	9	blood	blood	NOUN
bptjm-48	32	10	-	-	PUNCT
bptjm-48	32	11	brain	brain	NOUN
bptjm-48	32	12	barrier	barrier	NOUN
bptjm-48	32	13	and	and	CCONJ
bptjm-48	32	14	is	be	AUX
bptjm-48	32	15	stable	stable	ADJ
bptjm-48	32	16	at	at	ADP
bptjm-48	32	17	the	the	DET
bptjm-48	32	18	acidic	acidic	ADJ
bptjm-48	32	19	ph	ph	NOUN
bptjm-48	32	20	of	of	ADP
bptjm-48	32	21	the	the	DET
bptjm-48	32	22	stomach	stomach	NOUN
bptjm-48	32	23	and	and	CCONJ
bptjm-48	32	24	is	be	AUX
bptjm-48	32	25	therefore	therefore	ADV
bptjm-48	32	26	administered	administer	VERB
bptjm-48	32	27	orally.7	orally.7	NUM
bptjm-48	32	28	temozolomide	temozolomide	NOUN
bptjm-48	32	29	is	be	AUX
bptjm-48	32	30	currently	currently	ADV
bptjm-48	32	31	being	be	AUX
bptjm-48	32	32	tested	test	VERB
bptjm-48	32	33	,	,	PUNCT
bptjm-48	32	34	in	in	ADP
bptjm-48	32	35	a	a	DET
bptjm-48	32	36	phase	phase	NOUN
bptjm-48	32	37	ii	ii	NOUN
bptjm-48	32	38	interventional	interventional	ADJ
bptjm-48	32	39	clinical	clinical	ADJ
bptjm-48	32	40	trial	trial	NOUN
bptjm-48	32	41	led	lead	VERB
bptjm-48	32	42	by	by	ADP
bptjm-48	32	43	wen	wen	PROPN
bptjm-48	32	44	et	et	PROPN
bptjm-48	32	45	al	al	PROPN
bptjm-48	32	46	.	.	PROPN
bptjm-48	33	1	(	(	PUNCT
bptjm-48	33	2	nct02977780	nct02977780	ADJ
bptjm-48	33	3	)	)	PUNCT
bptjm-48	33	4	via	via	ADP
bptjm-48	33	5	combination	combination	NOUN
bptjm-48	33	6	therapy	therapy	NOUN
bptjm-48	33	7	with	with	ADP
bptjm-48	33	8	neratinib	neratinib	NOUN
bptjm-48	33	9	,	,	PUNCT
bptjm-48	33	10	to	to	PART
bptjm-48	33	11	study	study	VERB
bptjm-48	33	12	overall	overall	ADJ
bptjm-48	33	13	survival	survival	NOUN
bptjm-48	33	14	compared	compare	VERB
bptjm-48	33	15	to	to	ADP
bptjm-48	33	16	standard	standard	ADJ
bptjm-48	33	17	treatment	treatment	NOUN
bptjm-48	33	18	in	in	ADP
bptjm-48	33	19	glioblastoma	glioblastoma	NOUN
bptjm-48	33	20	patients.8	patients.8	PROPN
bptjm-48	33	21	3	3	NUM
bptjm-48	33	22	.	.	PUNCT
bptjm-48	34	1	neoantigen	neoantigen	PROPN
bptjm-48	34	2	background	background	PROPN
bptjm-48	34	3	neoantigens	neoantigen	NOUN
bptjm-48	34	4	are	be	AUX
bptjm-48	34	5	a	a	DET
bptjm-48	34	6	class	class	NOUN
bptjm-48	34	7	of	of	ADP
bptjm-48	34	8	proteins	protein	NOUN
bptjm-48	34	9	that	that	PRON
bptjm-48	34	10	arise	arise	VERB
bptjm-48	34	11	in	in	ADP
bptjm-48	34	12	cancer	cancer	NOUN
bptjm-48	34	13	cells	cell	NOUN
bptjm-48	34	14	with	with	ADP
bptjm-48	34	15	the	the	DET
bptjm-48	34	16	mutation	mutation	NOUN
bptjm-48	34	17	of	of	ADP
bptjm-48	34	18	tumor	tumor	NOUN
bptjm-48	34	19	dna	dna	PROPN
bptjm-48	34	20	.	.	PUNCT
bptjm-48	35	1	the	the	DET
bptjm-48	35	2	�	�	PROPN
bptjm-48	35	3	rst	rst	PROPN
bptjm-48	35	4	discovery	discovery	NOUN
bptjm-48	35	5	of	of	ADP
bptjm-48	35	6	neoantigens	neoantigen	NOUN
bptjm-48	35	7	was	be	AUX
bptjm-48	35	8	made	make	VERB
bptjm-48	35	9	in	in	ADP
bptjm-48	35	10	1988	1988	NUM
bptjm-48	35	11	by	by	ADP
bptjm-48	35	12	de	de	X
bptjm-48	35	13	plaen	plaen	PROPN
bptjm-48	35	14	and	and	CCONJ
bptjm-48	35	15	his	his	PRON
bptjm-48	35	16	colleagues.9	colleagues.9	NOUN
bptjm-48	35	17	by	by	ADP
bptjm-48	35	18	utilizing	utilize	VERB
bptjm-48	35	19	cdna	cdna	PROPN
bptjm-48	35	20	library	library	NOUN
bptjm-48	35	21	screening	screen	VERB
bptjm-48	35	22	on	on	ADP
bptjm-48	35	23	a	a	DET
bptjm-48	35	24	mouse	mouse	NOUN
bptjm-48	35	25	tumor	tumor	NOUN
bptjm-48	35	26	model	model	NOUN
bptjm-48	35	27	,	,	PUNCT
bptjm-48	35	28	they	they	PRON
bptjm-48	35	29	observed	observe	VERB
bptjm-48	35	30	a	a	DET
bptjm-48	35	31	single	single	ADJ
bptjm-48	35	32	nucleotide	nucleotide	NOUN
bptjm-48	35	33	di	di	NOUN
bptjm-48	35	34	�	�	PROPN
bptjm-48	35	35	erence	erence	NOUN
bptjm-48	35	36	between	between	ADP
bptjm-48	35	37	the	the	DET
bptjm-48	35	38	normal	normal	ADJ
bptjm-48	35	39	and	and	CCONJ
bptjm-48	35	40	tumor	tumor	NOUN
bptjm-48	35	41	gene	gene	NOUN
bptjm-48	35	42	,	,	PUNCT
bptjm-48	35	43	resulting	result	VERB
bptjm-48	35	44	in	in	ADP
bptjm-48	35	45	a	a	DET
bptjm-48	35	46	noticeable	noticeable	ADJ
bptjm-48	35	47	amino	amino	NOUN
bptjm-48	35	48	acid	acid	NOUN
bptjm-48	35	49	change	change	NOUN
bptjm-48	35	50	.	.	PUNCT
bptjm-48	36	1	this	this	DET
bptjm-48	36	2	novel	novel	PROPN
bptjm-48	36	3	�	�	NOUN
bptjm-48	36	4	nding	nding	NOUN
bptjm-48	36	5	led	lead	VERB
bptjm-48	36	6	to	to	ADP
bptjm-48	36	7	the	the	DET
bptjm-48	36	8	coining	coining	NOUN
bptjm-48	36	9	of	of	ADP
bptjm-48	36	10	the	the	DET
bptjm-48	36	11	term	term	NOUN
bptjm-48	36	12	“	"	PUNCT
bptjm-48	36	13	neoantigen	neoantigen	PROPN
bptjm-48	36	14	”	"	PUNCT
bptjm-48	36	15	which	which	PRON
bptjm-48	36	16	was	be	AUX
bptjm-48	36	17	used	use	VERB
bptjm-48	36	18	in	in	ADP
bptjm-48	36	19	further	further	ADJ
bptjm-48	36	20	studies	study	NOUN
bptjm-48	36	21	on	on	ADP
bptjm-48	36	22	human	human	ADJ
bptjm-48	36	23	tumors	tumor	NOUN
bptjm-48	36	24	including	include	VERB
bptjm-48	36	25	melanoma	melanoma	NOUN
bptjm-48	36	26	and	and	CCONJ
bptjm-48	36	27	renal	renal	ADJ
bptjm-48	36	28	cell	cell	NOUN
bptjm-48	36	29	carcinoma.9	carcinoma.9	PROPN
bptjm-48	36	30	neoantigens	neoantigen	NOUN
bptjm-48	36	31	have	have	AUX
bptjm-48	36	32	proven	prove	VERB
bptjm-48	36	33	e	e	NOUN
bptjm-48	36	34	�	�	NOUN
bptjm-48	36	35	cient	cient	VERB
bptjm-48	36	36	immunogenic	immunogenic	ADJ
bptjm-48	36	37	targets	target	NOUN
bptjm-48	36	38	because	because	SCONJ
bptjm-48	36	39	of	of	ADP
bptjm-48	36	40	their	their	PRON
bptjm-48	36	41	localization	localization	NOUN
bptjm-48	36	42	to	to	ADP
bptjm-48	36	43	cancer	cancer	NOUN
bptjm-48	36	44	patients	patient	NOUN
bptjm-48	36	45	.	.	PUNCT
bptjm-48	37	1	the	the	DET
bptjm-48	37	2	mechanism	mechanism	NOUN
bptjm-48	37	3	of	of	ADP
bptjm-48	37	4	action	action	NOUN
bptjm-48	37	5	by	by	ADP
bptjm-48	37	6	which	which	PRON
bptjm-48	37	7	they	they	PRON
bptjm-48	37	8	form	form	VERB
bptjm-48	37	9	explains	explain	VERB
bptjm-48	37	10	the	the	DET
bptjm-48	37	11	tumor	tumor	NOUN
bptjm-48	37	12	-	-	PUNCT
bptjm-48	37	13	speci	speci	NOUN
bptjm-48	37	14	�	�	PROPN
bptjm-48	37	15	city	city	NOUN
bptjm-48	37	16	of	of	ADP
bptjm-48	37	17	neoantigens	neoantigen	NOUN
bptjm-48	37	18	and	and	CCONJ
bptjm-48	37	19	their	their	PRON
bptjm-48	37	20	associated	associated	ADJ
bptjm-48	37	21	potency	potency	NOUN
bptjm-48	37	22	in	in	ADP
bptjm-48	37	23	developing	develop	VERB
bptjm-48	37	24	cancer	cancer	NOUN
bptjm-48	37	25	treatment	treatment	NOUN
bptjm-48	37	26	.	.	PUNCT
bptjm-48	38	1	first	first	ADV
bptjm-48	38	2	,	,	PUNCT
bptjm-48	38	3	mutations	mutation	NOUN
bptjm-48	38	4	in	in	ADP
bptjm-48	38	5	tumor	tumor	NOUN
bptjm-48	38	6	dna	dna	PROPN
bptjm-48	38	7	cause	cause	VERB
bptjm-48	38	8	rise	rise	NOUN
bptjm-48	38	9	of	of	ADP
bptjm-48	38	10	new	new	ADJ
bptjm-48	38	11	and	and	CCONJ
bptjm-48	38	12	mutated	mutate	VERB
bptjm-48	38	13	proteins	protein	NOUN
bptjm-48	38	14	in	in	ADP
bptjm-48	38	15	tumor	tumor	NOUN
bptjm-48	38	16	cells	cell	NOUN
bptjm-48	38	17	.	.	PUNCT
bptjm-48	39	1	after	after	ADP
bptjm-48	39	2	completion	completion	NOUN
bptjm-48	39	3	of	of	ADP
bptjm-48	39	4	function	function	NOUN
bptjm-48	39	5	,	,	PUNCT
bptjm-48	39	6	these	these	DET
bptjm-48	39	7	proteins	protein	NOUN
bptjm-48	39	8	are	be	AUX
bptjm-48	39	9	proteolyzed	proteolyze	VERB
bptjm-48	39	10	by	by	ADP
bptjm-48	39	11	the	the	DET
bptjm-48	39	12	proteasome	proteasome	NOUN
bptjm-48	39	13	and	and	CCONJ
bptjm-48	39	14	the	the	DET
bptjm-48	39	15	degraded	degraded	ADJ
bptjm-48	39	16	peptides	peptide	NOUN
bptjm-48	39	17	are	be	AUX
bptjm-48	39	18	sent	send	VERB
bptjm-48	39	19	to	to	ADP
bptjm-48	39	20	the	the	DET
bptjm-48	39	21	endoplasmic	endoplasmic	ADJ
bptjm-48	39	22	reticulum	reticulum	NOUN
bptjm-48	39	23	via	via	ADP
bptjm-48	39	24	a	a	DET
bptjm-48	39	25	transporter	transporter	NOUN
bptjm-48	39	26	associated	associate	VERB
bptjm-48	39	27	with	with	ADP
bptjm-48	39	28	antigen	antigen	NOUN
bptjm-48	39	29	processing	processing	NOUN
bptjm-48	39	30	(	(	PUNCT
bptjm-48	39	31	tap)protein.10	tap)protein.10	NOUN
bptjm-48	39	32	the	the	DET
bptjm-48	39	33	protein	protein	NOUN
bptjm-48	39	34	-	-	PUNCT
bptjm-48	39	35	peptide	peptide	NOUN
bptjm-48	39	36	complex	complex	NOUN
bptjm-48	39	37	is	be	AUX
bptjm-48	39	38	then	then	ADV
bptjm-48	39	39	sent	send	VERB
bptjm-48	39	40	to	to	ADP
bptjm-48	39	41	the	the	DET
bptjm-48	39	42	golgi	golgi	NOUN
bptjm-48	39	43	apparatus	apparatus	NOUN
bptjm-48	39	44	and	and	CCONJ
bptjm-48	39	45	then	then	ADV
bptjm-48	39	46	exported	export	VERB
bptjm-48	39	47	to	to	ADP
bptjm-48	39	48	the	the	DET
bptjm-48	39	49	plasma	plasma	NOUN
bptjm-48	39	50	membrane	membrane	NOUN
bptjm-48	39	51	with	with	ADP
bptjm-48	39	52	chaperone	chaperone	NOUN
bptjm-48	39	53	proteins	protein	NOUN
bptjm-48	39	54	.	.	PUNCT
bptjm-48	40	1	there	there	ADV
bptjm-48	40	2	,	,	PUNCT
bptjm-48	40	3	the	the	DET
bptjm-48	40	4	major	major	ADJ
bptjm-48	40	5	histocompatibility	histocompatibility	NOUN
bptjm-48	40	6	berkeley	berkeley	PROPN
bptjm-48	40	7	pharma	pharma	PROPN
bptjm-48	40	8	tech	tech	NOUN
bptjm-48	40	9	journal	journal	NOUN
bptjm-48	40	10	of	of	ADP
bptjm-48	40	11	medicine	medicine	NOUN
bptjm-48	40	12	|	|	ADV
bptjm-48	40	13	33	33	NUM
bptjm-48	40	14	complex	complex	ADJ
bptjm-48	40	15	(	(	PUNCT
bptjm-48	40	16	mhc	mhc	NOUN
bptjm-48	40	17	)	)	PUNCT
bptjm-48	40	18	displays	display	VERB
bptjm-48	40	19	protein	protein	NOUN
bptjm-48	40	20	fragments	fragment	NOUN
bptjm-48	40	21	(	(	PUNCT
bptjm-48	40	22	post	post	ADJ
bptjm-48	40	23	-	-	NOUN
bptjm-48	40	24	proteolysis	proteolysis	NOUN
bptjm-48	40	25	)	)	PUNCT
bptjm-48	40	26	to	to	ADP
bptjm-48	40	27	the	the	DET
bptjm-48	40	28	immune	immune	ADJ
bptjm-48	40	29	system	system	NOUN
bptjm-48	40	30	to	to	PART
bptjm-48	40	31	�	�	VERB
bptjm-48	40	32	ght	ght	PROPN
bptjm-48	40	33	infection	infection	NOUN
bptjm-48	40	34	by	by	ADP
bptjm-48	40	35	pathogens	pathogen	NOUN
bptjm-48	40	36	.	.	PUNCT
bptjm-48	41	1	neoantigens	neoantigen	NOUN
bptjm-48	41	2	are	be	AUX
bptjm-48	41	3	a	a	DET
bptjm-48	41	4	class	class	NOUN
bptjm-48	41	5	of	of	ADP
bptjm-48	41	6	proteins	protein	NOUN
bptjm-48	41	7	that	that	PRON
bptjm-48	41	8	arise	arise	VERB
bptjm-48	41	9	in	in	ADP
bptjm-48	41	10	cancer	cancer	NOUN
bptjm-48	41	11	cells	cell	NOUN
bptjm-48	41	12	with	with	ADP
bptjm-48	41	13	the	the	DET
bptjm-48	41	14	mutation	mutation	NOUN
bptjm-48	41	15	of	of	ADP
bptjm-48	41	16	tumor	tumor	NOUN
bptjm-48	41	17	dna	dna	PROPN
bptjm-48	41	18	.	.	PUNCT
bptjm-48	42	1	the	the	DET
bptjm-48	42	2	�	�	PROPN
bptjm-48	42	3	rst	rst	PROPN
bptjm-48	42	4	discovery	discovery	NOUN
bptjm-48	42	5	of	of	ADP
bptjm-48	42	6	neoantigens	neoantigen	NOUN
bptjm-48	42	7	was	be	AUX
bptjm-48	42	8	made	make	VERB
bptjm-48	42	9	in	in	ADP
bptjm-48	42	10	1988	1988	NUM
bptjm-48	42	11	by	by	ADP
bptjm-48	42	12	de	de	X
bptjm-48	42	13	plaen	plaen	PROPN
bptjm-48	42	14	and	and	CCONJ
bptjm-48	42	15	his	his	PRON
bptjm-48	42	16	colleagues.9	colleagues.9	NOUN
bptjm-48	42	17	by	by	ADP
bptjm-48	42	18	utilizing	utilize	VERB
bptjm-48	42	19	cdna	cdna	PROPN
bptjm-48	42	20	library	library	NOUN
bptjm-48	42	21	screening	screen	VERB
bptjm-48	42	22	on	on	ADP
bptjm-48	42	23	a	a	DET
bptjm-48	42	24	mouse	mouse	NOUN
bptjm-48	42	25	tumor	tumor	NOUN
bptjm-48	42	26	model	model	NOUN
bptjm-48	42	27	,	,	PUNCT
bptjm-48	42	28	they	they	PRON
bptjm-48	42	29	observed	observe	VERB
bptjm-48	42	30	a	a	DET
bptjm-48	42	31	single	single	ADJ
bptjm-48	42	32	nucleotide	nucleotide	NOUN
bptjm-48	42	33	di	di	NOUN
bptjm-48	42	34	�	�	PROPN
bptjm-48	42	35	erence	erence	NOUN
bptjm-48	42	36	between	between	ADP
bptjm-48	42	37	the	the	DET
bptjm-48	42	38	normal	normal	ADJ
bptjm-48	42	39	and	and	CCONJ
bptjm-48	42	40	tumor	tumor	NOUN
bptjm-48	42	41	gene	gene	NOUN
bptjm-48	42	42	,	,	PUNCT
bptjm-48	42	43	resulting	result	VERB
bptjm-48	42	44	in	in	ADP
bptjm-48	42	45	a	a	DET
bptjm-48	42	46	noticeable	noticeable	ADJ
bptjm-48	42	47	amino	amino	NOUN
bptjm-48	42	48	acid	acid	NOUN
bptjm-48	42	49	change	change	NOUN
bptjm-48	42	50	.	.	PUNCT
bptjm-48	43	1	this	this	DET
bptjm-48	43	2	novel	novel	PROPN
bptjm-48	43	3	�	�	NOUN
bptjm-48	43	4	nding	nding	NOUN
bptjm-48	43	5	led	lead	VERB
bptjm-48	43	6	to	to	ADP
bptjm-48	43	7	the	the	DET
bptjm-48	43	8	coining	coining	NOUN
bptjm-48	43	9	of	of	ADP
bptjm-48	43	10	the	the	DET
bptjm-48	43	11	term	term	NOUN
bptjm-48	43	12	“	"	PUNCT
bptjm-48	43	13	neoantigen	neoantigen	PROPN
bptjm-48	43	14	”	"	PUNCT
bptjm-48	43	15	which	which	PRON
bptjm-48	43	16	was	be	AUX
bptjm-48	43	17	used	use	VERB
bptjm-48	43	18	in	in	ADP
bptjm-48	43	19	further	further	ADJ
bptjm-48	43	20	studies	study	NOUN
bptjm-48	43	21	on	on	ADP
bptjm-48	43	22	human	human	ADJ
bptjm-48	43	23	tumors	tumor	NOUN
bptjm-48	43	24	including	include	VERB
bptjm-48	43	25	melanoma	melanoma	NOUN
bptjm-48	43	26	and	and	CCONJ
bptjm-48	43	27	renal	renal	ADJ
bptjm-48	43	28	cell	cell	NOUN
bptjm-48	43	29	carcinoma.9	carcinoma.9	PROPN
bptjm-48	43	30	neoantigens	neoantigen	NOUN
bptjm-48	43	31	have	have	AUX
bptjm-48	43	32	proven	prove	VERB
bptjm-48	43	33	e	e	NOUN
bptjm-48	43	34	�	�	NOUN
bptjm-48	43	35	cient	cient	VERB
bptjm-48	43	36	immunogenic	immunogenic	ADJ
bptjm-48	43	37	targets	target	NOUN
bptjm-48	43	38	because	because	SCONJ
bptjm-48	43	39	of	of	ADP
bptjm-48	43	40	their	their	PRON
bptjm-48	43	41	localization	localization	NOUN
bptjm-48	43	42	to	to	ADP
bptjm-48	43	43	cancer	cancer	NOUN
bptjm-48	43	44	patients	patient	NOUN
bptjm-48	43	45	.	.	PUNCT
bptjm-48	44	1	the	the	DET
bptjm-48	44	2	mechanism	mechanism	NOUN
bptjm-48	44	3	of	of	ADP
bptjm-48	44	4	action	action	NOUN
bptjm-48	44	5	by	by	ADP
bptjm-48	44	6	which	which	PRON
bptjm-48	44	7	they	they	PRON
bptjm-48	44	8	form	form	VERB
bptjm-48	44	9	explains	explain	VERB
bptjm-48	44	10	the	the	DET
bptjm-48	44	11	tumor	tumor	NOUN
bptjm-48	44	12	-	-	PUNCT
bptjm-48	44	13	speci	speci	NOUN
bptjm-48	44	14	�	�	PROPN
bptjm-48	44	15	city	city	NOUN
bptjm-48	44	16	of	of	ADP
bptjm-48	44	17	neoantigens	neoantigen	NOUN
bptjm-48	44	18	and	and	CCONJ
bptjm-48	44	19	their	their	PRON
bptjm-48	44	20	associated	associated	ADJ
bptjm-48	44	21	potency	potency	NOUN
bptjm-48	44	22	in	in	ADP
bptjm-48	44	23	developing	develop	VERB
bptjm-48	44	24	cancer	cancer	NOUN
bptjm-48	44	25	treatment	treatment	NOUN
bptjm-48	44	26	.	.	PUNCT
bptjm-48	45	1	first	first	ADV
bptjm-48	45	2	,	,	PUNCT
bptjm-48	45	3	mutations	mutation	NOUN
bptjm-48	45	4	in	in	ADP
bptjm-48	45	5	tumor	tumor	NOUN
bptjm-48	45	6	dna	dna	PROPN
bptjm-48	45	7	cause	cause	VERB
bptjm-48	45	8	rise	rise	NOUN
bptjm-48	45	9	of	of	ADP
bptjm-48	45	10	new	new	ADJ
bptjm-48	45	11	and	and	CCONJ
bptjm-48	45	12	mutated	mutate	VERB
bptjm-48	45	13	proteins	protein	NOUN
bptjm-48	45	14	in	in	ADP
bptjm-48	45	15	tumor	tumor	NOUN
bptjm-48	45	16	cells	cell	NOUN
bptjm-48	45	17	.	.	PUNCT
bptjm-48	46	1	after	after	ADP
bptjm-48	46	2	completion	completion	NOUN
bptjm-48	46	3	of	of	ADP
bptjm-48	46	4	function	function	NOUN
bptjm-48	46	5	,	,	PUNCT
bptjm-48	46	6	these	these	DET
bptjm-48	46	7	proteins	protein	NOUN
bptjm-48	46	8	are	be	AUX
bptjm-48	46	9	proteolyzed	proteolyze	VERB
bptjm-48	46	10	by	by	ADP
bptjm-48	46	11	the	the	DET
bptjm-48	46	12	proteasome	proteasome	NOUN
bptjm-48	46	13	and	and	CCONJ
bptjm-48	46	14	the	the	DET
bptjm-48	46	15	degraded	degraded	ADJ
bptjm-48	46	16	peptides	peptide	NOUN
bptjm-48	46	17	are	be	AUX
bptjm-48	46	18	sent	send	VERB
bptjm-48	46	19	to	to	ADP
bptjm-48	46	20	the	the	DET
bptjm-48	46	21	endoplasmic	endoplasmic	ADJ
bptjm-48	46	22	reticulum	reticulum	NOUN
bptjm-48	46	23	via	via	ADP
bptjm-48	46	24	a	a	DET
bptjm-48	46	25	transporter	transporter	NOUN
bptjm-48	46	26	associated	associate	VERB
bptjm-48	46	27	with	with	ADP
bptjm-48	46	28	antigen	antigen	NOUN
bptjm-48	46	29	processing	processing	NOUN
bptjm-48	46	30	(	(	PUNCT
bptjm-48	46	31	tap	tap	NOUN
bptjm-48	46	32	)	)	PUNCT
bptjm-48	46	33	protein.10	protein.10	NOUN
bptjm-48	46	34	the	the	DET
bptjm-48	46	35	protein	protein	NOUN
bptjm-48	46	36	-	-	PUNCT
bptjm-48	46	37	peptide	peptide	NOUN
bptjm-48	46	38	complex	complex	NOUN
bptjm-48	46	39	is	be	AUX
bptjm-48	46	40	then	then	ADV
bptjm-48	46	41	sent	send	VERB
bptjm-48	46	42	to	to	ADP
bptjm-48	46	43	the	the	DET
bptjm-48	46	44	golgi	golgi	NOUN
bptjm-48	46	45	apparatus	apparatus	NOUN
bptjm-48	46	46	and	and	CCONJ
bptjm-48	46	47	then	then	ADV
bptjm-48	46	48	exported	export	VERB
bptjm-48	46	49	to	to	ADP
bptjm-48	46	50	the	the	DET
bptjm-48	46	51	plasma	plasma	NOUN
bptjm-48	46	52	membrane	membrane	NOUN
bptjm-48	46	53	with	with	ADP
bptjm-48	46	54	chaperone	chaperone	NOUN
bptjm-48	46	55	proteins	protein	NOUN
bptjm-48	46	56	.	.	PUNCT
bptjm-48	47	1	there	there	ADV
bptjm-48	47	2	,	,	PUNCT
bptjm-48	47	3	the	the	DET
bptjm-48	47	4	major	major	ADJ
bptjm-48	47	5	histocompatibility	histocompatibility	NOUN
bptjm-48	47	6	complex	complex	NOUN
bptjm-48	47	7	(	(	PUNCT
bptjm-48	47	8	mhc	mhc	NOUN
bptjm-48	47	9	)	)	PUNCT
bptjm-48	47	10	displays	display	VERB
bptjm-48	47	11	protein	protein	NOUN
bptjm-48	47	12	fragments	fragment	NOUN
bptjm-48	47	13	(	(	PUNCT
bptjm-48	47	14	post	post	ADJ
bptjm-48	47	15	-	-	NOUN
bptjm-48	47	16	proteolysis	proteolysis	NOUN
bptjm-48	47	17	)	)	PUNCT
bptjm-48	47	18	to	to	ADP
bptjm-48	47	19	the	the	DET
bptjm-48	47	20	immune	immune	ADJ
bptjm-48	47	21	system	system	NOUN
bptjm-48	47	22	to	to	PART
bptjm-48	47	23	�	�	VERB
bptjm-48	47	24	ght	ght	PROPN
bptjm-48	47	25	infection	infection	NOUN
bptjm-48	47	26	by	by	ADP
bptjm-48	47	27	pathogens	pathogen	NOUN
bptjm-48	47	28	.	.	PUNCT
bptjm-48	48	1	figure	figure	NOUN
bptjm-48	48	2	2	2	NUM
bptjm-48	48	3	.	.	PUNCT
bptjm-48	48	4	mechanism	mechanism	NOUN
bptjm-48	48	5	of	of	ADP
bptjm-48	48	6	action	action	NOUN
bptjm-48	48	7	of	of	ADP
bptjm-48	48	8	neoantigens	neoantigens	PROPN
bptjm-48	48	9	berkeley	berkeley	PROPN
bptjm-48	48	10	pharma	pharma	PROPN
bptjm-48	48	11	tech	tech	NOUN
bptjm-48	48	12	journal	journal	NOUN
bptjm-48	48	13	of	of	ADP
bptjm-48	48	14	medicine	medicine	NOUN
bptjm-48	48	15	|	|	ADV
bptjm-48	48	16	34	34	NUM
bptjm-48	48	17	in	in	ADP
bptjm-48	48	18	humans	human	NOUN
bptjm-48	48	19	,	,	PUNCT
bptjm-48	48	20	the	the	DET
bptjm-48	48	21	mhc	mhc	PROPN
bptjm-48	48	22	is	be	AUX
bptjm-48	48	23	referred	refer	VERB
bptjm-48	48	24	to	to	ADP
bptjm-48	48	25	as	as	ADP
bptjm-48	48	26	human	human	ADJ
bptjm-48	48	27	leukocyte	leukocyte	NOUN
bptjm-48	48	28	antigens	antigen	NOUN
bptjm-48	48	29	(	(	PUNCT
bptjm-48	48	30	hla	hla	NOUN
bptjm-48	48	31	)	)	PUNCT
bptjm-48	48	32	,	,	PUNCT
bptjm-48	48	33	which	which	PRON
bptjm-48	48	34	are	be	AUX
bptjm-48	48	35	encoded	encode	VERB
bptjm-48	48	36	by	by	ADP
bptjm-48	48	37	genes	gene	NOUN
bptjm-48	48	38	on	on	ADP
bptjm-48	48	39	chromosome	chromosome	NOUN
bptjm-48	48	40	6.11	6.11	NUM
bptjm-48	48	41	hlas	hla	NOUN
bptjm-48	48	42	work	work	NOUN
bptjm-48	48	43	with	with	ADP
bptjm-48	48	44	t	t	PROPN
bptjm-48	48	45	cells	cell	NOUN
bptjm-48	48	46	to	to	PART
bptjm-48	48	47	identify	identify	VERB
bptjm-48	48	48	'	'	PUNCT
bptjm-48	48	49	self	self	NOUN
bptjm-48	48	50	'	'	PUNCT
bptjm-48	48	51	and	and	CCONJ
bptjm-48	48	52	'	'	PUNCT
bptjm-48	48	53	foreign	foreign	ADJ
bptjm-48	48	54	'	'	PUNCT
bptjm-48	48	55	cells	cell	NOUN
bptjm-48	48	56	and	and	CCONJ
bptjm-48	48	57	tissues	tissue	NOUN
bptjm-48	48	58	in	in	ADP
bptjm-48	48	59	the	the	DET
bptjm-48	48	60	body	body	NOUN
bptjm-48	48	61	by	by	ADP
bptjm-48	48	62	displaying	display	VERB
bptjm-48	48	63	short	short	ADJ
bptjm-48	48	64	polypeptides	polypeptide	NOUN
bptjm-48	48	65	to	to	ADP
bptjm-48	48	66	t	t	NOUN
bptjm-48	48	67	-	-	PUNCT
bptjm-48	48	68	cell	cell	NOUN
bptjm-48	48	69	receptors	receptor	NOUN
bptjm-48	48	70	.	.	PUNCT
bptjm-48	49	1	these	these	DET
bptjm-48	49	2	polypeptides	polypeptide	NOUN
bptjm-48	49	3	can	can	AUX
bptjm-48	49	4	be	be	AUX
bptjm-48	49	5	recognized	recognize	VERB
bptjm-48	49	6	as	as	ADP
bptjm-48	49	7	‘	'	PUNCT
bptjm-48	49	8	foreign	foreign	ADJ
bptjm-48	49	9	’	'	PUNCT
bptjm-48	49	10	by	by	ADP
bptjm-48	49	11	tumor	tumor	NOUN
bptjm-48	49	12	-	-	PUNCT
bptjm-48	49	13	in	in	ADP
bptjm-48	49	14	�	�	NOUN
bptjm-48	49	15	ltrating	ltrating	NOUN
bptjm-48	49	16	lymphocytes	lymphocyte	NOUN
bptjm-48	49	17	(	(	PUNCT
bptjm-48	49	18	tils	til	NOUN
bptjm-48	49	19	)	)	PUNCT
bptjm-48	49	20	which	which	PRON
bptjm-48	49	21	results	result	VERB
bptjm-48	49	22	in	in	ADP
bptjm-48	49	23	the	the	DET
bptjm-48	49	24	activation	activation	NOUN
bptjm-48	49	25	of	of	ADP
bptjm-48	49	26	strong	strong	ADJ
bptjm-48	49	27	tumor	tumor	NOUN
bptjm-48	49	28	-	-	PUNCT
bptjm-48	49	29	speci	speci	NOUN
bptjm-48	49	30	�	�	PROPN
bptjm-48	49	31	c	c	PROPN
bptjm-48	49	32	immune	immune	ADJ
bptjm-48	49	33	responses.12	responses.12	PROPN
bptjm-48	49	34	there	there	PRON
bptjm-48	49	35	are	be	VERB
bptjm-48	49	36	two	two	NUM
bptjm-48	49	37	main	main	ADJ
bptjm-48	49	38	groups	group	NOUN
bptjm-48	49	39	of	of	ADP
bptjm-48	49	40	mhc	mhc	PROPN
bptjm-48	49	41	molecules	molecule	NOUN
bptjm-48	49	42	,	,	PUNCT
bptjm-48	49	43	which	which	PRON
bptjm-48	49	44	bind	bind	VERB
bptjm-48	49	45	to	to	ADP
bptjm-48	49	46	di	di	NOUN
bptjm-48	49	47	�	�	PROPN
bptjm-48	49	48	erent	erent	NOUN
bptjm-48	49	49	peptide	peptide	NOUN
bptjm-48	49	50	sequences	sequence	NOUN
bptjm-48	49	51	and	and	CCONJ
bptjm-48	49	52	are	be	AUX
bptjm-48	49	53	recognized	recognize	VERB
bptjm-48	49	54	by	by	ADP
bptjm-48	49	55	separate	separate	ADJ
bptjm-48	49	56	t	t	PROPN
bptjm-48	49	57	-	-	PUNCT
bptjm-48	49	58	cell	cell	NOUN
bptjm-48	49	59	types	type	NOUN
bptjm-48	49	60	.	.	PUNCT
bptjm-48	50	1	mhc	mhc	NOUN
bptjm-48	50	2	-	-	PUNCT
bptjm-48	50	3	class	class	NOUN
bptjm-48	50	4	i	i	PRON
bptjm-48	50	5	genes	gene	VERB
bptjm-48	50	6	consist	consist	VERB
bptjm-48	50	7	of	of	ADP
bptjm-48	50	8	hla	hla	NOUN
bptjm-48	50	9	-	-	PUNCT
bptjm-48	50	10	a	a	NOUN
bptjm-48	50	11	,	,	PUNCT
bptjm-48	50	12	hla	hla	PROPN
bptjm-48	50	13	-	-	PUNCT
bptjm-48	50	14	b	b	NOUN
bptjm-48	50	15	and	and	CCONJ
bptjm-48	50	16	hla	hla	PROPN
bptjm-48	50	17	-	-	PUNCT
bptjm-48	50	18	c	c	NOUN
bptjm-48	50	19	,	,	PUNCT
bptjm-48	50	20	and	and	CCONJ
bptjm-48	50	21	their	their	PRON
bptjm-48	50	22	attached	attached	ADJ
bptjm-48	50	23	peptides	peptide	NOUN
bptjm-48	50	24	are	be	AUX
bptjm-48	50	25	recognized	recognize	VERB
bptjm-48	50	26	by	by	ADP
bptjm-48	50	27	cd8	cd8	PROPN
bptjm-48	50	28	+	+	PROPN
bptjm-48	50	29	t	t	PROPN
bptjm-48	50	30	-	-	PUNCT
bptjm-48	50	31	cells.11	cells.11	NOUN
bptjm-48	50	32	mhc	mhc	PROPN
bptjm-48	50	33	-	-	PUNCT
bptjm-48	50	34	class	class	NOUN
bptjm-48	50	35	ii	ii	NOUN
bptjm-48	50	36	genes	gene	NOUN
bptjm-48	50	37	,	,	PUNCT
bptjm-48	50	38	on	on	ADP
bptjm-48	50	39	the	the	DET
bptjm-48	50	40	other	other	ADJ
bptjm-48	50	41	hand	hand	NOUN
bptjm-48	50	42	,	,	PUNCT
bptjm-48	50	43	consist	consist	VERB
bptjm-48	50	44	of	of	ADP
bptjm-48	50	45	hla	hla	PROPN
bptjm-48	50	46	-	-	PUNCT
bptjm-48	50	47	dr	dr	PROPN
bptjm-48	50	48	,	,	PUNCT
bptjm-48	50	49	hla	hla	PROPN
bptjm-48	50	50	-	-	PUNCT
bptjm-48	50	51	dq	dq	NOUN
bptjm-48	50	52	and	and	CCONJ
bptjm-48	50	53	hla	hla	NOUN
bptjm-48	50	54	-	-	PUNCT
bptjm-48	50	55	dp	dp	NOUN
bptjm-48	50	56	,	,	PUNCT
bptjm-48	50	57	and	and	CCONJ
bptjm-48	50	58	attached	attach	VERB
bptjm-48	50	59	peptides	peptide	NOUN
bptjm-48	50	60	are	be	AUX
bptjm-48	50	61	recognized	recognize	VERB
bptjm-48	50	62	by	by	ADP
bptjm-48	50	63	cd4	cd4	PROPN
bptjm-48	50	64	+	+	PROPN
bptjm-48	50	65	t	t	PROPN
bptjm-48	50	66	-	-	PUNCT
bptjm-48	50	67	cells.11	cells.11	NOUN
bptjm-48	50	68	figure	figure	NOUN
bptjm-48	51	1	3	3	NUM
bptjm-48	51	2	.	.	PUNCT
bptjm-48	51	3	role	role	NOUN
bptjm-48	51	4	of	of	ADP
bptjm-48	51	5	the	the	DET
bptjm-48	51	6	major	major	ADJ
bptjm-48	51	7	histocompatibility	histocompatibility	NOUN
bptjm-48	51	8	complex	complex	NOUN
bptjm-48	51	9	(	(	PUNCT
bptjm-48	51	10	mhc	mhc	NOUN
bptjm-48	51	11	)	)	PUNCT
bptjm-48	51	12	neoantigens	neoantigen	NOUN
bptjm-48	51	13	are	be	AUX
bptjm-48	51	14	commonly	commonly	ADV
bptjm-48	51	15	confused	confuse	VERB
bptjm-48	51	16	with	with	ADP
bptjm-48	51	17	other	other	ADJ
bptjm-48	51	18	tumor	tumor	NOUN
bptjm-48	51	19	antigens	antigen	NOUN
bptjm-48	51	20	that	that	PRON
bptjm-48	51	21	exist	exist	VERB
bptjm-48	51	22	,	,	PUNCT
bptjm-48	51	23	of	of	ADP
bptjm-48	51	24	which	which	PRON
bptjm-48	51	25	there	there	PRON
bptjm-48	51	26	are	be	VERB
bptjm-48	51	27	three	three	NUM
bptjm-48	51	28	di	di	NOUN
bptjm-48	51	29	�	�	PROPN
bptjm-48	51	30	erent	erent	NOUN
bptjm-48	51	31	classi	classi	PROPN
bptjm-48	51	32	�	�	PROPN
bptjm-48	51	33	cations	cation	NOUN
bptjm-48	51	34	that	that	SCONJ
bptjm-48	51	35	t	t	PROPN
bptjm-48	51	36	-	-	PUNCT
bptjm-48	51	37	cells	cell	NOUN
bptjm-48	51	38	can	can	AUX
bptjm-48	51	39	target.11tumorassociated	target.11tumorassociate	VERB
bptjm-48	51	40	(	(	PUNCT
bptjm-48	51	41	taa	taa	X
bptjm-48	51	42	)	)	PUNCT
bptjm-48	51	43	antigens	antigen	NOUN
bptjm-48	51	44	are	be	AUX
bptjm-48	51	45	a	a	DET
bptjm-48	51	46	group	group	NOUN
bptjm-48	51	47	of	of	ADP
bptjm-48	51	48	proteins	protein	NOUN
bptjm-48	51	49	characterizedby	characterizedby	NOUN
bptjm-48	51	50	overexpression	overexpression	NOUN
bptjm-48	51	51	in	in	ADP
bptjm-48	51	52	cancer	cancer	NOUN
bptjm-48	51	53	cells	cell	NOUN
bptjm-48	51	54	compared	compare	VERB
bptjm-48	51	55	to	to	ADP
bptjm-48	51	56	normal	normal	ADJ
bptjm-48	51	57	tissue	tissue	NOUN
bptjm-48	51	58	.	.	PUNCT
bptjm-48	52	1	they	they	PRON
bptjm-48	52	2	consist	consist	VERB
bptjm-48	52	3	of	of	ADP
bptjm-48	52	4	differentiation	differentiation	NOUN
bptjm-48	52	5	antigens	antigen	NOUN
bptjm-48	52	6	,	,	PUNCT
bptjm-48	52	7	which	which	PRON
bptjm-48	52	8	are	be	AUX
bptjm-48	52	9	normal	normal	ADJ
bptjm-48	52	10	proteins	protein	NOUN
bptjm-48	52	11	that	that	PRON
bptjm-48	52	12	are	be	AUX
bptjm-48	52	13	increasingly	increasingly	ADV
bptjm-48	52	14	expressed	express	VERB
bptjm-48	52	15	due	due	ADJ
bptjm-48	52	16	to	to	ADP
bptjm-48	52	17	uncontrolled	uncontrolled	ADJ
bptjm-48	52	18	division	division	NOUN
bptjm-48	52	19	of	of	ADP
bptjm-48	52	20	cells	cell	NOUN
bptjm-48	52	21	that	that	PRON
bptjm-48	52	22	have	have	VERB
bptjm-48	52	23	speci	speci	ADJ
bptjm-48	52	24	�	�	PROPN
bptjm-48	52	25	c	c	PROPN
bptjm-48	52	26	functions	function	NOUN
bptjm-48	52	27	[	[	X
bptjm-48	52	28	eg	eg	NOUN
bptjm-48	52	29	.	.	PUNCT
bptjm-48	53	1	prostate	prostate	NOUN
bptjm-48	53	2	-	-	PUNCT
bptjm-48	53	3	speci	speci	NOUN
bptjm-48	53	4	�	�	PROPN
bptjm-48	53	5	c	c	PROPN
bptjm-48	53	6	antigen	antigen	NOUN
bptjm-48	53	7	(	(	PUNCT
bptjm-48	53	8	psa	psa	NOUN
bptjm-48	53	9	)	)	PUNCT
bptjm-48	53	10	in	in	ADP
bptjm-48	53	11	prostate	prostate	NOUN
bptjm-48	54	1	cancer.13	cancer.13	PRON
bptjm-48	54	2	the	the	DET
bptjm-48	54	3	other	other	ADJ
bptjm-48	54	4	class	class	NOUN
bptjm-48	54	5	is	be	AUX
bptjm-48	54	6	overexpressed	overexpressed	ADJ
bptjm-48	54	7	antigens	antigen	NOUN
bptjm-48	54	8	,	,	PUNCT
bptjm-48	54	9	which	which	PRON
bptjm-48	54	10	are	be	AUX
bptjm-48	54	11	proteins	protein	NOUN
bptjm-48	54	12	that	that	PRON
bptjm-48	54	13	are	be	AUX
bptjm-48	54	14	greatly	greatly	ADV
bptjm-48	54	15	expressed	express	VERB
bptjm-48	54	16	due	due	ADJ
bptjm-48	54	17	to	to	ADP
bptjm-48	54	18	mutated	mutate	VERB
bptjm-48	54	19	genes	gene	NOUN
bptjm-48	54	20	characteristic	characteristic	ADJ
bptjm-48	54	21	of	of	ADP
bptjm-48	54	22	cancer	cancer	NOUN
bptjm-48	54	23	[	[	X
bptjm-48	54	24	eg	eg	NOUN
bptjm-48	54	25	.	.	PUNCT
bptjm-48	55	1	hepsin	hepsin	PROPN
bptjm-48	55	2	in	in	ADP
bptjm-48	55	3	prostate	prostate	NOUN
bptjm-48	55	4	cancer].14	cancer].14	PROPN
bptjm-48	55	5	a	a	DET
bptjm-48	55	6	complete	complete	ADJ
bptjm-48	55	7	library	library	NOUN
bptjm-48	55	8	of	of	ADP
bptjm-48	55	9	tumor	tumor	NOUN
bptjm-48	55	10	-	-	PUNCT
bptjm-48	55	11	associated	associate	VERB
bptjm-48	55	12	antigens	antigen	NOUN
bptjm-48	55	13	can	can	AUX
bptjm-48	55	14	be	be	AUX
bptjm-48	55	15	found	find	VERB
bptjm-48	55	16	in	in	ADP
bptjm-48	55	17	the	the	DET
bptjm-48	55	18	cancer	cancer	NOUN
bptjm-48	55	19	antigenic	antigenic	ADJ
bptjm-48	55	20	peptide	peptide	NOUN
bptjm-48	55	21	database	database	NOUN
bptjm-48	55	22	:	:	PUNCT
bptjm-48	56	1	https://caped.icp.ucl.ac.be/peptide/list	https://caped.icp.ucl.ac.be/peptide/list	NOUN
bptjm-48	56	2	.	.	PUNCT
bptjm-48	57	1	cancer	cancer	NOUN
bptjm-48	57	2	testis	testis	NOUN
bptjm-48	57	3	(	(	PUNCT
bptjm-48	57	4	ct	ct	NOUN
bptjm-48	57	5	)	)	PUNCT
bptjm-48	57	6	antigens	antigen	NOUN
bptjm-48	57	7	are	be	AUX
bptjm-48	57	8	a	a	DET
bptjm-48	57	9	family	family	NOUN
bptjm-48	57	10	of	of	ADP
bptjm-48	57	11	taa	taa	PROPN
bptjm-48	57	12	that	that	PRON
bptjm-48	57	13	are	be	AUX
bptjm-48	57	14	strictly	strictly	ADV
bptjm-48	57	15	found	find	VERB
bptjm-48	57	16	on	on	ADP
bptjm-48	57	17	the	the	DET
bptjm-48	57	18	testis	testis	NOUN
bptjm-48	57	19	and	and	CCONJ
bptjm-48	57	20	placenta	placenta	PROPN
bptjm-48	57	21	.	.	PUNCT
bptjm-48	58	1	due	due	ADP
bptjm-48	58	2	to	to	ADP
bptjm-48	58	3	their	their	PRON
bptjm-48	58	4	expression	expression	NOUN
bptjm-48	58	5	speci	speci	NOUN
bptjm-48	58	6	�	�	PROPN
bptjm-48	58	7	city	city	NOUN
bptjm-48	58	8	in	in	ADP
bptjm-48	58	9	the	the	DET
bptjm-48	58	10	germ	germ	NOUN
bptjm-48	58	11	cells	cell	NOUN
bptjm-48	58	12	,	,	PUNCT
bptjm-48	58	13	ct	ct	NUM
bptjm-48	58	14	antigens	antigen	NOUN
bptjm-48	58	15	found	find	VERB
bptjm-48	58	16	in	in	ADP
bptjm-48	58	17	other	other	ADJ
bptjm-48	58	18	regions	region	NOUN
bptjm-48	58	19	of	of	ADP
bptjm-48	58	20	the	the	DET
bptjm-48	58	21	body	body	NOUN
bptjm-48	58	22	indicate	indicate	VERB
bptjm-48	58	23	oncogenic	oncogenic	ADJ
bptjm-48	58	24	causes	cause	NOUN
bptjm-48	58	25	.	.	PUNCT
bptjm-48	59	1	berkeley	berkeley	PROPN
bptjm-48	59	2	pharma	pharma	PROPN
bptjm-48	59	3	tech	tech	PROPN
bptjm-48	59	4	journal	journal	NOUN
bptjm-48	59	5	of	of	ADP
bptjm-48	59	6	medicine	medicine	NOUN
bptjm-48	59	7	|	|	ADV
bptjm-48	59	8	35	35	NUM
bptjm-48	59	9	https://caped.icp.ucl.ac.be/peptide/list	https://caped.icp.ucl.ac.be/peptide/list	NOUN
bptjm-48	59	10	hence	hence	ADV
bptjm-48	59	11	,	,	PUNCT
bptjm-48	59	12	ct	ct	NUM
bptjm-48	59	13	antigens	antigen	NOUN
bptjm-48	59	14	are	be	AUX
bptjm-48	59	15	considered	consider	VERB
bptjm-48	59	16	promising	promise	VERB
bptjm-48	59	17	therapeutic	therapeutic	ADJ
bptjm-48	59	18	targets	target	NOUN
bptjm-48	59	19	.	.	PUNCT
bptjm-48	60	1	there	there	PRON
bptjm-48	60	2	is	be	VERB
bptjm-48	60	3	also	also	ADV
bptjm-48	60	4	the	the	DET
bptjm-48	60	5	fact	fact	NOUN
bptjm-48	60	6	that	that	SCONJ
bptjm-48	60	7	the	the	DET
bptjm-48	60	8	testis	testis	NOUN
bptjm-48	60	9	do	do	AUX
bptjm-48	60	10	not	not	PART
bptjm-48	60	11	express	express	VERB
bptjm-48	60	12	mhc	mhc	NOUN
bptjm-48	60	13	-	-	PUNCT
bptjm-48	60	14	class	class	NOUN
bptjm-48	60	15	i	i	PRON
bptjm-48	60	16	,	,	PUNCT
bptjm-48	60	17	therefore	therefore	ADV
bptjm-48	60	18	ct	ct	NUM
bptjm-48	60	19	antigens	antigen	NOUN
bptjm-48	60	20	are	be	AUX
bptjm-48	60	21	recognized	recognize	VERB
bptjm-48	60	22	as	as	ADP
bptjm-48	60	23	‘	'	PUNCT
bptjm-48	60	24	non	non	ADJ
bptjm-48	60	25	-	-	NOUN
bptjm-48	60	26	self	self	NOUN
bptjm-48	60	27	.	.	PUNCT
bptjm-48	60	28	’	'	PUNCT
bptjm-48	61	1	a	a	DET
bptjm-48	61	2	comprehensive	comprehensive	ADJ
bptjm-48	61	3	list	list	NOUN
bptjm-48	61	4	of	of	ADP
bptjm-48	61	5	ct	ct	PROPN
bptjm-48	61	6	antigens	antigen	NOUN
bptjm-48	61	7	can	can	AUX
bptjm-48	61	8	be	be	AUX
bptjm-48	61	9	found	find	VERB
bptjm-48	61	10	in	in	ADP
bptjm-48	61	11	the	the	DET
bptjm-48	61	12	ctdatabase	ctdatabase	NOUN
bptjm-48	61	13	:	:	PUNCT
bptjm-48	61	14	http://www.cta.lncc.br/.	http://www.cta.lncc.br/.	NOUN
bptjm-48	61	15	finally	finally	ADV
bptjm-48	61	16	,	,	PUNCT
bptjm-48	61	17	viral	viral	ADJ
bptjm-48	61	18	antigens	antigen	NOUN
bptjm-48	61	19	are	be	AUX
bptjm-48	61	20	a	a	DET
bptjm-48	61	21	family	family	NOUN
bptjm-48	61	22	of	of	ADP
bptjm-48	61	23	taa	taa	PROPN
bptjm-48	61	24	that	that	PRON
bptjm-48	61	25	are	be	AUX
bptjm-48	61	26	caused	cause	VERB
bptjm-48	61	27	by	by	ADP
bptjm-48	61	28	a	a	DET
bptjm-48	61	29	viral	viral	ADJ
bptjm-48	61	30	infection	infection	NOUN
bptjm-48	61	31	.	.	PUNCT
bptjm-48	62	1	examples	example	NOUN
bptjm-48	62	2	include	include	VERB
bptjm-48	62	3	the	the	DET
bptjm-48	62	4	human	human	ADJ
bptjm-48	62	5	papillomavirus	papillomavirus	NOUN
bptjm-48	62	6	(	(	PUNCT
bptjm-48	62	7	hpv)which	hpv)which	PROPN
bptjm-48	62	8	can	can	AUX
bptjm-48	62	9	cause	cause	VERB
bptjm-48	62	10	cervical	cervical	ADJ
bptjm-48	62	11	and	and	CCONJ
bptjm-48	62	12	several	several	ADJ
bptjm-48	62	13	other	other	ADJ
bptjm-48	62	14	cancers	cancer	NOUN
bptjm-48	62	15	,	,	PUNCT
bptjm-48	62	16	as	as	ADV
bptjm-48	62	17	well	well	ADV
bptjm-48	62	18	as	as	ADP
bptjm-48	62	19	hepatitis	hepatitis	PROPN
bptjm-48	62	20	c	c	PROPN
bptjm-48	62	21	which	which	PRON
bptjm-48	62	22	may	may	AUX
bptjm-48	62	23	lead	lead	VERB
bptjm-48	62	24	to	to	ADP
bptjm-48	62	25	liver	liver	NOUN
bptjm-48	62	26	cancer	cancer	NOUN
bptjm-48	62	27	and	and	CCONJ
bptjm-48	62	28	non	non	ADJ
bptjm-48	62	29	-	-	ADJ
bptjm-48	62	30	hodgkin	hodgkin	NOUN
bptjm-48	62	31	's	's	PART
bptjm-48	62	32	lymphoma	lymphoma	NOUN
bptjm-48	62	33	.	.	PUNCT
bptjm-48	63	1	neoantigens	neoantigen	NOUN
bptjm-48	63	2	are	be	AUX
bptjm-48	63	3	unique	unique	ADJ
bptjm-48	63	4	to	to	ADP
bptjm-48	63	5	the	the	DET
bptjm-48	63	6	aforementioned	aforementioned	ADJ
bptjm-48	63	7	antigen	antigen	ADJ
bptjm-48	63	8	types	type	NOUN
bptjm-48	63	9	because	because	SCONJ
bptjm-48	63	10	they	they	PRON
bptjm-48	63	11	arise	arise	VERB
bptjm-48	63	12	from	from	ADP
bptjm-48	63	13	the	the	DET
bptjm-48	63	14	onset	onset	NOUN
bptjm-48	63	15	of	of	ADP
bptjm-48	63	16	cancer	cancer	NOUN
bptjm-48	63	17	,	,	PUNCT
bptjm-48	63	18	thus	thus	ADV
bptjm-48	63	19	it	it	PRON
bptjm-48	63	20	is	be	AUX
bptjm-48	63	21	the	the	DET
bptjm-48	63	22	genomic	genomic	ADJ
bptjm-48	63	23	mutations	mutation	NOUN
bptjm-48	63	24	from	from	ADP
bptjm-48	63	25	the	the	DET
bptjm-48	63	26	cancer	cancer	NOUN
bptjm-48	63	27	that	that	PRON
bptjm-48	63	28	lead	lead	VERB
bptjm-48	63	29	to	to	ADP
bptjm-48	63	30	the	the	DET
bptjm-48	63	31	rise	rise	NOUN
bptjm-48	63	32	of	of	ADP
bptjm-48	63	33	new	new	ADJ
bptjm-48	63	34	(	(	PUNCT
bptjm-48	63	35	neo-)antigens	neo-)antigen	NOUN
bptjm-48	63	36	in	in	ADP
bptjm-48	63	37	the	the	DET
bptjm-48	63	38	body.14	body.14	NOUN
bptjm-48	63	39	in	in	ADP
bptjm-48	63	40	exploring	explore	VERB
bptjm-48	63	41	neoantigen	neoantigen	NOUN
bptjm-48	63	42	-	-	PUNCT
bptjm-48	63	43	based	base	VERB
bptjm-48	63	44	treatment	treatment	NOUN
bptjm-48	63	45	,	,	PUNCT
bptjm-48	63	46	there	there	PRON
bptjm-48	63	47	is	be	VERB
bptjm-48	63	48	the	the	DET
bptjm-48	63	49	distinction	distinction	NOUN
bptjm-48	63	50	to	to	PART
bptjm-48	63	51	be	be	AUX
bptjm-48	63	52	made	make	VERB
bptjm-48	63	53	between	between	ADP
bptjm-48	63	54	public	public	ADJ
bptjm-48	63	55	and	and	CCONJ
bptjm-48	63	56	private	private	ADJ
bptjm-48	63	57	neoantigens	neoantigen	NOUN
bptjm-48	63	58	.	.	PUNCT
bptjm-48	64	1	public	public	NOUN
bptjm-48	64	2	(	(	PUNCT
bptjm-48	64	3	shared)neoantigens	shared)neoantigen	NOUN
bptjm-48	64	4	are	be	AUX
bptjm-48	64	5	common	common	ADJ
bptjm-48	64	6	across	across	ADP
bptjm-48	64	7	cancer	cancer	NOUN
bptjm-48	64	8	patients	patient	NOUN
bptjm-48	64	9	and	and	CCONJ
bptjm-48	64	10	typically	typically	ADV
bptjm-48	64	11	occur	occur	VERB
bptjm-48	64	12	in	in	ADP
bptjm-48	64	13	driver	driver	NOUN
bptjm-48	64	14	oncogenes	oncogene	NOUN
bptjm-48	64	15	and	and	CCONJ
bptjm-48	64	16	tumor	tumor	NOUN
bptjm-48	64	17	suppressor	suppressor	NOUN
bptjm-48	64	18	genes	gene	NOUN
bptjm-48	64	19	.	.	PUNCT
bptjm-48	65	1	private	private	ADJ
bptjm-48	65	2	(	(	PUNCT
bptjm-48	65	3	personalized)neoantigens	personalized)neoantigen	NOUN
bptjm-48	65	4	are	be	AUX
bptjm-48	65	5	unique	unique	ADJ
bptjm-48	65	6	to	to	ADP
bptjm-48	65	7	each	each	DET
bptjm-48	65	8	patient	patient	NOUN
bptjm-48	65	9	and	and	CCONJ
bptjm-48	65	10	therefore	therefore	ADV
bptjm-48	65	11	require	require	VERB
bptjm-48	65	12	individualized	individualized	ADJ
bptjm-48	65	13	treatment	treatment	NOUN
bptjm-48	65	14	.	.	PUNCT
bptjm-48	66	1	4	4	X
bptjm-48	66	2	.	.	NOUN
bptjm-48	66	3	potential	potential	ADJ
bptjm-48	66	4	treatment	treatment	NOUN
bptjm-48	66	5	methods	method	NOUN
bptjm-48	66	6	4.1	4.1	NUM
bptjm-48	66	7	neoantigen	neoantigen	ADV
bptjm-48	66	8	-	-	PUNCT
bptjm-48	66	9	based	base	VERB
bptjm-48	66	10	vaccines	vaccine	NOUN
bptjm-48	66	11	the	the	DET
bptjm-48	66	12	process	process	NOUN
bptjm-48	66	13	of	of	ADP
bptjm-48	66	14	creating	create	VERB
bptjm-48	66	15	a	a	DET
bptjm-48	66	16	neoantigen	neoantigen	NOUN
bptjm-48	66	17	vaccine	vaccine	NOUN
bptjm-48	66	18	typically	typically	ADV
bptjm-48	66	19	involves	involve	VERB
bptjm-48	66	20	sequencing	sequence	VERB
bptjm-48	66	21	the	the	DET
bptjm-48	66	22	patient	patient	NOUN
bptjm-48	66	23	's	's	PART
bptjm-48	66	24	tumor	tumor	NOUN
bptjm-48	66	25	cells	cell	NOUN
bptjm-48	66	26	to	to	PART
bptjm-48	66	27	identify	identify	VERB
bptjm-48	66	28	the	the	DET
bptjm-48	66	29	unique	unique	ADJ
bptjm-48	66	30	neoantigens	neoantigen	NOUN
bptjm-48	66	31	present	present	ADJ
bptjm-48	66	32	.	.	PUNCT
bptjm-48	67	1	once	once	SCONJ
bptjm-48	67	2	these	these	DET
bptjm-48	67	3	neoantigens	neoantigen	NOUN
bptjm-48	67	4	are	be	AUX
bptjm-48	67	5	identi	identi	ADJ
bptjm-48	67	6	�	�	NOUN
bptjm-48	67	7	ed	ed	NOUN
bptjm-48	67	8	,	,	PUNCT
bptjm-48	67	9	they	they	PRON
bptjm-48	67	10	can	can	AUX
bptjm-48	67	11	be	be	AUX
bptjm-48	67	12	used	use	VERB
bptjm-48	67	13	to	to	PART
bptjm-48	67	14	create	create	VERB
bptjm-48	67	15	a	a	DET
bptjm-48	67	16	personalized	personalized	ADJ
bptjm-48	67	17	vaccine	vaccine	NOUN
bptjm-48	67	18	that	that	PRON
bptjm-48	67	19	is	be	AUX
bptjm-48	67	20	tailored	tailor	VERB
bptjm-48	67	21	to	to	ADP
bptjm-48	67	22	the	the	DET
bptjm-48	67	23	patient	patient	NOUN
bptjm-48	67	24	's	's	PART
bptjm-48	67	25	speci	speci	ADJ
bptjm-48	67	26	�	�	PROPN
bptjm-48	67	27	c	c	NOUN
bptjm-48	67	28	cancer	cancer	NOUN
bptjm-48	67	29	.	.	PUNCT
bptjm-48	68	1	the	the	DET
bptjm-48	68	2	goal	goal	NOUN
bptjm-48	68	3	of	of	ADP
bptjm-48	68	4	the	the	DET
bptjm-48	68	5	vaccine	vaccine	NOUN
bptjm-48	68	6	is	be	AUX
bptjm-48	68	7	to	to	PART
bptjm-48	68	8	prime	prime	VERB
bptjm-48	68	9	the	the	DET
bptjm-48	68	10	immune	immune	ADJ
bptjm-48	68	11	system	system	NOUN
bptjm-48	68	12	to	to	PART
bptjm-48	68	13	recognize	recognize	VERB
bptjm-48	68	14	and	and	CCONJ
bptjm-48	68	15	attack	attack	VERB
bptjm-48	68	16	the	the	DET
bptjm-48	68	17	cancer	cancer	NOUN
bptjm-48	68	18	cells	cell	NOUN
bptjm-48	68	19	that	that	PRON
bptjm-48	68	20	display	display	VERB
bptjm-48	68	21	these	these	DET
bptjm-48	68	22	neoantigens	neoantigen	NOUN
bptjm-48	68	23	.	.	PUNCT
bptjm-48	69	1	this	this	DET
bptjm-48	69	2	approach	approach	NOUN
bptjm-48	69	3	has	have	VERB
bptjm-48	69	4	the	the	DET
bptjm-48	69	5	potential	potential	NOUN
bptjm-48	69	6	to	to	PART
bptjm-48	69	7	be	be	AUX
bptjm-48	69	8	more	more	ADJ
bptjm-48	69	9	e	e	NOUN
bptjm-48	69	10	�	�	NOUN
bptjm-48	69	11	ective	ective	ADJ
bptjm-48	69	12	than	than	ADP
bptjm-48	69	13	traditional	traditional	ADJ
bptjm-48	69	14	cancer	cancer	NOUN
bptjm-48	69	15	treatments	treatment	NOUN
bptjm-48	69	16	because	because	SCONJ
bptjm-48	69	17	it	it	PRON
bptjm-48	69	18	targets	target	VERB
bptjm-48	69	19	the	the	DET
bptjm-48	69	20	cancer	cancer	NOUN
bptjm-48	69	21	cells	cell	NOUN
bptjm-48	69	22	directly	directly	ADV
bptjm-48	69	23	while	while	SCONJ
bptjm-48	69	24	sparing	spare	VERB
bptjm-48	69	25	normal	normal	ADJ
bptjm-48	69	26	cells	cell	NOUN
bptjm-48	69	27	.	.	PUNCT
bptjm-48	70	1	berkeley	berkeley	PROPN
bptjm-48	70	2	pharma	pharma	PROPN
bptjm-48	70	3	tech	tech	PROPN
bptjm-48	70	4	journal	journal	NOUN
bptjm-48	70	5	of	of	ADP
bptjm-48	70	6	medicine	medicine	NOUN
bptjm-48	70	7	|	|	ADV
bptjm-48	70	8	36	36	NUM
bptjm-48	70	9	http://www.cta.lncc.br/	http://www.cta.lncc.br/	PROPN
bptjm-48	70	10	figure	figure	NOUN
bptjm-48	70	11	4	4	NUM
bptjm-48	70	12	.	.	PUNCT
bptjm-48	71	1	mechanism	mechanism	NOUN
bptjm-48	71	2	of	of	ADP
bptjm-48	71	3	action	action	NOUN
bptjm-48	71	4	for	for	ADP
bptjm-48	71	5	protein	protein	NOUN
bptjm-48	71	6	-	-	PUNCT
bptjm-48	71	7	peptide	peptide	NOUN
bptjm-48	71	8	vaccine	vaccine	NOUN
bptjm-48	71	9	4.2	4.2	NUM
bptjm-48	71	10	protein	protein	NOUN
bptjm-48	71	11	-	-	PUNCT
bptjm-48	71	12	peptide	peptide	NOUN
bptjm-48	71	13	vaccines	vaccine	NOUN
bptjm-48	71	14	protein	protein	NOUN
bptjm-48	71	15	peptide	peptide	NOUN
bptjm-48	71	16	vaccines	vaccine	NOUN
bptjm-48	71	17	contain	contain	VERB
bptjm-48	71	18	speci	speci	ADJ
bptjm-48	71	19	�	�	PROPN
bptjm-48	71	20	c	c	NOUN
bptjm-48	71	21	antigens	antigen	NOUN
bptjm-48	71	22	which	which	PRON
bptjm-48	71	23	are	be	AUX
bptjm-48	71	24	immunogenic	immunogenic	ADJ
bptjm-48	71	25	and	and	CCONJ
bptjm-48	71	26	unique	unique	ADJ
bptjm-48	71	27	to	to	ADP
bptjm-48	71	28	the	the	DET
bptjm-48	71	29	patient	patient	NOUN
bptjm-48	71	30	's	's	PART
bptjm-48	71	31	tumor	tumor	NOUN
bptjm-48	71	32	,	,	PUNCT
bptjm-48	71	33	with	with	ADP
bptjm-48	71	34	potential	potential	ADJ
bptjm-48	71	35	immunomodulating	immunomodulating	ADJ
bptjm-48	71	36	and	and	CCONJ
bptjm-48	71	37	antineoplastic	antineoplastic	ADJ
bptjm-48	71	38	activities.15	activities.15	NOUN
bptjm-48	71	39	upon	upon	SCONJ
bptjm-48	71	40	vaccination	vaccination	NOUN
bptjm-48	71	41	,	,	PUNCT
bptjm-48	71	42	with	with	ADP
bptjm-48	71	43	the	the	DET
bptjm-48	71	44	neoantigen	neoantigen	PROPN
bptjm-48	71	45	peptide	peptide	NOUN
bptjm-48	71	46	vaccine	vaccine	NOUN
bptjm-48	72	1	,	,	PUNCT
bptjm-48	72	2	the	the	DET
bptjm-48	72	3	peptides	peptide	NOUN
bptjm-48	72	4	stimulate	stimulate	VERB
bptjm-48	72	5	the	the	DET
bptjm-48	72	6	host	host	NOUN
bptjm-48	72	7	’s	’s	PART
bptjm-48	72	8	immune	immune	ADJ
bptjm-48	72	9	system	system	NOUN
bptjm-48	72	10	to	to	PART
bptjm-48	72	11	elicit	elicit	VERB
bptjm-48	72	12	a	a	DET
bptjm-48	72	13	speci	speci	ADJ
bptjm-48	72	14	�	�	PROPN
bptjm-48	72	15	c	c	PROPN
bptjm-48	72	16	cytotoxic	cytotoxic	ADJ
bptjm-48	72	17	t	t	NOUN
bptjm-48	72	18	-	-	PUNCT
bptjm-48	72	19	lymphocyte	lymphocyte	NOUN
bptjm-48	72	20	(	(	PUNCT
bptjm-48	72	21	ctl)response	ctl)response	NOUN
bptjm-48	72	22	against	against	ADP
bptjm-48	72	23	the	the	DET
bptjm-48	72	24	tumor	tumor	NOUN
bptjm-48	72	25	cells	cell	NOUN
bptjm-48	72	26	that	that	PRON
bptjm-48	72	27	are	be	AUX
bptjm-48	72	28	expressing	express	VERB
bptjm-48	72	29	the	the	DET
bptjm-48	72	30	targeted	target	VERB
bptjm-48	72	31	neoantigens	neoantigen	NOUN
bptjm-48	72	32	,	,	PUNCT
bptjm-48	72	33	thereby	thereby	ADV
bptjm-48	72	34	resulting	result	VERB
bptjm-48	72	35	in	in	ADP
bptjm-48	72	36	tumor	tumor	NOUN
bptjm-48	72	37	cell	cell	NOUN
bptjm-48	72	38	lysis	lysis	NOUN
bptjm-48	72	39	.	.	PUNCT
bptjm-48	73	1	according	accord	VERB
bptjm-48	73	2	to	to	ADP
bptjm-48	73	3	the	the	DET
bptjm-48	73	4	fda	fda	PROPN
bptjm-48	73	5	,	,	PUNCT
bptjm-48	73	6	with	with	ADP
bptjm-48	73	7	respect	respect	NOUN
bptjm-48	73	8	to	to	ADP
bptjm-48	73	9	the	the	DET
bptjm-48	73	10	mechanism	mechanism	NOUN
bptjm-48	73	11	of	of	ADP
bptjm-48	73	12	action	action	NOUN
bptjm-48	73	13	,	,	PUNCT
bptjm-48	73	14	neoantigen	neoantigen	NOUN
bptjm-48	73	15	-	-	PUNCT
bptjm-48	73	16	based	base	VERB
bptjm-48	73	17	protein	protein	NOUN
bptjm-48	73	18	-	-	PUNCT
bptjm-48	73	19	peptide	peptide	NOUN
bptjm-48	73	20	vaccines	vaccine	NOUN
bptjm-48	73	21	use	use	VERB
bptjm-48	73	22	short	short	ADJ
bptjm-48	73	23	peptide	peptide	NOUN
bptjm-48	73	24	fragments	fragment	NOUN
bptjm-48	73	25	to	to	PART
bptjm-48	73	26	induce	induce	VERB
bptjm-48	73	27	highly	highly	ADV
bptjm-48	73	28	targeted	target	VERB
bptjm-48	73	29	immune	immune	ADJ
bptjm-48	73	30	responses	response	NOUN
bptjm-48	73	31	while	while	SCONJ
bptjm-48	73	32	simultaneously	simultaneously	ADV
bptjm-48	73	33	avoiding	avoid	VERB
bptjm-48	73	34	allergic	allergic	ADJ
bptjm-48	73	35	responses	response	NOUN
bptjm-48	73	36	.	.	PUNCT
bptjm-48	74	1	peptide	peptide	NOUN
bptjm-48	74	2	epitopes	epitope	NOUN
bptjm-48	74	3	can	can	AUX
bptjm-48	74	4	bind	bind	VERB
bptjm-48	74	5	antibodies	antibody	NOUN
bptjm-48	74	6	in	in	ADP
bptjm-48	74	7	three	three	NUM
bptjm-48	74	8	conformations	conformation	NOUN
bptjm-48	74	9	:	:	PUNCT
bptjm-48	74	10	alpha	alpha	NOUN
bptjm-48	74	11	-	-	PUNCT
bptjm-48	74	12	helical	helical	ADJ
bptjm-48	74	13	,	,	PUNCT
bptjm-48	74	14	beta	beta	NOUN
bptjm-48	74	15	-	-	PUNCT
bptjm-48	74	16	strand	strand	NOUN
bptjm-48	74	17	/	/	SYM
bptjm-48	74	18	extended	extend	VERB
bptjm-48	74	19	,	,	PUNCT
bptjm-48	74	20	or	or	CCONJ
bptjm-48	74	21	loop	loop	NOUN
bptjm-48	74	22	.	.	PUNCT
bptjm-48	75	1	since	since	SCONJ
bptjm-48	75	2	the	the	DET
bptjm-48	75	3	peptide	peptide	NOUN
bptjm-48	75	4	epitope	epitope	PROPN
bptjm-48	75	5	’s	’s	PART
bptjm-48	75	6	spatial	spatial	ADJ
bptjm-48	75	7	conformation	conformation	NOUN
bptjm-48	75	8	among	among	ADP
bptjm-48	75	9	the	the	DET
bptjm-48	75	10	antigen	antigen	NOUN
bptjm-48	75	11	-	-	PUNCT
bptjm-48	75	12	antibody	antibody	NOUN
bptjm-48	75	13	complex	complex	NOUN
bptjm-48	75	14	is	be	AUX
bptjm-48	75	15	signi	signi	ADJ
bptjm-48	75	16	�	�	NOUN
bptjm-48	75	17	cant	cant	NOUN
bptjm-48	75	18	,	,	PUNCT
bptjm-48	75	19	vaccines	vaccine	NOUN
bptjm-48	75	20	must	must	AUX
bptjm-48	75	21	be	be	AUX
bptjm-48	75	22	engineered	engineer	VERB
bptjm-48	75	23	in	in	ADP
bptjm-48	75	24	a	a	DET
bptjm-48	75	25	conformationally	conformationally	ADV
bptjm-48	75	26	correct	correct	ADJ
bptjm-48	75	27	way	way	NOUN
bptjm-48	75	28	to	to	PART
bptjm-48	75	29	produce	produce	VERB
bptjm-48	75	30	optimal	optimal	ADJ
bptjm-48	75	31	results	result	NOUN
bptjm-48	75	32	.	.	PUNCT
bptjm-48	76	1	to	to	PART
bptjm-48	76	2	constrain	constrain	VERB
bptjm-48	76	3	peptide	peptide	ADJ
bptjm-48	76	4	epitopes	epitope	NOUN
bptjm-48	76	5	when	when	SCONJ
bptjm-48	76	6	epitope	epitope	PROPN
bptjm-48	76	7	conformation	conformation	NOUN
bptjm-48	76	8	is	be	AUX
bptjm-48	76	9	important	important	ADJ
bptjm-48	76	10	,	,	PUNCT
bptjm-48	76	11	some	some	DET
bptjm-48	76	12	methods	method	NOUN
bptjm-48	76	13	utilized	utilize	VERB
bptjm-48	76	14	include	include	VERB
bptjm-48	76	15	covalent	covalent	ADJ
bptjm-48	76	16	side	side	NOUN
bptjm-48	76	17	chain	chain	NOUN
bptjm-48	76	18	-	-	PUNCT
bptjm-48	76	19	side	side	NOUN
bptjm-48	76	20	chain	chain	NOUN
bptjm-48	76	21	cross	cross	NOUN
bptjm-48	76	22	linking	linking	NOUN
bptjm-48	76	23	and	and	CCONJ
bptjm-48	76	24	integration	integration	NOUN
bptjm-48	76	25	into	into	ADP
bptjm-48	76	26	a	a	DET
bptjm-48	76	27	larger	large	ADJ
bptjm-48	76	28	sca	sca	NOUN
bptjm-48	76	29	�	�	NOUN
bptjm-48	76	30	old	old	ADJ
bptjm-48	76	31	.	.	PUNCT
bptjm-48	77	1	emulsions	emulsion	NOUN
bptjm-48	77	2	,	,	PUNCT
bptjm-48	77	3	which	which	PRON
bptjm-48	77	4	act	act	VERB
bptjm-48	77	5	as	as	ADP
bptjm-48	77	6	delivery	delivery	NOUN
bptjm-48	77	7	systems	system	NOUN
bptjm-48	77	8	for	for	ADP
bptjm-48	77	9	various	various	ADJ
bptjm-48	77	10	peptides	peptide	NOUN
bptjm-48	77	11	,	,	PUNCT
bptjm-48	77	12	form	form	VERB
bptjm-48	77	13	a	a	DET
bptjm-48	77	14	depot	depot	NOUN
bptjm-48	77	15	at	at	ADP
bptjm-48	77	16	the	the	DET
bptjm-48	77	17	site	site	NOUN
bptjm-48	77	18	of	of	ADP
bptjm-48	77	19	injection	injection	NOUN
bptjm-48	77	20	that	that	PRON
bptjm-48	77	21	attracts	attract	VERB
bptjm-48	77	22	immune	immune	ADJ
bptjm-48	77	23	cells.16	cells.16	NOUN
bptjm-48	77	24	the	the	DET
bptjm-48	77	25	presence	presence	NOUN
bptjm-48	77	26	of	of	ADP
bptjm-48	77	27	antigen	antigen	ADJ
bptjm-48	77	28	depots	depot	NOUN
bptjm-48	77	29	at	at	ADP
bptjm-48	77	30	organs	organ	NOUN
bptjm-48	77	31	releasing	release	VERB
bptjm-48	77	32	low	low	ADJ
bptjm-48	77	33	-	-	PUNCT
bptjm-48	77	34	level	level	NOUN
bptjm-48	77	35	antigens	antigen	NOUN
bptjm-48	77	36	induces	induce	VERB
bptjm-48	77	37	a	a	DET
bptjm-48	77	38	strong	strong	ADJ
bptjm-48	77	39	immune	immune	ADJ
bptjm-48	77	40	response	response	NOUN
bptjm-48	77	41	and	and	CCONJ
bptjm-48	77	42	promotes	promote	VERB
bptjm-48	77	43	tolerance	tolerance	NOUN
bptjm-48	77	44	.	.	PUNCT
bptjm-48	78	1	the	the	DET
bptjm-48	78	2	stability	stability	NOUN
bptjm-48	78	3	of	of	ADP
bptjm-48	78	4	these	these	DET
bptjm-48	78	5	emulsions	emulsion	NOUN
bptjm-48	78	6	as	as	SCONJ
bptjm-48	78	7	delivery	delivery	NOUN
bptjm-48	78	8	systems	system	NOUN
bptjm-48	78	9	plays	play	VERB
bptjm-48	78	10	a	a	DET
bptjm-48	78	11	key	key	ADJ
bptjm-48	78	12	role	role	NOUN
bptjm-48	78	13	in	in	ADP
bptjm-48	78	14	vaccine	vaccine	NOUN
bptjm-48	78	15	safety	safety	NOUN
bptjm-48	78	16	and	and	CCONJ
bptjm-48	78	17	e	e	NOUN
bptjm-48	78	18	�	�	PROPN
bptjm-48	78	19	cacy.16	cacy.16	PROPN
bptjm-48	78	20	berkeley	berkeley	PROPN
bptjm-48	78	21	pharma	pharma	PROPN
bptjm-48	78	22	tech	tech	NOUN
bptjm-48	78	23	journal	journal	NOUN
bptjm-48	78	24	of	of	ADP
bptjm-48	78	25	medicine	medicine	NOUN
bptjm-48	78	26	|	|	ADV
bptjm-48	78	27	37	37	NUM
bptjm-48	78	28	the	the	DET
bptjm-48	78	29	process	process	NOUN
bptjm-48	78	30	of	of	ADP
bptjm-48	78	31	developing	develop	VERB
bptjm-48	78	32	a	a	DET
bptjm-48	78	33	neoantigen	neoantigen	ADV
bptjm-48	78	34	-	-	PUNCT
bptjm-48	78	35	based	base	VERB
bptjm-48	78	36	peptide	peptide	NOUN
bptjm-48	78	37	vaccine	vaccine	NOUN
bptjm-48	78	38	starts	start	VERB
bptjm-48	78	39	with	with	ADP
bptjm-48	78	40	extracting	extract	VERB
bptjm-48	78	41	a	a	DET
bptjm-48	78	42	sample	sample	NOUN
bptjm-48	78	43	of	of	ADP
bptjm-48	78	44	peripheral	peripheral	ADJ
bptjm-48	78	45	blood.17	blood.17	NOUN
bptjm-48	78	46	peripheral	peripheral	ADJ
bptjm-48	78	47	blood	blood	NOUN
bptjm-48	78	48	mononuclear	mononuclear	ADJ
bptjm-48	78	49	cells	cell	NOUN
bptjm-48	78	50	(	(	PUNCT
bptjm-48	78	51	pbmcs	pbmcs	NOUN
bptjm-48	78	52	)	)	PUNCT
bptjm-48	78	53	are	be	AUX
bptjm-48	78	54	then	then	ADV
bptjm-48	78	55	isolated	isolate	VERB
bptjm-48	78	56	from	from	ADP
bptjm-48	78	57	the	the	DET
bptjm-48	78	58	blood	blood	NOUN
bptjm-48	78	59	sample	sample	NOUN
bptjm-48	78	60	,	,	PUNCT
bptjm-48	78	61	and	and	CCONJ
bptjm-48	78	62	subsequently	subsequently	ADV
bptjm-48	78	63	are	be	AUX
bptjm-48	78	64	di	di	PROPN
bptjm-48	78	65	�	�	PROPN
bptjm-48	78	66	erentiated	erentiate	VERB
bptjm-48	78	67	into	into	ADP
bptjm-48	78	68	dendritic	dendritic	ADJ
bptjm-48	78	69	cells	cell	NOUN
bptjm-48	78	70	—	—	PUNCT
bptjm-48	78	71	the	the	DET
bptjm-48	78	72	antigen	antigen	NOUN
bptjm-48	78	73	presenting	present	VERB
bptjm-48	78	74	cells	cell	NOUN
bptjm-48	78	75	.	.	PUNCT
bptjm-48	79	1	simultaneously	simultaneously	ADV
bptjm-48	79	2	,	,	PUNCT
bptjm-48	79	3	the	the	DET
bptjm-48	79	4	peripheral	peripheral	ADJ
bptjm-48	79	5	blood	blood	NOUN
bptjm-48	79	6	sample	sample	NOUN
bptjm-48	79	7	and	and	CCONJ
bptjm-48	79	8	a	a	DET
bptjm-48	79	9	tumor	tumor	NOUN
bptjm-48	79	10	sample	sample	NOUN
bptjm-48	79	11	are	be	AUX
bptjm-48	79	12	run	run	VERB
bptjm-48	79	13	through	through	ADP
bptjm-48	79	14	sequencing	sequence	VERB
bptjm-48	79	15	and	and	CCONJ
bptjm-48	79	16	computational	computational	ADJ
bptjm-48	79	17	neoantigen	neoantigen	X
bptjm-48	79	18	identi	identi	X
bptjm-48	79	19	�	�	PROPN
bptjm-48	79	20	cation	cation	NOUN
bptjm-48	79	21	:	:	PUNCT
bptjm-48	79	22	whole	whole	ADJ
bptjm-48	79	23	-	-	PUNCT
bptjm-48	79	24	genome	genome	NOUN
bptjm-48	79	25	sequencing	sequencing	NOUN
bptjm-48	79	26	(	(	PUNCT
bptjm-48	79	27	wgs	wgs	NOUN
bptjm-48	79	28	)	)	PUNCT
bptjm-48	79	29	,	,	PUNCT
bptjm-48	79	30	whole	whole	ADJ
bptjm-48	79	31	-	-	PUNCT
bptjm-48	79	32	exome	exome	NOUN
bptjm-48	79	33	sequencing	sequencing	NOUN
bptjm-48	79	34	(	(	PUNCT
bptjm-48	79	35	wes	wes	PROPN
bptjm-48	79	36	)	)	PUNCT
bptjm-48	79	37	,	,	PUNCT
bptjm-48	79	38	and	and	CCONJ
bptjm-48	79	39	next	next	ADJ
bptjm-48	79	40	-	-	PUNCT
bptjm-48	79	41	generation	generation	NOUN
bptjm-48	79	42	sequencing	sequencing	NOUN
bptjm-48	79	43	(	(	PUNCT
bptjm-48	79	44	ngs).18	ngs).18	ADP
bptjm-48	79	45	the	the	DET
bptjm-48	79	46	identi	identi	PROPN
bptjm-48	79	47	�	�	PROPN
bptjm-48	79	48	ed	ed	ADJ
bptjm-48	79	49	neoantigens	neoantigen	NOUN
bptjm-48	79	50	are	be	AUX
bptjm-48	79	51	validated	validate	VERB
bptjm-48	79	52	in	in	ADP
bptjm-48	79	53	vitro	vitro	X
bptjm-48	79	54	via	via	ADP
bptjm-48	79	55	elispot	elispot	NOUN
bptjm-48	79	56	,	,	PUNCT
bptjm-48	79	57	mhc	mhc	PROPN
bptjm-48	79	58	tetramer	tetramer	VERB
bptjm-48	79	59	,	,	PUNCT
bptjm-48	79	60	and	and	CCONJ
bptjm-48	79	61	tumor	tumor	NOUN
bptjm-48	79	62	organoids	organoid	NOUN
bptjm-48	79	63	,	,	PUNCT
bptjm-48	79	64	which	which	PRON
bptjm-48	79	65	have	have	AUX
bptjm-48	79	66	shown	show	VERB
bptjm-48	79	67	in	in	ADP
bptjm-48	79	68	studies	study	NOUN
bptjm-48	79	69	to	to	PART
bptjm-48	79	70	retain	retain	VERB
bptjm-48	79	71	the	the	DET
bptjm-48	79	72	neoantigen	neoantigen	PROPN
bptjm-48	79	73	features	feature	NOUN
bptjm-48	79	74	of	of	ADP
bptjm-48	79	75	parental	parental	ADJ
bptjm-48	79	76	tumors	tumor	NOUN
bptjm-48	79	77	.	.	PUNCT
bptjm-48	80	1	then	then	ADV
bptjm-48	80	2	,	,	PUNCT
bptjm-48	80	3	the	the	DET
bptjm-48	80	4	selected	select	VERB
bptjm-48	80	5	neoantigens	neoantigen	NOUN
bptjm-48	80	6	are	be	AUX
bptjm-48	80	7	loaded	load	VERB
bptjm-48	80	8	onto	onto	ADP
bptjm-48	80	9	dendritic	dendritic	ADJ
bptjm-48	80	10	cells	cell	NOUN
bptjm-48	80	11	and	and	CCONJ
bptjm-48	80	12	integrated	integrate	VERB
bptjm-48	80	13	into	into	ADP
bptjm-48	80	14	peptide	peptide	ADJ
bptjm-48	80	15	vaccines	vaccine	NOUN
bptjm-48	80	16	for	for	ADP
bptjm-48	80	17	treatment.17	treatment.17	PROPN
bptjm-48	80	18	wgs	wgs	NOUN
bptjm-48	80	19	,	,	PUNCT
bptjm-48	80	20	one	one	NUM
bptjm-48	80	21	of	of	ADP
bptjm-48	80	22	the	the	DET
bptjm-48	80	23	previous	previous	ADJ
bptjm-48	80	24	sequencing	sequence	VERB
bptjm-48	80	25	identi	identi	ADJ
bptjm-48	80	26	�	�	PROPN
bptjm-48	80	27	cation	cation	NOUN
bptjm-48	80	28	methods	method	NOUN
bptjm-48	80	29	,	,	PUNCT
bptjm-48	80	30	determines	determine	VERB
bptjm-48	80	31	the	the	DET
bptjm-48	80	32	order	order	NOUN
bptjm-48	80	33	of	of	ADP
bptjm-48	80	34	the	the	DET
bptjm-48	80	35	nucleotides	nucleotide	NOUN
bptjm-48	80	36	in	in	ADP
bptjm-48	80	37	the	the	DET
bptjm-48	80	38	individual	individual	NOUN
bptjm-48	80	39	’s	’s	PART
bptjm-48	80	40	dna	dna	PROPN
bptjm-48	80	41	,	,	PUNCT
bptjm-48	80	42	however	however	ADV
bptjm-48	80	43	its	its	PRON
bptjm-48	80	44	production	production	NOUN
bptjm-48	80	45	of	of	ADP
bptjm-48	80	46	complex	complex	ADJ
bptjm-48	80	47	datasets	dataset	NOUN
bptjm-48	80	48	that	that	PRON
bptjm-48	80	49	require	require	VERB
bptjm-48	80	50	bioinformatics	bioinformatics	NOUN
bptjm-48	80	51	expertise	expertise	NOUN
bptjm-48	80	52	makes	make	VERB
bptjm-48	80	53	it	it	PRON
bptjm-48	80	54	ine	ine	PROPN
bptjm-48	80	55	�	�	PROPN
bptjm-48	80	56	cient	cient	PROPN
bptjm-48	80	57	timewise	timewise	ADV
bptjm-48	80	58	.	.	PUNCT
bptjm-48	81	1	wes	wes	NOUN
bptjm-48	81	2	utilizes	utilize	VERB
bptjm-48	81	3	probes	probe	NOUN
bptjm-48	81	4	and	and	CCONJ
bptjm-48	81	5	hybridization	hybridization	NOUN
bptjm-48	81	6	to	to	PART
bptjm-48	81	7	analyze	analyze	VERB
bptjm-48	81	8	the	the	DET
bptjm-48	81	9	exome	exome	NOUN
bptjm-48	81	10	,	,	PUNCT
bptjm-48	81	11	which	which	PRON
bptjm-48	81	12	despite	despite	SCONJ
bptjm-48	81	13	only	only	ADV
bptjm-48	81	14	constituting	constitute	VERB
bptjm-48	81	15	1	1	NUM
bptjm-48	81	16	-	-	SYM
bptjm-48	81	17	5	5	NUM
bptjm-48	81	18	%	%	NOUN
bptjm-48	81	19	of	of	ADP
bptjm-48	81	20	the	the	DET
bptjm-48	81	21	genome	genome	NOUN
bptjm-48	81	22	,	,	PUNCT
bptjm-48	81	23	contains	contain	VERB
bptjm-48	81	24	approximately	approximately	ADV
bptjm-48	81	25	85	85	NUM
bptjm-48	81	26	%	%	NOUN
bptjm-48	81	27	of	of	ADP
bptjm-48	81	28	disease	disease	NOUN
bptjm-48	81	29	-	-	PUNCT
bptjm-48	81	30	related	relate	VERB
bptjm-48	81	31	variants	variant	NOUN
bptjm-48	81	32	.	.	PUNCT
bptjm-48	82	1	wgs	wgs	NOUN
bptjm-48	82	2	is	be	AUX
bptjm-48	82	3	more	more	ADJ
bptjm-48	82	4	time	time	NOUN
bptjm-48	82	5	-	-	PUNCT
bptjm-48	82	6	e	e	NOUN
bptjm-48	82	7	�	�	NOUN
bptjm-48	82	8	cient	cient	NOUN
bptjm-48	82	9	and	and	CCONJ
bptjm-48	82	10	allows	allow	VERB
bptjm-48	82	11	for	for	ADP
bptjm-48	82	12	greater	great	ADJ
bptjm-48	82	13	sequencing	sequence	VERB
bptjm-48	82	14	capabilities	capability	NOUN
bptjm-48	82	15	.	.	PUNCT
bptjm-48	83	1	ngs	ng	NOUN
bptjm-48	83	2	,	,	PUNCT
bptjm-48	83	3	re	re	NOUN
bptjm-48	83	4	�	�	NOUN
bptjm-48	83	5	ective	ective	NOUN
bptjm-48	83	6	of	of	ADP
bptjm-48	83	7	wgs	wgs	NOUN
bptjm-48	83	8	,	,	PUNCT
bptjm-48	83	9	is	be	AUX
bptjm-48	83	10	used	use	VERB
bptjm-48	83	11	to	to	PART
bptjm-48	83	12	determine	determine	VERB
bptjm-48	83	13	nucleotide	nucleotide	ADJ
bptjm-48	83	14	sequences	sequence	NOUN
bptjm-48	83	15	in	in	ADP
bptjm-48	83	16	targeted	target	VERB
bptjm-48	83	17	regions	region	NOUN
bptjm-48	83	18	of	of	ADP
bptjm-48	83	19	dna	dna	NOUN
bptjm-48	83	20	and	and	CCONJ
bptjm-48	83	21	is	be	AUX
bptjm-48	83	22	capable	capable	ADJ
bptjm-48	83	23	of	of	ADP
bptjm-48	83	24	sequencing	sequence	VERB
bptjm-48	83	25	an	an	DET
bptjm-48	83	26	entire	entire	ADJ
bptjm-48	83	27	human	human	ADJ
bptjm-48	83	28	genome	genome	NOUN
bptjm-48	83	29	within	within	ADP
bptjm-48	83	30	one	one	NUM
bptjm-48	83	31	day.19	day.19	NOUN
bptjm-48	83	32	it	it	PRON
bptjm-48	83	33	’s	’	VERB
bptjm-48	83	34	evident	evident	ADJ
bptjm-48	83	35	that	that	SCONJ
bptjm-48	83	36	with	with	ADP
bptjm-48	83	37	these	these	DET
bptjm-48	83	38	three	three	NUM
bptjm-48	83	39	sequencing	sequence	VERB
bptjm-48	83	40	methods	method	NOUN
bptjm-48	83	41	,	,	PUNCT
bptjm-48	83	42	identifying	identify	VERB
bptjm-48	83	43	neoantigens	neoantigen	NOUN
bptjm-48	83	44	and	and	CCONJ
bptjm-48	83	45	somatic	somatic	ADJ
bptjm-48	83	46	mutations	mutation	NOUN
bptjm-48	83	47	would	would	AUX
bptjm-48	83	48	be	be	AUX
bptjm-48	83	49	carried	carry	VERB
bptjm-48	83	50	out	out	ADP
bptjm-48	83	51	e	e	NOUN
bptjm-48	83	52	�	�	NOUN
bptjm-48	83	53	ciently	ciently	ADV
bptjm-48	83	54	with	with	ADP
bptjm-48	83	55	regards	regard	NOUN
bptjm-48	83	56	to	to	ADP
bptjm-48	83	57	time	time	NOUN
bptjm-48	83	58	and	and	CCONJ
bptjm-48	83	59	costs	cost	NOUN
bptjm-48	83	60	.	.	PUNCT
bptjm-48	84	1	in	in	ADP
bptjm-48	84	2	two	two	NUM
bptjm-48	84	3	clinical	clinical	ADJ
bptjm-48	84	4	trials	trial	NOUN
bptjm-48	84	5	reported	report	VERB
bptjm-48	84	6	by	by	ADP
bptjm-48	84	7	hilf	hilf	PROPN
bptjm-48	84	8	et	et	PROPN
bptjm-48	84	9	al	al	PROPN
bptjm-48	84	10	.	.	PROPN
bptjm-48	85	1	(	(	PUNCT
bptjm-48	85	2	30568303	30568303	NUM
bptjm-48	85	3	)	)	PUNCT
bptjm-48	85	4	and	and	CCONJ
bptjm-48	85	5	keskin	keskin	PROPN
bptjm-48	85	6	et	et	PROPN
bptjm-48	85	7	al	al	PROPN
bptjm-48	85	8	.	.	PROPN
bptjm-48	86	1	(	(	PUNCT
bptjm-48	86	2	30568305	30568305	NUM
bptjm-48	86	3	)	)	PUNCT
bptjm-48	86	4	in	in	ADP
bptjm-48	86	5	2019	2019	NUM
bptjm-48	86	6	,	,	PUNCT
bptjm-48	86	7	neoantigen	neoantigen	NOUN
bptjm-48	86	8	-	-	PUNCT
bptjm-48	86	9	peptide	peptide	NOUN
bptjm-48	86	10	vaccines	vaccine	NOUN
bptjm-48	86	11	produced	produce	VERB
bptjm-48	86	12	somewhat	somewhat	ADV
bptjm-48	86	13	successful	successful	ADJ
bptjm-48	86	14	therapeutic	therapeutic	ADJ
bptjm-48	86	15	results	result	NOUN
bptjm-48	86	16	for	for	ADP
bptjm-48	86	17	glioblastoma.20,21	glioblastoma.20,21	NOUN
bptjm-48	86	18	in	in	ADP
bptjm-48	86	19	hilf	hilf	PROPN
bptjm-48	87	1	et	et	PROPN
bptjm-48	87	2	al	al	PROPN
bptjm-48	87	3	.	.	PROPN
bptjm-48	87	4	’s	’s	PART
bptjm-48	87	5	trial	trial	NOUN
bptjm-48	87	6	,	,	PUNCT
bptjm-48	87	7	�	�	PROPN
bptjm-48	87	8	fteen	fteen	VERB
bptjm-48	87	9	patients	patient	NOUN
bptjm-48	87	10	,	,	PUNCT
bptjm-48	87	11	all	all	PRON
bptjm-48	87	12	of	of	ADP
bptjm-48	87	13	whom	whom	PRON
bptjm-48	87	14	were	be	AUX
bptjm-48	87	15	recently	recently	ADV
bptjm-48	87	16	diagnosed	diagnose	VERB
bptjm-48	87	17	with	with	ADP
bptjm-48	87	18	glioblastoma	glioblastoma	NOUN
bptjm-48	87	19	,	,	PUNCT
bptjm-48	87	20	were	be	AUX
bptjm-48	87	21	found	find	VERB
bptjm-48	87	22	to	to	PART
bptjm-48	87	23	possess	possess	VERB
bptjm-48	87	24	the	the	DET
bptjm-48	87	25	human	human	ADJ
bptjm-48	87	26	leukocyte	leukocyte	NOUN
bptjm-48	87	27	antigen	antigen	NOUN
bptjm-48	87	28	(	(	PUNCT
bptjm-48	87	29	hla)-a*-2:01	hla)-a*-2:01	ADJ
bptjm-48	87	30	or	or	CCONJ
bptjm-48	87	31	hla	hla	PROPN
bptjm-48	87	32	-	-	PUNCT
bptjm-48	87	33	a*24:02	a*24:02	NOUN
bptjm-48	87	34	.	.	PUNCT
bptjm-48	88	1	in	in	ADP
bptjm-48	88	2	apvac1	apvac1	NOUN
bptjm-48	88	3	(	(	PUNCT
bptjm-48	88	4	actively	actively	ADV
bptjm-48	88	5	personalized	personalized	ADJ
bptjm-48	88	6	vaccine	vaccine	NOUN
bptjm-48	88	7	1	1	NUM
bptjm-48	88	8	)	)	PUNCT
bptjm-48	88	9	,	,	PUNCT
bptjm-48	88	10	patients	patient	NOUN
bptjm-48	88	11	received	receive	VERB
bptjm-48	88	12	a	a	DET
bptjm-48	88	13	vaccine	vaccine	NOUN
bptjm-48	88	14	that	that	PRON
bptjm-48	88	15	targeted	target	VERB
bptjm-48	88	16	unmutated	unmutated	ADJ
bptjm-48	88	17	antigens	antigen	NOUN
bptjm-48	88	18	,	,	PUNCT
bptjm-48	88	19	and	and	CCONJ
bptjm-48	88	20	in	in	ADP
bptjm-48	88	21	apvac2	apvac2	PROPN
bptjm-48	88	22	,	,	PUNCT
bptjm-48	88	23	the	the	DET
bptjm-48	88	24	vaccine	vaccine	NOUN
bptjm-48	88	25	targeted	target	VERB
bptjm-48	88	26	neoantigens	neoantigen	NOUN
bptjm-48	88	27	.	.	PUNCT
bptjm-48	89	1	compared	compare	VERB
bptjm-48	89	2	to	to	ADP
bptjm-48	89	3	classic	classic	ADJ
bptjm-48	89	4	treatment	treatment	NOUN
bptjm-48	89	5	,	,	PUNCT
bptjm-48	89	6	patients	patient	NOUN
bptjm-48	89	7	who	who	PRON
bptjm-48	89	8	received	receive	VERB
bptjm-48	89	9	apvac1	apvac1	NOUN
bptjm-48	89	10	and	and	CCONJ
bptjm-48	89	11	apvac2	apvac2	PROPN
bptjm-48	89	12	had	have	VERB
bptjm-48	89	13	an	an	DET
bptjm-48	89	14	increase	increase	NOUN
bptjm-48	89	15	in	in	ADP
bptjm-48	89	16	median	median	ADJ
bptjm-48	89	17	overall	overall	ADJ
bptjm-48	89	18	survival	survival	NOUN
bptjm-48	89	19	of	of	ADP
bptjm-48	89	20	29	29	NUM
bptjm-48	89	21	months	month	NOUN
bptjm-48	89	22	,	,	PUNCT
bptjm-48	89	23	and	and	CCONJ
bptjm-48	89	24	an	an	DET
bptjm-48	89	25	increase	increase	NOUN
bptjm-48	89	26	in	in	ADP
bptjm-48	89	27	median	median	ADJ
bptjm-48	89	28	progression	progression	NOUN
bptjm-48	89	29	-	-	PUNCT
bptjm-48	89	30	free	free	ADJ
bptjm-48	89	31	survival	survival	NOUN
bptjm-48	89	32	of	of	ADP
bptjm-48	89	33	14.2	14.2	NUM
bptjm-48	89	34	berkeley	berkeley	PROPN
bptjm-48	89	35	pharma	pharma	PROPN
bptjm-48	89	36	tech	tech	NOUN
bptjm-48	89	37	journal	journal	NOUN
bptjm-48	89	38	of	of	ADP
bptjm-48	89	39	medicine	medicine	NOUN
bptjm-48	89	40	|	|	ADV
bptjm-48	89	41	38	38	NUM
bptjm-48	89	42	months	month	NOUN
bptjm-48	89	43	.	.	PUNCT
bptjm-48	90	1	in	in	ADP
bptjm-48	90	2	the	the	DET
bptjm-48	90	3	tumor	tumor	NOUN
bptjm-48	90	4	,	,	PUNCT
bptjm-48	90	5	the	the	DET
bptjm-48	90	6	vaccine	vaccine	NOUN
bptjm-48	90	7	injection	injection	NOUN
bptjm-48	90	8	induced	induce	VERB
bptjm-48	90	9	t	t	NOUN
bptjm-48	90	10	-	-	PUNCT
bptjm-48	90	11	cell	cell	NOUN
bptjm-48	90	12	expansion	expansion	NOUN
bptjm-48	90	13	;	;	PUNCT
bptjm-48	90	14	however	however	ADV
bptjm-48	90	15	,	,	PUNCT
bptjm-48	90	16	at	at	ADP
bptjm-48	90	17	the	the	DET
bptjm-48	90	18	vaccine	vaccine	NOUN
bptjm-48	90	19	’s	’s	PART
bptjm-48	90	20	injection	injection	NOUN
bptjm-48	90	21	site	site	NOUN
bptjm-48	90	22	,	,	PUNCT
bptjm-48	90	23	nearly	nearly	ADV
bptjm-48	90	24	all	all	DET
bptjm-48	90	25	patients	patient	NOUN
bptjm-48	90	26	experienced	experience	VERB
bptjm-48	90	27	some	some	DET
bptjm-48	90	28	form	form	NOUN
bptjm-48	90	29	of	of	ADP
bptjm-48	90	30	disease.20	disease.20	PROPN
bptjm-48	90	31	in	in	ADP
bptjm-48	90	32	a	a	DET
bptjm-48	90	33	trial	trial	NOUN
bptjm-48	90	34	led	lead	VERB
bptjm-48	90	35	by	by	ADP
bptjm-48	90	36	keskin	keskin	PROPN
bptjm-48	90	37	et	et	PROPN
bptjm-48	90	38	al	al	PROPN
bptjm-48	90	39	.	.	PROPN
bptjm-48	90	40	,	,	PUNCT
bptjm-48	90	41	ten	ten	NUM
bptjm-48	90	42	patients	patient	NOUN
bptjm-48	90	43	with	with	ADP
bptjm-48	90	44	newly	newly	ADV
bptjm-48	90	45	diagnosed	diagnose	VERB
bptjm-48	90	46	glioblastoma	glioblastoma	NOUN
bptjm-48	90	47	were	be	AUX
bptjm-48	90	48	treated	treat	VERB
bptjm-48	90	49	with	with	ADP
bptjm-48	90	50	the	the	DET
bptjm-48	90	51	personalized	personalize	VERB
bptjm-48	90	52	neoantigen	neoantigen	NOUN
bptjm-48	90	53	-	-	PUNCT
bptjm-48	90	54	based	base	VERB
bptjm-48	90	55	vaccine	vaccine	NOUN
bptjm-48	90	56	after	after	ADP
bptjm-48	90	57	being	be	AUX
bptjm-48	90	58	treated	treat	VERB
bptjm-48	90	59	surgically	surgically	ADV
bptjm-48	90	60	and	and	CCONJ
bptjm-48	90	61	with	with	ADP
bptjm-48	90	62	radiotherapy	radiotherapy	NOUN
bptjm-48	90	63	.	.	PUNCT
bptjm-48	91	1	though	though	SCONJ
bptjm-48	91	2	some	some	PRON
bptjm-48	91	3	experienced	experience	VERB
bptjm-48	91	4	an	an	DET
bptjm-48	91	5	increase	increase	NOUN
bptjm-48	91	6	in	in	ADP
bptjm-48	91	7	cd8	cd8	PROPN
bptjm-48	91	8	+	+	PROPN
bptjm-48	91	9	t	t	NOUN
bptjm-48	91	10	cells	cell	NOUN
bptjm-48	91	11	in	in	ADP
bptjm-48	91	12	the	the	DET
bptjm-48	91	13	environment	environment	NOUN
bptjm-48	91	14	of	of	ADP
bptjm-48	91	15	recurrent	recurrent	ADJ
bptjm-48	91	16	tumors	tumor	NOUN
bptjm-48	91	17	,	,	PUNCT
bptjm-48	91	18	as	as	ADV
bptjm-48	91	19	well	well	ADV
bptjm-48	91	20	as	as	ADP
bptjm-48	91	21	a	a	DET
bptjm-48	91	22	small	small	ADJ
bptjm-48	91	23	increase	increase	NOUN
bptjm-48	91	24	of	of	ADP
bptjm-48	91	25	pd-1	pd-1	X
bptjm-48	91	26	+	+	ADJ
bptjm-48	91	27	tumor	tumor	NOUN
bptjm-48	91	28	in	in	ADP
bptjm-48	91	29	�	�	PROPN
bptjm-48	91	30	ltrating	ltrate	VERB
bptjm-48	91	31	cd8	cd8	PROPN
bptjm-48	91	32	+	+	PROPN
bptjm-48	91	33	t	t	NOUN
bptjm-48	91	34	cells	cell	NOUN
bptjm-48	91	35	,	,	PUNCT
bptjm-48	91	36	all	all	PRON
bptjm-48	91	37	of	of	ADP
bptjm-48	91	38	the	the	DET
bptjm-48	91	39	patients	patient	NOUN
bptjm-48	91	40	ended	end	VERB
bptjm-48	91	41	up	up	ADP
bptjm-48	91	42	dying	die	VERB
bptjm-48	91	43	as	as	ADP
bptjm-48	91	44	a	a	DET
bptjm-48	91	45	result	result	NOUN
bptjm-48	91	46	of	of	ADP
bptjm-48	91	47	disease	disease	NOUN
bptjm-48	91	48	progression	progression	NOUN
bptjm-48	91	49	,	,	PUNCT
bptjm-48	91	50	with	with	ADP
bptjm-48	91	51	an	an	DET
bptjm-48	91	52	average	average	ADJ
bptjm-48	91	53	survival	survival	NOUN
bptjm-48	91	54	of	of	ADP
bptjm-48	91	55	16.8	16.8	NUM
bptjm-48	91	56	months	month	NOUN
bptjm-48	91	57	and	and	CCONJ
bptjm-48	91	58	progression	progression	NOUN
bptjm-48	91	59	-	-	PUNCT
bptjm-48	91	60	free	free	ADJ
bptjm-48	91	61	survival	survival	NOUN
bptjm-48	91	62	of	of	ADP
bptjm-48	91	63	7.6	7.6	NUM
bptjm-48	91	64	months.21	months.21	PROPN
bptjm-48	91	65	reardon	reardon	PROPN
bptjm-48	91	66	et	et	PROPN
bptjm-48	91	67	al	al	PROPN
bptjm-48	91	68	.	.	PROPN
bptjm-48	92	1	(	(	PUNCT
bptjm-48	92	2	nct02287428	nct02287428	ADV
bptjm-48	92	3	)	)	PUNCT
bptjm-48	92	4	is	be	AUX
bptjm-48	92	5	conducting	conduct	VERB
bptjm-48	92	6	an	an	DET
bptjm-48	92	7	ongoing	ongoing	ADJ
bptjm-48	92	8	phase	phase	NOUN
bptjm-48	92	9	i	i	PRON
bptjm-48	92	10	interventional	interventional	ADJ
bptjm-48	92	11	clinical	clinical	ADJ
bptjm-48	92	12	trial	trial	NOUN
bptjm-48	92	13	studying	study	VERB
bptjm-48	92	14	the	the	DET
bptjm-48	92	15	neoantigen	neoantigen	NOUN
bptjm-48	92	16	-	-	PUNCT
bptjm-48	92	17	speci	speci	X
bptjm-48	92	18	�	�	PROPN
bptjm-48	92	19	c	c	PROPN
bptjm-48	92	20	peptide	peptide	NOUN
bptjm-48	92	21	vaccine	vaccine	NOUN
bptjm-48	92	22	neovax	neovax	PROPN
bptjm-48	92	23	,	,	PUNCT
bptjm-48	92	24	alongside	alongside	ADP
bptjm-48	92	25	the	the	DET
bptjm-48	92	26	monoclonal	monoclonal	NOUN
bptjm-48	92	27	antibody	antibody	NOUN
bptjm-48	92	28	pembrolizumab	pembrolizumab	NOUN
bptjm-48	92	29	,	,	PUNCT
bptjm-48	92	30	radiation	radiation	NOUN
bptjm-48	92	31	therapy	therapy	NOUN
bptjm-48	92	32	,	,	PUNCT
bptjm-48	92	33	and	and	CCONJ
bptjm-48	92	34	temozolomide	temozolomide	NOUN
bptjm-48	92	35	in	in	ADP
bptjm-48	92	36	subjects	subject	NOUN
bptjm-48	92	37	with	with	ADP
bptjm-48	92	38	glioblastoma.22	glioblastoma.22	NOUN
bptjm-48	92	39	the	the	DET
bptjm-48	92	40	clinical	clinical	ADJ
bptjm-48	92	41	trial	trial	NOUN
bptjm-48	92	42	involves	involve	VERB
bptjm-48	92	43	�	�	PROPN
bptjm-48	92	44	ve	ve	NOUN
bptjm-48	92	45	cohorts	cohort	NOUN
bptjm-48	92	46	,	,	PUNCT
bptjm-48	92	47	each	each	PRON
bptjm-48	92	48	receiving	receive	VERB
bptjm-48	92	49	either	either	CCONJ
bptjm-48	92	50	separate	separate	ADJ
bptjm-48	92	51	individual	individual	ADJ
bptjm-48	92	52	or	or	CCONJ
bptjm-48	92	53	combinations	combination	NOUN
bptjm-48	92	54	of	of	ADP
bptjm-48	92	55	treatments	treatment	NOUN
bptjm-48	92	56	.	.	PUNCT
bptjm-48	93	1	the	the	DET
bptjm-48	93	2	�	�	PROPN
bptjm-48	93	3	rst	rst	PROPN
bptjm-48	93	4	cohort	cohort	NOUN
bptjm-48	93	5	receives	receive	VERB
bptjm-48	93	6	neovax	neovax	PROPN
bptjm-48	93	7	and	and	CCONJ
bptjm-48	93	8	radiation	radiation	NOUN
bptjm-48	93	9	therapy	therapy	NOUN
bptjm-48	93	10	,	,	PUNCT
bptjm-48	93	11	the	the	DET
bptjm-48	93	12	second	second	ADJ
bptjm-48	93	13	starts	start	VERB
bptjm-48	93	14	pembrolizumab	pembrolizumab	NOUN
bptjm-48	93	15	within	within	ADP
bptjm-48	93	16	two	two	NUM
bptjm-48	93	17	weeks	week	NOUN
bptjm-48	93	18	of	of	ADP
bptjm-48	93	19	the	the	DET
bptjm-48	93	20	start	start	NOUN
bptjm-48	93	21	of	of	ADP
bptjm-48	93	22	radiation	radiation	NOUN
bptjm-48	93	23	therapy	therapy	NOUN
bptjm-48	93	24	and	and	CCONJ
bptjm-48	93	25	continues	continue	VERB
bptjm-48	93	26	triweekly	triweekly	ADV
bptjm-48	93	27	for	for	ADP
bptjm-48	93	28	two	two	NUM
bptjm-48	93	29	years	year	NOUN
bptjm-48	93	30	,	,	PUNCT
bptjm-48	93	31	the	the	DET
bptjm-48	93	32	third	third	ADJ
bptjm-48	93	33	starts	start	VERB
bptjm-48	93	34	pembrolizumab	pembrolizumab	NOUN
bptjm-48	93	35	about	about	ADV
bptjm-48	93	36	three	three	NUM
bptjm-48	93	37	weeks	week	NOUN
bptjm-48	93	38	after	after	ADP
bptjm-48	93	39	completion	completion	NOUN
bptjm-48	93	40	of	of	ADP
bptjm-48	93	41	neovax	neovax	PROPN
bptjm-48	93	42	priming	priming	NOUN
bptjm-48	93	43	and	and	CCONJ
bptjm-48	93	44	continues	continue	VERB
bptjm-48	93	45	triweekly	triweekly	ADV
bptjm-48	93	46	for	for	ADP
bptjm-48	93	47	two	two	NUM
bptjm-48	93	48	years	year	NOUN
bptjm-48	93	49	,	,	PUNCT
bptjm-48	93	50	the	the	DET
bptjm-48	93	51	fourth	fourth	ADJ
bptjm-48	93	52	receives	receive	VERB
bptjm-48	93	53	a	a	DET
bptjm-48	93	54	single	single	ADJ
bptjm-48	93	55	dose	dose	NOUN
bptjm-48	93	56	of	of	ADP
bptjm-48	93	57	pembrolizumab	pembrolizumab	NOUN
bptjm-48	93	58	two	two	NUM
bptjm-48	93	59	weeks	week	NOUN
bptjm-48	93	60	after	after	ADP
bptjm-48	93	61	the	the	DET
bptjm-48	93	62	start	start	NOUN
bptjm-48	93	63	of	of	ADP
bptjm-48	93	64	radiation	radiation	NOUN
bptjm-48	93	65	therapy	therapy	NOUN
bptjm-48	93	66	and	and	CCONJ
bptjm-48	93	67	restarts	restart	NOUN
bptjm-48	93	68	concurrently	concurrently	ADV
bptjm-48	93	69	three	three	NUM
bptjm-48	93	70	weeks	week	NOUN
bptjm-48	93	71	after	after	ADP
bptjm-48	93	72	completing	complete	VERB
bptjm-48	93	73	neovax	neovax	PROPN
bptjm-48	93	74	priming	priming	NOUN
bptjm-48	93	75	,	,	PUNCT
bptjm-48	93	76	and	and	CCONJ
bptjm-48	93	77	the	the	DET
bptjm-48	93	78	�	�	NOUN
bptjm-48	93	79	fth	fth	NOUN
bptjm-48	93	80	enrolls	enroll	VERB
bptjm-48	93	81	patients	patient	NOUN
bptjm-48	93	82	with	with	ADP
bptjm-48	93	83	tumors	tumor	NOUN
bptjm-48	93	84	for	for	ADP
bptjm-48	93	85	which	which	PRON
bptjm-48	93	86	the	the	DET
bptjm-48	93	87	mgmt	mgmt	NOUN
bptjm-48	93	88	status	status	NOUN
bptjm-48	93	89	is	be	AUX
bptjm-48	93	90	(	(	PUNCT
bptjm-48	93	91	partially	partially	ADV
bptjm-48	93	92	)	)	PUNCT
bptjm-48	93	93	methylated	methylate	VERB
bptjm-48	93	94	and	and	CCONJ
bptjm-48	93	95	receives	receive	VERB
bptjm-48	93	96	standard	standard	ADJ
bptjm-48	93	97	temozolomide	temozolomide	NOUN
bptjm-48	93	98	with	with	ADP
bptjm-48	93	99	radiation	radiation	NOUN
bptjm-48	93	100	and	and	CCONJ
bptjm-48	93	101	adjuvantly	adjuvantly	ADV
bptjm-48	93	102	for	for	ADP
bptjm-48	93	103	six	six	NUM
bptjm-48	93	104	cycles	cycle	NOUN
bptjm-48	93	105	after	after	ADP
bptjm-48	93	106	radiation	radiation	NOUN
bptjm-48	93	107	therapy	therapy	NOUN
bptjm-48	93	108	.	.	PUNCT
bptjm-48	94	1	the	the	DET
bptjm-48	94	2	primary	primary	ADJ
bptjm-48	94	3	outcomes	outcome	NOUN
bptjm-48	94	4	are	be	AUX
bptjm-48	94	5	the	the	DET
bptjm-48	94	6	number	number	NOUN
bptjm-48	94	7	of	of	ADP
bptjm-48	94	8	participants	participant	NOUN
bptjm-48	94	9	with	with	ADP
bptjm-48	94	10	adverse	adverse	ADJ
bptjm-48	94	11	events	event	NOUN
bptjm-48	94	12	to	to	PART
bptjm-48	94	13	determine	determine	VERB
bptjm-48	94	14	the	the	DET
bptjm-48	94	15	tolerability	tolerability	NOUN
bptjm-48	94	16	and	and	CCONJ
bptjm-48	94	17	safety	safety	NOUN
bptjm-48	94	18	(	(	PUNCT
bptjm-48	94	19	all	all	DET
bptjm-48	94	20	cohorts	cohort	NOUN
bptjm-48	94	21	)	)	PUNCT
bptjm-48	94	22	,	,	PUNCT
bptjm-48	94	23	the	the	DET
bptjm-48	94	24	number	number	NOUN
bptjm-48	94	25	of	of	ADP
bptjm-48	94	26	participants	participant	NOUN
bptjm-48	94	27	with	with	ADP
bptjm-48	94	28	at	at	ADV
bptjm-48	94	29	least	least	ADJ
bptjm-48	94	30	ten	ten	NUM
bptjm-48	94	31	actionable	actionable	ADJ
bptjm-48	94	32	peptides	peptide	NOUN
bptjm-48	94	33	to	to	PART
bptjm-48	94	34	measure	measure	VERB
bptjm-48	94	35	the	the	DET
bptjm-48	94	36	feasibility	feasibility	NOUN
bptjm-48	94	37	of	of	ADP
bptjm-48	94	38	the	the	DET
bptjm-48	94	39	study	study	NOUN
bptjm-48	94	40	(	(	PUNCT
bptjm-48	94	41	cohort	cohort	NOUN
bptjm-48	94	42	1	1	NUM
bptjm-48	94	43	)	)	PUNCT
bptjm-48	94	44	,	,	PUNCT
bptjm-48	94	45	and	and	CCONJ
bptjm-48	94	46	the	the	DET
bptjm-48	94	47	number	number	NOUN
bptjm-48	94	48	of	of	ADP
bptjm-48	94	49	participants	participant	NOUN
bptjm-48	94	50	able	able	ADJ
bptjm-48	94	51	to	to	PART
bptjm-48	94	52	initiate	initiate	VERB
bptjm-48	94	53	vaccine	vaccine	NOUN
bptjm-48	94	54	therapy	therapy	NOUN
bptjm-48	94	55	after	after	ADP
bptjm-48	94	56	radiation	radiation	NOUN
bptjm-48	94	57	therapy	therapy	NOUN
bptjm-48	94	58	within	within	ADP
bptjm-48	94	59	12	12	NUM
bptjm-48	94	60	weeks	week	NOUN
bptjm-48	94	61	of	of	ADP
bptjm-48	94	62	the	the	DET
bptjm-48	94	63	date	date	NOUN
bptjm-48	94	64	of	of	ADP
bptjm-48	94	65	surgery	surgery	NOUN
bptjm-48	94	66	(	(	PUNCT
bptjm-48	94	67	cohort	cohort	NOUN
bptjm-48	94	68	1	1	NUM
bptjm-48	94	69	)	)	PUNCT
bptjm-48	94	70	.	.	PUNCT
bptjm-48	95	1	the	the	DET
bptjm-48	95	2	secondary	secondary	ADJ
bptjm-48	95	3	outcomes	outcome	NOUN
bptjm-48	95	4	are	be	AUX
bptjm-48	95	5	the	the	DET
bptjm-48	95	6	number	number	NOUN
bptjm-48	95	7	of	of	ADP
bptjm-48	95	8	participants	participant	NOUN
bptjm-48	95	9	who	who	PRON
bptjm-48	95	10	experience	experience	VERB
bptjm-48	95	11	ifn	ifn	PROPN
bptjm-48	95	12	-	-	PUNCT
bptjm-48	95	13	γ	γ	NOUN
bptjm-48	95	14	t	t	NOUN
bptjm-48	95	15	-	-	PUNCT
bptjm-48	95	16	cell	cell	NOUN
bptjm-48	95	17	responses	response	NOUN
bptjm-48	95	18	at	at	ADP
bptjm-48	95	19	week	week	NOUN
bptjm-48	95	20	16	16	NUM
bptjm-48	95	21	(	(	PUNCT
bptjm-48	95	22	all	all	DET
bptjm-48	95	23	cohorts	cohort	NOUN
bptjm-48	95	24	)	)	PUNCT
bptjm-48	95	25	,	,	PUNCT
bptjm-48	95	26	the	the	DET
bptjm-48	95	27	number	number	NOUN
bptjm-48	95	28	of	of	ADP
bptjm-48	95	29	participants	participant	NOUN
bptjm-48	95	30	who	who	PRON
bptjm-48	95	31	are	be	AUX
bptjm-48	95	32	alive	alive	ADJ
bptjm-48	95	33	and	and	CCONJ
bptjm-48	95	34	do	do	AUX
bptjm-48	95	35	n’t	not	PART
bptjm-48	95	36	demonstrate	demonstrate	VERB
bptjm-48	95	37	glioblastoma	glioblastoma	NOUN
bptjm-48	95	38	progression	progression	NOUN
bptjm-48	95	39	eight	eight	NUM
bptjm-48	95	40	months	month	NOUN
bptjm-48	95	41	after	after	ADP
bptjm-48	95	42	resective	resective	ADJ
bptjm-48	95	43	surgery	surgery	NOUN
bptjm-48	95	44	(	(	PUNCT
bptjm-48	95	45	cohorts	cohort	NOUN
bptjm-48	95	46	1	1	NUM
bptjm-48	95	47	,	,	PUNCT
bptjm-48	95	48	1a	1a	NUM
bptjm-48	95	49	,	,	PUNCT
bptjm-48	95	50	1b	1b	NUM
bptjm-48	95	51	,	,	PUNCT
bptjm-48	95	52	1c	1c	NUM
bptjm-48	95	53	)	)	PUNCT
bptjm-48	95	54	,	,	PUNCT
bptjm-48	95	55	and	and	CCONJ
bptjm-48	95	56	the	the	DET
bptjm-48	95	57	number	number	NOUN
bptjm-48	95	58	of	of	ADP
bptjm-48	95	59	participants	participant	NOUN
bptjm-48	95	60	who	who	PRON
bptjm-48	95	61	are	be	AUX
bptjm-48	95	62	alive	alive	ADJ
bptjm-48	95	63	without	without	ADP
bptjm-48	95	64	having	have	VERB
bptjm-48	95	65	glioblastoma	glioblastoma	NOUN
bptjm-48	95	66	progression	progression	NOUN
bptjm-48	95	67	eleven	eleven	NUM
bptjm-48	95	68	months	month	NOUN
bptjm-48	95	69	after	after	ADP
bptjm-48	95	70	berkeley	berkeley	PROPN
bptjm-48	95	71	pharma	pharma	PROPN
bptjm-48	95	72	tech	tech	NOUN
bptjm-48	95	73	journal	journal	NOUN
bptjm-48	95	74	of	of	ADP
bptjm-48	95	75	medicine	medicine	NOUN
bptjm-48	95	76	|	|	ADV
bptjm-48	95	77	39	39	NUM
bptjm-48	95	78	resective	resective	ADJ
bptjm-48	95	79	surgery	surgery	NOUN
bptjm-48	95	80	(	(	PUNCT
bptjm-48	95	81	cohort	cohort	NOUN
bptjm-48	95	82	1d).22	1d).22	NUM
bptjm-48	95	83	as	as	SCONJ
bptjm-48	95	84	the	the	DET
bptjm-48	95	85	study	study	NOUN
bptjm-48	95	86	is	be	AUX
bptjm-48	95	87	ongoing	ongoing	ADJ
bptjm-48	95	88	,	,	PUNCT
bptjm-48	95	89	�	�	PROPN
bptjm-48	95	90	nal	nal	ADJ
bptjm-48	95	91	results	result	NOUN
bptjm-48	95	92	and	and	CCONJ
bptjm-48	95	93	data	datum	NOUN
bptjm-48	95	94	have	have	AUX
bptjm-48	95	95	not	not	PART
bptjm-48	95	96	been	be	AUX
bptjm-48	95	97	collected	collect	VERB
bptjm-48	95	98	yet	yet	ADV
bptjm-48	95	99	.	.	PUNCT
bptjm-48	96	1	4.3	4.3	NUM
bptjm-48	96	2	nucleic	nucleic	ADJ
bptjm-48	96	3	acid	acid	NOUN
bptjm-48	96	4	(	(	PUNCT
bptjm-48	96	5	dna	dna	NOUN
bptjm-48	96	6	and	and	CCONJ
bptjm-48	96	7	mrna	mrna	PROPN
bptjm-48	96	8	vaccines	vaccine	NOUN
bptjm-48	96	9	)	)	PUNCT
bptjm-48	96	10	nucleic	nucleic	ADJ
bptjm-48	96	11	acid	acid	NOUN
bptjm-48	96	12	vaccines	vaccine	NOUN
bptjm-48	96	13	are	be	AUX
bptjm-48	96	14	another	another	DET
bptjm-48	96	15	category	category	NOUN
bptjm-48	96	16	of	of	ADP
bptjm-48	96	17	treatment	treatment	NOUN
bptjm-48	96	18	methods	method	NOUN
bptjm-48	96	19	available	available	ADJ
bptjm-48	96	20	for	for	ADP
bptjm-48	96	21	cancer	cancer	NOUN
bptjm-48	96	22	patients	patient	NOUN
bptjm-48	96	23	,	,	PUNCT
bptjm-48	96	24	of	of	ADP
bptjm-48	96	25	which	which	PRON
bptjm-48	96	26	there	there	PRON
bptjm-48	96	27	are	be	VERB
bptjm-48	96	28	two	two	NUM
bptjm-48	96	29	types	type	NOUN
bptjm-48	96	30	:	:	PUNCT
bptjm-48	96	31	deoxyribonucleic	deoxyribonucleic	ADJ
bptjm-48	96	32	acid	acid	NOUN
bptjm-48	96	33	(	(	PUNCT
bptjm-48	96	34	dna	dna	PROPN
bptjm-48	96	35	)	)	PUNCT
bptjm-48	96	36	and	and	CCONJ
bptjm-48	96	37	messenger	messenger	NOUN
bptjm-48	96	38	ribonucleic	ribonucleic	ADJ
bptjm-48	96	39	acid	acid	PROPN
bptjm-48	96	40	(	(	PUNCT
bptjm-48	96	41	mrna	mrna	PROPN
bptjm-48	96	42	)	)	PUNCT
bptjm-48	96	43	vaccines.23	vaccines.23	ADJ
bptjm-48	96	44	for	for	ADP
bptjm-48	96	45	dna	dna	PROPN
bptjm-48	96	46	vaccines	vaccine	NOUN
bptjm-48	96	47	,	,	PUNCT
bptjm-48	96	48	a	a	DET
bptjm-48	96	49	bacterial	bacterial	ADJ
bptjm-48	96	50	plasmid	plasmid	NOUN
bptjm-48	96	51	is	be	AUX
bptjm-48	96	52	used	use	VERB
bptjm-48	96	53	as	as	ADP
bptjm-48	96	54	a	a	DET
bptjm-48	96	55	vector	vector	NOUN
bptjm-48	96	56	to	to	PART
bptjm-48	96	57	introduce	introduce	VERB
bptjm-48	96	58	a	a	DET
bptjm-48	96	59	gene	gene	NOUN
bptjm-48	96	60	encoding	encode	VERB
bptjm-48	96	61	antigens	antigen	NOUN
bptjm-48	96	62	.	.	PUNCT
bptjm-48	97	1	the	the	DET
bptjm-48	97	2	plasmids	plasmid	NOUN
bptjm-48	97	3	then	then	ADV
bptjm-48	97	4	replicate	replicate	VERB
bptjm-48	97	5	,	,	PUNCT
bptjm-48	97	6	and	and	CCONJ
bptjm-48	97	7	by	by	ADP
bptjm-48	97	8	using	use	VERB
bptjm-48	97	9	antibiotics	antibiotic	NOUN
bptjm-48	97	10	,	,	PUNCT
bptjm-48	97	11	the	the	DET
bptjm-48	97	12	vectors	vector	NOUN
bptjm-48	97	13	exhibiting	exhibit	VERB
bptjm-48	97	14	antibiotic	antibiotic	ADJ
bptjm-48	97	15	resistance	resistance	NOUN
bptjm-48	97	16	can	can	AUX
bptjm-48	97	17	be	be	AUX
bptjm-48	97	18	separated	separate	VERB
bptjm-48	97	19	.	.	PUNCT
bptjm-48	98	1	dna	dna	PROPN
bptjm-48	98	2	vaccines	vaccine	NOUN
bptjm-48	98	3	are	be	AUX
bptjm-48	98	4	able	able	ADJ
bptjm-48	98	5	to	to	PART
bptjm-48	98	6	activate	activate	VERB
bptjm-48	98	7	both	both	CCONJ
bptjm-48	98	8	humoral	humoral	ADJ
bptjm-48	98	9	and	and	CCONJ
bptjm-48	98	10	cellular	cellular	ADJ
bptjm-48	98	11	immune	immune	ADJ
bptjm-48	98	12	responses	response	NOUN
bptjm-48	98	13	,	,	PUNCT
bptjm-48	98	14	and	and	CCONJ
bptjm-48	98	15	they	they	PRON
bptjm-48	98	16	can	can	AUX
bptjm-48	98	17	be	be	AUX
bptjm-48	98	18	delivered	deliver	VERB
bptjm-48	98	19	intramuscularly	intramuscularly	ADV
bptjm-48	98	20	(	(	PUNCT
bptjm-48	98	21	i	i	NOUN
bptjm-48	98	22	m	m	PROPN
bptjm-48	98	23	)	)	PUNCT
bptjm-48	98	24	,	,	PUNCT
bptjm-48	98	25	intradermally	intradermally	ADV
bptjm-48	98	26	(	(	PUNCT
bptjm-48	98	27	i	i	PROPN
bptjm-48	98	28	d	d	PROPN
bptjm-48	98	29	)	)	PUNCT
bptjm-48	98	30	,	,	PUNCT
bptjm-48	98	31	mucosally	mucosally	ADV
bptjm-48	98	32	,	,	PUNCT
bptjm-48	98	33	and/or	and/or	CCONJ
bptjm-48	98	34	transdermally	transdermally	ADV
bptjm-48	98	35	.	.	PUNCT
bptjm-48	99	1	the	the	DET
bptjm-48	99	2	process	process	NOUN
bptjm-48	99	3	by	by	ADP
bptjm-48	99	4	which	which	PRON
bptjm-48	99	5	genomic	genomic	NOUN
bptjm-48	99	6	alterations	alteration	NOUN
bptjm-48	99	7	occur	occur	VERB
bptjm-48	99	8	include	include	VERB
bptjm-48	99	9	internalization	internalization	NOUN
bptjm-48	99	10	of	of	ADP
bptjm-48	99	11	the	the	DET
bptjm-48	99	12	dna	dna	PROPN
bptjm-48	99	13	vaccine	vaccine	NOUN
bptjm-48	99	14	into	into	ADP
bptjm-48	99	15	the	the	DET
bptjm-48	99	16	cell	cell	NOUN
bptjm-48	99	17	,	,	PUNCT
bptjm-48	99	18	transcription	transcription	NOUN
bptjm-48	99	19	of	of	ADP
bptjm-48	99	20	the	the	DET
bptjm-48	99	21	genomic	genomic	ADJ
bptjm-48	99	22	information	information	NOUN
bptjm-48	99	23	at	at	ADP
bptjm-48	99	24	the	the	DET
bptjm-48	99	25	nucleus	nucleus	NOUN
bptjm-48	99	26	,	,	PUNCT
bptjm-48	99	27	and	and	CCONJ
bptjm-48	99	28	translation	translation	NOUN
bptjm-48	99	29	of	of	ADP
bptjm-48	99	30	that	that	DET
bptjm-48	99	31	info	info	NOUN
bptjm-48	99	32	within	within	ADP
bptjm-48	99	33	the	the	DET
bptjm-48	99	34	cytoplasm.24	cytoplasm.24	NOUN
bptjm-48	99	35	this	this	PRON
bptjm-48	99	36	ultimately	ultimately	ADV
bptjm-48	99	37	leads	lead	VERB
bptjm-48	99	38	to	to	ADP
bptjm-48	99	39	expression	expression	NOUN
bptjm-48	99	40	of	of	ADP
bptjm-48	99	41	proteins	protein	NOUN
bptjm-48	99	42	in	in	ADP
bptjm-48	99	43	vaccinated	vaccinated	ADJ
bptjm-48	99	44	hosts	host	NOUN
bptjm-48	99	45	,	,	PUNCT
bptjm-48	99	46	however	however	ADV
bptjm-48	99	47	there	there	PRON
bptjm-48	99	48	are	be	VERB
bptjm-48	99	49	three	three	NUM
bptjm-48	99	50	distinct	distinct	ADJ
bptjm-48	99	51	mechanisms	mechanism	NOUN
bptjm-48	99	52	by	by	ADP
bptjm-48	99	53	which	which	PRON
bptjm-48	99	54	these	these	DET
bptjm-48	99	55	proteins	protein	NOUN
bptjm-48	99	56	reach	reach	VERB
bptjm-48	99	57	the	the	DET
bptjm-48	99	58	t	t	NOUN
bptjm-48	99	59	-	-	PUNCT
bptjm-48	99	60	cells	cell	NOUN
bptjm-48	99	61	for	for	ADP
bptjm-48	99	62	recognition	recognition	NOUN
bptjm-48	99	63	and	and	CCONJ
bptjm-48	99	64	targeting	target	VERB
bptjm-48	99	65	.	.	PUNCT
bptjm-48	100	1	one	one	NUM
bptjm-48	100	2	way	way	NOUN
bptjm-48	100	3	includes	include	VERB
bptjm-48	100	4	the	the	DET
bptjm-48	100	5	use	use	NOUN
bptjm-48	100	6	of	of	ADP
bptjm-48	100	7	mhc	mhc	PROPN
bptjm-48	100	8	i	i	PRON
bptjm-48	100	9	complexes	complexe	VERB
bptjm-48	100	10	in	in	ADP
bptjm-48	100	11	somatic	somatic	ADJ
bptjm-48	100	12	cells	cell	NOUN
bptjm-48	100	13	,	,	PUNCT
bptjm-48	100	14	which	which	PRON
bptjm-48	100	15	presents	present	VERB
bptjm-48	100	16	proteins	protein	NOUN
bptjm-48	100	17	to	to	ADP
bptjm-48	100	18	cd8	cd8	PROPN
bptjm-48	100	19	+	+	PROPN
bptjm-48	100	20	t	t	NOUN
bptjm-48	100	21	cells	cell	NOUN
bptjm-48	100	22	.	.	PUNCT
bptjm-48	101	1	another	another	DET
bptjm-48	101	2	method	method	NOUN
bptjm-48	101	3	uses	use	VERB
bptjm-48	101	4	professional	professional	ADJ
bptjm-48	101	5	antigen	antigen	NOUN
bptjm-48	101	6	presenting	present	VERB
bptjm-48	101	7	cells	cell	NOUN
bptjm-48	101	8	(	(	PUNCT
bptjm-48	101	9	apcs	apc	NOUN
bptjm-48	101	10	)	)	PUNCT
bptjm-48	101	11	,	,	PUNCT
bptjm-48	101	12	like	like	ADP
bptjm-48	101	13	dendritic	dendritic	ADJ
bptjm-48	101	14	cells	cell	NOUN
bptjm-48	101	15	(	(	PUNCT
bptjm-48	101	16	dcs),that	dcs),that	PROPN
bptjm-48	101	17	are	be	AUX
bptjm-48	101	18	transfected	transfecte	VERB
bptjm-48	101	19	with	with	ADP
bptjm-48	101	20	plasmid	plasmid	ADJ
bptjm-48	101	21	dna	dna	NOUN
bptjm-48	101	22	and	and	CCONJ
bptjm-48	101	23	then	then	ADV
bptjm-48	101	24	present	present	ADJ
bptjm-48	101	25	antigens	antigen	NOUN
bptjm-48	101	26	to	to	ADP
bptjm-48	101	27	t	t	NOUN
bptjm-48	101	28	cells	cell	NOUN
bptjm-48	101	29	through	through	ADP
bptjm-48	101	30	mhc	mhc	PROPN
bptjm-48	101	31	i	i	PROPN
bptjm-48	101	32	or	or	CCONJ
bptjm-48	101	33	ii	ii	NOUN
bptjm-48	101	34	complexes	complex	NOUN
bptjm-48	101	35	.	.	PUNCT
bptjm-48	102	1	a	a	DET
bptjm-48	102	2	third	third	ADJ
bptjm-48	102	3	way	way	NOUN
bptjm-48	102	4	involves	involve	VERB
bptjm-48	102	5	the	the	DET
bptjm-48	102	6	phagocytosis	phagocytosis	NOUN
bptjm-48	102	7	of	of	ADP
bptjm-48	102	8	plasmid	plasmid	NOUN
bptjm-48	102	9	-	-	PUNCT
bptjm-48	102	10	transfected	transfecte	VERB
bptjm-48	102	11	somatic	somatic	ADJ
bptjm-48	102	12	cells	cell	NOUN
bptjm-48	102	13	by	by	ADP
bptjm-48	102	14	apcs	apc	NOUN
bptjm-48	102	15	,	,	PUNCT
bptjm-48	102	16	resulting	result	VERB
bptjm-48	102	17	in	in	ADP
bptjm-48	102	18	the	the	DET
bptjm-48	102	19	cross	cross	NOUN
bptjm-48	102	20	priming	priming	NOUN
bptjm-48	102	21	and	and	CCONJ
bptjm-48	102	22	presentation	presentation	NOUN
bptjm-48	102	23	of	of	ADP
bptjm-48	102	24	antigens	antigen	NOUN
bptjm-48	102	25	to	to	ADP
bptjm-48	102	26	both	both	CCONJ
bptjm-48	102	27	cd4	cd4	PROPN
bptjm-48	102	28	+	+	PROPN
bptjm-48	102	29	and	and	CCONJ
bptjm-48	102	30	cd8	cd8	PROPN
bptjm-48	102	31	+	+	PROPN
bptjm-48	102	32	t	t	PROPN
bptjm-48	102	33	cells.23	cells.23	PROPN
bptjm-48	102	34	berkeley	berkeley	PROPN
bptjm-48	102	35	pharma	pharma	PROPN
bptjm-48	102	36	tech	tech	NOUN
bptjm-48	102	37	journal	journal	NOUN
bptjm-48	102	38	of	of	ADP
bptjm-48	102	39	medicine	medicine	NOUN
bptjm-48	102	40	|	|	ADV
bptjm-48	102	41	40	40	NUM
bptjm-48	102	42	figure	figure	NOUN
bptjm-48	102	43	5	5	NUM
bptjm-48	102	44	.	.	PUNCT
bptjm-48	102	45	molecular	molecular	ADJ
bptjm-48	102	46	mechanism	mechanism	NOUN
bptjm-48	102	47	of	of	ADP
bptjm-48	102	48	dna	dna	PROPN
bptjm-48	102	49	vaccines	vaccine	NOUN
bptjm-48	102	50	there	there	PRON
bptjm-48	102	51	are	be	VERB
bptjm-48	102	52	several	several	ADJ
bptjm-48	102	53	current	current	ADJ
bptjm-48	102	54	clinical	clinical	ADJ
bptjm-48	102	55	trials	trial	NOUN
bptjm-48	102	56	experimenting	experiment	VERB
bptjm-48	102	57	with	with	ADP
bptjm-48	102	58	the	the	DET
bptjm-48	102	59	use	use	NOUN
bptjm-48	102	60	of	of	ADP
bptjm-48	102	61	dna	dna	PROPN
bptjm-48	102	62	vaccines	vaccine	NOUN
bptjm-48	102	63	in	in	ADP
bptjm-48	102	64	patients	patient	NOUN
bptjm-48	102	65	with	with	ADP
bptjm-48	102	66	glioblastoma	glioblastoma	NOUN
bptjm-48	102	67	.	.	PUNCT
bptjm-48	103	1	in	in	ADP
bptjm-48	103	2	johanns	johanns	PROPN
bptjm-48	103	3	et	et	PROPN
bptjm-48	103	4	al	al	PROPN
bptjm-48	103	5	,	,	PUNCT
bptjm-48	103	6	the	the	DET
bptjm-48	103	7	initiative	initiative	NOUN
bptjm-48	103	8	is	be	AUX
bptjm-48	103	9	to	to	PART
bptjm-48	103	10	evaluate	evaluate	VERB
bptjm-48	103	11	the	the	DET
bptjm-48	103	12	safety	safety	NOUN
bptjm-48	103	13	,	,	PUNCT
bptjm-48	103	14	feasibility	feasibility	NOUN
bptjm-48	103	15	,	,	PUNCT
bptjm-48	103	16	and	and	CCONJ
bptjm-48	103	17	immunogenicity	immunogenicity	NOUN
bptjm-48	103	18	of	of	ADP
bptjm-48	103	19	a	a	DET
bptjm-48	103	20	personalized	personalized	ADJ
bptjm-48	103	21	neoantigen	neoantigen	NOUN
bptjm-48	103	22	-	-	PUNCT
bptjm-48	103	23	based	base	VERB
bptjm-48	103	24	vaccine	vaccine	NOUN
bptjm-48	103	25	in	in	ADP
bptjm-48	103	26	subjects	subject	NOUN
bptjm-48	103	27	with	with	ADP
bptjm-48	103	28	newly	newly	ADV
bptjm-48	103	29	diagnosed	diagnose	VERB
bptjm-48	103	30	,	,	PUNCT
bptjm-48	103	31	unmethylated	unmethylate	VERB
bptjm-48	103	32	glioblastoma.25	glioblastoma.25	NOUN
bptjm-48	103	33	in	in	ADP
bptjm-48	103	34	this	this	DET
bptjm-48	103	35	trial	trial	NOUN
bptjm-48	103	36	,	,	PUNCT
bptjm-48	103	37	patients	patient	NOUN
bptjm-48	103	38	will	will	AUX
bptjm-48	103	39	each	each	PRON
bptjm-48	103	40	receive	receive	VERB
bptjm-48	103	41	standard	standard	ADJ
bptjm-48	103	42	radiation	radiation	NOUN
bptjm-48	103	43	therapy	therapy	NOUN
bptjm-48	103	44	as	as	ADV
bptjm-48	103	45	well	well	ADV
bptjm-48	103	46	as	as	ADP
bptjm-48	103	47	administered	administer	VERB
bptjm-48	103	48	neoantigen	neoantigen	PROPN
bptjm-48	103	49	dna	dna	PROPN
bptjm-48	103	50	vaccines	vaccine	NOUN
bptjm-48	103	51	using	use	VERB
bptjm-48	103	52	the	the	DET
bptjm-48	103	53	cellectra	cellectra	ADJ
bptjm-48	103	54	®	®	PROPN
bptjm-48	103	55	2000	2000	NUM
bptjm-48	103	56	ep	ep	PROPN
bptjm-48	103	57	device	device	NOUN
bptjm-48	103	58	.	.	PUNCT
bptjm-48	104	1	the	the	DET
bptjm-48	104	2	vaccine	vaccine	NOUN
bptjm-48	104	3	used	use	VERB
bptjm-48	104	4	is	be	AUX
bptjm-48	104	5	a	a	DET
bptjm-48	104	6	combination	combination	NOUN
bptjm-48	104	7	of	of	ADP
bptjm-48	104	8	gnos	gno	NOUN
bptjm-48	104	9	-	-	PUNCT
bptjm-48	104	10	pv01	pv01	PROPN
bptjm-48	104	11	+	+	NUM
bptjm-48	104	12	ino-9012	ino-9012	NOUN
bptjm-48	104	13	,	,	PUNCT
bptjm-48	104	14	dna	dna	PROPN
bptjm-48	104	15	vaccines	vaccine	NOUN
bptjm-48	104	16	which	which	PRON
bptjm-48	104	17	have	have	AUX
bptjm-48	104	18	previously	previously	ADV
bptjm-48	104	19	shown	show	VERB
bptjm-48	104	20	immunogenicity	immunogenicity	NOUN
bptjm-48	104	21	in	in	ADP
bptjm-48	104	22	newly	newly	ADV
bptjm-48	104	23	diagnosed	diagnose	VERB
bptjm-48	104	24	gbm	gbm	NOUN
bptjm-48	104	25	patients	patient	NOUN
bptjm-48	104	26	when	when	SCONJ
bptjm-48	104	27	administered	administer	VERB
bptjm-48	104	28	alongside	alongside	ADP
bptjm-48	104	29	libtayo	libtayo	NOUN
bptjm-48	104	30	,	,	PUNCT
bptjm-48	104	31	radiation	radiation	NOUN
bptjm-48	104	32	,	,	PUNCT
bptjm-48	104	33	and	and	CCONJ
bptjm-48	104	34	temozolomide	temozolomide	NOUN
bptjm-48	104	35	.	.	PUNCT
bptjm-48	105	1	safety	safety	NOUN
bptjm-48	105	2	of	of	ADP
bptjm-48	105	3	the	the	DET
bptjm-48	105	4	vaccine	vaccine	NOUN
bptjm-48	105	5	will	will	AUX
bptjm-48	105	6	be	be	AUX
bptjm-48	105	7	determined	determine	VERB
bptjm-48	105	8	by	by	ADP
bptjm-48	105	9	dose	dose	NOUN
bptjm-48	105	10	-	-	PUNCT
bptjm-48	105	11	limiting	limit	VERB
bptjm-48	105	12	toxicities	toxicity	NOUN
bptjm-48	105	13	,	,	PUNCT
bptjm-48	105	14	as	as	ADP
bptjm-48	105	15	per	per	ADP
bptjm-48	105	16	the	the	DET
bptjm-48	105	17	common	common	ADJ
bptjm-48	105	18	terminology	terminology	NOUN
bptjm-48	105	19	criteria	criterion	NOUN
bptjm-48	105	20	for	for	ADP
bptjm-48	105	21	adverse	adverse	ADJ
bptjm-48	105	22	events	event	NOUN
bptjm-48	105	23	version	version	NOUN
bptjm-48	105	24	5.0	5.0	NUM
bptjm-48	105	25	(	(	PUNCT
bptjm-48	105	26	ctcae	ctcae	NOUN
bptjm-48	105	27	v5	v5	PROPN
bptjm-48	105	28	)	)	PUNCT
bptjm-48	105	29	published	publish	VERB
bptjm-48	105	30	by	by	ADP
bptjm-48	105	31	the	the	DET
bptjm-48	105	32	u.s	u.s	PROPN
bptjm-48	105	33	.	.	PROPN
bptjm-48	105	34	department	department	PROPN
bptjm-48	105	35	of	of	ADP
bptjm-48	105	36	health	health	PROPN
bptjm-48	105	37	and	and	CCONJ
bptjm-48	105	38	human	human	PROPN
bptjm-48	105	39	services	service	NOUN
bptjm-48	105	40	(	(	PUNCT
bptjm-48	105	41	usdhhs	usdhhs	NOUN
bptjm-48	105	42	)	)	PUNCT
bptjm-48	105	43	.	.	PUNCT
bptjm-48	106	1	alongside	alongside	ADP
bptjm-48	106	2	safety	safety	NOUN
bptjm-48	106	3	,	,	PUNCT
bptjm-48	106	4	feasibility	feasibility	NOUN
bptjm-48	106	5	of	of	ADP
bptjm-48	106	6	this	this	DET
bptjm-48	106	7	dna	dna	PROPN
bptjm-48	106	8	vaccine	vaccine	NOUN
bptjm-48	106	9	is	be	AUX
bptjm-48	106	10	also	also	ADV
bptjm-48	106	11	being	be	AUX
bptjm-48	106	12	considered	consider	VERB
bptjm-48	106	13	,	,	PUNCT
bptjm-48	106	14	for	for	ADP
bptjm-48	106	15	which	which	PRON
bptjm-48	106	16	there	there	PRON
bptjm-48	106	17	are	be	VERB
bptjm-48	106	18	three	three	NUM
bptjm-48	106	19	necessary	necessary	ADJ
bptjm-48	106	20	conditions	condition	NOUN
bptjm-48	106	21	:	:	PUNCT
bptjm-48	106	22	e	e	X
bptjm-48	106	23	�	�	NOUN
bptjm-48	106	24	ciency	ciency	NOUN
bptjm-48	106	25	of	of	ADP
bptjm-48	106	26	vaccine	vaccine	NOUN
bptjm-48	106	27	manufacturing	manufacturing	NOUN
bptjm-48	106	28	,	,	PUNCT
bptjm-48	106	29	administration	administration	NOUN
bptjm-48	106	30	,	,	PUNCT
bptjm-48	106	31	and	and	CCONJ
bptjm-48	106	32	ability	ability	NOUN
bptjm-48	106	33	of	of	ADP
bptjm-48	106	34	the	the	DET
bptjm-48	106	35	vaccine	vaccine	NOUN
bptjm-48	106	36	to	to	PART
bptjm-48	106	37	identify	identify	VERB
bptjm-48	106	38	neoantigens	neoantigen	NOUN
bptjm-48	106	39	in	in	ADP
bptjm-48	106	40	the	the	DET
bptjm-48	106	41	patient	patient	NOUN
bptjm-48	106	42	.	.	PUNCT
bptjm-48	107	1	additionally	additionally	ADV
bptjm-48	107	2	,	,	PUNCT
bptjm-48	107	3	the	the	DET
bptjm-48	107	4	immunogenicity	immunogenicity	NOUN
bptjm-48	107	5	of	of	ADP
bptjm-48	107	6	the	the	DET
bptjm-48	107	7	vaccine	vaccine	NOUN
bptjm-48	107	8	will	will	AUX
bptjm-48	107	9	be	be	AUX
bptjm-48	107	10	determined	determine	VERB
bptjm-48	107	11	by	by	ADP
bptjm-48	107	12	percentage	percentage	NOUN
bptjm-48	107	13	of	of	ADP
bptjm-48	107	14	neoantigens	neoantigen	NOUN
bptjm-48	107	15	that	that	PRON
bptjm-48	107	16	elicit	elicit	VERB
bptjm-48	107	17	a	a	DET
bptjm-48	107	18	neoantigen	neoantigen	PROPN
bptjm-48	107	19	-	-	PUNCT
bptjm-48	107	20	speci	speci	X
bptjm-48	107	21	�	�	PROPN
bptjm-48	107	22	c	c	PROPN
bptjm-48	107	23	t	t	PROPN
bptjm-48	107	24	cell	cell	NOUN
bptjm-48	107	25	response	response	NOUN
bptjm-48	107	26	,	,	PUNCT
bptjm-48	107	27	as	as	ADV
bptjm-48	107	28	well	well	ADV
bptjm-48	107	29	as	as	ADP
bptjm-48	107	30	the	the	DET
bptjm-48	107	31	associated	associated	PROPN
bptjm-48	107	32	cd8	cd8	PROPN
bptjm-48	107	33	t	t	PROPN
bptjm-48	107	34	-	-	PUNCT
bptjm-48	107	35	cell	cell	NOUN
bptjm-48	107	36	response	response	NOUN
bptjm-48	107	37	,	,	PUNCT
bptjm-48	107	38	and	and	CCONJ
bptjm-48	107	39	overall	overall	ADJ
bptjm-48	107	40	survival	survival	PROPN
bptjm-48	107	41	rate.25	rate.25	PROPN
bptjm-48	107	42	berkeley	berkeley	PROPN
bptjm-48	107	43	pharma	pharma	PROPN
bptjm-48	107	44	tech	tech	NOUN
bptjm-48	107	45	journal	journal	NOUN
bptjm-48	107	46	of	of	ADP
bptjm-48	107	47	medicine	medicine	NOUN
bptjm-48	107	48	|	|	ADV
bptjm-48	107	49	41	41	NUM
bptjm-48	107	50	some	some	DET
bptjm-48	107	51	clinical	clinical	ADJ
bptjm-48	107	52	trials	trial	NOUN
bptjm-48	107	53	are	be	AUX
bptjm-48	107	54	testing	test	VERB
bptjm-48	107	55	the	the	DET
bptjm-48	107	56	use	use	NOUN
bptjm-48	107	57	of	of	ADP
bptjm-48	107	58	dna	dna	PROPN
bptjm-48	107	59	vaccines	vaccine	NOUN
bptjm-48	107	60	in	in	ADP
bptjm-48	107	61	combination	combination	NOUN
bptjm-48	107	62	with	with	ADP
bptjm-48	107	63	other	other	ADJ
bptjm-48	107	64	immunotherapies	immunotherapy	NOUN
bptjm-48	107	65	to	to	PART
bptjm-48	107	66	achieve	achieve	VERB
bptjm-48	107	67	a	a	DET
bptjm-48	107	68	higher	high	ADJ
bptjm-48	107	69	magnitude	magnitude	NOUN
bptjm-48	107	70	and	and	CCONJ
bptjm-48	107	71	breadth	breadth	NOUN
bptjm-48	107	72	of	of	ADP
bptjm-48	107	73	neoantigen	neoantigen	PROPN
bptjm-48	107	74	-	-	PUNCT
bptjm-48	107	75	speci	speci	X
bptjm-48	107	76	�	�	PROPN
bptjm-48	107	77	c	c	PROPN
bptjm-48	107	78	t	t	NOUN
bptjm-48	107	79	cell	cell	NOUN
bptjm-48	107	80	responses	response	NOUN
bptjm-48	107	81	.	.	PUNCT
bptjm-48	108	1	in	in	ADP
bptjm-48	108	2	another	another	DET
bptjm-48	108	3	trial	trial	NOUN
bptjm-48	108	4	by	by	ADP
bptjm-48	108	5	johanns	johanns	PROPN
bptjm-48	108	6	et	et	PROPN
bptjm-48	108	7	al	al	PROPN
bptjm-48	108	8	,	,	PUNCT
bptjm-48	108	9	a	a	DET
bptjm-48	108	10	personalized	personalized	ADJ
bptjm-48	108	11	neoantigen	neoantigen	NOUN
bptjm-48	108	12	vaccine	vaccine	NOUN
bptjm-48	108	13	is	be	AUX
bptjm-48	108	14	being	be	AUX
bptjm-48	108	15	used	use	VERB
bptjm-48	108	16	concurrently	concurrently	ADV
bptjm-48	108	17	with	with	ADP
bptjm-48	108	18	retifanlimab	retifanlimab	NOUN
bptjm-48	108	19	pd-1	pd-1	ADP
bptjm-48	108	20	blockade	blockade	NOUN
bptjm-48	108	21	therapy	therapy	NOUN
bptjm-48	108	22	for	for	ADP
bptjm-48	108	23	patients	patient	NOUN
bptjm-48	108	24	who	who	PRON
bptjm-48	108	25	are	be	AUX
bptjm-48	108	26	newly	newly	ADV
bptjm-48	108	27	diagnosed	diagnose	VERB
bptjm-48	108	28	with	with	ADP
bptjm-48	108	29	glioblastoma.26	glioblastoma.26	NOUN
bptjm-48	108	30	this	this	DET
bptjm-48	108	31	work	work	NOUN
bptjm-48	108	32	extends	extend	VERB
bptjm-48	108	33	to	to	ADP
bptjm-48	108	34	other	other	ADJ
bptjm-48	108	35	cancer	cancer	NOUN
bptjm-48	108	36	types	type	NOUN
bptjm-48	108	37	as	as	ADV
bptjm-48	108	38	well	well	ADV
bptjm-48	108	39	.	.	PUNCT
bptjm-48	109	1	in	in	ADP
bptjm-48	109	2	gillanders	gillander	NOUN
bptjm-48	109	3	et	et	PROPN
bptjm-48	109	4	al	al	PROPN
bptjm-48	109	5	,	,	PUNCT
bptjm-48	109	6	patients	patient	NOUN
bptjm-48	109	7	with	with	ADP
bptjm-48	109	8	triple	triple	ADJ
bptjm-48	109	9	negative	negative	ADJ
bptjm-48	109	10	breast	breast	NOUN
bptjm-48	109	11	cancer	cancer	NOUN
bptjm-48	109	12	(	(	PUNCT
bptjm-48	109	13	tnbc	tnbc	ADV
bptjm-48	109	14	)	)	PUNCT
bptjm-48	109	15	are	be	AUX
bptjm-48	109	16	being	be	AUX
bptjm-48	109	17	actively	actively	ADV
bptjm-48	109	18	recruited	recruit	VERB
bptjm-48	109	19	to	to	PART
bptjm-48	109	20	conduct	conduct	VERB
bptjm-48	109	21	a	a	DET
bptjm-48	109	22	study	study	NOUN
bptjm-48	109	23	on	on	ADP
bptjm-48	109	24	the	the	DET
bptjm-48	109	25	e	e	PROPN
bptjm-48	109	26	�	�	PROPN
bptjm-48	109	27	cacy	cacy	NOUN
bptjm-48	109	28	of	of	ADP
bptjm-48	109	29	adjuvant	adjuvant	ADJ
bptjm-48	109	30	therapies	therapy	NOUN
bptjm-48	109	31	after	after	ADP
bptjm-48	109	32	administering	administer	VERB
bptjm-48	109	33	neoantigen	neoantigen	NOUN
bptjm-48	109	34	-	-	PUNCT
bptjm-48	109	35	based	base	VERB
bptjm-48	109	36	dna	dna	PROPN
bptjm-48	109	37	vaccines	vaccine	NOUN
bptjm-48	109	38	.	.	PUNCT
bptjm-48	110	1	in	in	ADP
bptjm-48	110	2	this	this	DET
bptjm-48	110	3	trial	trial	NOUN
bptjm-48	110	4	,	,	PUNCT
bptjm-48	110	5	both	both	DET
bptjm-48	110	6	groups	group	NOUN
bptjm-48	110	7	will	will	AUX
bptjm-48	110	8	be	be	AUX
bptjm-48	110	9	given	give	VERB
bptjm-48	110	10	standard	standard	ADJ
bptjm-48	110	11	therapy	therapy	NOUN
bptjm-48	110	12	as	as	SCONJ
bptjm-48	110	13	needed	need	VERB
bptjm-48	110	14	(	(	PUNCT
bptjm-48	110	15	ie	ie	X
bptjm-48	110	16	.	.	PUNCT
bptjm-48	111	1	chemotherapy	chemotherapy	NOUN
bptjm-48	111	2	,	,	PUNCT
bptjm-48	111	3	surgery	surgery	NOUN
bptjm-48	111	4	,	,	PUNCT
bptjm-48	111	5	radiation	radiation	NOUN
bptjm-48	111	6	therapy	therapy	NOUN
bptjm-48	111	7	,	,	PUNCT
bptjm-48	111	8	etc	etc	X
bptjm-48	111	9	.	.	X
bptjm-48	111	10	)	)	PUNCT
bptjm-48	112	1	,	,	PUNCT
bptjm-48	112	2	however	however	ADV
bptjm-48	112	3	one	one	NUM
bptjm-48	112	4	group	group	NOUN
bptjm-48	112	5	of	of	ADP
bptjm-48	112	6	patients	patient	NOUN
bptjm-48	112	7	will	will	AUX
bptjm-48	112	8	be	be	AUX
bptjm-48	112	9	given	give	VERB
bptjm-48	112	10	the	the	DET
bptjm-48	112	11	dna	dna	PROPN
bptjm-48	112	12	vaccine	vaccine	NOUN
bptjm-48	112	13	alone	alone	ADV
bptjm-48	112	14	.	.	PUNCT
bptjm-48	113	1	the	the	DET
bptjm-48	113	2	other	other	ADJ
bptjm-48	113	3	group	group	NOUN
bptjm-48	113	4	will	will	AUX
bptjm-48	113	5	be	be	AUX
bptjm-48	113	6	given	give	VERB
bptjm-48	113	7	the	the	DET
bptjm-48	113	8	vaccine	vaccine	NOUN
bptjm-48	113	9	along	along	ADP
bptjm-48	113	10	with	with	ADP
bptjm-48	113	11	durvalumab	durvalumab	NOUN
bptjm-48	113	12	to	to	PART
bptjm-48	113	13	test	test	VERB
bptjm-48	113	14	for	for	ADP
bptjm-48	113	15	increased	increase	VERB
bptjm-48	113	16	immunogenicity	immunogenicity	NOUN
bptjm-48	113	17	.	.	PUNCT
bptjm-48	114	1	27	27	NUM
bptjm-48	114	2	the	the	DET
bptjm-48	114	3	purpose	purpose	NOUN
bptjm-48	114	4	of	of	ADP
bptjm-48	114	5	these	these	DET
bptjm-48	114	6	clinical	clinical	ADJ
bptjm-48	114	7	trials	trial	NOUN
bptjm-48	114	8	,	,	PUNCT
bptjm-48	114	9	by	by	ADP
bptjm-48	114	10	both	both	CCONJ
bptjm-48	114	11	johanns	johanns	ADJ
bptjm-48	114	12	and	and	CCONJ
bptjm-48	114	13	gillanders	gillander	NOUN
bptjm-48	114	14	et	et	PROPN
bptjm-48	114	15	al	al	PROPN
bptjm-48	114	16	,	,	PUNCT
bptjm-48	114	17	is	be	AUX
bptjm-48	114	18	to	to	PART
bptjm-48	114	19	investigate	investigate	VERB
bptjm-48	114	20	the	the	DET
bptjm-48	114	21	e	e	NOUN
bptjm-48	114	22	�	�	NOUN
bptjm-48	114	23	ects	ect	NOUN
bptjm-48	114	24	of	of	ADP
bptjm-48	114	25	using	use	VERB
bptjm-48	114	26	certain	certain	ADJ
bptjm-48	114	27	dna	dna	NOUN
bptjm-48	114	28	vaccines	vaccine	NOUN
bptjm-48	114	29	in	in	ADP
bptjm-48	114	30	combination	combination	NOUN
bptjm-48	114	31	with	with	ADP
bptjm-48	114	32	standard	standard	ADJ
bptjm-48	114	33	therapies	therapy	NOUN
bptjm-48	114	34	.	.	PUNCT
bptjm-48	115	1	the	the	DET
bptjm-48	115	2	�	�	NOUN
bptjm-48	115	3	ndings	nding	NOUN
bptjm-48	115	4	from	from	ADP
bptjm-48	115	5	these	these	DET
bptjm-48	115	6	trials	trial	NOUN
bptjm-48	115	7	will	will	AUX
bptjm-48	115	8	lead	lead	VERB
bptjm-48	115	9	to	to	ADP
bptjm-48	115	10	future	future	ADJ
bptjm-48	115	11	advancements	advancement	NOUN
bptjm-48	115	12	in	in	ADP
bptjm-48	115	13	the	the	DET
bptjm-48	115	14	treatments	treatment	NOUN
bptjm-48	115	15	used	use	VERB
bptjm-48	115	16	for	for	ADP
bptjm-48	115	17	diagnosed	diagnose	VERB
bptjm-48	115	18	gbm	gbm	NOUN
bptjm-48	115	19	patients	patient	NOUN
bptjm-48	115	20	.	.	PUNCT
bptjm-48	116	1	the	the	DET
bptjm-48	116	2	other	other	ADJ
bptjm-48	116	3	type	type	NOUN
bptjm-48	116	4	of	of	ADP
bptjm-48	116	5	nucleic	nucleic	ADJ
bptjm-48	116	6	acid	acid	NOUN
bptjm-48	116	7	vaccines	vaccine	NOUN
bptjm-48	116	8	,	,	PUNCT
bptjm-48	116	9	mrna	mrna	PROPN
bptjm-48	116	10	vaccines	vaccine	NOUN
bptjm-48	116	11	,	,	PUNCT
bptjm-48	116	12	currently	currently	ADV
bptjm-48	116	13	holds	hold	VERB
bptjm-48	116	14	two	two	NUM
bptjm-48	116	15	widely	widely	ADV
bptjm-48	116	16	acknowledged	acknowledge	VERB
bptjm-48	116	17	forms	form	NOUN
bptjm-48	116	18	:	:	PUNCT
bptjm-48	116	19	non	non	ADJ
bptjm-48	116	20	-	-	ADJ
bptjm-48	116	21	amplifying	amplifying	ADJ
bptjm-48	116	22	mrna	mrna	NOUN
bptjm-48	116	23	and	and	CCONJ
bptjm-48	116	24	self	self	NOUN
bptjm-48	116	25	-	-	PUNCT
bptjm-48	116	26	amplifying	amplify	VERB
bptjm-48	116	27	mrna	mrna	NOUN
bptjm-48	116	28	,	,	PUNCT
bptjm-48	116	29	and	and	CCONJ
bptjm-48	116	30	each	each	PRON
bptjm-48	116	31	bears	bear	VERB
bptjm-48	116	32	its	its	PRON
bptjm-48	116	33	mechanistic	mechanistic	PROPN
bptjm-48	116	34	di	di	NOUN
bptjm-48	116	35	�	�	PROPN
bptjm-48	116	36	erences.23	erences.23	PROPN
bptjm-48	116	37	the	the	DET
bptjm-48	116	38	main	main	ADJ
bptjm-48	116	39	di	di	NOUN
bptjm-48	116	40	�	�	NOUN
bptjm-48	116	41	erence	erence	NOUN
bptjm-48	116	42	between	between	ADP
bptjm-48	116	43	the	the	DET
bptjm-48	116	44	two	two	NUM
bptjm-48	116	45	is	be	AUX
bptjm-48	116	46	in	in	ADP
bptjm-48	116	47	the	the	DET
bptjm-48	116	48	additional	additional	ADJ
bptjm-48	116	49	length	length	NOUN
bptjm-48	116	50	of	of	ADP
bptjm-48	116	51	self	self	NOUN
bptjm-48	116	52	-	-	PUNCT
bptjm-48	116	53	amplifying	amplify	VERB
bptjm-48	116	54	mrna	mrna	NOUN
bptjm-48	116	55	,	,	PUNCT
bptjm-48	116	56	which	which	PRON
bptjm-48	116	57	is	be	AUX
bptjm-48	116	58	attributed	attribute	VERB
bptjm-48	116	59	to	to	ADP
bptjm-48	116	60	the	the	DET
bptjm-48	116	61	nonstructural	nonstructural	ADJ
bptjm-48	116	62	proteins	protein	NOUN
bptjm-48	116	63	that	that	PRON
bptjm-48	116	64	extend	extend	VERB
bptjm-48	116	65	the	the	DET
bptjm-48	116	66	duration	duration	NOUN
bptjm-48	116	67	and	and	CCONJ
bptjm-48	116	68	amplitude	amplitude	NOUN
bptjm-48	116	69	of	of	ADP
bptjm-48	116	70	gene	gene	NOUN
bptjm-48	116	71	of	of	ADP
bptjm-48	116	72	interest	interest	NOUN
bptjm-48	116	73	(	(	PUNCT
bptjm-48	116	74	goi	goi	PROPN
bptjm-48	116	75	)	)	PUNCT
bptjm-48	116	76	expression.23	expression.23	VERB
bptjm-48	116	77	in	in	ADP
bptjm-48	116	78	contrast	contrast	NOUN
bptjm-48	116	79	to	to	ADP
bptjm-48	116	80	dna	dna	PROPN
bptjm-48	116	81	vaccines	vaccine	NOUN
bptjm-48	116	82	,	,	PUNCT
bptjm-48	116	83	mrna	mrna	PROPN
bptjm-48	116	84	vaccines	vaccine	NOUN
bptjm-48	116	85	do	do	AUX
bptjm-48	116	86	not	not	PART
bptjm-48	116	87	have	have	VERB
bptjm-48	116	88	to	to	PART
bptjm-48	116	89	be	be	AUX
bptjm-48	116	90	transcribed	transcribe	VERB
bptjm-48	116	91	by	by	ADP
bptjm-48	116	92	the	the	DET
bptjm-48	116	93	host	host	NOUN
bptjm-48	116	94	.	.	PUNCT
bptjm-48	117	1	instead	instead	ADV
bptjm-48	117	2	,	,	PUNCT
bptjm-48	117	3	the	the	DET
bptjm-48	117	4	antigen	antigen	NOUN
bptjm-48	117	5	-	-	PUNCT
bptjm-48	117	6	encoding	encode	VERB
bptjm-48	117	7	genetic	genetic	ADJ
bptjm-48	117	8	information	information	NOUN
bptjm-48	117	9	is	be	AUX
bptjm-48	117	10	directly	directly	ADV
bptjm-48	117	11	delivered	deliver	VERB
bptjm-48	117	12	to	to	ADP
bptjm-48	117	13	antigen	antigen	NOUN
bptjm-48	117	14	-	-	PUNCT
bptjm-48	117	15	presenting	present	VERB
bptjm-48	117	16	cells	cell	NOUN
bptjm-48	117	17	(	(	PUNCT
bptjm-48	117	18	apcs	apc	NOUN
bptjm-48	117	19	)	)	PUNCT
bptjm-48	117	20	.	.	PUNCT
bptjm-48	118	1	after	after	ADP
bptjm-48	118	2	reaching	reach	VERB
bptjm-48	118	3	the	the	DET
bptjm-48	118	4	host	host	NOUN
bptjm-48	118	5	cell	cell	NOUN
bptjm-48	118	6	,	,	PUNCT
bptjm-48	118	7	the	the	DET
bptjm-48	118	8	mrna	mrna	NOUN
bptjm-48	118	9	can	can	AUX
bptjm-48	118	10	be	be	AUX
bptjm-48	118	11	released	release	VERB
bptjm-48	118	12	and	and	CCONJ
bptjm-48	118	13	translated	translate	VERB
bptjm-48	118	14	into	into	ADP
bptjm-48	118	15	proteins	protein	NOUN
bptjm-48	118	16	which	which	PRON
bptjm-48	118	17	are	be	AUX
bptjm-48	118	18	then	then	ADV
bptjm-48	118	19	proteolyzed	proteolyze	VERB
bptjm-48	118	20	into	into	ADP
bptjm-48	118	21	peptide	peptide	ADJ
bptjm-48	118	22	epitopes	epitope	NOUN
bptjm-48	118	23	.	.	PUNCT
bptjm-48	119	1	then	then	ADV
bptjm-48	119	2	,	,	PUNCT
bptjm-48	119	3	the	the	DET
bptjm-48	119	4	epitopes	epitope	NOUN
bptjm-48	119	5	are	be	AUX
bptjm-48	119	6	sent	send	VERB
bptjm-48	119	7	to	to	ADP
bptjm-48	119	8	the	the	DET
bptjm-48	119	9	golgi	golgi	NOUN
bptjm-48	119	10	apparatus	apparatus	NOUN
bptjm-48	119	11	,	,	PUNCT
bptjm-48	119	12	after	after	ADP
bptjm-48	119	13	which	which	PRON
bptjm-48	119	14	they	they	PRON
bptjm-48	119	15	are	be	AUX
bptjm-48	119	16	transported	transport	VERB
bptjm-48	119	17	to	to	ADP
bptjm-48	119	18	the	the	DET
bptjm-48	119	19	plasma	plasma	NOUN
bptjm-48	119	20	membrane	membrane	NOUN
bptjm-48	119	21	and	and	CCONJ
bptjm-48	119	22	combined	combine	VERB
bptjm-48	119	23	with	with	ADP
bptjm-48	119	24	mhc	mhc	PROPN
bptjm-48	119	25	class	class	NOUN
bptjm-48	119	26	i	i	PRON
bptjm-48	119	27	complexes	complexe	VERB
bptjm-48	119	28	via	via	ADP
bptjm-48	119	29	a	a	DET
bptjm-48	119	30	cross	cross	NOUN
bptjm-48	119	31	-	-	ADJ
bptjm-48	119	32	presentation	presentation	NOUN
bptjm-48	119	33	pathway.23	pathway.23	VERB
bptjm-48	119	34	an	an	DET
bptjm-48	119	35	immune	immune	ADJ
bptjm-48	119	36	response	response	NOUN
bptjm-48	119	37	arises	arise	VERB
bptjm-48	119	38	when	when	SCONJ
bptjm-48	119	39	cd8	cd8	PROPN
bptjm-48	119	40	+	+	PROPN
bptjm-48	119	41	t	t	NOUN
bptjm-48	119	42	cells	cell	NOUN
bptjm-48	119	43	are	be	AUX
bptjm-48	119	44	activated	activate	VERB
bptjm-48	119	45	as	as	ADP
bptjm-48	119	46	a	a	DET
bptjm-48	119	47	result	result	NOUN
bptjm-48	119	48	of	of	ADP
bptjm-48	119	49	the	the	DET
bptjm-48	119	50	peptides	peptide	NOUN
bptjm-48	119	51	reaching	reach	VERB
bptjm-48	119	52	the	the	DET
bptjm-48	119	53	cell	cell	NOUN
bptjm-48	119	54	surface	surface	NOUN
bptjm-48	119	55	of	of	ADP
bptjm-48	119	56	apcs	apcs	PROPN
bptjm-48	119	57	.	.	PROPN
bptjm-48	120	1	berkeley	berkeley	PROPN
bptjm-48	120	2	pharma	pharma	PROPN
bptjm-48	120	3	tech	tech	PROPN
bptjm-48	120	4	journal	journal	NOUN
bptjm-48	120	5	of	of	ADP
bptjm-48	120	6	medicine	medicine	NOUN
bptjm-48	120	7	|	|	ADV
bptjm-48	120	8	42	42	NUM
bptjm-48	120	9	figure	figure	NOUN
bptjm-48	120	10	6	6	NUM
bptjm-48	120	11	.	.	PUNCT
bptjm-48	121	1	molecular	molecular	ADJ
bptjm-48	121	2	mechanism	mechanism	NOUN
bptjm-48	121	3	of	of	ADP
bptjm-48	121	4	mrna	mrna	PROPN
bptjm-48	121	5	vaccines	vaccine	NOUN
bptjm-48	121	6	currently	currently	ADV
bptjm-48	121	7	,	,	PUNCT
bptjm-48	121	8	there	there	PRON
bptjm-48	121	9	are	be	VERB
bptjm-48	121	10	studies	study	NOUN
bptjm-48	121	11	being	be	AUX
bptjm-48	121	12	done	do	VERB
bptjm-48	121	13	assessing	assess	VERB
bptjm-48	121	14	the	the	DET
bptjm-48	121	15	potency	potency	NOUN
bptjm-48	121	16	of	of	ADP
bptjm-48	121	17	mrna	mrna	PROPN
bptjm-48	121	18	vaccines	vaccine	NOUN
bptjm-48	121	19	in	in	ADP
bptjm-48	121	20	patients	patient	NOUN
bptjm-48	121	21	with	with	ADP
bptjm-48	121	22	glioblastoma	glioblastoma	NOUN
bptjm-48	121	23	(	(	PUNCT
bptjm-48	121	24	gbm	gbm	NOUN
bptjm-48	121	25	)	)	PUNCT
bptjm-48	121	26	.	.	PUNCT
bptjm-48	122	1	in	in	ADP
bptjm-48	122	2	sayour	sayour	PROPN
bptjm-48	122	3	et	et	PROPN
bptjm-48	122	4	al	al	PROPN
bptjm-48	122	5	,	,	PUNCT
bptjm-48	122	6	the	the	DET
bptjm-48	122	7	objective	objective	NOUN
bptjm-48	122	8	is	be	AUX
bptjm-48	122	9	to	to	PART
bptjm-48	122	10	�	�	VERB
bptjm-48	122	11	rst	rst	PROPN
bptjm-48	122	12	assess	assess	VERB
bptjm-48	122	13	the	the	DET
bptjm-48	122	14	manufacturing	manufacturing	NOUN
bptjm-48	122	15	feasibility	feasibility	NOUN
bptjm-48	122	16	and	and	CCONJ
bptjm-48	122	17	safety	safety	NOUN
bptjm-48	122	18	of	of	ADP
bptjm-48	122	19	a	a	DET
bptjm-48	122	20	rna	rna	NOUN
bptjm-48	122	21	-	-	PUNCT
bptjm-48	122	22	lipid	lipid	NOUN
bptjm-48	122	23	particle	particle	NOUN
bptjm-48	122	24	(	(	PUNCT
bptjm-48	122	25	rna	rna	NOUN
bptjm-48	122	26	-	-	PUNCT
bptjm-48	122	27	lp	lp	NOUN
bptjm-48	122	28	)	)	PUNCT
bptjm-48	122	29	vaccine	vaccine	NOUN
bptjm-48	122	30	and	and	CCONJ
bptjm-48	122	31	then	then	ADV
bptjm-48	122	32	evaluate	evaluate	VERB
bptjm-48	122	33	the	the	DET
bptjm-48	122	34	maximum	maximum	ADJ
bptjm-48	122	35	tolerated	tolerate	VERB
bptjm-48	122	36	dose	dose	NOUN
bptjm-48	122	37	in	in	ADP
bptjm-48	122	38	gbm	gbm	PROPN
bptjm-48	122	39	patients.28	patients.28	PROPN
bptjm-48	122	40	participants	participant	NOUN
bptjm-48	122	41	will	will	AUX
bptjm-48	122	42	take	take	VERB
bptjm-48	122	43	part	part	NOUN
bptjm-48	122	44	in	in	ADP
bptjm-48	122	45	a	a	DET
bptjm-48	122	46	dose	dose	NOUN
bptjm-48	122	47	-	-	PUNCT
bptjm-48	122	48	escalation	escalation	NOUN
bptjm-48	122	49	study	study	NOUN
bptjm-48	122	50	using	use	VERB
bptjm-48	122	51	the	the	DET
bptjm-48	122	52	bayesian	bayesian	NOUN
bptjm-48	122	53	optimal	optimal	ADJ
bptjm-48	122	54	interval	interval	NOUN
bptjm-48	122	55	(	(	PUNCT
bptjm-48	122	56	boin	boin	NOUN
bptjm-48	122	57	)	)	PUNCT
bptjm-48	122	58	design	design	NOUN
bptjm-48	122	59	with	with	ADP
bptjm-48	122	60	an	an	DET
bptjm-48	122	61	initial	initial	ADJ
bptjm-48	122	62	embedded	embed	VERB
bptjm-48	122	63	accelerated	accelerate	VERB
bptjm-48	122	64	titration	titration	NOUN
bptjm-48	122	65	design	design	NOUN
bptjm-48	122	66	(	(	PUNCT
bptjm-48	122	67	atd).28	atd).28	ADJ
bptjm-48	122	68	in	in	ADP
bptjm-48	122	69	other	other	ADJ
bptjm-48	122	70	studies	study	NOUN
bptjm-48	122	71	,	,	PUNCT
bptjm-48	122	72	such	such	ADJ
bptjm-48	122	73	as	as	ADP
bptjm-48	122	74	desjardins	desjardin	NOUN
bptjm-48	122	75	et	et	PROPN
bptjm-48	122	76	al	al	PROPN
bptjm-48	122	77	,	,	PUNCT
bptjm-48	122	78	mrna	mrna	PROPN
bptjm-48	122	79	is	be	AUX
bptjm-48	122	80	currently	currently	ADV
bptjm-48	122	81	being	be	AUX
bptjm-48	122	82	combined	combine	VERB
bptjm-48	122	83	with	with	ADP
bptjm-48	122	84	dendritic	dendritic	ADJ
bptjm-48	122	85	cell	cell	NOUN
bptjm-48	122	86	vaccines	vaccine	NOUN
bptjm-48	122	87	and	and	CCONJ
bptjm-48	122	88	then	then	ADV
bptjm-48	122	89	evaluated	evaluate	VERB
bptjm-48	122	90	for	for	ADP
bptjm-48	122	91	feasibility	feasibility	NOUN
bptjm-48	122	92	,	,	PUNCT
bptjm-48	122	93	potential	potential	ADJ
bptjm-48	122	94	adverse	adverse	ADJ
bptjm-48	122	95	e	e	NOUN
bptjm-48	122	96	�	�	NOUN
bptjm-48	122	97	ects	ect	NOUN
bptjm-48	122	98	,	,	PUNCT
bptjm-48	122	99	and	and	CCONJ
bptjm-48	122	100	survival	survival	ADJ
bptjm-48	122	101	rates.29	rates.29	NOUN
bptjm-48	122	102	similar	similar	ADJ
bptjm-48	122	103	to	to	ADP
bptjm-48	122	104	clinical	clinical	ADJ
bptjm-48	122	105	trials	trial	NOUN
bptjm-48	122	106	using	use	VERB
bptjm-48	122	107	dna	dna	PROPN
bptjm-48	122	108	vaccines	vaccine	NOUN
bptjm-48	122	109	,	,	PUNCT
bptjm-48	122	110	the	the	DET
bptjm-48	122	111	purpose	purpose	NOUN
bptjm-48	122	112	of	of	ADP
bptjm-48	122	113	the	the	DET
bptjm-48	122	114	experiments	experiment	NOUN
bptjm-48	122	115	led	lead	VERB
bptjm-48	122	116	by	by	ADP
bptjm-48	122	117	sayour	sayour	NOUN
bptjm-48	122	118	and	and	CCONJ
bptjm-48	122	119	desjardins	desjardin	NOUN
bptjm-48	122	120	et	et	PROPN
bptjm-48	122	121	al	al	PROPN
bptjm-48	122	122	.	.	PROPN
bptjm-48	122	123	is	be	AUX
bptjm-48	122	124	to	to	PART
bptjm-48	122	125	advance	advance	VERB
bptjm-48	122	126	the	the	DET
bptjm-48	122	127	therapies	therapy	NOUN
bptjm-48	122	128	available	available	ADJ
bptjm-48	122	129	for	for	ADP
bptjm-48	122	130	gbm	gbm	NOUN
bptjm-48	122	131	patients	patient	NOUN
bptjm-48	122	132	.	.	PUNCT
bptjm-48	123	1	as	as	SCONJ
bptjm-48	123	2	their	their	PRON
bptjm-48	123	3	approach	approach	NOUN
bptjm-48	123	4	uses	use	VERB
bptjm-48	123	5	less	less	ADV
bptjm-48	123	6	-	-	PUNCT
bptjm-48	123	7	studied	study	VERB
bptjm-48	123	8	mrna	mrna	PROPN
bptjm-48	123	9	vaccines	vaccine	NOUN
bptjm-48	123	10	,	,	PUNCT
bptjm-48	123	11	the	the	DET
bptjm-48	123	12	current	current	ADJ
bptjm-48	123	13	initiative	initiative	NOUN
bptjm-48	123	14	is	be	AUX
bptjm-48	123	15	to	to	PART
bptjm-48	123	16	evaluate	evaluate	VERB
bptjm-48	123	17	the	the	DET
bptjm-48	123	18	potency	potency	NOUN
bptjm-48	123	19	of	of	ADP
bptjm-48	123	20	these	these	DET
bptjm-48	123	21	vaccines	vaccine	NOUN
bptjm-48	123	22	in	in	ADP
bptjm-48	123	23	patients	patient	NOUN
bptjm-48	123	24	.	.	PUNCT
bptjm-48	124	1	4.4	4.4	NUM
bptjm-48	124	2	autologous	autologous	ADJ
bptjm-48	124	3	dendritic	dendritic	ADJ
bptjm-48	124	4	cells	cell	NOUN
bptjm-48	124	5	(	(	PUNCT
bptjm-48	124	6	dc	dc	PROPN
bptjm-48	124	7	)	)	PUNCT
bptjm-48	124	8	vaccines	vaccine	NOUN
bptjm-48	124	9	autologous	autologous	ADJ
bptjm-48	124	10	dc	dc	PROPN
bptjm-48	124	11	vaccines	vaccine	NOUN
bptjm-48	124	12	are	be	AUX
bptjm-48	124	13	composed	compose	VERB
bptjm-48	124	14	of	of	ADP
bptjm-48	124	15	autologous	autologous	ADJ
bptjm-48	124	16	,	,	PUNCT
bptjm-48	124	17	immature	immature	ADJ
bptjm-48	124	18	dendritic	dendritic	ADJ
bptjm-48	124	19	cells	cell	NOUN
bptjm-48	124	20	(	(	PUNCT
bptjm-48	124	21	dcs	dcs	PROPN
bptjm-48	124	22	)	)	PUNCT
bptjm-48	124	23	with	with	ADP
bptjm-48	124	24	potential	potential	ADJ
bptjm-48	124	25	immunostimulating	immunostimulating	NOUN
bptjm-48	124	26	and	and	CCONJ
bptjm-48	124	27	antineoplastic	antineoplastic	ADJ
bptjm-48	124	28	abilities	ability	NOUN
bptjm-48	124	29	.	.	PUNCT
bptjm-48	125	1	upon	upon	SCONJ
bptjm-48	125	2	leukapheresis	leukapheresis	NOUN
bptjm-48	125	3	,	,	PUNCT
bptjm-48	125	4	immature	immature	ADJ
bptjm-48	125	5	dendritic	dendritic	ADJ
bptjm-48	125	6	cells	cell	NOUN
bptjm-48	125	7	are	be	AUX
bptjm-48	125	8	isolated	isolate	VERB
bptjm-48	125	9	and	and	CCONJ
bptjm-48	125	10	re	re	VERB
bptjm-48	125	11	-	-	VERB
bptjm-48	125	12	administered	administer	VERB
bptjm-48	125	13	intratumorally	intratumorally	ADV
bptjm-48	125	14	.	.	PUNCT
bptjm-48	126	1	the	the	DET
bptjm-48	126	2	immature	immature	ADJ
bptjm-48	126	3	dcs	dcs	PROPN
bptjm-48	126	4	internalize	internalize	VERB
bptjm-48	126	5	and	and	CCONJ
bptjm-48	126	6	process	process	VERB
bptjm-48	126	7	berkeley	berkeley	PROPN
bptjm-48	126	8	pharma	pharma	PROPN
bptjm-48	126	9	tech	tech	NOUN
bptjm-48	126	10	journal	journal	NOUN
bptjm-48	126	11	of	of	ADP
bptjm-48	126	12	medicine	medicine	NOUN
bptjm-48	127	1	|	|	ADV
bptjm-48	127	2	43	43	NUM
bptjm-48	127	3	the	the	DET
bptjm-48	127	4	neoantigens	neoantigen	NOUN
bptjm-48	127	5	or	or	CCONJ
bptjm-48	127	6	tumor	tumor	NOUN
bptjm-48	127	7	-	-	PUNCT
bptjm-48	127	8	associated	associate	VERB
bptjm-48	127	9	antigens	antigen	NOUN
bptjm-48	127	10	(	(	PUNCT
bptjm-48	127	11	taas	taas	NOUN
bptjm-48	127	12	)	)	PUNCT
bptjm-48	127	13	,	,	PUNCT
bptjm-48	127	14	migrate	migrate	VERB
bptjm-48	127	15	to	to	ADP
bptjm-48	127	16	the	the	DET
bptjm-48	127	17	lymphatic	lymphatic	ADJ
bptjm-48	127	18	system	system	NOUN
bptjm-48	127	19	,	,	PUNCT
bptjm-48	127	20	and	and	CCONJ
bptjm-48	127	21	expose	expose	VERB
bptjm-48	127	22	the	the	DET
bptjm-48	127	23	immune	immune	ADJ
bptjm-48	127	24	system	system	NOUN
bptjm-48	127	25	to	to	ADP
bptjm-48	127	26	the	the	DET
bptjm-48	127	27	taas	taas	NOUN
bptjm-48	127	28	,	,	PUNCT
bptjm-48	127	29	thereby	thereby	ADV
bptjm-48	127	30	inducing	induce	VERB
bptjm-48	127	31	a	a	DET
bptjm-48	127	32	speci	speci	ADJ
bptjm-48	127	33	�	�	NOUN
bptjm-48	127	34	c	c	PROPN
bptjm-48	127	35	cytotoxic	cytotoxic	ADJ
bptjm-48	127	36	t	t	NOUN
bptjm-48	127	37	-	-	PUNCT
bptjm-48	127	38	lymphocyte	lymphocyte	NOUN
bptjm-48	127	39	(	(	PUNCT
bptjm-48	127	40	ctl	ctl	PROPN
bptjm-48	127	41	)	)	PUNCT
bptjm-48	127	42	response	response	NOUN
bptjm-48	127	43	against	against	ADP
bptjm-48	127	44	the	the	DET
bptjm-48	127	45	cancer	cancer	NOUN
bptjm-48	127	46	cells	cell	NOUN
bptjm-48	127	47	,	,	PUNCT
bptjm-48	127	48	leading	lead	VERB
bptjm-48	127	49	to	to	ADP
bptjm-48	127	50	tumor	tumor	NOUN
bptjm-48	127	51	cell	cell	NOUN
bptjm-48	127	52	lysis	lysis	NOUN
bptjm-48	127	53	.	.	PUNCT
bptjm-48	128	1	the	the	DET
bptjm-48	128	2	process	process	NOUN
bptjm-48	128	3	of	of	ADP
bptjm-48	128	4	vaccination	vaccination	NOUN
bptjm-48	128	5	has	have	VERB
bptjm-48	128	6	the	the	DET
bptjm-48	128	7	potential	potential	NOUN
bptjm-48	128	8	to	to	PART
bptjm-48	128	9	either	either	CCONJ
bptjm-48	128	10	reinforce	reinforce	VERB
bptjm-48	128	11	the	the	DET
bptjm-48	128	12	reaction	reaction	NOUN
bptjm-48	128	13	against	against	ADP
bptjm-48	128	14	taas	taas	NOUN
bptjm-48	128	15	or	or	CCONJ
bptjm-48	128	16	induce	induce	VERB
bptjm-48	128	17	a	a	DET
bptjm-48	128	18	new	new	ADJ
bptjm-48	128	19	reaction	reaction	NOUN
bptjm-48	128	20	.	.	PUNCT
bptjm-48	129	1	the	the	DET
bptjm-48	129	2	mechanism	mechanism	NOUN
bptjm-48	129	3	of	of	ADP
bptjm-48	129	4	action	action	NOUN
bptjm-48	129	5	for	for	ADP
bptjm-48	129	6	dc	dc	PROPN
bptjm-48	129	7	vaccines	vaccine	NOUN
bptjm-48	129	8	involves	involve	VERB
bptjm-48	129	9	the	the	DET
bptjm-48	129	10	mhc	mhc	PROPN
bptjm-48	129	11	-	-	PUNCT
bptjm-48	129	12	ii	ii	PROPN
bptjm-48	129	13	molecules	molecule	NOUN
bptjm-48	129	14	on	on	ADP
bptjm-48	129	15	the	the	DET
bptjm-48	129	16	surface	surface	NOUN
bptjm-48	129	17	of	of	ADP
bptjm-48	129	18	the	the	DET
bptjm-48	129	19	dcs	dcs	PROPN
bptjm-48	129	20	,	,	PUNCT
bptjm-48	129	21	which	which	PRON
bptjm-48	129	22	make	make	VERB
bptjm-48	129	23	them	they	PRON
bptjm-48	129	24	professional	professional	ADJ
bptjm-48	129	25	antigen	antigen	NOUN
bptjm-48	129	26	-	-	PUNCT
bptjm-48	129	27	presenting	present	VERB
bptjm-48	129	28	cells	cell	NOUN
bptjm-48	129	29	(	(	PUNCT
bptjm-48	129	30	apcs	apc	NOUN
bptjm-48	129	31	)	)	PUNCT
bptjm-48	129	32	.	.	PUNCT
bptjm-48	130	1	the	the	DET
bptjm-48	130	2	dcs	dcs	PROPN
bptjm-48	130	3	move	move	VERB
bptjm-48	130	4	between	between	ADP
bptjm-48	130	5	lymphoid	lymphoid	NOUN
bptjm-48	130	6	and	and	CCONJ
bptjm-48	130	7	nonlymphoid	nonlymphoid	VERB
bptjm-48	130	8	tissues	tissue	NOUN
bptjm-48	130	9	to	to	PART
bptjm-48	130	10	regulate	regulate	VERB
bptjm-48	130	11	chemokine	chemokine	ADJ
bptjm-48	130	12	gradients	gradient	NOUN
bptjm-48	130	13	and	and	CCONJ
bptjm-48	130	14	cytokine	cytokine	ADJ
bptjm-48	130	15	gradients	gradient	NOUN
bptjm-48	130	16	and	and	CCONJ
bptjm-48	130	17	active	active	ADJ
bptjm-48	130	18	t	t	PROPN
bptjm-48	130	19	-	-	PUNCT
bptjm-48	130	20	killers	killers	PROPN
bptjm-48	130	21	.	.	PUNCT
bptjm-48	131	1	to	to	PART
bptjm-48	131	2	create	create	VERB
bptjm-48	131	3	a	a	DET
bptjm-48	131	4	dc	dc	PROPN
bptjm-48	131	5	vaccine	vaccine	NOUN
bptjm-48	131	6	,	,	PUNCT
bptjm-48	131	7	immature	immature	ADJ
bptjm-48	131	8	dendritic	dendritic	ADJ
bptjm-48	131	9	cells	cell	NOUN
bptjm-48	131	10	are	be	AUX
bptjm-48	131	11	isolated	isolate	VERB
bptjm-48	131	12	from	from	ADP
bptjm-48	131	13	human	human	ADJ
bptjm-48	131	14	blood	blood	NOUN
bptjm-48	131	15	,	,	PUNCT
bptjm-48	131	16	then	then	ADV
bptjm-48	131	17	utilize	utilize	VERB
bptjm-48	131	18	a	a	DET
bptjm-48	131	19	cytokine	cytokine	ADJ
bptjm-48	131	20	cocktail	cocktail	NOUN
bptjm-48	131	21	and	and	CCONJ
bptjm-48	131	22	autologous	autologous	ADJ
bptjm-48	131	23	tumor	tumor	NOUN
bptjm-48	131	24	antigens	antigen	NOUN
bptjm-48	131	25	to	to	PART
bptjm-48	131	26	promote	promote	VERB
bptjm-48	131	27	maturation	maturation	NOUN
bptjm-48	131	28	,	,	PUNCT
bptjm-48	131	29	then	then	ADV
bptjm-48	131	30	readminister	readminister	VERB
bptjm-48	131	31	the	the	DET
bptjm-48	131	32	autologous	autologous	ADJ
bptjm-48	131	33	dcs	dcs	PROPN
bptjm-48	131	34	back	back	ADV
bptjm-48	131	35	into	into	ADP
bptjm-48	131	36	the	the	DET
bptjm-48	131	37	human	human	ADJ
bptjm-48	131	38	body	body	NOUN
bptjm-48	131	39	via	via	ADP
bptjm-48	131	40	the	the	DET
bptjm-48	131	41	dc	dc	PROPN
bptjm-48	131	42	vaccine.30	vaccine.30	NOUN
bptjm-48	131	43	figure	figure	VERB
bptjm-48	131	44	7	7	NUM
bptjm-48	131	45	.	.	PUNCT
bptjm-48	132	1	an	an	DET
bptjm-48	132	2	overview	overview	NOUN
bptjm-48	132	3	of	of	ADP
bptjm-48	132	4	the	the	DET
bptjm-48	132	5	mechanism	mechanism	NOUN
bptjm-48	132	6	of	of	ADP
bptjm-48	132	7	action	action	NOUN
bptjm-48	132	8	of	of	ADP
bptjm-48	132	9	autologous	autologous	ADJ
bptjm-48	132	10	dc	dc	PROPN
bptjm-48	132	11	vaccines	vaccine	NOUN
bptjm-48	132	12	the	the	DET
bptjm-48	132	13	e	e	PROPN
bptjm-48	132	14	�	�	PROPN
bptjm-48	132	15	cacy	cacy	NOUN
bptjm-48	132	16	of	of	ADP
bptjm-48	132	17	the	the	DET
bptjm-48	132	18	dc	dc	PROPN
bptjm-48	132	19	vaccine	vaccine	NOUN
bptjm-48	132	20	is	be	AUX
bptjm-48	132	21	dependent	dependent	ADJ
bptjm-48	132	22	on	on	ADP
bptjm-48	132	23	the	the	DET
bptjm-48	132	24	quantity	quantity	NOUN
bptjm-48	132	25	of	of	ADP
bptjm-48	132	26	neoantigens	neoantigen	NOUN
bptjm-48	132	27	present	present	ADJ
bptjm-48	132	28	in	in	ADP
bptjm-48	132	29	the	the	DET
bptjm-48	132	30	tumor	tumor	NOUN
bptjm-48	132	31	.	.	PUNCT
bptjm-48	133	1	the	the	DET
bptjm-48	133	2	tumor	tumor	ADJ
bptjm-48	133	3	mutational	mutational	ADJ
bptjm-48	133	4	burden	burden	NOUN
bptjm-48	133	5	(	(	PUNCT
bptjm-48	133	6	tmb	tmb	NOUN
bptjm-48	133	7	)	)	PUNCT
bptjm-48	133	8	,	,	PUNCT
bptjm-48	133	9	representing	represent	VERB
bptjm-48	133	10	the	the	DET
bptjm-48	133	11	frequency	frequency	NOUN
bptjm-48	133	12	of	of	ADP
bptjm-48	133	13	neoantigen	neoantigen	PROPN
bptjm-48	133	14	-	-	PUNCT
bptjm-48	133	15	associated	associate	VERB
bptjm-48	133	16	mutations	mutation	NOUN
bptjm-48	133	17	per	per	ADP
bptjm-48	133	18	megabase	megabase	NOUN
bptjm-48	133	19	,	,	PUNCT
bptjm-48	133	20	is	be	AUX
bptjm-48	133	21	about	about	ADV
bptjm-48	133	22	10	10	NUM
bptjm-48	133	23	mutations/1.4	mutations/1.4	PROPN
bptjm-48	133	24	mb.31	mb.31	PROPN
bptjm-48	133	25	for	for	ADP
bptjm-48	133	26	patients	patient	NOUN
bptjm-48	133	27	undergoing	undergo	VERB
bptjm-48	133	28	tmz	tmz	PROPN
bptjm-48	133	29	chemotherapy	chemotherapy	NOUN
bptjm-48	133	30	,	,	PUNCT
bptjm-48	133	31	the	the	DET
bptjm-48	133	32	tmb	tmb	PROPN
bptjm-48	133	33	typically	typically	ADV
bptjm-48	133	34	experiences	experience	VERB
bptjm-48	133	35	an	an	DET
bptjm-48	133	36	increase	increase	NOUN
bptjm-48	133	37	,	,	PUNCT
bptjm-48	133	38	thus	thus	ADV
bptjm-48	133	39	making	make	VERB
bptjm-48	133	40	neoantigen	neoantigen	ADJ
bptjm-48	133	41	discovery	discovery	PROPN
bptjm-48	133	42	more	more	ADV
bptjm-48	133	43	feasible	feasible	ADJ
bptjm-48	133	44	.	.	PUNCT
bptjm-48	134	1	berkeley	berkeley	PROPN
bptjm-48	134	2	pharma	pharma	PROPN
bptjm-48	134	3	tech	tech	PROPN
bptjm-48	134	4	journal	journal	NOUN
bptjm-48	134	5	of	of	ADP
bptjm-48	134	6	medicine	medicine	NOUN
bptjm-48	134	7	|	|	ADV
bptjm-48	134	8	44	44	NUM
bptjm-48	134	9	the	the	DET
bptjm-48	134	10	autologous	autologous	ADJ
bptjm-48	134	11	neoantigen	neoantigen	NOUN
bptjm-48	134	12	-	-	PUNCT
bptjm-48	134	13	based	base	VERB
bptjm-48	134	14	dc	dc	PROPN
bptjm-48	134	15	vaccine	vaccine	NOUN
bptjm-48	134	16	neo	neo	NOUN
bptjm-48	134	17	-	-	ADJ
bptjm-48	134	18	modc	modc	ADJ
bptjm-48	134	19	was	be	AUX
bptjm-48	134	20	tested	test	VERB
bptjm-48	134	21	in	in	ADP
bptjm-48	134	22	a	a	DET
bptjm-48	134	23	patient	patient	NOUN
bptjm-48	134	24	with	with	ADP
bptjm-48	134	25	advanced	advanced	ADJ
bptjm-48	134	26	metastatic	metastatic	ADJ
bptjm-48	134	27	gastric	gastric	ADJ
bptjm-48	134	28	cancer	cancer	NOUN
bptjm-48	134	29	(	(	PUNCT
bptjm-48	134	30	35661819	35661819	NUM
bptjm-48	134	31	)	)	PUNCT
bptjm-48	134	32	.	.	PUNCT
bptjm-48	135	1	the	the	DET
bptjm-48	135	2	patient	patient	NOUN
bptjm-48	135	3	had	have	AUX
bptjm-48	135	4	initially	initially	ADV
bptjm-48	135	5	undergone	undergo	VERB
bptjm-48	135	6	laparoscopic	laparoscopic	NOUN
bptjm-48	135	7	-	-	PUNCT
bptjm-48	135	8	assisted	assist	VERB
bptjm-48	135	9	d2	d2	PROPN
bptjm-48	135	10	radical	radical	ADJ
bptjm-48	135	11	distal	distal	NOUN
bptjm-48	135	12	gastrectomy	gastrectomy	NOUN
bptjm-48	135	13	.	.	PUNCT
bptjm-48	136	1	multiplex	multiplex	PROPN
bptjm-48	136	2	immunohistochemistry	immunohistochemistry	PROPN
bptjm-48	136	3	(	(	PUNCT
bptjm-48	136	4	ihc	ihc	PROPN
bptjm-48	136	5	)	)	PUNCT
bptjm-48	136	6	revealed	reveal	VERB
bptjm-48	136	7	low	low	ADJ
bptjm-48	136	8	expression	expression	NOUN
bptjm-48	136	9	of	of	ADP
bptjm-48	136	10	pd-1	pd-1	ADJ
bptjm-48	136	11	and	and	CCONJ
bptjm-48	136	12	high	high	ADJ
bptjm-48	136	13	expression	expression	NOUN
bptjm-48	136	14	of	of	ADP
bptjm-48	136	15	pd	pd	PROPN
bptjm-48	136	16	-	-	PROPN
bptjm-48	136	17	l1	l1	PROPN
bptjm-48	136	18	.	.	PUNCT
bptjm-48	137	1	once	once	SCONJ
bptjm-48	137	2	the	the	DET
bptjm-48	137	3	patient	patient	NOUN
bptjm-48	137	4	chose	choose	VERB
bptjm-48	137	5	to	to	PART
bptjm-48	137	6	alter	alter	VERB
bptjm-48	137	7	their	their	PRON
bptjm-48	137	8	treatment	treatment	NOUN
bptjm-48	137	9	to	to	PART
bptjm-48	137	10	receive	receive	VERB
bptjm-48	137	11	the	the	DET
bptjm-48	137	12	aforementioned	aforementioned	ADJ
bptjm-48	137	13	trial	trial	NOUN
bptjm-48	137	14	’s	’s	PART
bptjm-48	137	15	treatment	treatment	NOUN
bptjm-48	137	16	methods	method	NOUN
bptjm-48	137	17	,	,	PUNCT
bptjm-48	137	18	neo	neo	NOUN
bptjm-48	137	19	-	-	ADJ
bptjm-48	137	20	modc	modc	ADJ
bptjm-48	137	21	vaccines	vaccine	NOUN
bptjm-48	137	22	were	be	AUX
bptjm-48	137	23	created	create	VERB
bptjm-48	137	24	using	use	VERB
bptjm-48	137	25	autologous	autologous	ADJ
bptjm-48	137	26	dendritic	dendritic	ADJ
bptjm-48	137	27	cells	cell	NOUN
bptjm-48	137	28	generated	generate	VERB
bptjm-48	137	29	from	from	ADP
bptjm-48	137	30	monocytes	monocyte	NOUN
bptjm-48	137	31	in	in	ADP
bptjm-48	137	32	peripheral	peripheral	ADJ
bptjm-48	137	33	blood	blood	NOUN
bptjm-48	137	34	mononuclear	mononuclear	VERB
bptjm-48	137	35	cells.14	cells.14	PROPN
bptjm-48	137	36	neo	neo	PROPN
bptjm-48	137	37	-	-	ADJ
bptjm-48	137	38	modc	modc	ADJ
bptjm-48	137	39	was	be	AUX
bptjm-48	137	40	administered	administer	VERB
bptjm-48	137	41	on	on	ADP
bptjm-48	137	42	its	its	PRON
bptjm-48	137	43	own	own	ADJ
bptjm-48	137	44	initially	initially	ADV
bptjm-48	137	45	,	,	PUNCT
bptjm-48	137	46	however	however	ADV
bptjm-48	137	47	after	after	ADP
bptjm-48	137	48	two	two	NUM
bptjm-48	137	49	months	month	NOUN
bptjm-48	137	50	,	,	PUNCT
bptjm-48	137	51	due	due	ADP
bptjm-48	137	52	to	to	ADP
bptjm-48	137	53	continued	continue	VERB
bptjm-48	137	54	progression	progression	NOUN
bptjm-48	137	55	of	of	ADP
bptjm-48	137	56	the	the	DET
bptjm-48	137	57	tumor	tumor	NOUN
bptjm-48	137	58	,	,	PUNCT
bptjm-48	137	59	it	it	PRON
bptjm-48	137	60	was	be	AUX
bptjm-48	137	61	administered	administer	VERB
bptjm-48	137	62	alongside	alongside	ADP
bptjm-48	137	63	combination	combination	NOUN
bptjm-48	137	64	therapy	therapy	NOUN
bptjm-48	137	65	with	with	ADP
bptjm-48	137	66	nivolumab	nivolumab	NOUN
bptjm-48	137	67	—	—	PUNCT
bptjm-48	137	68	a	a	DET
bptjm-48	137	69	monoclonal	monoclonal	NOUN
bptjm-48	137	70	antibody	antibody	NOUN
bptjm-48	137	71	used	use	VERB
bptjm-48	137	72	to	to	PART
bptjm-48	137	73	treat	treat	VERB
bptjm-48	137	74	di	di	NOUN
bptjm-48	137	75	�	�	PROPN
bptjm-48	137	76	erent	erent	NOUN
bptjm-48	137	77	forms	form	NOUN
bptjm-48	137	78	of	of	ADP
bptjm-48	137	79	cancer	cancer	NOUN
bptjm-48	137	80	.	.	PUNCT
bptjm-48	138	1	the	the	DET
bptjm-48	138	2	neo	neo	ADJ
bptjm-48	138	3	-	-	ADJ
bptjm-48	138	4	modc	modc	ADJ
bptjm-48	138	5	vaccine	vaccine	NOUN
bptjm-48	138	6	elicited	elicit	VERB
bptjm-48	138	7	a	a	DET
bptjm-48	138	8	healthy	healthy	ADJ
bptjm-48	138	9	immunogenic	immunogenic	ADJ
bptjm-48	138	10	response	response	NOUN
bptjm-48	138	11	via	via	ADP
bptjm-48	138	12	an	an	DET
bptjm-48	138	13	increase	increase	NOUN
bptjm-48	138	14	in	in	ADP
bptjm-48	138	15	neoantigen	neoantigen	PROPN
bptjm-48	138	16	-	-	PUNCT
bptjm-48	138	17	speci	speci	X
bptjm-48	138	18	�	�	PROPN
bptjm-48	138	19	c	c	PROPN
bptjm-48	138	20	cd4	cd4	PROPN
bptjm-48	138	21	+	+	PROPN
bptjm-48	138	22	and	and	CCONJ
bptjm-48	138	23	cd8	cd8	PROPN
bptjm-48	138	24	+	+	PROPN
bptjm-48	138	25	t	t	PROPN
bptjm-48	138	26	cell	cell	NOUN
bptjm-48	138	27	activation	activation	NOUN
bptjm-48	138	28	,	,	PUNCT
bptjm-48	138	29	as	as	ADV
bptjm-48	138	30	well	well	ADV
bptjm-48	138	31	as	as	ADP
bptjm-48	138	32	an	an	DET
bptjm-48	138	33	increase	increase	NOUN
bptjm-48	138	34	in	in	ADP
bptjm-48	138	35	neoantigen	neoantigen	PROPN
bptjm-48	138	36	-	-	PUNCT
bptjm-48	138	37	speci	speci	X
bptjm-48	138	38	�	�	PROPN
bptjm-48	138	39	c	c	PROPN
bptjm-48	138	40	t	t	NOUN
bptjm-48	138	41	cell	cell	NOUN
bptjm-48	138	42	clones	clone	NOUN
bptjm-48	138	43	in	in	ADP
bptjm-48	138	44	peripheral	peripheral	ADJ
bptjm-48	138	45	blood	blood	NOUN
bptjm-48	138	46	.	.	PUNCT
bptjm-48	139	1	upon	upon	SCONJ
bptjm-48	139	2	the	the	DET
bptjm-48	139	3	onset	onset	NOUN
bptjm-48	139	4	of	of	ADP
bptjm-48	139	5	combination	combination	NOUN
bptjm-48	139	6	therapy	therapy	NOUN
bptjm-48	139	7	,	,	PUNCT
bptjm-48	139	8	the	the	DET
bptjm-48	139	9	tumor	tumor	NOUN
bptjm-48	139	10	volume	volume	NOUN
bptjm-48	139	11	experienced	experience	VERB
bptjm-48	139	12	a	a	DET
bptjm-48	139	13	rapid	rapid	ADJ
bptjm-48	139	14	decrease	decrease	NOUN
bptjm-48	139	15	,	,	PUNCT
bptjm-48	139	16	and	and	CCONJ
bptjm-48	139	17	continued	continued	ADJ
bptjm-48	139	18	application	application	NOUN
bptjm-48	139	19	of	of	ADP
bptjm-48	139	20	the	the	DET
bptjm-48	139	21	neo	neo	ADJ
bptjm-48	139	22	-	-	ADJ
bptjm-48	139	23	modc	modc	ADJ
bptjm-48	139	24	vaccine	vaccine	NOUN
bptjm-48	139	25	resulted	result	VERB
bptjm-48	139	26	in	in	ADP
bptjm-48	139	27	complete	complete	ADJ
bptjm-48	139	28	regression	regression	NOUN
bptjm-48	139	29	for	for	ADP
bptjm-48	139	30	25	25	NUM
bptjm-48	139	31	months	month	NOUN
bptjm-48	139	32	until	until	ADP
bptjm-48	139	33	the	the	DET
bptjm-48	139	34	present	present	NOUN
bptjm-48	139	35	.	.	PUNCT
bptjm-48	140	1	to	to	PART
bptjm-48	140	2	study	study	VERB
bptjm-48	140	3	t	t	PROPN
bptjm-48	140	4	cell	cell	NOUN
bptjm-48	140	5	clone	clone	NOUN
bptjm-48	140	6	activation	activation	NOUN
bptjm-48	140	7	due	due	ADP
bptjm-48	140	8	to	to	ADP
bptjm-48	140	9	the	the	DET
bptjm-48	140	10	neo	neo	ADJ
bptjm-48	140	11	-	-	ADJ
bptjm-48	140	12	modc	modc	ADJ
bptjm-48	140	13	vaccine	vaccine	NOUN
bptjm-48	140	14	,	,	PUNCT
bptjm-48	140	15	primary	primary	ADJ
bptjm-48	140	16	tumor	tumor	NOUN
bptjm-48	140	17	tissue	tissue	NOUN
bptjm-48	140	18	and	and	CCONJ
bptjm-48	140	19	blood	blood	NOUN
bptjm-48	140	20	samples	sample	NOUN
bptjm-48	140	21	at	at	ADP
bptjm-48	140	22	di	di	NOUN
bptjm-48	140	23	�	�	PROPN
bptjm-48	140	24	erent	erent	NOUN
bptjm-48	140	25	intervals	interval	NOUN
bptjm-48	140	26	of	of	ADP
bptjm-48	140	27	vaccination	vaccination	NOUN
bptjm-48	140	28	were	be	AUX
bptjm-48	140	29	collected	collect	VERB
bptjm-48	140	30	.	.	PUNCT
bptjm-48	141	1	activated	activate	VERB
bptjm-48	141	2	peripheral	peripheral	ADJ
bptjm-48	141	3	blood	blood	NOUN
bptjm-48	141	4	lymphocytes	lymphocyte	NOUN
bptjm-48	141	5	(	(	PUNCT
bptjm-48	141	6	pbls	pbls	ADJ
bptjm-48	141	7	)	)	PUNCT
bptjm-48	141	8	containing	contain	VERB
bptjm-48	141	9	mutant	mutant	ADJ
bptjm-48	141	10	peptides	peptide	NOUN
bptjm-48	141	11	,	,	PUNCT
bptjm-48	141	12	tcrb	tcrb	NOUN
bptjm-48	141	13	clonotypes	clonotype	NOUN
bptjm-48	141	14	,	,	PUNCT
bptjm-48	141	15	and	and	CCONJ
bptjm-48	141	16	cdr3	cdr3	ADJ
bptjm-48	141	17	-	-	PUNCT
bptjm-48	141	18	regions	region	NOUN
bptjm-48	141	19	of	of	ADP
bptjm-48	141	20	the	the	DET
bptjm-48	141	21	tcrb	tcrb	NOUN
bptjm-48	141	22	chain	chain	NOUN
bptjm-48	141	23	were	be	AUX
bptjm-48	141	24	also	also	ADV
bptjm-48	141	25	analyzed	analyze	VERB
bptjm-48	141	26	.	.	PUNCT
bptjm-48	142	1	approximately	approximately	ADV
bptjm-48	142	2	35.3	35.3	NUM
bptjm-48	142	3	%	%	NOUN
bptjm-48	142	4	to	to	ADP
bptjm-48	142	5	86.5	86.5	NUM
bptjm-48	142	6	%	%	NOUN
bptjm-48	142	7	of	of	ADP
bptjm-48	142	8	tcrb	tcrb	NOUN
bptjm-48	142	9	clones	clone	NOUN
bptjm-48	142	10	in	in	ADP
bptjm-48	142	11	pbls	pbls	NOUN
bptjm-48	142	12	were	be	AUX
bptjm-48	142	13	found	find	VERB
bptjm-48	142	14	in	in	ADP
bptjm-48	142	15	the	the	DET
bptjm-48	142	16	tumor	tumor	NOUN
bptjm-48	142	17	tissues	tissue	NOUN
bptjm-48	142	18	,	,	PUNCT
bptjm-48	142	19	and	and	CCONJ
bptjm-48	142	20	the	the	DET
bptjm-48	142	21	frequency	frequency	NOUN
bptjm-48	142	22	of	of	ADP
bptjm-48	142	23	tumor	tumor	NOUN
bptjm-48	142	24	-	-	PUNCT
bptjm-48	142	25	enriched	enrich	VERB
bptjm-48	142	26	tcrb	tcrb	NOUN
bptjm-48	142	27	clones	clone	NOUN
bptjm-48	142	28	in	in	ADP
bptjm-48	142	29	pbls	pbls	NOUN
bptjm-48	142	30	increased	increase	VERB
bptjm-48	142	31	from	from	ADP
bptjm-48	142	32	0	0	NUM
bptjm-48	142	33	%	%	NOUN
bptjm-48	142	34	to	to	PART
bptjm-48	142	35	16.8	16.8	NUM
bptjm-48	142	36	%	%	NOUN
bptjm-48	142	37	after	after	ADP
bptjm-48	142	38	four	four	NUM
bptjm-48	142	39	doses	dose	NOUN
bptjm-48	142	40	of	of	ADP
bptjm-48	142	41	neo	neo	NOUN
bptjm-48	142	42	-	-	NOUN
bptjm-48	142	43	modc.14	modc.14	NOUN
bptjm-48	142	44	evidently	evidently	ADV
bptjm-48	142	45	,	,	PUNCT
bptjm-48	142	46	neo	neo	ADJ
bptjm-48	142	47	-	-	ADJ
bptjm-48	142	48	modc	modc	ADJ
bptjm-48	142	49	induced	induced	ADJ
bptjm-48	142	50	immunogenicity	immunogenicity	NOUN
bptjm-48	142	51	,	,	PUNCT
bptjm-48	142	52	however	however	ADV
bptjm-48	142	53	it	it	PRON
bptjm-48	142	54	required	require	VERB
bptjm-48	142	55	concurrent	concurrent	ADJ
bptjm-48	142	56	administration	administration	NOUN
bptjm-48	142	57	of	of	ADP
bptjm-48	142	58	nivolumab	nivolumab	NOUN
bptjm-48	142	59	to	to	PART
bptjm-48	142	60	produce	produce	VERB
bptjm-48	142	61	signi	signi	PROPN
bptjm-48	142	62	�	�	NOUN
bptjm-48	142	63	cant	cant	NOUN
bptjm-48	142	64	results	result	NOUN
bptjm-48	142	65	in	in	ADP
bptjm-48	142	66	tumor	tumor	NOUN
bptjm-48	142	67	regression	regression	NOUN
bptjm-48	142	68	.	.	PUNCT
bptjm-48	143	1	4.5	4.5	NUM
bptjm-48	143	2	immune	immune	ADJ
bptjm-48	143	3	checkpoint	checkpoint	NOUN
bptjm-48	143	4	blockade	blockade	NOUN
bptjm-48	143	5	therapy	therapy	NOUN
bptjm-48	143	6	many	many	ADJ
bptjm-48	143	7	signaling	signal	VERB
bptjm-48	143	8	pathways	pathway	NOUN
bptjm-48	143	9	associated	associate	VERB
bptjm-48	143	10	with	with	ADP
bptjm-48	143	11	the	the	DET
bptjm-48	143	12	development	development	NOUN
bptjm-48	143	13	of	of	ADP
bptjm-48	143	14	cancer	cancer	NOUN
bptjm-48	143	15	.	.	PUNCT
bptjm-48	144	1	but	but	CCONJ
bptjm-48	144	2	there	there	PRON
bptjm-48	144	3	are	be	VERB
bptjm-48	144	4	also	also	ADV
bptjm-48	144	5	key	key	ADJ
bptjm-48	144	6	regulatory	regulatory	ADJ
bptjm-48	144	7	checkpoints	checkpoint	NOUN
bptjm-48	144	8	termed	term	VERB
bptjm-48	144	9	immune	immune	ADJ
bptjm-48	144	10	checkpoints	checkpoint	NOUN
bptjm-48	144	11	that	that	PRON
bptjm-48	144	12	can	can	AUX
bptjm-48	144	13	negatively	negatively	ADV
bptjm-48	144	14	regulate	regulate	VERB
bptjm-48	144	15	these	these	DET
bptjm-48	144	16	same	same	ADJ
bptjm-48	144	17	signaling	signal	VERB
bptjm-48	144	18	pathways	pathway	NOUN
bptjm-48	144	19	.	.	PUNCT
bptjm-48	145	1	immune	immune	ADJ
bptjm-48	145	2	checkpoint	checkpoint	NOUN
bptjm-48	145	3	blockade	blockade	NOUN
bptjm-48	145	4	therapy	therapy	NOUN
bptjm-48	145	5	takes	take	VERB
bptjm-48	145	6	advantage	advantage	NOUN
bptjm-48	145	7	of	of	ADP
bptjm-48	145	8	these	these	DET
bptjm-48	145	9	checkpoints	checkpoint	NOUN
bptjm-48	145	10	and	and	CCONJ
bptjm-48	145	11	suppresses	suppress	VERB
bptjm-48	145	12	them	they	PRON
bptjm-48	145	13	,	,	PUNCT
bptjm-48	145	14	thereby	thereby	ADV
bptjm-48	145	15	limiting	limit	VERB
bptjm-48	145	16	tumor	tumor	NOUN
bptjm-48	145	17	progression	progression	NOUN
bptjm-48	145	18	.	.	PUNCT
bptjm-48	146	1	some	some	DET
bptjm-48	146	2	known	know	VERB
bptjm-48	146	3	signaling	signal	VERB
bptjm-48	146	4	molecules	molecule	NOUN
bptjm-48	146	5	berkeley	berkeley	PROPN
bptjm-48	146	6	pharma	pharma	PROPN
bptjm-48	146	7	tech	tech	NOUN
bptjm-48	146	8	journal	journal	NOUN
bptjm-48	146	9	of	of	ADP
bptjm-48	146	10	medicine	medicine	NOUN
bptjm-48	146	11	|	|	ADV
bptjm-48	146	12	45	45	NUM
bptjm-48	146	13	associated	associate	VERB
bptjm-48	146	14	with	with	ADP
bptjm-48	146	15	pathways	pathway	NOUN
bptjm-48	146	16	that	that	PRON
bptjm-48	146	17	lead	lead	VERB
bptjm-48	146	18	to	to	ADP
bptjm-48	146	19	cancer	cancer	NOUN
bptjm-48	146	20	development	development	NOUN
bptjm-48	146	21	include	include	VERB
bptjm-48	146	22	pd-1	pd-1	ADP
bptjm-48	146	23	,	,	PUNCT
bptjm-48	146	24	pd	pd	PROPN
bptjm-48	146	25	-	-	PROPN
bptjm-48	146	26	l1	l1	PROPN
bptjm-48	146	27	,	,	PUNCT
bptjm-48	146	28	and	and	CCONJ
bptjm-48	146	29	ctla-4.32,33	ctla-4.32,33	PROPN
bptjm-48	146	30	figure	figure	NOUN
bptjm-48	146	31	8	8	NUM
bptjm-48	146	32	.	.	PUNCT
bptjm-48	147	1	mechanisms	mechanism	NOUN
bptjm-48	147	2	of	of	ADP
bptjm-48	147	3	immune	immune	ADJ
bptjm-48	147	4	checkpoint	checkpoint	NOUN
bptjm-48	147	5	inhibitors	inhibitor	NOUN
bptjm-48	147	6	(	(	PUNCT
bptjm-48	147	7	icis	icis	PROPN
bptjm-48	147	8	)	)	PUNCT
bptjm-48	147	9	.	.	PUNCT
bptjm-48	148	1	icis	icis	PROPN
bptjm-48	148	2	act	act	PROPN
bptjm-48	148	3	on	on	ADP
bptjm-48	148	4	certain	certain	ADJ
bptjm-48	148	5	key	key	ADJ
bptjm-48	148	6	proteins	protein	NOUN
bptjm-48	148	7	involved	involve	VERB
bptjm-48	148	8	in	in	ADP
bptjm-48	148	9	the	the	DET
bptjm-48	148	10	signaling	signal	VERB
bptjm-48	148	11	pathways	pathway	NOUN
bptjm-48	148	12	that	that	PRON
bptjm-48	148	13	activate	activate	VERB
bptjm-48	148	14	t	t	NOUN
bptjm-48	148	15	cells	cell	NOUN
bptjm-48	148	16	.	.	PUNCT
bptjm-48	149	1	(	(	PUNCT
bptjm-48	149	2	a	a	X
bptjm-48	149	3	)	)	PUNCT
bptjm-48	149	4	t	t	NOUN
bptjm-48	149	5	cells	cell	NOUN
bptjm-48	149	6	,	,	PUNCT
bptjm-48	149	7	via	via	ADP
bptjm-48	149	8	their	their	PRON
bptjm-48	149	9	cd28	cd28	PROPN
bptjm-48	149	10	protein	protein	NOUN
bptjm-48	149	11	,	,	PUNCT
bptjm-48	149	12	interact	interact	VERB
bptjm-48	149	13	with	with	ADP
bptjm-48	149	14	antigen	antigen	ADV
bptjm-48	149	15	-	-	PUNCT
bptjm-48	149	16	presenting	present	VERB
bptjm-48	149	17	cells	cell	NOUN
bptjm-48	149	18	(	(	PUNCT
bptjm-48	149	19	acps	acp	NOUN
bptjm-48	149	20	)	)	PUNCT
bptjm-48	149	21	and	and	CCONJ
bptjm-48	149	22	their	their	PRON
bptjm-48	149	23	cd80	cd80	PROPN
bptjm-48	149	24	or	or	CCONJ
bptjm-48	149	25	cd86	cd86	PROPN
bptjm-48	149	26	proteins	protein	NOUN
bptjm-48	149	27	.	.	PUNCT
bptjm-48	150	1	this	this	DET
bptjm-48	150	2	interaction	interaction	NOUN
bptjm-48	150	3	can	can	AUX
bptjm-48	150	4	lead	lead	VERB
bptjm-48	150	5	to	to	ADP
bptjm-48	150	6	subsequent	subsequent	ADJ
bptjm-48	150	7	activation	activation	NOUN
bptjm-48	150	8	of	of	ADP
bptjm-48	150	9	the	the	DET
bptjm-48	150	10	t	t	NOUN
bptjm-48	150	11	-	-	PUNCT
bptjm-48	150	12	cell	cell	NOUN
bptjm-48	150	13	.	.	PUNCT
bptjm-48	151	1	another	another	DET
bptjm-48	151	2	signaling	signal	VERB
bptjm-48	151	3	protein	protein	NOUN
bptjm-48	151	4	on	on	ADP
bptjm-48	151	5	the	the	DET
bptjm-48	151	6	same	same	ADJ
bptjm-48	151	7	t	t	NOUN
bptjm-48	151	8	-	-	PUNCT
bptjm-48	151	9	cell	cell	NOUN
bptjm-48	151	10	,	,	PUNCT
bptjm-48	151	11	ctla-4	ctla-4	NOUN
bptjm-48	151	12	,	,	PUNCT
bptjm-48	151	13	has	have	VERB
bptjm-48	151	14	more	more	ADJ
bptjm-48	151	15	a	a	DET
bptjm-48	151	16	�	�	NOUN
bptjm-48	151	17	nity	nity	NOUN
bptjm-48	151	18	for	for	ADP
bptjm-48	151	19	the	the	DET
bptjm-48	151	20	cd80	cd80	PROPN
bptjm-48	151	21	and	and	CCONJ
bptjm-48	151	22	cd86	cd86	PROPN
bptjm-48	151	23	proteins	protein	NOUN
bptjm-48	151	24	and	and	CCONJ
bptjm-48	151	25	can	can	AUX
bptjm-48	151	26	lead	lead	VERB
bptjm-48	151	27	to	to	ADP
bptjm-48	151	28	subsequent	subsequent	ADJ
bptjm-48	151	29	inactivation	inactivation	NOUN
bptjm-48	151	30	of	of	ADP
bptjm-48	151	31	the	the	DET
bptjm-48	151	32	t	t	NOUN
bptjm-48	151	33	-	-	PUNCT
bptjm-48	151	34	cell	cell	NOUN
bptjm-48	151	35	.	.	PUNCT
bptjm-48	152	1	anti	anti	ADJ
bptjm-48	152	2	-	-	ADJ
bptjm-48	152	3	ctla-4	ctla-4	NOUN
bptjm-48	152	4	inhibitors	inhibitor	NOUN
bptjm-48	152	5	prevent	prevent	VERB
bptjm-48	152	6	the	the	DET
bptjm-48	152	7	inactivation	inactivation	NOUN
bptjm-48	152	8	of	of	ADP
bptjm-48	152	9	the	the	DET
bptjm-48	152	10	respective	respective	ADJ
bptjm-48	152	11	t	t	PROPN
bptjm-48	152	12	-	-	PUNCT
bptjm-48	152	13	cell	cell	NOUN
bptjm-48	152	14	by	by	ADP
bptjm-48	152	15	disrupting	disrupt	VERB
bptjm-48	152	16	the	the	DET
bptjm-48	152	17	function	function	NOUN
bptjm-48	152	18	of	of	ADP
bptjm-48	152	19	the	the	DET
bptjm-48	152	20	ctla-4	ctla-4	NOUN
bptjm-48	152	21	protein	protein	NOUN
bptjm-48	152	22	.	.	PUNCT
bptjm-48	153	1	(	(	PUNCT
bptjm-48	153	2	b	b	X
bptjm-48	153	3	)	)	PUNCT
bptjm-48	153	4	cytotoxic	cytotoxic	ADJ
bptjm-48	153	5	t	t	PROPN
bptjm-48	153	6	cells	cell	NOUN
bptjm-48	153	7	cd8	cd8	PROPN
bptjm-48	153	8	+	+	PROPN
bptjm-48	153	9	interact	interact	VERB
bptjm-48	153	10	via	via	ADP
bptjm-48	153	11	their	their	PRON
bptjm-48	153	12	pd-1	pd-1	ADJ
bptjm-48	153	13	protein	protein	NOUN
bptjm-48	153	14	with	with	ADP
bptjm-48	153	15	tumor	tumor	NOUN
bptjm-48	153	16	cells	cell	NOUN
bptjm-48	153	17	via	via	ADP
bptjm-48	153	18	their	their	PRON
bptjm-48	153	19	berkeley	berkeley	PROPN
bptjm-48	153	20	pharma	pharma	PROPN
bptjm-48	153	21	tech	tech	NOUN
bptjm-48	153	22	journal	journal	NOUN
bptjm-48	153	23	of	of	ADP
bptjm-48	153	24	medicine	medicine	NOUN
bptjm-48	153	25	|	|	ADV
bptjm-48	153	26	46	46	NUM
bptjm-48	153	27	pd	pd	PROPN
bptjm-48	153	28	-	-	PUNCT
bptjm-48	153	29	l1	l1	PROPN
bptjm-48	153	30	protein	protein	NOUN
bptjm-48	153	31	.	.	PUNCT
bptjm-48	154	1	the	the	DET
bptjm-48	154	2	interaction	interaction	NOUN
bptjm-48	154	3	between	between	ADP
bptjm-48	154	4	these	these	DET
bptjm-48	154	5	signaling	signal	VERB
bptjm-48	154	6	proteins	protein	NOUN
bptjm-48	154	7	can	can	AUX
bptjm-48	154	8	lead	lead	VERB
bptjm-48	154	9	to	to	ADP
bptjm-48	154	10	negative	negative	ADJ
bptjm-48	154	11	regulation	regulation	NOUN
bptjm-48	154	12	of	of	ADP
bptjm-48	154	13	the	the	DET
bptjm-48	154	14	anti	anti	ADJ
bptjm-48	154	15	-	-	ADJ
bptjm-48	154	16	tumor	tumor	ADJ
bptjm-48	154	17	t	t	NOUN
bptjm-48	154	18	cell	cell	NOUN
bptjm-48	154	19	response	response	NOUN
bptjm-48	154	20	.	.	PUNCT
bptjm-48	155	1	anti	anti	ADJ
bptjm-48	155	2	-	-	ADJ
bptjm-48	155	3	pd-1	pd-1	ADJ
bptjm-48	155	4	and	and	CCONJ
bptjm-48	155	5	anti	anti	ADJ
bptjm-48	155	6	-	-	ADJ
bptjm-48	155	7	pd	pd	ADJ
bptjm-48	155	8	-	-	PUNCT
bptjm-48	155	9	l1	l1	PROPN
bptjm-48	155	10	inhibitors	inhibitor	NOUN
bptjm-48	155	11	prevent	prevent	VERB
bptjm-48	155	12	the	the	DET
bptjm-48	155	13	binding	binding	NOUN
bptjm-48	155	14	of	of	ADP
bptjm-48	155	15	pd-1	pd-1	ADJ
bptjm-48	155	16	and	and	CCONJ
bptjm-48	155	17	pd	pd	PROPN
bptjm-48	155	18	-	-	PROPN
bptjm-48	155	19	l1	l1	PROPN
bptjm-48	155	20	and	and	CCONJ
bptjm-48	155	21	thus	thus	ADV
bptjm-48	155	22	prevents	prevent	VERB
bptjm-48	155	23	inactivation	inactivation	NOUN
bptjm-48	155	24	of	of	ADP
bptjm-48	155	25	t	t	PROPN
bptjm-48	155	26	cell	cell	NOUN
bptjm-48	155	27	anti	anti	ADJ
bptjm-48	155	28	-	-	ADJ
bptjm-48	155	29	tumor	tumor	ADJ
bptjm-48	155	30	responses	response	NOUN
bptjm-48	155	31	.	.	PUNCT
bptjm-48	156	1	figure	figure	NOUN
bptjm-48	156	2	9	9	NUM
bptjm-48	156	3	.	.	PUNCT
bptjm-48	157	1	a	a	DET
bptjm-48	157	2	comparison	comparison	NOUN
bptjm-48	157	3	of	of	ADP
bptjm-48	157	4	normal	normal	ADJ
bptjm-48	157	5	t	t	NOUN
bptjm-48	157	6	-	-	PUNCT
bptjm-48	157	7	cell	cell	NOUN
bptjm-48	157	8	receptor	receptor	NOUN
bptjm-48	157	9	binding	bind	VERB
bptjm-48	157	10	vs.	vs.	ADP
bptjm-48	157	11	t	t	PROPN
bptjm-48	157	12	-	-	PUNCT
bptjm-48	157	13	cell	cell	NOUN
bptjm-48	157	14	receptorbinding	receptorbinde	VERB
bptjm-48	157	15	after	after	ADP
bptjm-48	157	16	the	the	DET
bptjm-48	157	17	addition	addition	NOUN
bptjm-48	157	18	of	of	ADP
bptjm-48	157	19	anti	anti	ADJ
bptjm-48	157	20	-	-	ADJ
bptjm-48	157	21	pd	pd	ADJ
bptjm-48	157	22	-	-	PUNCT
bptjm-48	157	23	l1	l1	PROPN
bptjm-48	157	24	ligand	ligand	NOUN
bptjm-48	157	25	and	and	CCONJ
bptjm-48	157	26	pd-1	pd-1	ADV
bptjm-48	157	27	blockade.(a	blockade.(a	NOUN
bptjm-48	157	28	)	)	PUNCT
bptjm-48	157	29	t	t	NOUN
bptjm-48	157	30	-	-	PUNCT
bptjm-48	157	31	cell	cell	NOUN
bptjm-48	157	32	binds	bind	VERB
bptjm-48	157	33	to	to	ADP
bptjm-48	157	34	pdl1	pdl1	NOUN
bptjm-48	157	35	on	on	ADP
bptjm-48	157	36	tumor	tumor	NOUN
bptjm-48	157	37	cells	cell	NOUN
bptjm-48	157	38	via	via	ADP
bptjm-48	157	39	pd-1	pd-1	VERB
bptjm-48	157	40	receptor	receptor	NOUN
bptjm-48	157	41	;	;	PUNCT
bptjm-48	157	42	anti	anti	ADJ
bptjm-48	157	43	-	-	ADJ
bptjm-48	157	44	tumor	tumor	ADJ
bptjm-48	157	45	killing	killing	NOUN
bptjm-48	157	46	response	response	NOUN
bptjm-48	157	47	is	be	AUX
bptjm-48	157	48	inhibited	inhibit	VERB
bptjm-48	157	49	.	.	PUNCT
bptjm-48	158	1	(	(	PUNCT
bptjm-48	158	2	b	b	X
bptjm-48	158	3	)	)	PUNCT
bptjm-48	158	4	tcell	tcell	NOUN
bptjm-48	158	5	’s	’s	PART
bptjm-48	158	6	pd-1	pd-1	ADP
bptjm-48	158	7	receptor	receptor	NOUN
bptjm-48	158	8	binds	bind	VERB
bptjm-48	158	9	toanti	toanti	PROPN
bptjm-48	158	10	pd-1	pd-1	ADP
bptjm-48	158	11	and	and	CCONJ
bptjm-48	158	12	pd	pd	PROPN
bptjm-48	158	13	-	-	PROPN
bptjm-48	158	14	l1	l1	PROPN
bptjm-48	158	15	binds	bind	VERB
bptjm-48	158	16	to	to	ADP
bptjm-48	158	17	anti	anti	ADJ
bptjm-48	158	18	-	-	ADJ
bptjm-48	158	19	pd	pd	ADJ
bptjm-48	158	20	-	-	PUNCT
bptjm-48	158	21	l1	l1	PROPN
bptjm-48	158	22	;	;	PUNCT
bptjm-48	158	23	subsequent	subsequent	ADJ
bptjm-48	158	24	activation	activation	NOUN
bptjm-48	158	25	of	of	ADP
bptjm-48	158	26	theanti	theanti	ADJ
bptjm-48	158	27	-	-	ADJ
bptjm-48	158	28	tumor	tumor	ADJ
bptjm-48	158	29	killing	killing	NOUN
bptjm-48	158	30	response	response	NOUN
bptjm-48	158	31	is	be	AUX
bptjm-48	158	32	observed	observe	VERB
bptjm-48	158	33	.	.	PUNCT
bptjm-48	159	1	more	more	ADJ
bptjm-48	159	2	speci	speci	ADJ
bptjm-48	159	3	�	�	NOUN
bptjm-48	159	4	cally	cally	ADV
bptjm-48	159	5	,	,	PUNCT
bptjm-48	159	6	monoclonal	monoclonal	NOUN
bptjm-48	159	7	antibodies	antibody	NOUN
bptjm-48	159	8	are	be	AUX
bptjm-48	159	9	being	be	AUX
bptjm-48	159	10	used	use	VERB
bptjm-48	159	11	to	to	PART
bptjm-48	159	12	target	target	VERB
bptjm-48	159	13	these	these	DET
bptjm-48	159	14	signaling	signal	VERB
bptjm-48	159	15	molecules	molecule	NOUN
bptjm-48	159	16	.	.	PUNCT
bptjm-48	160	1	when	when	SCONJ
bptjm-48	160	2	understanding	understand	VERB
bptjm-48	160	3	the	the	DET
bptjm-48	160	4	mechanisms	mechanism	NOUN
bptjm-48	160	5	by	by	ADP
bptjm-48	160	6	which	which	PRON
bptjm-48	160	7	monoclonal	monoclonal	NOUN
bptjm-48	160	8	antibodies	antibody	NOUN
bptjm-48	160	9	function	function	NOUN
bptjm-48	160	10	,	,	PUNCT
bptjm-48	160	11	we	we	PRON
bptjm-48	160	12	focus	focus	VERB
bptjm-48	160	13	on	on	ADP
bptjm-48	160	14	a	a	DET
bptjm-48	160	15	key	key	ADJ
bptjm-48	160	16	immune	immune	ADJ
bptjm-48	160	17	cell	cell	NOUN
bptjm-48	160	18	,	,	PUNCT
bptjm-48	160	19	the	the	DET
bptjm-48	160	20	b	b	NOUN
bptjm-48	160	21	cell	cell	NOUN
bptjm-48	160	22	.	.	PUNCT
bptjm-48	161	1	b	b	NOUN
bptjm-48	161	2	cells	cell	NOUN
bptjm-48	161	3	are	be	AUX
bptjm-48	161	4	a	a	DET
bptjm-48	161	5	very	very	ADV
bptjm-48	161	6	important	important	ADJ
bptjm-48	161	7	part	part	NOUN
bptjm-48	161	8	of	of	ADP
bptjm-48	161	9	the	the	DET
bptjm-48	161	10	immune	immune	ADJ
bptjm-48	161	11	system	system	NOUN
bptjm-48	161	12	since	since	SCONJ
bptjm-48	161	13	they	they	PRON
bptjm-48	161	14	have	have	VERB
bptjm-48	161	15	antibodies	antibody	NOUN
bptjm-48	161	16	on	on	ADP
bptjm-48	161	17	their	their	PRON
bptjm-48	161	18	surface	surface	NOUN
bptjm-48	161	19	membrane	membrane	NOUN
bptjm-48	161	20	.	.	PUNCT
bptjm-48	162	1	moreover	moreover	ADV
bptjm-48	162	2	,	,	PUNCT
bptjm-48	162	3	each	each	DET
bptjm-48	162	4	b	b	NOUN
bptjm-48	162	5	cell	cell	NOUN
bptjm-48	162	6	has	have	VERB
bptjm-48	162	7	antibodies	antibody	NOUN
bptjm-48	162	8	that	that	PRON
bptjm-48	162	9	are	be	AUX
bptjm-48	162	10	speci	speci	ADJ
bptjm-48	162	11	�	�	PROPN
bptjm-48	162	12	c	c	NOUN
bptjm-48	162	13	to	to	ADP
bptjm-48	162	14	one	one	NUM
bptjm-48	162	15	antigen	antigen	NOUN
bptjm-48	162	16	and	and	CCONJ
bptjm-48	162	17	are	be	AUX
bptjm-48	162	18	useless	useless	ADJ
bptjm-48	162	19	against	against	ADP
bptjm-48	162	20	other	other	ADJ
bptjm-48	162	21	antigens	antigen	NOUN
bptjm-48	162	22	.	.	PUNCT
bptjm-48	163	1	this	this	PRON
bptjm-48	163	2	can	can	AUX
bptjm-48	163	3	be	be	AUX
bptjm-48	163	4	advantageous	advantageous	ADJ
bptjm-48	163	5	or	or	CCONJ
bptjm-48	163	6	disadvantageous	disadvantageous	ADJ
bptjm-48	163	7	depending	depend	VERB
bptjm-48	163	8	on	on	ADP
bptjm-48	163	9	the	the	DET
bptjm-48	163	10	type	type	NOUN
bptjm-48	163	11	of	of	ADP
bptjm-48	163	12	antibody	antibody	NOUN
bptjm-48	163	13	and	and	CCONJ
bptjm-48	163	14	respective	respective	ADJ
bptjm-48	163	15	antigen	antigen	NOUN
bptjm-48	163	16	.	.	PUNCT
bptjm-48	164	1	when	when	SCONJ
bptjm-48	164	2	a	a	DET
bptjm-48	164	3	b	b	NOUN
bptjm-48	164	4	cell	cell	NOUN
bptjm-48	164	5	and	and	CCONJ
bptjm-48	164	6	its	its	PRON
bptjm-48	164	7	antibody	antibody	NOUN
bptjm-48	164	8	interact	interact	VERB
bptjm-48	164	9	with	with	ADP
bptjm-48	164	10	a	a	DET
bptjm-48	164	11	berkeley	berkeley	PROPN
bptjm-48	164	12	pharma	pharma	PROPN
bptjm-48	164	13	tech	tech	NOUN
bptjm-48	164	14	journal	journal	NOUN
bptjm-48	164	15	of	of	ADP
bptjm-48	164	16	medicine	medicine	NOUN
bptjm-48	164	17	|	|	ADV
bptjm-48	164	18	47	47	NUM
bptjm-48	164	19	speci	speci	PROPN
bptjm-48	164	20	�	�	PROPN
bptjm-48	164	21	c	c	PROPN
bptjm-48	164	22	antigen	antigen	NOUN
bptjm-48	164	23	,	,	PUNCT
bptjm-48	164	24	the	the	DET
bptjm-48	164	25	b	b	PROPN
bptjm-48	164	26	cell	cell	NOUN
bptjm-48	164	27	becomes	become	VERB
bptjm-48	164	28	activated	activated	ADJ
bptjm-48	164	29	and	and	CCONJ
bptjm-48	164	30	di	di	NOUN
bptjm-48	164	31	�	�	PROPN
bptjm-48	164	32	erentiates	erentiate	VERB
bptjm-48	164	33	into	into	ADP
bptjm-48	164	34	either	either	CCONJ
bptjm-48	164	35	a	a	DET
bptjm-48	164	36	plasma	plasma	NOUN
bptjm-48	164	37	cell	cell	NOUN
bptjm-48	164	38	or	or	CCONJ
bptjm-48	164	39	memory	memory	NOUN
bptjm-48	164	40	b	b	NOUN
bptjm-48	164	41	cell	cell	NOUN
bptjm-48	164	42	.	.	PUNCT
bptjm-48	165	1	plasma	plasma	NOUN
bptjm-48	165	2	cells	cell	NOUN
bptjm-48	165	3	produce	produce	VERB
bptjm-48	165	4	a	a	DET
bptjm-48	165	5	vast	vast	ADJ
bptjm-48	165	6	amount	amount	NOUN
bptjm-48	165	7	of	of	ADP
bptjm-48	165	8	their	their	PRON
bptjm-48	165	9	speci	speci	ADJ
bptjm-48	165	10	�	�	PROPN
bptjm-48	165	11	c	c	NOUN
bptjm-48	165	12	antibody	antibody	NOUN
bptjm-48	165	13	and	and	CCONJ
bptjm-48	165	14	memory	memory	NOUN
bptjm-48	165	15	b	b	PROPN
bptjm-48	165	16	cells	cell	NOUN
bptjm-48	165	17	remain	remain	VERB
bptjm-48	165	18	in	in	ADP
bptjm-48	165	19	the	the	DET
bptjm-48	165	20	host	host	NOUN
bptjm-48	165	21	and	and	CCONJ
bptjm-48	165	22	serve	serve	VERB
bptjm-48	165	23	as	as	ADP
bptjm-48	165	24	a	a	DET
bptjm-48	165	25	part	part	NOUN
bptjm-48	165	26	of	of	ADP
bptjm-48	165	27	immune	immune	ADJ
bptjm-48	165	28	memory	memory	NOUN
bptjm-48	165	29	so	so	SCONJ
bptjm-48	165	30	that	that	SCONJ
bptjm-48	165	31	if	if	SCONJ
bptjm-48	165	32	they	they	PRON
bptjm-48	165	33	are	be	AUX
bptjm-48	165	34	needed	need	VERB
bptjm-48	165	35	again	again	ADV
bptjm-48	165	36	,	,	PUNCT
bptjm-48	165	37	they	they	PRON
bptjm-48	165	38	can	can	AUX
bptjm-48	165	39	be	be	AUX
bptjm-48	165	40	activated.32,34	activated.32,34	ADJ
bptjm-48	165	41	looking	look	VERB
bptjm-48	165	42	further	far	ADV
bptjm-48	165	43	into	into	ADP
bptjm-48	165	44	antibodies	antibody	NOUN
bptjm-48	165	45	or	or	CCONJ
bptjm-48	165	46	immunoglobulins	immunoglobulin	NOUN
bptjm-48	165	47	,	,	PUNCT
bptjm-48	165	48	they	they	PRON
bptjm-48	165	49	are	be	AUX
bptjm-48	165	50	made	make	VERB
bptjm-48	165	51	up	up	ADP
bptjm-48	165	52	of	of	ADP
bptjm-48	165	53	two	two	NUM
bptjm-48	165	54	heavy	heavy	ADJ
bptjm-48	165	55	chains	chain	NOUN
bptjm-48	165	56	and	and	CCONJ
bptjm-48	165	57	two	two	NUM
bptjm-48	165	58	light	light	ADJ
bptjm-48	165	59	chains	chain	NOUN
bptjm-48	165	60	and	and	CCONJ
bptjm-48	165	61	are	be	AUX
bptjm-48	165	62	arranged	arrange	VERB
bptjm-48	165	63	in	in	ADP
bptjm-48	165	64	a	a	DET
bptjm-48	165	65	y	y	NOUN
bptjm-48	165	66	-	-	PUNCT
bptjm-48	165	67	shape	shape	NOUN
bptjm-48	165	68	.	.	PUNCT
bptjm-48	166	1	the	the	DET
bptjm-48	166	2	lower	low	ADJ
bptjm-48	166	3	portion	portion	NOUN
bptjm-48	166	4	of	of	ADP
bptjm-48	166	5	the	the	DET
bptjm-48	166	6	antibody	antibody	NOUN
bptjm-48	166	7	contains	contain	VERB
bptjm-48	166	8	an	an	DET
bptjm-48	166	9	fc	fc	PROPN
bptjm-48	166	10	portion	portion	NOUN
bptjm-48	166	11	,	,	PUNCT
bptjm-48	166	12	which	which	PRON
bptjm-48	166	13	remains	remain	VERB
bptjm-48	166	14	the	the	DET
bptjm-48	166	15	same	same	ADJ
bptjm-48	166	16	amongst	amongst	ADP
bptjm-48	166	17	all	all	DET
bptjm-48	166	18	antibodies	antibody	NOUN
bptjm-48	166	19	and	and	CCONJ
bptjm-48	166	20	is	be	AUX
bptjm-48	166	21	then	then	ADV
bptjm-48	166	22	used	use	VERB
bptjm-48	166	23	to	to	PART
bptjm-48	166	24	bind	bind	VERB
bptjm-48	166	25	to	to	ADP
bptjm-48	166	26	cells	cell	NOUN
bptjm-48	166	27	of	of	ADP
bptjm-48	166	28	the	the	DET
bptjm-48	166	29	immune	immune	ADJ
bptjm-48	166	30	system	system	NOUN
bptjm-48	166	31	.	.	PUNCT
bptjm-48	167	1	cells	cell	NOUN
bptjm-48	167	2	of	of	ADP
bptjm-48	167	3	the	the	DET
bptjm-48	167	4	immune	immune	ADJ
bptjm-48	167	5	system	system	NOUN
bptjm-48	167	6	have	have	VERB
bptjm-48	167	7	an	an	DET
bptjm-48	167	8	fc	fc	NOUN
bptjm-48	167	9	receptor	receptor	NOUN
bptjm-48	167	10	that	that	PRON
bptjm-48	167	11	binds	bind	VERB
bptjm-48	167	12	to	to	ADP
bptjm-48	167	13	the	the	DET
bptjm-48	167	14	fc	fc	PROPN
bptjm-48	167	15	portion	portion	NOUN
bptjm-48	167	16	of	of	ADP
bptjm-48	167	17	the	the	DET
bptjm-48	167	18	antibody	antibody	NOUN
bptjm-48	167	19	.	.	PUNCT
bptjm-48	168	1	the	the	DET
bptjm-48	168	2	upper	upper	ADJ
bptjm-48	168	3	portion	portion	NOUN
bptjm-48	168	4	of	of	ADP
bptjm-48	168	5	the	the	DET
bptjm-48	168	6	antibody	antibody	NOUN
bptjm-48	168	7	contains	contain	VERB
bptjm-48	168	8	the	the	DET
bptjm-48	168	9	variable	variable	ADJ
bptjm-48	168	10	region	region	NOUN
bptjm-48	168	11	,	,	PUNCT
bptjm-48	168	12	which	which	PRON
bptjm-48	168	13	has	have	VERB
bptjm-48	168	14	many	many	ADJ
bptjm-48	168	15	con	con	NOUN
bptjm-48	168	16	�	�	NOUN
bptjm-48	168	17	gurations	guration	NOUN
bptjm-48	168	18	and	and	CCONJ
bptjm-48	168	19	is	be	AUX
bptjm-48	168	20	designed	design	VERB
bptjm-48	168	21	to	to	PART
bptjm-48	168	22	attach	attach	VERB
bptjm-48	168	23	only	only	ADV
bptjm-48	168	24	a	a	DET
bptjm-48	168	25	single	single	ADJ
bptjm-48	168	26	type	type	NOUN
bptjm-48	168	27	of	of	ADP
bptjm-48	168	28	antigen	antigen	NOUN
bptjm-48	168	29	.	.	PUNCT
bptjm-48	169	1	there	there	PRON
bptjm-48	169	2	are	be	VERB
bptjm-48	169	3	many	many	ADJ
bptjm-48	169	4	ways	way	NOUN
bptjm-48	169	5	by	by	ADP
bptjm-48	169	6	which	which	PRON
bptjm-48	169	7	antibodies	antibodie	VERB
bptjm-48	169	8	can	can	AUX
bptjm-48	169	9	stimulate	stimulate	VERB
bptjm-48	169	10	the	the	DET
bptjm-48	169	11	immune	immune	ADJ
bptjm-48	169	12	response	response	NOUN
bptjm-48	169	13	which	which	PRON
bptjm-48	169	14	include	include	VERB
bptjm-48	169	15	by	by	ADP
bptjm-48	169	16	activating	activate	VERB
bptjm-48	169	17	the	the	DET
bptjm-48	169	18	classical	classical	ADJ
bptjm-48	169	19	complement	complement	NOUN
bptjm-48	169	20	system	system	NOUN
bptjm-48	169	21	,	,	PUNCT
bptjm-48	169	22	by	by	ADP
bptjm-48	169	23	attaching	attach	VERB
bptjm-48	169	24	themselves	themselves	PRON
bptjm-48	169	25	to	to	ADP
bptjm-48	169	26	antigens	antigen	NOUN
bptjm-48	169	27	in	in	ADP
bptjm-48	169	28	order	order	NOUN
bptjm-48	169	29	to	to	PART
bptjm-48	169	30	neutralize	neutralize	VERB
bptjm-48	169	31	toxins	toxin	NOUN
bptjm-48	169	32	,	,	PUNCT
bptjm-48	169	33	by	by	ADP
bptjm-48	169	34	attaching	attach	VERB
bptjm-48	169	35	themselves	themselves	PRON
bptjm-48	169	36	to	to	ADP
bptjm-48	169	37	certain	certain	ADJ
bptjm-48	169	38	receptors	receptor	NOUN
bptjm-48	169	39	to	to	PART
bptjm-48	169	40	disrupt	disrupt	VERB
bptjm-48	169	41	function	function	NOUN
bptjm-48	169	42	of	of	ADP
bptjm-48	169	43	that	that	DET
bptjm-48	169	44	receptor	receptor	NOUN
bptjm-48	169	45	,	,	PUNCT
bptjm-48	169	46	by	by	ADP
bptjm-48	169	47	attaching	attach	VERB
bptjm-48	169	48	themselves	themselves	PRON
bptjm-48	169	49	to	to	ADP
bptjm-48	169	50	a	a	DET
bptjm-48	169	51	certain	certain	ADJ
bptjm-48	169	52	pathogen	pathogen	NOUN
bptjm-48	169	53	or	or	CCONJ
bptjm-48	169	54	disease	disease	NOUN
bptjm-48	169	55	causing	cause	VERB
bptjm-48	169	56	agent	agent	NOUN
bptjm-48	169	57	and	and	CCONJ
bptjm-48	169	58	agglutinate	agglutinate	ADJ
bptjm-48	169	59	,	,	PUNCT
bptjm-48	169	60	or	or	CCONJ
bptjm-48	169	61	by	by	ADP
bptjm-48	169	62	acting	act	VERB
bptjm-48	169	63	as	as	ADP
bptjm-48	169	64	opsonins	opsonin	NOUN
bptjm-48	169	65	,	,	PUNCT
bptjm-48	169	66	which	which	PRON
bptjm-48	169	67	involves	involve	VERB
bptjm-48	169	68	antibodies	antibody	NOUN
bptjm-48	169	69	attaching	attach	VERB
bptjm-48	169	70	themselves	themselves	PRON
bptjm-48	169	71	to	to	ADP
bptjm-48	169	72	pathogens	pathogen	NOUN
bptjm-48	169	73	or	or	CCONJ
bptjm-48	169	74	disease	disease	NOUN
bptjm-48	169	75	causing	cause	VERB
bptjm-48	169	76	agents	agent	NOUN
bptjm-48	169	77	and	and	CCONJ
bptjm-48	169	78	making	make	VERB
bptjm-48	169	79	it	it	PRON
bptjm-48	169	80	convenient	convenient	ADJ
bptjm-48	169	81	for	for	SCONJ
bptjm-48	169	82	the	the	DET
bptjm-48	169	83	phagocytes	phagocyte	NOUN
bptjm-48	169	84	to	to	PART
bptjm-48	169	85	recognize	recognize	VERB
bptjm-48	169	86	and	and	CCONJ
bptjm-48	169	87	destroy	destroy	VERB
bptjm-48	169	88	those	those	DET
bptjm-48	169	89	pathogens	pathogen	NOUN
bptjm-48	169	90	that	that	PRON
bptjm-48	169	91	would	would	AUX
bptjm-48	169	92	have	have	AUX
bptjm-48	169	93	otherwise	otherwise	ADV
bptjm-48	169	94	not	not	PART
bptjm-48	169	95	been	be	AUX
bptjm-48	169	96	able	able	ADJ
bptjm-48	169	97	to	to	PART
bptjm-48	169	98	recognize	recognize	VERB
bptjm-48	169	99	them	they	PRON
bptjm-48	169	100	because	because	SCONJ
bptjm-48	169	101	of	of	ADP
bptjm-48	169	102	primitive	primitive	ADJ
bptjm-48	169	103	recognition	recognition	NOUN
bptjm-48	169	104	structures	structure	NOUN
bptjm-48	169	105	associated	associate	VERB
bptjm-48	169	106	with	with	ADP
bptjm-48	169	107	certain	certain	ADJ
bptjm-48	169	108	immune	immune	ADJ
bptjm-48	169	109	cells.32,33,35	cells.32,33,35	NOUN
bptjm-48	169	110	another	another	DET
bptjm-48	169	111	very	very	ADV
bptjm-48	169	112	important	important	ADJ
bptjm-48	169	113	role	role	NOUN
bptjm-48	169	114	they	they	PRON
bptjm-48	169	115	can	can	AUX
bptjm-48	169	116	play	play	VERB
bptjm-48	169	117	is	be	AUX
bptjm-48	169	118	simulating	simulate	VERB
bptjm-48	169	119	antibody	antibody	NOUN
bptjm-48	169	120	-	-	PUNCT
bptjm-48	169	121	dependent	dependent	ADJ
bptjm-48	169	122	cell	cell	NOUN
bptjm-48	169	123	mediated	mediate	VERB
bptjm-48	169	124	cytotoxicity	cytotoxicity	NOUN
bptjm-48	169	125	,	,	PUNCT
bptjm-48	169	126	in	in	ADP
bptjm-48	169	127	which	which	PRON
bptjm-48	169	128	antibodies	antibodie	VERB
bptjm-48	169	129	attach	attach	VERB
bptjm-48	169	130	themselves	themselves	PRON
bptjm-48	169	131	to	to	ADP
bptjm-48	169	132	pathogens	pathogen	NOUN
bptjm-48	169	133	or	or	CCONJ
bptjm-48	169	134	abnormal	abnormal	ADJ
bptjm-48	169	135	cells	cell	NOUN
bptjm-48	169	136	and	and	CCONJ
bptjm-48	169	137	then	then	ADV
bptjm-48	169	138	they	they	PRON
bptjm-48	169	139	help	help	VERB
bptjm-48	169	140	immune	immune	ADJ
bptjm-48	169	141	cells	cell	NOUN
bptjm-48	169	142	to	to	PART
bptjm-48	169	143	recognize	recognize	VERB
bptjm-48	169	144	the	the	DET
bptjm-48	169	145	pathogen	pathogen	NOUN
bptjm-48	169	146	and	and	CCONJ
bptjm-48	169	147	destroy	destroy	VERB
bptjm-48	169	148	it.32,35	it.32,35	ADJ
bptjm-48	169	149	utilizing	utilize	VERB
bptjm-48	169	150	the	the	DET
bptjm-48	169	151	information	information	NOUN
bptjm-48	169	152	that	that	PRON
bptjm-48	169	153	antibodies	antibodie	VERB
bptjm-48	169	154	provide	provide	VERB
bptjm-48	169	155	an	an	DET
bptjm-48	169	156	e	e	NOUN
bptjm-48	169	157	�	�	NOUN
bptjm-48	169	158	ective	ective	ADJ
bptjm-48	169	159	way	way	NOUN
bptjm-48	169	160	of	of	ADP
bptjm-48	169	161	targeting	target	VERB
bptjm-48	169	162	certain	certain	ADJ
bptjm-48	169	163	disease	disease	NOUN
bptjm-48	169	164	-	-	PUNCT
bptjm-48	169	165	causing	cause	VERB
bptjm-48	169	166	agents	agent	NOUN
bptjm-48	169	167	and	and	CCONJ
bptjm-48	169	168	are	be	AUX
bptjm-48	169	169	very	very	ADV
bptjm-48	169	170	speci	speci	ADJ
bptjm-48	169	171	�	�	X
bptjm-48	169	172	c	c	NOUN
bptjm-48	169	173	as	as	ADP
bptjm-48	169	174	to	to	ADP
bptjm-48	169	175	what	what	PRON
bptjm-48	169	176	antigen	antigen	NOUN
bptjm-48	169	177	they	they	PRON
bptjm-48	169	178	target	target	VERB
bptjm-48	169	179	,	,	PUNCT
bptjm-48	169	180	this	this	PRON
bptjm-48	169	181	can	can	AUX
bptjm-48	169	182	be	be	AUX
bptjm-48	169	183	translated	translate	VERB
bptjm-48	169	184	over	over	ADP
bptjm-48	169	185	to	to	ADP
bptjm-48	169	186	mechanisms	mechanism	NOUN
bptjm-48	169	187	by	by	ADP
bptjm-48	169	188	which	which	PRON
bptjm-48	169	189	monoclonal	monoclonal	NOUN
bptjm-48	169	190	antibodies	antibodie	VERB
bptjm-48	169	191	function	function	NOUN
bptjm-48	169	192	.	.	PUNCT
bptjm-48	170	1	when	when	SCONJ
bptjm-48	170	2	treating	treat	VERB
bptjm-48	170	3	a	a	DET
bptjm-48	170	4	patient	patient	NOUN
bptjm-48	170	5	,	,	PUNCT
bptjm-48	170	6	it	it	PRON
bptjm-48	170	7	is	be	AUX
bptjm-48	170	8	possible	possible	ADJ
bptjm-48	170	9	to	to	PART
bptjm-48	170	10	translate	translate	VERB
bptjm-48	170	11	this	this	DET
bptjm-48	170	12	key	key	ADJ
bptjm-48	170	13	process	process	NOUN
bptjm-48	170	14	of	of	ADP
bptjm-48	170	15	recognition	recognition	NOUN
bptjm-48	170	16	and	and	CCONJ
bptjm-48	170	17	subsequent	subsequent	ADJ
bptjm-48	170	18	action	action	NOUN
bptjm-48	170	19	to	to	ADP
bptjm-48	170	20	stopping	stop	VERB
bptjm-48	170	21	a	a	DET
bptjm-48	170	22	disease	disease	NOUN
bptjm-48	170	23	-	-	PUNCT
bptjm-48	170	24	causing	cause	VERB
bptjm-48	170	25	pathway	pathway	NOUN
bptjm-48	170	26	.	.	PUNCT
bptjm-48	171	1	certain	certain	ADJ
bptjm-48	171	2	proteins	protein	NOUN
bptjm-48	171	3	or	or	CCONJ
bptjm-48	171	4	antigens	antigen	NOUN
bptjm-48	171	5	that	that	PRON
bptjm-48	171	6	are	be	AUX
bptjm-48	171	7	associated	associate	VERB
bptjm-48	171	8	with	with	ADP
bptjm-48	171	9	harmful	harmful	ADJ
bptjm-48	171	10	processes	process	NOUN
bptjm-48	171	11	can	can	AUX
bptjm-48	171	12	be	be	AUX
bptjm-48	171	13	identi	identi	ADJ
bptjm-48	171	14	�	�	NOUN
bptjm-48	171	15	ed	ed	NOUN
bptjm-48	171	16	and	and	CCONJ
bptjm-48	171	17	targeted	target	VERB
bptjm-48	171	18	by	by	ADP
bptjm-48	171	19	monoclonal	monoclonal	NOUN
bptjm-48	171	20	antibodies	antibody	NOUN
bptjm-48	171	21	.	.	PUNCT
bptjm-48	172	1	monoclonal	monoclonal	NOUN
bptjm-48	172	2	antibodies	antibody	NOUN
bptjm-48	172	3	are	be	AUX
bptjm-48	172	4	a	a	DET
bptjm-48	172	5	single	single	ADJ
bptjm-48	172	6	type	type	NOUN
bptjm-48	172	7	of	of	ADP
bptjm-48	172	8	antibody	antibody	NOUN
bptjm-48	173	1	[	[	X
bptjm-48	173	2	mp1	mp1	X
bptjm-48	173	3	]	]	X
bptjm-48	173	4	that	that	PRON
bptjm-48	173	5	target	target	VERB
bptjm-48	173	6	a	a	DET
bptjm-48	173	7	speci	speci	ADJ
bptjm-48	173	8	�	�	PROPN
bptjm-48	173	9	c	c	NOUN
bptjm-48	173	10	protein	protein	NOUN
bptjm-48	173	11	.	.	PUNCT
bptjm-48	174	1	there	there	PRON
bptjm-48	174	2	are	be	VERB
bptjm-48	174	3	many	many	ADJ
bptjm-48	174	4	types	type	NOUN
bptjm-48	174	5	of	of	ADP
bptjm-48	174	6	monoclonal	monoclonal	NOUN
bptjm-48	174	7	antibodies	antibody	NOUN
bptjm-48	174	8	on	on	ADP
bptjm-48	174	9	the	the	DET
bptjm-48	174	10	market	market	NOUN
bptjm-48	174	11	today	today	NOUN
bptjm-48	174	12	that	that	PRON
bptjm-48	174	13	have	have	VERB
bptjm-48	174	14	their	their	PRON
bptjm-48	174	15	own	own	ADJ
bptjm-48	174	16	speci	speci	ADJ
bptjm-48	174	17	�	�	PROPN
bptjm-48	174	18	c	c	PROPN
bptjm-48	174	19	target	target	NOUN
bptjm-48	174	20	protein.33,34	protein.33,34	NOUN
bptjm-48	174	21	many	many	ADJ
bptjm-48	174	22	berkeley	berkeley	PROPN
bptjm-48	174	23	pharma	pharma	PROPN
bptjm-48	174	24	tech	tech	NOUN
bptjm-48	174	25	journal	journal	NOUN
bptjm-48	174	26	of	of	ADP
bptjm-48	174	27	medicine	medicine	NOUN
bptjm-48	174	28	|	|	ADV
bptjm-48	174	29	48	48	NUM
bptjm-48	174	30	monoclonal	monoclonal	NOUN
bptjm-48	174	31	antibodies	antibody	NOUN
bptjm-48	174	32	have	have	AUX
bptjm-48	174	33	been	be	AUX
bptjm-48	174	34	designed	design	VERB
bptjm-48	174	35	to	to	PART
bptjm-48	174	36	target	target	VERB
bptjm-48	174	37	previously	previously	ADV
bptjm-48	174	38	mentioned	mention	VERB
bptjm-48	174	39	key	key	ADJ
bptjm-48	174	40	signaling	signal	VERB
bptjm-48	174	41	molecules	molecule	NOUN
bptjm-48	174	42	to	to	PART
bptjm-48	174	43	inhibit	inhibit	VERB
bptjm-48	174	44	immunosuppression	immunosuppression	NOUN
bptjm-48	174	45	and	and	CCONJ
bptjm-48	174	46	restore	restore	VERB
bptjm-48	174	47	antitumor	antitumor	PROPN
bptjm-48	174	48	responses	response	NOUN
bptjm-48	174	49	of	of	ADP
bptjm-48	174	50	the	the	DET
bptjm-48	174	51	immune	immune	ADJ
bptjm-48	174	52	system	system	NOUN
bptjm-48	174	53	.	.	PUNCT
bptjm-48	175	1	these	these	DET
bptjm-48	175	2	antibodies	antibody	NOUN
bptjm-48	175	3	include	include	VERB
bptjm-48	175	4	nivolumab	nivolumab	NOUN
bptjm-48	175	5	,	,	PUNCT
bptjm-48	175	6	ipilimumab	ipilimumab	ADV
bptjm-48	175	7	,	,	PUNCT
bptjm-48	175	8	avelumab	avelumab	NOUN
bptjm-48	175	9	,	,	PUNCT
bptjm-48	175	10	atezolizumab	atezolizumab	PROPN
bptjm-48	175	11	,	,	PUNCT
bptjm-48	175	12	retifanlimab	retifanlimab	NOUN
bptjm-48	175	13	,	,	PUNCT
bptjm-48	175	14	and	and	CCONJ
bptjm-48	175	15	many	many	ADJ
bptjm-48	175	16	more	more	ADJ
bptjm-48	175	17	that	that	PRON
bptjm-48	175	18	have	have	AUX
bptjm-48	175	19	proven	prove	VERB
bptjm-48	175	20	to	to	PART
bptjm-48	175	21	be	be	AUX
bptjm-48	175	22	e	e	NOUN
bptjm-48	175	23	�	�	NOUN
bptjm-48	175	24	cacious	cacious	ADJ
bptjm-48	175	25	against	against	ADP
bptjm-48	175	26	many	many	ADJ
bptjm-48	175	27	cancer	cancer	NOUN
bptjm-48	175	28	types	type	NOUN
bptjm-48	175	29	,	,	PUNCT
bptjm-48	175	30	including	include	VERB
bptjm-48	175	31	glioblastoma.32	glioblastoma.32	PROPN
bptjm-48	175	32	multiple	multiple	ADJ
bptjm-48	175	33	clinical	clinical	ADJ
bptjm-48	175	34	studies	study	NOUN
bptjm-48	175	35	have	have	AUX
bptjm-48	175	36	been	be	AUX
bptjm-48	175	37	undertaken	undertake	VERB
bptjm-48	175	38	to	to	PART
bptjm-48	175	39	understand	understand	VERB
bptjm-48	175	40	the	the	DET
bptjm-48	175	41	e	e	PROPN
bptjm-48	175	42	�	�	PROPN
bptjm-48	175	43	cacy	cacy	NOUN
bptjm-48	175	44	of	of	ADP
bptjm-48	175	45	monoclonal	monoclonal	NOUN
bptjm-48	175	46	antibodies	antibody	NOUN
bptjm-48	175	47	against	against	ADP
bptjm-48	175	48	cancer	cancer	NOUN
bptjm-48	175	49	.	.	PUNCT
bptjm-48	176	1	figure	figure	NOUN
bptjm-48	176	2	10	10	NUM
bptjm-48	176	3	.	.	PUNCT
bptjm-48	177	1	an	an	DET
bptjm-48	177	2	overview	overview	NOUN
bptjm-48	177	3	of	of	ADP
bptjm-48	177	4	the	the	DET
bptjm-48	177	5	mechanism	mechanism	NOUN
bptjm-48	177	6	of	of	ADP
bptjm-48	177	7	action	action	NOUN
bptjm-48	177	8	for	for	ADP
bptjm-48	177	9	a	a	DET
bptjm-48	177	10	monoclonalantibody	monoclonalantibody	NOUN
bptjm-48	177	11	berkeley	berkeley	PROPN
bptjm-48	177	12	pharma	pharma	PROPN
bptjm-48	177	13	tech	tech	NOUN
bptjm-48	177	14	journal	journal	NOUN
bptjm-48	177	15	of	of	ADP
bptjm-48	177	16	medicine	medicine	NOUN
bptjm-48	177	17	|	|	ADV
bptjm-48	177	18	49	49	NUM
bptjm-48	177	19	figure	figure	NOUN
bptjm-48	177	20	11	11	NUM
bptjm-48	177	21	.	.	PUNCT
bptjm-48	178	1	monoclonal	monoclonal	NOUN
bptjm-48	178	2	antibodies	antibody	NOUN
bptjm-48	178	3	(	(	PUNCT
bptjm-48	178	4	mab	mab	PROPN
bptjm-48	178	5	)	)	PUNCT
bptjm-48	178	6	against	against	ADP
bptjm-48	178	7	tumor	tumor	NOUN
bptjm-48	178	8	cells	cell	NOUN
bptjm-48	178	9	.	.	PUNCT
bptjm-48	179	1	monoclonal	monoclonal	NOUN
bptjm-48	179	2	antibodies	antibody	NOUN
bptjm-48	179	3	can	can	AUX
bptjm-48	179	4	be	be	AUX
bptjm-48	179	5	found	find	VERB
bptjm-48	179	6	in	in	ADP
bptjm-48	179	7	many	many	ADJ
bptjm-48	179	8	di	di	NOUN
bptjm-48	179	9	�	�	PROPN
bptjm-48	179	10	erent	erent	NOUN
bptjm-48	179	11	forms	form	NOUN
bptjm-48	179	12	and	and	CCONJ
bptjm-48	179	13	thus	thus	ADV
bptjm-48	179	14	based	base	VERB
bptjm-48	179	15	in	in	ADP
bptjm-48	179	16	many	many	ADJ
bptjm-48	179	17	di	di	NOUN
bptjm-48	179	18	�	�	PROPN
bptjm-48	179	19	erent	erent	NOUN
bptjm-48	179	20	ways	way	NOUN
bptjm-48	179	21	.	.	PUNCT
bptjm-48	180	1	mabs	mab	NOUN
bptjm-48	180	2	can	can	AUX
bptjm-48	180	3	be	be	AUX
bptjm-48	180	4	organized	organize	VERB
bptjm-48	180	5	into	into	ADP
bptjm-48	180	6	three	three	NUM
bptjm-48	180	7	categories	category	NOUN
bptjm-48	180	8	:	:	PUNCT
bptjm-48	180	9	(	(	PUNCT
bptjm-48	180	10	1	1	X
bptjm-48	180	11	)	)	PUNCT
bptjm-48	180	12	naked	naked	ADJ
bptjm-48	180	13	-	-	PUNCT
bptjm-48	180	14	mab	mab	NOUN
bptjm-48	180	15	,	,	PUNCT
bptjm-48	180	16	(	(	PUNCT
bptjm-48	180	17	2	2	X
bptjm-48	180	18	)	)	PUNCT
bptjm-48	180	19	immunoconjugates	immunoconjugate	VERB
bptjm-48	180	20	,	,	PUNCT
bptjm-48	180	21	(	(	PUNCT
bptjm-48	180	22	3	3	X
bptjm-48	180	23	)	)	PUNCT
bptjm-48	180	24	multistep	multistep	NOUN
bptjm-48	180	25	targeting	targeting	NOUN
bptjm-48	180	26	.	.	PUNCT
bptjm-48	181	1	all	all	DET
bptjm-48	181	2	these	these	DET
bptjm-48	181	3	categories	category	NOUN
bptjm-48	181	4	represent	represent	VERB
bptjm-48	181	5	recombinant	recombinant	ADJ
bptjm-48	181	6	or	or	CCONJ
bptjm-48	181	7	“	"	PUNCT
bptjm-48	181	8	chimeric	chimeric	ADJ
bptjm-48	181	9	”	"	PUNCT
bptjm-48	181	10	mabs	mab	NOUN
bptjm-48	181	11	that	that	PRON
bptjm-48	181	12	are	be	AUX
bptjm-48	181	13	capable	capable	ADJ
bptjm-48	181	14	of	of	ADP
bptjm-48	181	15	mediating	mediate	VERB
bptjm-48	181	16	antibody	antibody	NOUN
bptjm-48	181	17	dependent	dependent	ADJ
bptjm-48	181	18	cellular	cellular	ADJ
bptjm-48	181	19	toxicity	toxicity	NOUN
bptjm-48	181	20	.	.	PUNCT
bptjm-48	182	1	one	one	NUM
bptjm-48	182	2	such	such	ADJ
bptjm-48	182	3	phase	phase	NOUN
bptjm-48	182	4	i	i	PRON
bptjm-48	182	5	clinical	clinical	ADJ
bptjm-48	182	6	trial	trial	NOUN
bptjm-48	182	7	,	,	PUNCT
bptjm-48	182	8	observed	observe	VERB
bptjm-48	182	9	treatment	treatment	NOUN
bptjm-48	182	10	with	with	ADP
bptjm-48	182	11	neo	neo	NOUN
bptjm-48	182	12	-	-	ADJ
bptjm-48	182	13	modc	modc	ADJ
bptjm-48	182	14	(	(	PUNCT
bptjm-48	182	15	vaccine	vaccine	NOUN
bptjm-48	182	16	)	)	PUNCT
bptjm-48	182	17	and	and	CCONJ
bptjm-48	182	18	nivolumab	nivolumab	ADV
bptjm-48	182	19	,	,	PUNCT
bptjm-48	182	20	which	which	PRON
bptjm-48	182	21	is	be	AUX
bptjm-48	182	22	a	a	DET
bptjm-48	182	23	monoclonal	monoclonal	NOUN
bptjm-48	182	24	antibody	antibody	NOUN
bptjm-48	182	25	currently	currently	ADV
bptjm-48	182	26	being	be	AUX
bptjm-48	182	27	studied	study	VERB
bptjm-48	182	28	for	for	ADP
bptjm-48	182	29	glioblastoma	glioblastoma	NOUN
bptjm-48	182	30	therapy	therapy	NOUN
bptjm-48	182	31	(	(	PUNCT
bptjm-48	182	32	fda	fda	PROPN
bptjm-48	182	33	)	)	PUNCT
bptjm-48	182	34	.	.	PUNCT
bptjm-48	183	1	pd	pd	PROPN
bptjm-48	183	2	-	-	PROPN
bptjm-48	183	3	l1	l1	PROPN
bptjm-48	183	4	and	and	CCONJ
bptjm-48	183	5	pd	pd	PROPN
bptjm-48	183	6	-	-	PUNCT
bptjm-48	183	7	l2	l2	NOUN
bptjm-48	183	8	are	be	AUX
bptjm-48	183	9	ligands	ligand	NOUN
bptjm-48	183	10	that	that	PRON
bptjm-48	183	11	typically	typically	ADV
bptjm-48	183	12	bind	bind	VERB
bptjm-48	183	13	to	to	ADP
bptjm-48	183	14	pd-1	pd-1	ADJ
bptjm-48	183	15	receptors	receptor	NOUN
bptjm-48	183	16	in	in	ADP
bptjm-48	183	17	t	t	NOUN
bptjm-48	183	18	-	-	PUNCT
bptjm-48	183	19	cells	cell	NOUN
bptjm-48	183	20	,	,	PUNCT
bptjm-48	183	21	which	which	PRON
bptjm-48	183	22	subsequently	subsequently	ADV
bptjm-48	183	23	inhibit	inhibit	VERB
bptjm-48	183	24	t	t	NOUN
bptjm-48	183	25	-	-	PUNCT
bptjm-48	183	26	cell	cell	NOUN
bptjm-48	183	27	proliferation	proliferation	NOUN
bptjm-48	183	28	and	and	CCONJ
bptjm-48	183	29	cytokine	cytokine	ADJ
bptjm-48	183	30	production	production	NOUN
bptjm-48	183	31	(	(	PUNCT
bptjm-48	183	32	fda).14	fda).14	PRON
bptjm-48	183	33	nivolumab	nivolumab	NOUN
bptjm-48	183	34	competitively	competitively	ADV
bptjm-48	183	35	inhibits	inhibit	VERB
bptjm-48	183	36	pd-1	pd-1	ADP
bptjm-48	183	37	by	by	ADP
bptjm-48	183	38	binding	bind	VERB
bptjm-48	183	39	to	to	ADP
bptjm-48	183	40	the	the	DET
bptjm-48	183	41	pd-1	pd-1	ADJ
bptjm-48	183	42	receptor	receptor	NOUN
bptjm-48	183	43	and	and	CCONJ
bptjm-48	183	44	preventing	prevent	VERB
bptjm-48	183	45	pd	pd	NOUN
bptjm-48	183	46	-	-	PROPN
bptjm-48	183	47	l1	l1	PROPN
bptjm-48	183	48	and	and	CCONJ
bptjm-48	183	49	pd	pd	NOUN
bptjm-48	183	50	-	-	PUNCT
bptjm-48	183	51	l2	l2	NOUN
bptjm-48	183	52	from	from	ADP
bptjm-48	183	53	binding	bind	VERB
bptjm-48	183	54	,	,	PUNCT
bptjm-48	183	55	thus	thus	ADV
bptjm-48	183	56	allowing	allow	VERB
bptjm-48	183	57	enhanced	enhanced	ADJ
bptjm-48	183	58	t	t	NOUN
bptjm-48	183	59	-	-	PUNCT
bptjm-48	183	60	cell	cell	NOUN
bptjm-48	183	61	function	function	NOUN
bptjm-48	183	62	as	as	ADV
bptjm-48	183	63	well	well	ADV
bptjm-48	183	64	as	as	ADP
bptjm-48	183	65	a	a	DET
bptjm-48	183	66	resulting	result	VERB
bptjm-48	183	67	anti	anti	ADJ
bptjm-48	183	68	-	-	ADJ
bptjm-48	183	69	tumor	tumor	ADJ
bptjm-48	183	70	response	response	NOUN
bptjm-48	183	71	.	.	PUNCT
bptjm-48	184	1	the	the	DET
bptjm-48	184	2	recommended	recommend	VERB
bptjm-48	184	3	dosage	dosage	NOUN
bptjm-48	184	4	for	for	ADP
bptjm-48	184	5	nivolumab	nivolumab	NOUN
bptjm-48	184	6	,	,	PUNCT
bptjm-48	184	7	as	as	SCONJ
bptjm-48	184	8	tested	test	VERB
bptjm-48	184	9	in	in	ADP
bptjm-48	184	10	unresectable	unresectable	ADJ
bptjm-48	184	11	and	and	CCONJ
bptjm-48	184	12	metastatic	metastatic	ADJ
bptjm-48	184	13	melanoma	melanoma	NOUN
bptjm-48	184	14	,	,	PUNCT
bptjm-48	184	15	metastatic	metastatic	ADJ
bptjm-48	184	16	non	non	ADJ
bptjm-48	184	17	-	-	ADJ
bptjm-48	184	18	small	small	ADJ
bptjm-48	184	19	cell	cell	NOUN
bptjm-48	184	20	lung	lung	NOUN
bptjm-48	184	21	cancer	cancer	NOUN
bptjm-48	184	22	,	,	PUNCT
bptjm-48	184	23	advanced	advanced	ADJ
bptjm-48	184	24	renal	renal	ADJ
bptjm-48	184	25	cell	cell	NOUN
bptjm-48	184	26	carcinoma	carcinoma	NOUN
bptjm-48	184	27	,	,	PUNCT
bptjm-48	184	28	and	and	CCONJ
bptjm-48	184	29	classic	classic	ADJ
bptjm-48	184	30	hodgkin	hodgkin	NOUN
bptjm-48	184	31	lymphoma	lymphoma	NOUN
bptjm-48	184	32	is	be	AUX
bptjm-48	184	33	typically	typically	ADV
bptjm-48	184	34	240	240	NUM
bptjm-48	184	35	mg	mg	NOUN
bptjm-48	184	36	per	per	ADP
bptjm-48	184	37	2	2	NUM
bptjm-48	184	38	weeks	week	NOUN
bptjm-48	184	39	or	or	CCONJ
bptjm-48	184	40	480	480	NUM
bptjm-48	184	41	mg	mg	NUM
bptjm-48	184	42	4	4	NUM
bptjm-48	184	43	weeks	week	NOUN
bptjm-48	184	44	,	,	PUNCT
bptjm-48	184	45	as	as	ADV
bptjm-48	184	46	well	well	ADV
bptjm-48	184	47	as	as	ADP
bptjm-48	184	48	3	3	NUM
bptjm-48	184	49	mg	mg	NUM
bptjm-48	184	50	/	/	SYM
bptjm-48	184	51	kg	kg	NOUN
bptjm-48	184	52	every	every	DET
bptjm-48	184	53	2	2	NUM
bptjm-48	184	54	weeks	week	NOUN
bptjm-48	184	55	for	for	ADP
bptjm-48	184	56	pediatric	pediatric	ADJ
bptjm-48	184	57	patients	patient	NOUN
bptjm-48	184	58	under	under	ADP
bptjm-48	184	59	40	40	NUM
bptjm-48	184	60	kg	kg	NOUN
bptjm-48	184	61	.	.	PUNCT
bptjm-48	185	1	some	some	DET
bptjm-48	185	2	possible	possible	ADJ
bptjm-48	185	3	adverse	adverse	ADJ
bptjm-48	185	4	reactions	reaction	NOUN
bptjm-48	185	5	include	include	VERB
bptjm-48	185	6	fatigue	fatigue	NOUN
bptjm-48	185	7	,	,	PUNCT
bptjm-48	185	8	rashes	rash	NOUN
bptjm-48	185	9	,	,	PUNCT
bptjm-48	185	10	musculoskeletal	musculoskeletal	ADJ
bptjm-48	185	11	pain	pain	NOUN
bptjm-48	185	12	,	,	PUNCT
bptjm-48	185	13	pruritus	pruritus	NOUN
bptjm-48	185	14	,	,	PUNCT
bptjm-48	185	15	diarrhea	diarrhea	PROPN
bptjm-48	185	16	,	,	PUNCT
bptjm-48	185	17	nausea	nausea	NOUN
bptjm-48	185	18	,	,	PUNCT
bptjm-48	185	19	asthenia	asthenia	PROPN
bptjm-48	185	20	,	,	PUNCT
bptjm-48	185	21	dyspnea	dyspnea	PROPN
bptjm-48	185	22	,	,	PUNCT
bptjm-48	185	23	arthralgia	arthralgia	NOUN
bptjm-48	185	24	,	,	PUNCT
bptjm-48	185	25	urinary	urinary	ADJ
bptjm-48	185	26	tract	tract	NOUN
bptjm-48	185	27	infection	infection	NOUN
bptjm-48	185	28	,	,	PUNCT
bptjm-48	185	29	and	and	CCONJ
bptjm-48	185	30	upper	upper	ADJ
bptjm-48	185	31	respiratory	respiratory	ADJ
bptjm-48	185	32	tract	tract	NOUN
bptjm-48	185	33	infection	infection	NOUN
bptjm-48	185	34	.	.	PUNCT
bptjm-48	186	1	although	although	SCONJ
bptjm-48	186	2	its	its	PRON
bptjm-48	186	3	safety	safety	NOUN
bptjm-48	186	4	has	have	AUX
bptjm-48	186	5	not	not	PART
bptjm-48	186	6	been	be	AUX
bptjm-48	186	7	assessed	assess	VERB
bptjm-48	186	8	in	in	ADP
bptjm-48	186	9	humans	human	NOUN
bptjm-48	186	10	yet	yet	ADV
bptjm-48	186	11	,	,	PUNCT
bptjm-48	186	12	there	there	PRON
bptjm-48	186	13	were	be	VERB
bptjm-48	186	14	no	no	DET
bptjm-48	186	15	notable	notable	ADJ
bptjm-48	186	16	e	e	NOUN
bptjm-48	186	17	�	�	NOUN
bptjm-48	186	18	ects	ect	NOUN
bptjm-48	186	19	caused	cause	VERB
bptjm-48	186	20	by	by	ADP
bptjm-48	186	21	berkeley	berkeley	PROPN
bptjm-48	186	22	pharma	pharma	PROPN
bptjm-48	186	23	tech	tech	NOUN
bptjm-48	186	24	journal	journal	NOUN
bptjm-48	186	25	of	of	ADP
bptjm-48	186	26	medicine	medicine	NOUN
bptjm-48	186	27	|	|	ADV
bptjm-48	186	28	50	50	NUM
bptjm-48	186	29	nivolumab	nivolumab	NOUN
bptjm-48	186	30	in	in	ADP
bptjm-48	186	31	the	the	DET
bptjm-48	186	32	male	male	ADJ
bptjm-48	186	33	and	and	CCONJ
bptjm-48	186	34	female	female	ADJ
bptjm-48	186	35	reproductive	reproductive	ADJ
bptjm-48	186	36	organs	organ	NOUN
bptjm-48	186	37	in	in	ADP
bptjm-48	186	38	monkeys	monkey	NOUN
bptjm-48	186	39	,	,	PUNCT
bptjm-48	186	40	however	however	ADV
bptjm-48	186	41	in	in	ADP
bptjm-48	186	42	animal	animal	NOUN
bptjm-48	186	43	models	model	NOUN
bptjm-48	186	44	inhibition	inhibition	NOUN
bptjm-48	186	45	of	of	ADP
bptjm-48	186	46	pd-1	pd-1	VERB
bptjm-48	186	47	signaling	signal	VERB
bptjm-48	186	48	led	lead	VERB
bptjm-48	186	49	to	to	ADP
bptjm-48	186	50	an	an	DET
bptjm-48	186	51	increase	increase	NOUN
bptjm-48	186	52	in	in	ADP
bptjm-48	186	53	the	the	DET
bptjm-48	186	54	severity	severity	NOUN
bptjm-48	186	55	of	of	ADP
bptjm-48	186	56	some	some	DET
bptjm-48	186	57	diseases	disease	NOUN
bptjm-48	186	58	,	,	PUNCT
bptjm-48	186	59	such	such	ADJ
bptjm-48	186	60	as	as	ADP
bptjm-48	186	61	tuberculosis	tuberculosis	NOUN
bptjm-48	186	62	in	in	ADP
bptjm-48	186	63	mice.14	mice.14	PROPN
bptjm-48	186	64	phase	phase	NOUN
bptjm-48	186	65	ii	ii	PROPN
bptjm-48	186	66	clinical	clinical	ADJ
bptjm-48	186	67	trial	trial	NOUN
bptjm-48	186	68	nct03718767	nct03718767	NOUN
bptjm-48	186	69	was	be	AUX
bptjm-48	186	70	an	an	DET
bptjm-48	186	71	interventional	interventional	ADJ
bptjm-48	186	72	study	study	NOUN
bptjm-48	186	73	of	of	ADP
bptjm-48	186	74	neoadjuvant	neoadjuvant	ADJ
bptjm-48	186	75	nivolumab	nivolumab	NOUN
bptjm-48	186	76	in	in	ADP
bptjm-48	186	77	patients	patient	NOUN
bptjm-48	186	78	with	with	ADP
bptjm-48	186	79	glioblastoma	glioblastoma	NOUN
bptjm-48	186	80	.	.	PUNCT
bptjm-48	187	1	the	the	DET
bptjm-48	187	2	patients	patient	NOUN
bptjm-48	187	3	were	be	AUX
bptjm-48	187	4	due	due	ADJ
bptjm-48	187	5	to	to	PART
bptjm-48	187	6	receive	receive	VERB
bptjm-48	187	7	3	3	NUM
bptjm-48	187	8	mg	mg	ADP
bptjm-48	187	9	of	of	ADP
bptjm-48	187	10	nivolumab	nivolumab	NOUN
bptjm-48	187	11	every	every	DET
bptjm-48	187	12	2	2	NUM
bptjm-48	187	13	weeks	week	NOUN
bptjm-48	187	14	(	(	PUNCT
bptjm-48	187	15	anti	anti	ADJ
bptjm-48	187	16	-	-	ADJ
bptjm-48	187	17	pd	pd	ADJ
bptjm-48	187	18	-	-	PUNCT
bptjm-48	187	19	l1	l1	PROPN
bptjm-48	187	20	and	and	CCONJ
bptjm-48	187	21	pd	pd	NOUN
bptjm-48	187	22	-	-	NOUN
bptjm-48	187	23	l2	l2	NOUN
bptjm-48	187	24	)	)	PUNCT
bptjm-48	187	25	.	.	PUNCT
bptjm-48	188	1	its	its	PRON
bptjm-48	188	2	primary	primary	ADJ
bptjm-48	188	3	outcome	outcome	NOUN
bptjm-48	188	4	measures	measure	NOUN
bptjm-48	188	5	were	be	AUX
bptjm-48	188	6	changes	change	NOUN
bptjm-48	188	7	in	in	ADP
bptjm-48	188	8	the	the	DET
bptjm-48	188	9	level	level	NOUN
bptjm-48	188	10	of	of	ADP
bptjm-48	188	11	expression	expression	NOUN
bptjm-48	188	12	of	of	ADP
bptjm-48	188	13	pd	pd	PROPN
bptjm-48	188	14	-	-	PROPN
bptjm-48	188	15	l1	l1	PROPN
bptjm-48	188	16	by	by	ADP
bptjm-48	188	17	tumor	tumor	NOUN
bptjm-48	188	18	cells	cell	NOUN
bptjm-48	188	19	and	and	CCONJ
bptjm-48	188	20	lymphocytes	lymphocyte	NOUN
bptjm-48	188	21	,	,	PUNCT
bptjm-48	188	22	measured	measure	VERB
bptjm-48	188	23	from	from	ADP
bptjm-48	188	24	the	the	DET
bptjm-48	188	25	baseline	baseline	NOUN
bptjm-48	188	26	until	until	ADP
bptjm-48	188	27	the	the	DET
bptjm-48	188	28	end	end	NOUN
bptjm-48	188	29	of	of	ADP
bptjm-48	188	30	nivolumab	nivolumab	NOUN
bptjm-48	188	31	treatment	treatment	NOUN
bptjm-48	188	32	.	.	PUNCT
bptjm-48	189	1	the	the	DET
bptjm-48	189	2	secondary	secondary	ADJ
bptjm-48	189	3	outcome	outcome	NOUN
bptjm-48	189	4	measures	measure	NOUN
bptjm-48	189	5	were	be	AUX
bptjm-48	189	6	e	e	NOUN
bptjm-48	189	7	�	�	NOUN
bptjm-48	189	8	cacy	cacy	NOUN
bptjm-48	189	9	,	,	PUNCT
bptjm-48	189	10	with	with	ADP
bptjm-48	189	11	the	the	DET
bptjm-48	189	12	response	response	NOUN
bptjm-48	189	13	rate	rate	NOUN
bptjm-48	189	14	assessed	assess	VERB
bptjm-48	189	15	by	by	ADP
bptjm-48	189	16	response	response	NOUN
bptjm-48	189	17	assessment	assessment	NOUN
bptjm-48	189	18	in	in	ADP
bptjm-48	189	19	neuro	neuro	NOUN
bptjm-48	189	20	-	-	PUNCT
bptjm-48	189	21	oncology	oncology	NOUN
bptjm-48	189	22	(	(	PUNCT
bptjm-48	189	23	rano	rano	NOUN
bptjm-48	189	24	)	)	PUNCT
bptjm-48	189	25	criteria	criterion	NOUN
bptjm-48	189	26	,	,	PUNCT
bptjm-48	189	27	and	and	CCONJ
bptjm-48	189	28	safety	safety	NOUN
bptjm-48	189	29	,	,	PUNCT
bptjm-48	189	30	with	with	ADP
bptjm-48	189	31	toxicity	toxicity	NOUN
bptjm-48	189	32	being	be	AUX
bptjm-48	189	33	assessed	assess	VERB
bptjm-48	189	34	by	by	ADP
bptjm-48	189	35	common	common	ADJ
bptjm-48	189	36	toxicity	toxicity	NOUN
bptjm-48	189	37	criteria	criterion	NOUN
bptjm-48	189	38	(	(	PUNCT
bptjm-48	189	39	ctc	ctc	NOUN
bptjm-48	189	40	)	)	PUNCT
bptjm-48	189	41	.	.	PUNCT
bptjm-48	190	1	the	the	DET
bptjm-48	190	2	study	study	NOUN
bptjm-48	190	3	revealed	reveal	VERB
bptjm-48	190	4	that	that	SCONJ
bptjm-48	190	5	neoadjuvant	neoadjuvant	ADJ
bptjm-48	190	6	nivolumab	nivolumab	NOUN
bptjm-48	190	7	resulted	result	VERB
bptjm-48	190	8	in	in	ADP
bptjm-48	190	9	enhanced	enhanced	ADJ
bptjm-48	190	10	expression	expression	NOUN
bptjm-48	190	11	of	of	ADP
bptjm-48	190	12	chemokine	chemokine	ADJ
bptjm-48	190	13	transcripts	transcript	NOUN
bptjm-48	190	14	,	,	PUNCT
bptjm-48	190	15	higher	high	ADJ
bptjm-48	190	16	immune	immune	ADJ
bptjm-48	190	17	cell	cell	NOUN
bptjm-48	190	18	in	in	ADP
bptjm-48	190	19	�	�	PROPN
bptjm-48	190	20	ltration	ltration	NOUN
bptjm-48	190	21	and	and	CCONJ
bptjm-48	190	22	augmented	augment	VERB
bptjm-48	190	23	tcr	tcr	PROPN
bptjm-48	190	24	clonal	clonal	ADJ
bptjm-48	190	25	diversity	diversity	NOUN
bptjm-48	190	26	among	among	ADP
bptjm-48	190	27	tumor	tumor	NOUN
bptjm-48	190	28	-	-	PUNCT
bptjm-48	190	29	in	in	ADP
bptjm-48	190	30	�	�	PROPN
bptjm-48	190	31	ltrating	ltrating	NOUN
bptjm-48	190	32	t	t	PROPN
bptjm-48	190	33	lymphocytes	lymphocyte	NOUN
bptjm-48	190	34	,	,	PUNCT
bptjm-48	190	35	supporting	support	VERB
bptjm-48	190	36	a	a	DET
bptjm-48	190	37	local	local	ADJ
bptjm-48	190	38	immunomodulatory	immunomodulatory	ADJ
bptjm-48	190	39	e	e	NOUN
bptjm-48	190	40	�	�	NOUN
bptjm-48	190	41	ect	ect	VERB
bptjm-48	190	42	of	of	ADP
bptjm-48	190	43	treatment.36	treatment.36	NOUN
bptjm-48	190	44	as	as	ADP
bptjm-48	190	45	such	such	ADJ
bptjm-48	190	46	,	,	PUNCT
bptjm-48	190	47	the	the	DET
bptjm-48	190	48	use	use	NOUN
bptjm-48	190	49	of	of	ADP
bptjm-48	190	50	neoadjuvant	neoadjuvant	ADJ
bptjm-48	190	51	nivolumab	nivolumab	NOUN
bptjm-48	190	52	can	can	AUX
bptjm-48	190	53	be	be	AUX
bptjm-48	190	54	used	use	VERB
bptjm-48	190	55	a	a	DET
bptjm-48	190	56	method	method	NOUN
bptjm-48	190	57	of	of	ADP
bptjm-48	190	58	early	early	ADJ
bptjm-48	190	59	termination	termination	NOUN
bptjm-48	190	60	for	for	ADP
bptjm-48	190	61	developing	develop	VERB
bptjm-48	190	62	tumor	tumor	NOUN
bptjm-48	190	63	.	.	PUNCT
bptjm-48	191	1	some	some	DET
bptjm-48	191	2	key	key	ADJ
bptjm-48	191	3	things	thing	NOUN
bptjm-48	191	4	to	to	PART
bptjm-48	191	5	mention	mention	VERB
bptjm-48	191	6	are	be	AUX
bptjm-48	191	7	that	that	SCONJ
bptjm-48	191	8	this	this	DET
bptjm-48	191	9	study	study	NOUN
bptjm-48	191	10	involved	involve	VERB
bptjm-48	191	11	the	the	DET
bptjm-48	191	12	use	use	NOUN
bptjm-48	191	13	of	of	ADP
bptjm-48	191	14	patients	patient	NOUN
bptjm-48	191	15	who	who	PRON
bptjm-48	191	16	have	have	VERB
bptjm-48	191	17	idh1	idh1	NOUN
bptjm-48	191	18	or	or	CCONJ
bptjm-48	191	19	idh2	idh2	PROPN
bptjm-48	191	20	mutated	mutate	VERB
bptjm-48	191	21	gliomas	glioma	NOUN
bptjm-48	191	22	with	with	ADP
bptjm-48	191	23	hyper	hyper	ADJ
bptjm-48	191	24	mutator	mutator	NOUN
bptjm-48	191	25	phenotypes	phenotype	NOUN
bptjm-48	191	26	(	(	PUNCT
bptjm-48	191	27	hmp	hmp	PROPN
bptjm-48	191	28	)	)	PUNCT
bptjm-48	191	29	.	.	PUNCT
bptjm-48	192	1	these	these	DET
bptjm-48	192	2	patients	patient	NOUN
bptjm-48	192	3	had	have	VERB
bptjm-48	192	4	a	a	DET
bptjm-48	192	5	high	high	ADJ
bptjm-48	192	6	number	number	NOUN
bptjm-48	192	7	of	of	ADP
bptjm-48	192	8	mutations	mutation	NOUN
bptjm-48	192	9	in	in	ADP
bptjm-48	192	10	their	their	PRON
bptjm-48	192	11	tumors	tumor	NOUN
bptjm-48	192	12	and	and	CCONJ
bptjm-48	192	13	the	the	DET
bptjm-48	192	14	study	study	NOUN
bptjm-48	192	15	revolved	revolve	VERB
bptjm-48	192	16	around	around	ADP
bptjm-48	192	17	understanding	understanding	NOUN
bptjm-48	192	18	if	if	SCONJ
bptjm-48	192	19	neoadjuvant	neoadjuvant	ADJ
bptjm-48	192	20	nivolumab	nivolumab	NOUN
bptjm-48	192	21	can	can	AUX
bptjm-48	192	22	stop	stop	VERB
bptjm-48	192	23	or	or	CCONJ
bptjm-48	192	24	reduce	reduce	VERB
bptjm-48	192	25	tumor	tumor	NOUN
bptjm-48	192	26	size	size	NOUN
bptjm-48	192	27	,	,	PUNCT
bptjm-48	192	28	showing	show	VERB
bptjm-48	192	29	characteristics	characteristic	NOUN
bptjm-48	192	30	of	of	ADP
bptjm-48	192	31	controlled	control	VERB
bptjm-48	192	32	tumor	tumor	NOUN
bptjm-48	192	33	growth	growth	NOUN
bptjm-48	192	34	.	.	PUNCT
bptjm-48	193	1	one	one	NUM
bptjm-48	193	2	of	of	ADP
bptjm-48	193	3	the	the	DET
bptjm-48	193	4	drawbacks	drawback	NOUN
bptjm-48	193	5	of	of	ADP
bptjm-48	193	6	this	this	DET
bptjm-48	193	7	study	study	NOUN
bptjm-48	193	8	was	be	AUX
bptjm-48	193	9	their	their	PRON
bptjm-48	193	10	secondary	secondary	ADJ
bptjm-48	193	11	outcome	outcome	NOUN
bptjm-48	193	12	measure	measure	NOUN
bptjm-48	193	13	of	of	ADP
bptjm-48	193	14	improvements	improvement	NOUN
bptjm-48	193	15	in	in	ADP
bptjm-48	193	16	quality	quality	NOUN
bptjm-48	193	17	of	of	ADP
bptjm-48	193	18	life	life	NOUN
bptjm-48	193	19	,	,	PUNCT
bptjm-48	193	20	which	which	PRON
bptjm-48	193	21	was	be	AUX
bptjm-48	193	22	self	self	NOUN
bptjm-48	193	23	-	-	PUNCT
bptjm-48	193	24	reported	report	VERB
bptjm-48	193	25	alongside	alongside	ADP
bptjm-48	193	26	symptom	symptom	NOUN
bptjm-48	193	27	severity	severity	NOUN
bptjm-48	193	28	and	and	CCONJ
bptjm-48	193	29	interference	interference	NOUN
bptjm-48	193	30	with	with	ADP
bptjm-48	193	31	daily	daily	ADJ
bptjm-48	193	32	activities	activity	NOUN
bptjm-48	193	33	.	.	PUNCT
bptjm-48	194	1	self	self	NOUN
bptjm-48	194	2	-	-	PUNCT
bptjm-48	194	3	reporting	reporting	NOUN
bptjm-48	194	4	may	may	AUX
bptjm-48	194	5	lead	lead	VERB
bptjm-48	194	6	to	to	ADP
bptjm-48	194	7	biases	bias	NOUN
bptjm-48	194	8	or	or	CCONJ
bptjm-48	194	9	false	false	ADJ
bptjm-48	194	10	speculation	speculation	NOUN
bptjm-48	194	11	in	in	ADP
bptjm-48	194	12	the	the	DET
bptjm-48	194	13	reports	report	NOUN
bptjm-48	194	14	from	from	ADP
bptjm-48	194	15	the	the	DET
bptjm-48	194	16	patients	patient	NOUN
bptjm-48	194	17	’	'	PUNCT
bptjm-48	194	18	end	end	NOUN
bptjm-48	194	19	,	,	PUNCT
bptjm-48	194	20	which	which	PRON
bptjm-48	194	21	in	in	ADP
bptjm-48	194	22	turn	turn	NOUN
bptjm-48	194	23	would	would	AUX
bptjm-48	194	24	produce	produce	VERB
bptjm-48	194	25	skewed	skewed	ADJ
bptjm-48	194	26	secondary	secondary	ADJ
bptjm-48	194	27	results	result	NOUN
bptjm-48	194	28	.	.	PUNCT
bptjm-48	195	1	an	an	DET
bptjm-48	195	2	additional	additional	ADJ
bptjm-48	195	3	combined	combined	ADJ
bptjm-48	195	4	monoclonal	monoclonal	NOUN
bptjm-48	195	5	antibody	antibody	NOUN
bptjm-48	195	6	treatment	treatment	NOUN
bptjm-48	195	7	for	for	ADP
bptjm-48	195	8	glioblastoma	glioblastoma	NOUN
bptjm-48	195	9	(	(	PUNCT
bptjm-48	195	10	nct03367715	nct03367715	NOUN
bptjm-48	195	11	)	)	PUNCT
bptjm-48	195	12	that	that	PRON
bptjm-48	195	13	is	be	AUX
bptjm-48	195	14	currently	currently	ADV
bptjm-48	195	15	being	be	AUX
bptjm-48	195	16	studied	study	VERB
bptjm-48	195	17	involves	involve	VERB
bptjm-48	195	18	nivolumab	nivolumab	NOUN
bptjm-48	195	19	and	and	CCONJ
bptjm-48	195	20	ipilimumab	ipilimumab	NOUN
bptjm-48	195	21	(	(	PUNCT
bptjm-48	195	22	fda	fda	PROPN
bptjm-48	195	23	)	)	PUNCT
bptjm-48	195	24	.	.	PUNCT
bptjm-48	196	1	for	for	ADP
bptjm-48	196	2	the	the	DET
bptjm-48	196	3	mechanism	mechanism	NOUN
bptjm-48	196	4	of	of	ADP
bptjm-48	196	5	action	action	NOUN
bptjm-48	196	6	,	,	PUNCT
bptjm-48	196	7	ipilimumab	ipilimumab	NOUN
bptjm-48	196	8	binds	bind	VERB
bptjm-48	196	9	to	to	ADP
bptjm-48	196	10	ctla-4	ctla-4	NOUN
bptjm-48	196	11	to	to	PART
bptjm-48	196	12	block	block	VERB
bptjm-48	196	13	its	its	PRON
bptjm-48	196	14	interaction	interaction	NOUN
bptjm-48	196	15	with	with	ADP
bptjm-48	196	16	the	the	DET
bptjm-48	196	17	ligands	ligand	NOUN
bptjm-48	196	18	cd80	cd80	PROPN
bptjm-48	196	19	and	and	CCONJ
bptjm-48	196	20	cd86	cd86	PROPN
bptjm-48	196	21	—	—	PUNCT
bptjm-48	196	22	which	which	PRON
bptjm-48	196	23	negatively	negatively	ADV
bptjm-48	196	24	regulate	regulate	VERB
bptjm-48	196	25	t	t	NOUN
bptjm-48	196	26	-	-	PUNCT
bptjm-48	196	27	cells	cell	NOUN
bptjm-48	196	28	,	,	PUNCT
bptjm-48	196	29	therefore	therefore	ADV
bptjm-48	196	30	resulting	result	VERB
bptjm-48	196	31	in	in	ADP
bptjm-48	196	32	tumor	tumor	NOUN
bptjm-48	196	33	penetrating	penetrate	VERB
bptjm-48	196	34	t	t	PROPN
bptjm-48	196	35	-	-	PUNCT
bptjm-48	196	36	e	e	NOUN
bptjm-48	196	37	�	�	PROPN
bptjm-48	196	38	ector	ector	NOUN
bptjm-48	196	39	cell	cell	NOUN
bptjm-48	196	40	activation	activation	NOUN
bptjm-48	196	41	and	and	CCONJ
bptjm-48	196	42	proliferation	proliferation	NOUN
bptjm-48	196	43	(	(	PUNCT
bptjm-48	196	44	fda	fda	PROPN
bptjm-48	196	45	)	)	PUNCT
bptjm-48	196	46	.	.	PUNCT
bptjm-48	197	1	inhibiting	inhibit	VERB
bptjm-48	197	2	ctla-4	ctla-4	PRON
bptjm-48	197	3	signaling	signal	VERB
bptjm-48	197	4	reduces	reduce	VERB
bptjm-48	197	5	t	t	NOUN
bptjm-48	197	6	-	-	PUNCT
bptjm-48	197	7	regulatory	regulatory	ADJ
bptjm-48	197	8	cell	cell	NOUN
bptjm-48	197	9	function	function	NOUN
bptjm-48	197	10	,	,	PUNCT
bptjm-48	197	11	contributing	contribute	VERB
bptjm-48	197	12	to	to	ADP
bptjm-48	197	13	an	an	DET
bptjm-48	197	14	increase	increase	NOUN
bptjm-48	197	15	in	in	ADP
bptjm-48	197	16	berkeley	berkeley	PROPN
bptjm-48	197	17	pharma	pharma	PROPN
bptjm-48	197	18	tech	tech	NOUN
bptjm-48	197	19	journal	journal	NOUN
bptjm-48	197	20	of	of	ADP
bptjm-48	197	21	medicine	medicine	NOUN
bptjm-48	197	22	|	|	ADV
bptjm-48	197	23	51	51	NUM
bptjm-48	197	24	https://clinicaltrials.gov/ct2/show/nct03718767	https://clinicaltrials.gov/ct2/show/nct03718767	NOUN
bptjm-48	197	25	https://clinicaltrials.gov/ct2/show/nct03367715?term=nivolumab%2c+ipilimumab&cond=glioblastoma&draw=2&rank=1	https://clinicaltrials.gov/ct2/show/nct03367715?term=nivolumab%2c+ipilimumab&cond=glioblastoma&draw=2&rank=1	NOUN
bptjm-48	197	26	t	t	PROPN
bptjm-48	197	27	cell	cell	NOUN
bptjm-48	197	28	responsiveness	responsiveness	NOUN
bptjm-48	197	29	.	.	PUNCT
bptjm-48	198	1	when	when	SCONJ
bptjm-48	198	2	ipilimumab	ipilimumab	NOUN
bptjm-48	198	3	and	and	CCONJ
bptjm-48	198	4	nivolumab	nivolumab	NOUN
bptjm-48	198	5	are	be	AUX
bptjm-48	198	6	used	use	VERB
bptjm-48	198	7	concurrently	concurrently	ADV
bptjm-48	198	8	,	,	PUNCT
bptjm-48	198	9	pd-1	pd-1	ADJ
bptjm-48	198	10	and	and	CCONJ
bptjm-48	198	11	ctla-4	ctla-4	PRON
bptjm-48	198	12	dual	dual	ADJ
bptjm-48	198	13	inhibition	inhibition	NOUN
bptjm-48	198	14	results	result	NOUN
bptjm-48	198	15	in	in	ADP
bptjm-48	198	16	enhanced	enhance	VERB
bptjm-48	198	17	t	t	PROPN
bptjm-48	198	18	-	-	PUNCT
bptjm-48	198	19	cell	cell	NOUN
bptjm-48	198	20	function	function	NOUN
bptjm-48	198	21	that	that	PRON
bptjm-48	198	22	is	be	AUX
bptjm-48	198	23	more	more	ADJ
bptjm-48	198	24	e	e	NOUN
bptjm-48	198	25	�	�	NOUN
bptjm-48	198	26	ective	ective	ADJ
bptjm-48	198	27	than	than	ADP
bptjm-48	198	28	either	either	CCONJ
bptjm-48	198	29	antibody	antibody	NOUN
bptjm-48	198	30	on	on	ADP
bptjm-48	198	31	its	its	PRON
bptjm-48	198	32	own	own	ADJ
bptjm-48	198	33	,	,	PUNCT
bptjm-48	198	34	and	and	CCONJ
bptjm-48	198	35	they	they	PRON
bptjm-48	198	36	’ve	’ve	AUX
bptjm-48	198	37	shown	show	VERB
bptjm-48	198	38	to	to	PART
bptjm-48	198	39	produce	produce	VERB
bptjm-48	198	40	more	more	ADJ
bptjm-48	198	41	signi	signi	ADJ
bptjm-48	198	42	�	�	NOUN
bptjm-48	198	43	cant	cant	VERB
bptjm-48	198	44	antitumor	antitumor	PROPN
bptjm-48	198	45	responses.38	responses.38	PROPN
bptjm-48	198	46	currently	currently	ADV
bptjm-48	198	47	,	,	PUNCT
bptjm-48	198	48	there	there	PRON
bptjm-48	198	49	are	be	VERB
bptjm-48	198	50	many	many	ADJ
bptjm-48	198	51	trials	trial	NOUN
bptjm-48	198	52	being	be	AUX
bptjm-48	198	53	conducted	conduct	VERB
bptjm-48	198	54	to	to	PART
bptjm-48	198	55	test	test	VERB
bptjm-48	198	56	the	the	DET
bptjm-48	198	57	e	e	PROPN
bptjm-48	198	58	�	�	PROPN
bptjm-48	198	59	cacy	cacy	NOUN
bptjm-48	198	60	of	of	ADP
bptjm-48	198	61	single	single	ADJ
bptjm-48	198	62	-	-	PUNCT
bptjm-48	198	63	monoclonal	monoclonal	NOUN
bptjm-48	198	64	antibody	antibody	NOUN
bptjm-48	198	65	treatments	treatment	NOUN
bptjm-48	198	66	as	as	ADV
bptjm-48	198	67	well	well	ADV
bptjm-48	198	68	as	as	ADP
bptjm-48	198	69	combined	combine	VERB
bptjm-48	198	70	monoclonal	monoclonal	NOUN
bptjm-48	198	71	antibody	antibody	NOUN
bptjm-48	198	72	treatments	treatment	NOUN
bptjm-48	198	73	.	.	PUNCT
bptjm-48	199	1	the	the	DET
bptjm-48	199	2	aforementioned	aforementioned	ADJ
bptjm-48	199	3	trials	trial	NOUN
bptjm-48	199	4	are	be	AUX
bptjm-48	199	5	just	just	ADV
bptjm-48	199	6	some	some	PRON
bptjm-48	199	7	of	of	ADP
bptjm-48	199	8	those	those	DET
bptjm-48	199	9	few	few	ADJ
bptjm-48	199	10	.	.	PUNCT
bptjm-48	200	1	4.6	4.6	NUM
bptjm-48	200	2	adoptive	adoptive	ADJ
bptjm-48	200	3	cell	cell	NOUN
bptjm-48	200	4	therapies	therapy	NOUN
bptjm-48	200	5	(	(	PUNCT
bptjm-48	200	6	act	act	PROPN
bptjm-48	200	7	)	)	PUNCT
bptjm-48	200	8	adoptive	adoptive	ADJ
bptjm-48	200	9	cell	cell	NOUN
bptjm-48	200	10	therapies	therapy	NOUN
bptjm-48	200	11	(	(	PUNCT
bptjm-48	200	12	act	act	PROPN
bptjm-48	200	13	)	)	PUNCT
bptjm-48	200	14	involve	involve	VERB
bptjm-48	200	15	the	the	DET
bptjm-48	200	16	use	use	NOUN
bptjm-48	200	17	of	of	ADP
bptjm-48	200	18	in	in	ADP
bptjm-48	200	19	vitro	vitro	X
bptjm-48	200	20	ampli	ampli	NOUN
bptjm-48	200	21	�	�	NOUN
bptjm-48	200	22	cation	cation	NOUN
bptjm-48	200	23	of	of	ADP
bptjm-48	200	24	key	key	ADJ
bptjm-48	200	25	immune	immune	ADJ
bptjm-48	200	26	cells	cell	NOUN
bptjm-48	200	27	,	,	PUNCT
bptjm-48	200	28	which	which	PRON
bptjm-48	200	29	include	include	VERB
bptjm-48	200	30	dendritic	dendritic	ADJ
bptjm-48	200	31	cells	cell	NOUN
bptjm-48	200	32	(	(	PUNCT
bptjm-48	200	33	dc	dc	PROPN
bptjm-48	200	34	)	)	PUNCT
bptjm-48	200	35	,	,	PUNCT
bptjm-48	200	36	tumor	tumor	NOUN
bptjm-48	200	37	-	-	PUNCT
bptjm-48	200	38	in	in	ADP
bptjm-48	200	39	�	�	NOUN
bptjm-48	200	40	ltrating	ltrating	NOUN
bptjm-48	200	41	lymphocytes	lymphocyte	NOUN
bptjm-48	200	42	(	(	PUNCT
bptjm-48	200	43	til	til	ADJ
bptjm-48	200	44	)	)	PUNCT
bptjm-48	200	45	and	and	CCONJ
bptjm-48	200	46	cytokine	cytokine	NOUN
bptjm-48	200	47	-	-	PUNCT
bptjm-48	200	48	induced	induce	VERB
bptjm-48	200	49	killer	killer	NOUN
bptjm-48	200	50	cells	cell	NOUN
bptjm-48	200	51	.	.	PUNCT
bptjm-48	201	1	these	these	DET
bptjm-48	201	2	cells	cell	NOUN
bptjm-48	201	3	are	be	AUX
bptjm-48	201	4	extracted	extract	VERB
bptjm-48	201	5	from	from	ADP
bptjm-48	201	6	a	a	DET
bptjm-48	201	7	patient	patient	NOUN
bptjm-48	201	8	,	,	PUNCT
bptjm-48	201	9	are	be	AUX
bptjm-48	201	10	ampli	ampli	NOUN
bptjm-48	201	11	�	�	NOUN
bptjm-48	201	12	ed	ed	NOUN
bptjm-48	201	13	,	,	PUNCT
bptjm-48	201	14	and	and	CCONJ
bptjm-48	201	15	then	then	ADV
bptjm-48	201	16	injected	inject	VERB
bptjm-48	201	17	back	back	ADV
bptjm-48	201	18	into	into	ADP
bptjm-48	201	19	the	the	DET
bptjm-48	201	20	patient	patient	NOUN
bptjm-48	201	21	to	to	PART
bptjm-48	201	22	enhance	enhance	VERB
bptjm-48	201	23	the	the	DET
bptjm-48	201	24	tumor	tumor	NOUN
bptjm-48	201	25	-	-	PUNCT
bptjm-48	201	26	killing	kill	VERB
bptjm-48	201	27	response	response	NOUN
bptjm-48	201	28	.	.	PUNCT
bptjm-48	202	1	more	more	ADJ
bptjm-48	202	2	speci	speci	ADJ
bptjm-48	202	3	�	�	NOUN
bptjm-48	202	4	cally	cally	ADV
bptjm-48	202	5	til	til	ADV
bptjm-48	202	6	based	base	VERB
bptjm-48	202	7	cell	cell	NOUN
bptjm-48	202	8	therapies	therapy	NOUN
bptjm-48	202	9	have	have	AUX
bptjm-48	202	10	proven	prove	VERB
bptjm-48	202	11	to	to	PART
bptjm-48	202	12	be	be	AUX
bptjm-48	202	13	e	e	NOUN
bptjm-48	202	14	�	�	NOUN
bptjm-48	202	15	cacious	cacious	ADJ
bptjm-48	202	16	in	in	ADP
bptjm-48	202	17	recognizing	recognize	VERB
bptjm-48	202	18	antigenic	antigenic	ADJ
bptjm-48	202	19	epitopes	epitope	NOUN
bptjm-48	202	20	on	on	ADP
bptjm-48	202	21	the	the	DET
bptjm-48	202	22	surface	surface	NOUN
bptjm-48	202	23	of	of	ADP
bptjm-48	202	24	tumor	tumor	NOUN
bptjm-48	202	25	cells	cell	NOUN
bptjm-48	202	26	and	and	CCONJ
bptjm-48	202	27	killing	kill	VERB
bptjm-48	202	28	them.39,40,41	them.39,40,41	PROPN
bptjm-48	202	29	act	act	NOUN
bptjm-48	202	30	with	with	ADP
bptjm-48	202	31	tils	til	NOUN
bptjm-48	202	32	has	have	AUX
bptjm-48	202	33	been	be	AUX
bptjm-48	202	34	proven	prove	VERB
bptjm-48	202	35	to	to	PART
bptjm-48	202	36	be	be	AUX
bptjm-48	202	37	e	e	NOUN
bptjm-48	202	38	�	�	NOUN
bptjm-48	202	39	cacious	cacious	ADJ
bptjm-48	202	40	against	against	ADP
bptjm-48	202	41	metastatic	metastatic	ADJ
bptjm-48	202	42	melanoma.42	melanoma.42	NOUN
bptjm-48	202	43	neoantigen	neoantigen	PROPN
bptjm-48	202	44	speci	speci	PROPN
bptjm-48	202	45	�	�	PROPN
bptjm-48	202	46	c	c	PROPN
bptjm-48	202	47	t	t	NOUN
bptjm-48	202	48	cells	cell	NOUN
bptjm-48	202	49	were	be	AUX
bptjm-48	202	50	detected	detect	VERB
bptjm-48	202	51	in	in	ADP
bptjm-48	202	52	the	the	DET
bptjm-48	202	53	tils	til	NOUN
bptjm-48	202	54	of	of	ADP
bptjm-48	202	55	patients	patient	NOUN
bptjm-48	202	56	with	with	ADP
bptjm-48	202	57	metastatic	metastatic	ADJ
bptjm-48	202	58	melanoma	melanoma	NOUN
bptjm-48	202	59	and	and	CCONJ
bptjm-48	202	60	neoantigens	neoantigen	NOUN
bptjm-48	202	61	were	be	AUX
bptjm-48	202	62	identi	identi	X
bptjm-48	202	63	�	�	PROPN
bptjm-48	202	64	ed	ed	NOUN
bptjm-48	202	65	that	that	PRON
bptjm-48	202	66	increased	increase	VERB
bptjm-48	202	67	the	the	DET
bptjm-48	202	68	response	response	NOUN
bptjm-48	202	69	of	of	ADP
bptjm-48	202	70	t	t	PROPN
bptjm-48	202	71	lymphocytes	lymphocyte	VERB
bptjm-48	202	72	in	in	ADP
bptjm-48	202	73	the	the	DET
bptjm-48	202	74	peripheral	peripheral	ADJ
bptjm-48	202	75	blood	blood	NOUN
bptjm-48	202	76	post	post	NOUN
bptjm-48	202	77	-	-	ADJ
bptjm-48	202	78	til	til	ADJ
bptjm-48	202	79	infusion.33,43	infusion.33,43	NOUN
bptjm-48	202	80	however	however	ADV
bptjm-48	202	81	,	,	PUNCT
bptjm-48	202	82	the	the	DET
bptjm-48	202	83	process	process	NOUN
bptjm-48	202	84	that	that	PRON
bptjm-48	202	85	goes	go	VERB
bptjm-48	202	86	into	into	ADP
bptjm-48	202	87	amplifying	amplifying	ADJ
bptjm-48	202	88	t	t	NOUN
bptjm-48	202	89	cells	cell	NOUN
bptjm-48	202	90	is	be	AUX
bptjm-48	202	91	complex	complex	ADJ
bptjm-48	202	92	and	and	CCONJ
bptjm-48	202	93	it	it	PRON
bptjm-48	202	94	is	be	AUX
bptjm-48	202	95	di	di	NOUN
bptjm-48	202	96	�	�	PROPN
bptjm-48	202	97	cult	cult	NOUN
bptjm-48	202	98	to	to	PART
bptjm-48	202	99	obtain	obtain	VERB
bptjm-48	202	100	high	high	ADJ
bptjm-48	202	101	a	a	DET
bptjm-48	202	102	�	�	NOUN
bptjm-48	202	103	nity	nity	NOUN
bptjm-48	202	104	tcr+	tcr+	PROPN
bptjm-48	202	105	t	t	NOUN
bptjm-48	202	106	cells	cell	NOUN
bptjm-48	202	107	and	and	CCONJ
bptjm-48	202	108	t	t	NOUN
bptjm-48	202	109	cells	cell	NOUN
bptjm-48	202	110	produced	produce	VERB
bptjm-48	202	111	in	in	ADP
bptjm-48	202	112	vitro	vitro	X
bptjm-48	202	113	do	do	AUX
bptjm-48	202	114	not	not	PART
bptjm-48	202	115	last	last	VERB
bptjm-48	202	116	for	for	ADP
bptjm-48	202	117	a	a	DET
bptjm-48	202	118	prolonged	prolonged	ADJ
bptjm-48	202	119	period	period	NOUN
bptjm-48	202	120	of	of	ADP
bptjm-48	202	121	time	time	NOUN
bptjm-48	202	122	following	follow	VERB
bptjm-48	202	123	infusion.33,40,42	infusion.33,40,42	NOUN
bptjm-48	202	124	in	in	ADP
bptjm-48	202	125	addition	addition	NOUN
bptjm-48	202	126	,	,	PUNCT
bptjm-48	202	127	the	the	DET
bptjm-48	202	128	tissue	tissue	NOUN
bptjm-48	202	129	from	from	ADP
bptjm-48	202	130	which	which	PRON
bptjm-48	202	131	these	these	DET
bptjm-48	202	132	t	t	NOUN
bptjm-48	202	133	cells	cell	NOUN
bptjm-48	202	134	are	be	AUX
bptjm-48	202	135	extracted	extract	VERB
bptjm-48	202	136	and	and	CCONJ
bptjm-48	202	137	then	then	ADV
bptjm-48	202	138	ampli	ampli	VERB
bptjm-48	202	139	�	�	PROPN
bptjm-48	202	140	ed	ed	PROPN
bptjm-48	202	141	can	can	AUX
bptjm-48	202	142	lead	lead	VERB
bptjm-48	202	143	to	to	ADP
bptjm-48	202	144	variation	variation	NOUN
bptjm-48	202	145	amongst	amongst	ADP
bptjm-48	202	146	the	the	DET
bptjm-48	202	147	types	type	NOUN
bptjm-48	202	148	of	of	ADP
bptjm-48	202	149	antigens	antigen	NOUN
bptjm-48	202	150	produced	produce	VERB
bptjm-48	202	151	,	,	PUNCT
bptjm-48	202	152	making	make	VERB
bptjm-48	202	153	it	it	PRON
bptjm-48	202	154	less	less	ADV
bptjm-48	202	155	likely	likely	ADJ
bptjm-48	202	156	for	for	ADP
bptjm-48	202	157	a	a	DET
bptjm-48	202	158	shared	share	VERB
bptjm-48	202	159	/	/	SYM
bptjm-48	202	160	public	public	ADJ
bptjm-48	202	161	treatment	treatment	NOUN
bptjm-48	202	162	method.41,42	method.41,42	NOUN
bptjm-48	202	163	berkeley	berkeley	PROPN
bptjm-48	202	164	pharma	pharma	PROPN
bptjm-48	202	165	tech	tech	NOUN
bptjm-48	202	166	journal	journal	NOUN
bptjm-48	202	167	of	of	ADP
bptjm-48	202	168	medicine	medicine	NOUN
bptjm-48	202	169	|	|	ADV
bptjm-48	202	170	52	52	NUM
bptjm-48	202	171	figure	figure	NOUN
bptjm-48	202	172	12	12	NUM
bptjm-48	202	173	.	.	PUNCT
bptjm-48	203	1	a	a	DET
bptjm-48	203	2	sample	sample	NOUN
bptjm-48	203	3	work	work	NOUN
bptjm-48	203	4	�	�	PROPN
bptjm-48	203	5	ow	ow	PROPN
bptjm-48	203	6	of	of	ADP
bptjm-48	203	7	t	t	PROPN
bptjm-48	203	8	-	-	PUNCT
bptjm-48	203	9	cell	cell	NOUN
bptjm-48	203	10	therapy	therapy	NOUN
bptjm-48	203	11	in	in	ADP
bptjm-48	203	12	a	a	DET
bptjm-48	203	13	phase	phase	NOUN
bptjm-48	203	14	iii	iii	NUM
bptjm-48	203	15	clinical	clinical	ADJ
bptjm-48	203	16	trial	trial	NOUN
bptjm-48	203	17	nct05685004	nct05685004	VERB
bptjm-48	203	18	a	a	DET
bptjm-48	203	19	combination	combination	NOUN
bptjm-48	203	20	of	of	ADP
bptjm-48	203	21	tvi	tvi	NOUN
bptjm-48	203	22	-	-	PUNCT
bptjm-48	203	23	brain-1	brain-1	NUM
bptjm-48	203	24	immunotherapy	immunotherapy	NOUN
bptjm-48	203	25	and	and	CCONJ
bptjm-48	203	26	standard	standard	ADJ
bptjm-48	203	27	therapy	therapy	NOUN
bptjm-48	203	28	compared	compare	VERB
bptjm-48	203	29	to	to	ADP
bptjm-48	203	30	standard	standard	ADJ
bptjm-48	203	31	therapy	therapy	NOUN
bptjm-48	203	32	alone	alone	ADV
bptjm-48	203	33	as	as	ADP
bptjm-48	203	34	a	a	DET
bptjm-48	203	35	treatment	treatment	NOUN
bptjm-48	203	36	for	for	ADP
bptjm-48	203	37	newly	newly	ADV
bptjm-48	203	38	diagnosed	diagnose	VERB
bptjm-48	203	39	mgmt	mgmt	NOUN
bptjm-48	203	40	unmethylated	unmethylate	VERB
bptjm-48	203	41	glioblastoma	glioblastoma	NOUN
bptjm-48	203	42	patients	patient	NOUN
bptjm-48	203	43	.	.	PUNCT
bptjm-48	204	1	the	the	DET
bptjm-48	204	2	general	general	ADJ
bptjm-48	204	3	procedures	procedure	NOUN
bptjm-48	204	4	include	include	VERB
bptjm-48	204	5	the	the	DET
bptjm-48	204	6	collection	collection	NOUN
bptjm-48	204	7	and	and	CCONJ
bptjm-48	204	8	testing	testing	NOUN
bptjm-48	204	9	of	of	ADP
bptjm-48	204	10	cancer	cancer	NOUN
bptjm-48	204	11	tissue	tissue	NOUN
bptjm-48	204	12	samples	sample	NOUN
bptjm-48	204	13	after	after	ADP
bptjm-48	204	14	surgery	surgery	NOUN
bptjm-48	204	15	and	and	CCONJ
bptjm-48	204	16	chemoradiation	chemoradiation	NOUN
bptjm-48	204	17	therapy	therapy	NOUN
bptjm-48	204	18	(	(	PUNCT
bptjm-48	204	19	radiation	radiation	NOUN
bptjm-48	204	20	and	and	CCONJ
bptjm-48	204	21	temozolomide	temozolomide	NOUN
bptjm-48	204	22	)	)	PUNCT
bptjm-48	204	23	.	.	PUNCT
bptjm-48	205	1	for	for	SCONJ
bptjm-48	205	2	the	the	DET
bptjm-48	205	3	patients	patient	NOUN
bptjm-48	205	4	randomized	randomize	VERB
bptjm-48	205	5	into	into	ADP
bptjm-48	205	6	the	the	DET
bptjm-48	205	7	investigational	investigational	ADJ
bptjm-48	205	8	study	study	NOUN
bptjm-48	205	9	treatment	treatment	NOUN
bptjm-48	205	10	group	group	NOUN
bptjm-48	205	11	,	,	PUNCT
bptjm-48	205	12	they	they	PRON
bptjm-48	205	13	will	will	AUX
bptjm-48	205	14	also	also	ADV
bptjm-48	205	15	receive	receive	VERB
bptjm-48	205	16	two	two	NUM
bptjm-48	205	17	vaccinations	vaccination	NOUN
bptjm-48	205	18	created	create	VERB
bptjm-48	205	19	from	from	ADP
bptjm-48	205	20	their	their	PRON
bptjm-48	205	21	own	own	ADJ
bptjm-48	205	22	cancer	cancer	NOUN
bptjm-48	205	23	cells	cell	NOUN
bptjm-48	205	24	,	,	PUNCT
bptjm-48	205	25	undergo	undergo	VERB
bptjm-48	205	26	leukapheresis	leukapheresis	NOUN
bptjm-48	205	27	to	to	PART
bptjm-48	205	28	collect	collect	VERB
bptjm-48	205	29	immune	immune	ADJ
bptjm-48	205	30	t	t	PROPN
bptjm-48	205	31	-	-	PUNCT
bptjm-48	205	32	cells	cell	NOUN
bptjm-48	205	33	from	from	ADP
bptjm-48	205	34	their	their	PRON
bptjm-48	205	35	blood	blood	NOUN
bptjm-48	205	36	,	,	PUNCT
bptjm-48	205	37	and	and	CCONJ
bptjm-48	205	38	transfer	transfer	NOUN
bptjm-48	205	39	of	of	ADP
bptjm-48	205	40	those	those	DET
bptjm-48	205	41	activated	activate	VERB
bptjm-48	205	42	e	e	NOUN
bptjm-48	205	43	�	�	PROPN
bptjm-48	205	44	ector	ector	PROPN
bptjm-48	205	45	t	t	PROPN
bptjm-48	205	46	-	-	PUNCT
bptjm-48	205	47	cells	cell	NOUN
bptjm-48	205	48	after	after	ADP
bptjm-48	205	49	chemoradiation	chemoradiation	NOUN
bptjm-48	205	50	therapy	therapy	NOUN
bptjm-48	205	51	.	.	PUNCT
bptjm-48	206	1	all	all	DET
bptjm-48	206	2	patients	patient	NOUN
bptjm-48	206	3	are	be	AUX
bptjm-48	206	4	followed	follow	VERB
bptjm-48	206	5	with	with	ADP
bptjm-48	206	6	mris	mris	PROPN
bptjm-48	206	7	at	at	ADP
bptjm-48	206	8	follow	follow	NOUN
bptjm-48	206	9	-	-	PUNCT
bptjm-48	206	10	up	up	ADP
bptjm-48	206	11	visits	visit	NOUN
bptjm-48	206	12	.	.	PUNCT
bptjm-48	207	1	this	this	DET
bptjm-48	207	2	study	study	NOUN
bptjm-48	207	3	acknowledged	acknowledge	VERB
bptjm-48	207	4	mgmt	mgmt	PROPN
bptjm-48	207	5	promoter	promoter	NOUN
bptjm-48	207	6	methylation	methylation	NOUN
bptjm-48	207	7	changes	change	NOUN
bptjm-48	207	8	and	and	CCONJ
bptjm-48	207	9	investigated	investigate	VERB
bptjm-48	207	10	whether	whether	SCONJ
bptjm-48	207	11	these	these	DET
bptjm-48	207	12	changes	change	NOUN
bptjm-48	207	13	should	should	AUX
bptjm-48	207	14	be	be	AUX
bptjm-48	207	15	considered	consider	VERB
bptjm-48	207	16	in	in	ADP
bptjm-48	207	17	the	the	DET
bptjm-48	207	18	treatment	treatment	NOUN
bptjm-48	207	19	decision.44,45	decision.44,45	NOUN
bptjm-48	207	20	there	there	PRON
bptjm-48	207	21	is	be	VERB
bptjm-48	207	22	a	a	DET
bptjm-48	207	23	related	related	ADJ
bptjm-48	207	24	therapy	therapy	NOUN
bptjm-48	207	25	called	call	VERB
bptjm-48	207	26	the	the	DET
bptjm-48	207	27	chimeric	chimeric	ADJ
bptjm-48	207	28	antigen	antigen	ADJ
bptjm-48	207	29	receptor	receptor	NOUN
bptjm-48	207	30	(	(	PUNCT
bptjm-48	207	31	car	car	NOUN
bptjm-48	207	32	)	)	PUNCT
bptjm-48	207	33	t	t	NOUN
bptjm-48	207	34	cell	cell	NOUN
bptjm-48	207	35	therapy	therapy	NOUN
bptjm-48	207	36	which	which	PRON
bptjm-48	207	37	utilizes	utilize	VERB
bptjm-48	207	38	an	an	DET
bptjm-48	207	39	antibody	antibody	NOUN
bptjm-48	207	40	and	and	CCONJ
bptjm-48	207	41	t	t	NOUN
bptjm-48	207	42	cell	cell	NOUN
bptjm-48	207	43	receptor	receptor	NOUN
bptjm-48	207	44	complex	complex	NOUN
bptjm-48	207	45	.	.	PUNCT
bptjm-48	208	1	car	car	NOUN
bptjm-48	208	2	can	can	AUX
bptjm-48	208	3	be	be	AUX
bptjm-48	208	4	used	use	VERB
bptjm-48	208	5	to	to	PART
bptjm-48	208	6	modulate	modulate	VERB
bptjm-48	208	7	host	host	NOUN
bptjm-48	208	8	t	t	NOUN
bptjm-48	208	9	cells	cell	NOUN
bptjm-48	208	10	in	in	ADP
bptjm-48	208	11	order	order	NOUN
bptjm-48	208	12	to	to	PART
bptjm-48	208	13	enhance	enhance	VERB
bptjm-48	208	14	the	the	DET
bptjm-48	208	15	cancer	cancer	NOUN
bptjm-48	208	16	killing	killing	NOUN
bptjm-48	208	17	response	response	NOUN
bptjm-48	208	18	of	of	ADP
bptjm-48	208	19	the	the	DET
bptjm-48	208	20	immune	immune	ADJ
bptjm-48	208	21	system.41	system.41	NOUN
bptjm-48	208	22	car	car	NOUN
bptjm-48	208	23	t	t	NOUN
bptjm-48	208	24	-	-	PUNCT
bptjm-48	208	25	cell	cell	NOUN
bptjm-48	208	26	therapy	therapy	NOUN
bptjm-48	208	27	is	be	AUX
bptjm-48	208	28	a	a	DET
bptjm-48	208	29	type	type	NOUN
bptjm-48	208	30	of	of	ADP
bptjm-48	208	31	immunotherapy	immunotherapy	NOUN
bptjm-48	208	32	that	that	PRON
bptjm-48	208	33	uses	use	VERB
bptjm-48	208	34	a	a	DET
bptjm-48	208	35	patient	patient	NOUN
bptjm-48	208	36	's	's	PART
bptjm-48	208	37	own	own	ADJ
bptjm-48	208	38	immune	immune	ADJ
bptjm-48	208	39	cells	cell	NOUN
bptjm-48	208	40	,	,	PUNCT
bptjm-48	208	41	called	call	VERB
bptjm-48	208	42	t	t	PROPN
bptjm-48	208	43	-	-	PUNCT
bptjm-48	208	44	cells	cell	NOUN
bptjm-48	208	45	,	,	PUNCT
bptjm-48	208	46	to	to	PART
bptjm-48	208	47	�	�	PROPN
bptjm-48	208	48	ght	ght	PROPN
bptjm-48	208	49	cancer	cancer	NOUN
bptjm-48	208	50	.	.	PUNCT
bptjm-48	209	1	the	the	DET
bptjm-48	209	2	therapy	therapy	NOUN
bptjm-48	209	3	involves	involve	VERB
bptjm-48	209	4	genetically	genetically	ADV
bptjm-48	209	5	modifying	modify	VERB
bptjm-48	209	6	a	a	DET
bptjm-48	209	7	patient	patient	NOUN
bptjm-48	209	8	's	's	PART
bptjm-48	209	9	t	t	NOUN
bptjm-48	209	10	-	-	PUNCT
bptjm-48	209	11	cells	cell	NOUN
bptjm-48	209	12	in	in	ADP
bptjm-48	209	13	the	the	DET
bptjm-48	209	14	laboratory	laboratory	NOUN
bptjm-48	209	15	to	to	PART
bptjm-48	209	16	produce	produce	VERB
bptjm-48	209	17	chimeric	chimeric	ADJ
bptjm-48	209	18	antigen	antigen	ADJ
bptjm-48	209	19	receptors	receptor	NOUN
bptjm-48	209	20	(	(	PUNCT
bptjm-48	209	21	cars	car	NOUN
bptjm-48	209	22	)	)	PUNCT
bptjm-48	209	23	on	on	ADP
bptjm-48	209	24	their	their	PRON
bptjm-48	209	25	berkeley	berkeley	PROPN
bptjm-48	209	26	pharma	pharma	PROPN
bptjm-48	209	27	tech	tech	NOUN
bptjm-48	209	28	journal	journal	NOUN
bptjm-48	209	29	of	of	ADP
bptjm-48	209	30	medicine	medicine	NOUN
bptjm-48	210	1	|	|	ADV
bptjm-48	210	2	53	53	NUM
bptjm-48	210	3	https://clinicaltrials.gov/ct2/show/nct05685004?term=nct05685004&draw=2&rank=1	https://clinicaltrials.gov/ct2/show/nct05685004?term=nct05685004&draw=2&rank=1	NOUN
bptjm-48	210	4	surface.40,41,46	surface.40,41,46	NOUN
bptjm-48	210	5	these	these	DET
bptjm-48	210	6	receptors	receptor	NOUN
bptjm-48	210	7	can	can	AUX
bptjm-48	210	8	then	then	ADV
bptjm-48	210	9	recognize	recognize	VERB
bptjm-48	210	10	and	and	CCONJ
bptjm-48	210	11	bind	bind	VERB
bptjm-48	210	12	to	to	ADP
bptjm-48	210	13	speci	speci	PROPN
bptjm-48	210	14	�	�	PROPN
bptjm-48	210	15	c	c	NOUN
bptjm-48	210	16	proteins	protein	NOUN
bptjm-48	210	17	on	on	ADP
bptjm-48	210	18	cancer	cancer	NOUN
bptjm-48	210	19	cells	cell	NOUN
bptjm-48	210	20	,	,	PUNCT
bptjm-48	210	21	which	which	PRON
bptjm-48	210	22	helps	help	VERB
bptjm-48	210	23	the	the	DET
bptjm-48	210	24	t	t	NOUN
bptjm-48	210	25	-	-	PUNCT
bptjm-48	210	26	cells	cell	NOUN
bptjm-48	210	27	to	to	PART
bptjm-48	210	28	identify	identify	VERB
bptjm-48	210	29	and	and	CCONJ
bptjm-48	210	30	attack	attack	VERB
bptjm-48	210	31	the	the	DET
bptjm-48	210	32	cancer	cancer	NOUN
bptjm-48	210	33	cells	cell	NOUN
bptjm-48	210	34	.	.	PUNCT
bptjm-48	211	1	however	however	ADV
bptjm-48	211	2	,	,	PUNCT
bptjm-48	211	3	the	the	DET
bptjm-48	211	4	use	use	NOUN
bptjm-48	211	5	of	of	ADP
bptjm-48	211	6	car	car	NOUN
bptjm-48	211	7	t	t	NOUN
bptjm-48	211	8	-	-	PUNCT
bptjm-48	211	9	cell	cell	NOUN
bptjm-48	211	10	therapy	therapy	NOUN
bptjm-48	211	11	for	for	ADP
bptjm-48	211	12	the	the	DET
bptjm-48	211	13	treatment	treatment	NOUN
bptjm-48	211	14	of	of	ADP
bptjm-48	211	15	solid	solid	ADJ
bptjm-48	211	16	tumors	tumor	NOUN
bptjm-48	211	17	is	be	AUX
bptjm-48	211	18	still	still	ADV
bptjm-48	211	19	being	be	AUX
bptjm-48	211	20	studied	study	VERB
bptjm-48	211	21	in	in	ADP
bptjm-48	211	22	the	the	DET
bptjm-48	211	23	early	early	ADJ
bptjm-48	211	24	stages	stage	NOUN
bptjm-48	211	25	of	of	ADP
bptjm-48	211	26	clinical	clinical	ADJ
bptjm-48	211	27	testing	testing	NOUN
bptjm-48	211	28	.	.	PUNCT
bptjm-48	212	1	one	one	NUM
bptjm-48	212	2	of	of	ADP
bptjm-48	212	3	the	the	DET
bptjm-48	212	4	challenges	challenge	NOUN
bptjm-48	212	5	in	in	ADP
bptjm-48	212	6	treating	treat	VERB
bptjm-48	212	7	solid	solid	ADJ
bptjm-48	212	8	tumors	tumor	NOUN
bptjm-48	212	9	with	with	ADP
bptjm-48	212	10	car	car	NOUN
bptjm-48	212	11	t	t	NOUN
bptjm-48	212	12	-	-	PUNCT
bptjm-48	212	13	cell	cell	NOUN
bptjm-48	212	14	therapy	therapy	NOUN
bptjm-48	212	15	is	be	AUX
bptjm-48	212	16	that	that	SCONJ
bptjm-48	212	17	the	the	DET
bptjm-48	212	18	car	car	NOUN
bptjm-48	212	19	t	t	NOUN
bptjm-48	212	20	-	-	PUNCT
bptjm-48	212	21	cells	cell	NOUN
bptjm-48	212	22	need	need	VERB
bptjm-48	212	23	to	to	PART
bptjm-48	212	24	be	be	AUX
bptjm-48	212	25	able	able	ADJ
bptjm-48	212	26	to	to	PART
bptjm-48	212	27	penetrate	penetrate	VERB
bptjm-48	212	28	the	the	DET
bptjm-48	212	29	tumor	tumor	NOUN
bptjm-48	212	30	microenvironment	microenvironment	NOUN
bptjm-48	212	31	and	and	CCONJ
bptjm-48	212	32	e	e	NOUN
bptjm-48	212	33	�	�	NOUN
bptjm-48	212	34	ectively	ectively	ADV
bptjm-48	212	35	target	target	VERB
bptjm-48	212	36	the	the	DET
bptjm-48	212	37	cancer	cancer	NOUN
bptjm-48	212	38	cells	cell	NOUN
bptjm-48	212	39	,	,	PUNCT
bptjm-48	212	40	which	which	PRON
bptjm-48	212	41	can	can	AUX
bptjm-48	212	42	be	be	AUX
bptjm-48	212	43	di	di	NOUN
bptjm-48	212	44	�	�	PROPN
bptjm-48	212	45	cult	cult	NOUN
bptjm-48	212	46	to	to	ADP
bptjm-48	212	47	achieve.41,46	achieve.41,46	NOUN
bptjm-48	212	48	figure	figure	NOUN
bptjm-48	212	49	13	13	NUM
bptjm-48	212	50	.	.	PUNCT
bptjm-48	213	1	a	a	DET
bptjm-48	213	2	simple	simple	ADJ
bptjm-48	213	3	work	work	NOUN
bptjm-48	213	4	�	�	NOUN
bptjm-48	213	5	ow	ow	PROPN
bptjm-48	213	6	of	of	ADP
bptjm-48	213	7	car	car	NOUN
bptjm-48	213	8	-	-	PUNCT
bptjm-48	213	9	t	t	NOUN
bptjm-48	213	10	cell	cell	NOUN
bptjm-48	213	11	therapy	therapy	NOUN
bptjm-48	213	12	in	in	ADP
bptjm-48	213	13	a	a	DET
bptjm-48	213	14	phase	phase	NOUN
bptjm-48	213	15	i	i	PRON
bptjm-48	213	16	clinical	clinical	ADJ
bptjm-48	213	17	trial	trial	NOUN
bptjm-48	213	18	nct04003649	nct04003649	NOUN
bptjm-48	213	19	,	,	PUNCT
bptjm-48	213	20	the	the	DET
bptjm-48	213	21	e	e	PROPN
bptjm-48	213	22	�	�	PROPN
bptjm-48	213	23	cacy	cacy	NOUN
bptjm-48	213	24	of	of	ADP
bptjm-48	213	25	il13r	il13r	ADJ
bptjm-48	213	26	alpha	alpha	NOUN
bptjm-48	213	27	2	2	NUM
bptjm-48	213	28	-	-	PUNCT
bptjm-48	213	29	car	car	NOUN
bptjm-48	213	30	t	t	NOUN
bptjm-48	213	31	cells	cell	NOUN
bptjm-48	213	32	when	when	SCONJ
bptjm-48	213	33	given	give	VERB
bptjm-48	213	34	alone	alone	ADV
bptjm-48	213	35	or	or	CCONJ
bptjm-48	213	36	together	together	ADV
bptjm-48	213	37	with	with	ADP
bptjm-48	213	38	nivolumab	nivolumab	NOUN
bptjm-48	213	39	and	and	CCONJ
bptjm-48	213	40	ipilimumab	ipilimumab	VERB
bptjm-48	213	41	and	and	CCONJ
bptjm-48	213	42	their	their	PRON
bptjm-48	213	43	e	e	NOUN
bptjm-48	213	44	�	�	NOUN
bptjm-48	213	45	ects	ect	VERB
bptjm-48	213	46	on	on	ADP
bptjm-48	213	47	treating	treat	VERB
bptjm-48	213	48	patients	patient	NOUN
bptjm-48	213	49	with	with	ADP
bptjm-48	213	50	glioblastoma	glioblastoma	NOUN
bptjm-48	213	51	that	that	PRON
bptjm-48	213	52	has	have	AUX
bptjm-48	213	53	come	come	VERB
bptjm-48	213	54	back	back	ADV
bptjm-48	213	55	(	(	PUNCT
bptjm-48	213	56	recurrent	recurrent	NOUN
bptjm-48	213	57	)	)	PUNCT
bptjm-48	213	58	or	or	CCONJ
bptjm-48	213	59	does	do	AUX
bptjm-48	213	60	not	not	PART
bptjm-48	213	61	respond	respond	VERB
bptjm-48	213	62	to	to	ADP
bptjm-48	213	63	treatment	treatment	NOUN
bptjm-48	213	64	(	(	PUNCT
bptjm-48	213	65	refractory	refractory	NOUN
bptjm-48	213	66	)	)	PUNCT
bptjm-48	213	67	.	.	PUNCT
bptjm-48	214	1	biological	biological	ADJ
bptjm-48	214	2	therapies	therapy	NOUN
bptjm-48	214	3	,	,	PUNCT
bptjm-48	214	4	such	such	ADJ
bptjm-48	214	5	as	as	ADP
bptjm-48	214	6	il13r	il13r	ADJ
bptjm-48	214	7	alpha	alpha	NOUN
bptjm-48	214	8	2	2	NUM
bptjm-48	214	9	-	-	PUNCT
bptjm-48	214	10	car	car	NOUN
bptjm-48	214	11	t	t	NOUN
bptjm-48	214	12	cells	cell	NOUN
bptjm-48	214	13	,	,	PUNCT
bptjm-48	214	14	use	use	VERB
bptjm-48	214	15	substances	substance	NOUN
bptjm-48	214	16	made	make	VERB
bptjm-48	214	17	from	from	ADP
bptjm-48	214	18	living	live	VERB
bptjm-48	214	19	organisms	organism	NOUN
bptjm-48	214	20	that	that	PRON
bptjm-48	214	21	may	may	AUX
bptjm-48	214	22	attack	attack	VERB
bptjm-48	214	23	speci	speci	NOUN
bptjm-48	214	24	�	�	PROPN
bptjm-48	214	25	c	c	PROPN
bptjm-48	214	26	glioma	glioma	NOUN
bptjm-48	214	27	cells	cell	NOUN
bptjm-48	214	28	and	and	CCONJ
bptjm-48	214	29	stop	stop	VERB
bptjm-48	214	30	them	they	PRON
bptjm-48	214	31	from	from	ADP
bptjm-48	214	32	growing	grow	VERB
bptjm-48	214	33	or	or	CCONJ
bptjm-48	214	34	kill	kill	VERB
bptjm-48	214	35	them	they	PRON
bptjm-48	214	36	.	.	PUNCT
bptjm-48	215	1	immunotherapy	immunotherapy	NOUN
bptjm-48	215	2	with	with	ADP
bptjm-48	215	3	monoclonal	monoclonal	NOUN
bptjm-48	215	4	antibodies	antibody	NOUN
bptjm-48	215	5	,	,	PUNCT
bptjm-48	215	6	such	such	ADJ
bptjm-48	215	7	as	as	ADP
bptjm-48	215	8	nivolumab	nivolumab	NOUN
bptjm-48	215	9	and	and	CCONJ
bptjm-48	215	10	ipilimumab	ipilimumab	ADV
bptjm-48	215	11	,	,	PUNCT
bptjm-48	215	12	may	may	AUX
bptjm-48	215	13	help	help	VERB
bptjm-48	215	14	the	the	DET
bptjm-48	215	15	body	body	NOUN
bptjm-48	215	16	's	's	PART
bptjm-48	215	17	immune	immune	ADJ
bptjm-48	215	18	system	system	NOUN
bptjm-48	215	19	attack	attack	VERB
bptjm-48	215	20	the	the	DET
bptjm-48	215	21	cancer	cancer	NOUN
bptjm-48	215	22	,	,	PUNCT
bptjm-48	215	23	and	and	CCONJ
bptjm-48	215	24	may	may	AUX
bptjm-48	215	25	interfere	interfere	VERB
bptjm-48	215	26	with	with	ADP
bptjm-48	215	27	the	the	DET
bptjm-48	215	28	ability	ability	NOUN
bptjm-48	215	29	of	of	ADP
bptjm-48	215	30	tumor	tumor	NOUN
bptjm-48	215	31	cells	cell	NOUN
bptjm-48	215	32	to	to	PART
bptjm-48	215	33	grow	grow	VERB
bptjm-48	215	34	and	and	CCONJ
bptjm-48	215	35	spread.47	spread.47	VERB
bptjm-48	215	36	it	it	PRON
bptjm-48	215	37	was	be	AUX
bptjm-48	215	38	found	find	VERB
bptjm-48	215	39	that	that	SCONJ
bptjm-48	215	40	il13r	il13r	ADJ
bptjm-48	215	41	alpha	alpha	NOUN
bptjm-48	215	42	2	2	NUM
bptjm-48	215	43	-	-	PUNCT
bptjm-48	215	44	car	car	NOUN
bptjm-48	215	45	t	t	PROPN
bptjm-48	215	46	berkeley	berkeley	PROPN
bptjm-48	215	47	pharma	pharma	PROPN
bptjm-48	215	48	tech	tech	NOUN
bptjm-48	215	49	journal	journal	NOUN
bptjm-48	215	50	of	of	ADP
bptjm-48	215	51	medicine	medicine	NOUN
bptjm-48	215	52	|	|	ADV
bptjm-48	215	53	54	54	NUM
bptjm-48	215	54	https://clinicaltrials.gov/ct2/show/record/nct04003649?term=car+t&recrs=ad&cond=glioblastoma&draw=4&rank=5	https://clinicaltrials.gov/ct2/show/record/nct04003649?term=car+t&recrs=ad&cond=glioblastoma&draw=4&rank=5	NOUN
bptjm-48	215	55	cells	cell	NOUN
bptjm-48	215	56	enhance	enhance	VERB
bptjm-48	215	57	anti	anti	ADJ
bptjm-48	215	58	-	-	ADJ
bptjm-48	215	59	tumor	tumor	ADJ
bptjm-48	215	60	activity	activity	NOUN
bptjm-48	215	61	and	and	CCONJ
bptjm-48	215	62	t	t	NOUN
bptjm-48	215	63	-	-	PUNCT
bptjm-48	215	64	cell	cell	NOUN
bptjm-48	215	65	persistence	persistence	NOUN
bptjm-48	215	66	and	and	CCONJ
bptjm-48	215	67	showed	show	VERB
bptjm-48	215	68	evidence	evidence	NOUN
bptjm-48	215	69	of	of	ADP
bptjm-48	215	70	bioactivity	bioactivity	NOUN
bptjm-48	215	71	in	in	ADP
bptjm-48	215	72	patients	patient	NOUN
bptjm-48	215	73	.	.	PUNCT
bptjm-48	216	1	in	in	ADP
bptjm-48	216	2	addition	addition	NOUN
bptjm-48	216	3	,	,	PUNCT
bptjm-48	216	4	it	it	PRON
bptjm-48	216	5	was	be	AUX
bptjm-48	216	6	found	find	VERB
bptjm-48	216	7	that	that	SCONJ
bptjm-48	216	8	local	local	ADJ
bptjm-48	216	9	intracranial	intracranial	ADJ
bptjm-48	216	10	delivery	delivery	NOUN
bptjm-48	216	11	of	of	ADP
bptjm-48	216	12	car	car	NOUN
bptjm-48	216	13	t	t	NOUN
bptjm-48	216	14	cells	cell	NOUN
bptjm-48	216	15	increased	increase	VERB
bptjm-48	216	16	anti	anti	ADJ
bptjm-48	216	17	-	-	ADJ
bptjm-48	216	18	tumor	tumor	ADJ
bptjm-48	216	19	e	e	NOUN
bptjm-48	216	20	�	�	NOUN
bptjm-48	216	21	cacy	cacy	NOUN
bptjm-48	216	22	as	as	SCONJ
bptjm-48	216	23	compared	compare	VERB
bptjm-48	216	24	to	to	ADP
bptjm-48	216	25	intravenous	intravenous	ADJ
bptjm-48	216	26	administration.40,47	administration.40,47	PROPN
bptjm-48	216	27	overall	overall	PROPN
bptjm-48	216	28	,	,	PUNCT
bptjm-48	216	29	this	this	DET
bptjm-48	216	30	study	study	NOUN
bptjm-48	216	31	de	de	PROPN
bptjm-48	216	32	�	�	PROPN
bptjm-48	216	33	ned	ned	ADJ
bptjm-48	216	34	parameters	parameter	NOUN
bptjm-48	216	35	for	for	ADP
bptjm-48	216	36	the	the	DET
bptjm-48	216	37	clinical	clinical	ADJ
bptjm-48	216	38	translation	translation	NOUN
bptjm-48	216	39	of	of	ADP
bptjm-48	216	40	car	car	NOUN
bptjm-48	216	41	t	t	NOUN
bptjm-48	216	42	cell	cell	NOUN
bptjm-48	216	43	therapy	therapy	NOUN
bptjm-48	216	44	for	for	ADP
bptjm-48	216	45	the	the	DET
bptjm-48	216	46	treatment	treatment	NOUN
bptjm-48	216	47	of	of	ADP
bptjm-48	216	48	brain	brain	NOUN
bptjm-48	216	49	tumors	tumor	NOUN
bptjm-48	216	50	.	.	PUNCT
bptjm-48	217	1	4.7	4.7	NUM
bptjm-48	217	2	combination	combination	NOUN
bptjm-48	217	3	therapies	therapy	NOUN
bptjm-48	217	4	with	with	ADP
bptjm-48	217	5	neoantigen	neoantigen	NOUN
bptjm-48	217	6	-	-	PUNCT
bptjm-48	217	7	based	base	VERB
bptjm-48	217	8	vaccines	vaccine	NOUN
bptjm-48	217	9	the	the	DET
bptjm-48	217	10	use	use	NOUN
bptjm-48	217	11	of	of	ADP
bptjm-48	217	12	tumor	tumor	NOUN
bptjm-48	217	13	vaccines	vaccine	NOUN
bptjm-48	217	14	,	,	PUNCT
bptjm-48	217	15	monoclonal	monoclonal	NOUN
bptjm-48	217	16	antibodies	antibody	NOUN
bptjm-48	217	17	,	,	PUNCT
bptjm-48	217	18	and	and	CCONJ
bptjm-48	217	19	adoptive	adoptive	ADJ
bptjm-48	217	20	cell	cell	NOUN
bptjm-48	217	21	therapies	therapy	NOUN
bptjm-48	217	22	are	be	AUX
bptjm-48	217	23	potential	potential	ADJ
bptjm-48	217	24	and	and	CCONJ
bptjm-48	217	25	e	e	NOUN
bptjm-48	217	26	�	�	NOUN
bptjm-48	217	27	cacious	cacious	ADJ
bptjm-48	217	28	treatment	treatment	NOUN
bptjm-48	217	29	methods	method	NOUN
bptjm-48	217	30	for	for	ADP
bptjm-48	217	31	glioblastoma	glioblastoma	NOUN
bptjm-48	217	32	.	.	PUNCT
bptjm-48	218	1	speci	speci	PROPN
bptjm-48	218	2	�	�	PROPN
bptjm-48	218	3	cally	cally	ADV
bptjm-48	218	4	looking	look	VERB
bptjm-48	218	5	at	at	ADP
bptjm-48	218	6	tumor	tumor	NOUN
bptjm-48	218	7	vaccines	vaccine	NOUN
bptjm-48	218	8	,	,	PUNCT
bptjm-48	218	9	they	they	PRON
bptjm-48	218	10	have	have	VERB
bptjm-48	218	11	extreme	extreme	ADJ
bptjm-48	218	12	potential	potential	NOUN
bptjm-48	218	13	when	when	SCONJ
bptjm-48	218	14	developing	develop	VERB
bptjm-48	218	15	personalized	personalized	ADJ
bptjm-48	218	16	treatment	treatment	NOUN
bptjm-48	218	17	methods	method	NOUN
bptjm-48	218	18	for	for	ADP
bptjm-48	218	19	patients	patient	NOUN
bptjm-48	218	20	.	.	PUNCT
bptjm-48	219	1	anti	anti	ADJ
bptjm-48	219	2	-	-	ADJ
bptjm-48	219	3	tumor	tumor	ADJ
bptjm-48	219	4	vaccines	vaccine	NOUN
bptjm-48	219	5	,	,	PUNCT
bptjm-48	219	6	such	such	ADJ
bptjm-48	219	7	as	as	ADP
bptjm-48	219	8	the	the	DET
bptjm-48	219	9	proposed	propose	VERB
bptjm-48	219	10	neoantigen	neoantigen	NOUN
bptjm-48	219	11	vaccines	vaccine	NOUN
bptjm-48	219	12	,	,	PUNCT
bptjm-48	219	13	activate	activate	VERB
bptjm-48	219	14	certain	certain	ADJ
bptjm-48	219	15	pathways	pathway	NOUN
bptjm-48	219	16	in	in	ADP
bptjm-48	219	17	the	the	DET
bptjm-48	219	18	host	host	NOUN
bptjm-48	219	19	immune	immune	ADJ
bptjm-48	219	20	system	system	NOUN
bptjm-48	219	21	that	that	PRON
bptjm-48	219	22	can	can	AUX
bptjm-48	219	23	create	create	VERB
bptjm-48	219	24	a	a	DET
bptjm-48	219	25	susceptible	susceptible	ADJ
bptjm-48	219	26	environment	environment	NOUN
bptjm-48	219	27	for	for	ADP
bptjm-48	219	28	concurrent	concurrent	ADJ
bptjm-48	219	29	or	or	CCONJ
bptjm-48	219	30	subsequent	subsequent	ADJ
bptjm-48	219	31	treatment	treatment	NOUN
bptjm-48	219	32	methods.48,49	methods.48,49	NOUN
bptjm-48	219	33	this	this	PRON
bptjm-48	219	34	is	be	AUX
bptjm-48	219	35	an	an	DET
bptjm-48	219	36	important	important	ADJ
bptjm-48	219	37	aspect	aspect	NOUN
bptjm-48	219	38	to	to	PART
bptjm-48	219	39	note	note	VERB
bptjm-48	219	40	when	when	SCONJ
bptjm-48	219	41	considering	consider	VERB
bptjm-48	219	42	neoantigen	neoantigen	NOUN
bptjm-48	219	43	-	-	PUNCT
bptjm-48	219	44	based	base	VERB
bptjm-48	219	45	vaccines	vaccine	NOUN
bptjm-48	219	46	as	as	ADP
bptjm-48	219	47	a	a	DET
bptjm-48	219	48	treatment	treatment	NOUN
bptjm-48	219	49	method	method	NOUN
bptjm-48	219	50	for	for	ADP
bptjm-48	219	51	glioblastoma	glioblastoma	NOUN
bptjm-48	219	52	.	.	PUNCT
bptjm-48	220	1	as	as	SCONJ
bptjm-48	220	2	shown	show	VERB
bptjm-48	220	3	in	in	ADP
bptjm-48	220	4	previous	previous	ADJ
bptjm-48	220	5	clinical	clinical	ADJ
bptjm-48	220	6	trials	trial	NOUN
bptjm-48	220	7	and	and	CCONJ
bptjm-48	220	8	studies	study	NOUN
bptjm-48	220	9	,	,	PUNCT
bptjm-48	220	10	cancer	cancer	NOUN
bptjm-48	220	11	vaccines	vaccine	NOUN
bptjm-48	220	12	are	be	AUX
bptjm-48	220	13	a	a	DET
bptjm-48	220	14	very	very	ADV
bptjm-48	220	15	innovative	innovative	ADJ
bptjm-48	220	16	way	way	NOUN
bptjm-48	220	17	to	to	PART
bptjm-48	220	18	approach	approach	VERB
bptjm-48	220	19	cancer	cancer	NOUN
bptjm-48	220	20	treatment	treatment	NOUN
bptjm-48	220	21	but	but	CCONJ
bptjm-48	220	22	they	they	PRON
bptjm-48	220	23	have	have	VERB
bptjm-48	220	24	very	very	ADV
bptjm-48	220	25	low	low	ADJ
bptjm-48	220	26	e	e	NOUN
bptjm-48	220	27	�	�	NOUN
bptjm-48	220	28	cacy	cacy	NOUN
bptjm-48	220	29	,	,	PUNCT
bptjm-48	220	30	with	with	ADP
bptjm-48	220	31	an	an	DET
bptjm-48	220	32	objective	objective	ADJ
bptjm-48	220	33	clinical	clinical	ADJ
bptjm-48	220	34	response	response	NOUN
bptjm-48	220	35	rate	rate	NOUN
bptjm-48	220	36	of	of	ADP
bptjm-48	220	37	only	only	ADV
bptjm-48	220	38	>	>	PUNCT
bptjm-48	220	39	7	7	NUM
bptjm-48	220	40	%	%	NOUN
bptjm-48	220	41	and	and	CCONJ
bptjm-48	220	42	an	an	DET
bptjm-48	220	43	overall	overall	ADJ
bptjm-48	220	44	rate	rate	NOUN
bptjm-48	220	45	of	of	ADP
bptjm-48	220	46	clinical	clinical	ADJ
bptjm-48	220	47	bene	bene	PROPN
bptjm-48	220	48	�	�	PROPN
bptjm-48	220	49	t	t	PROPN
bptjm-48	220	50	of	of	ADP
bptjm-48	220	51	only	only	ADJ
bptjm-48	220	52	~20%.49,50	~20%.49,50	NOUN
bptjm-48	220	53	there	there	PRON
bptjm-48	220	54	is	be	VERB
bptjm-48	220	55	no	no	DET
bptjm-48	220	56	question	question	NOUN
bptjm-48	220	57	that	that	SCONJ
bptjm-48	220	58	cancer	cancer	NOUN
bptjm-48	220	59	vaccines	vaccine	NOUN
bptjm-48	220	60	stimulate	stimulate	VERB
bptjm-48	220	61	and	and	CCONJ
bptjm-48	220	62	modulate	modulate	VERB
bptjm-48	220	63	the	the	DET
bptjm-48	220	64	immune	immune	ADJ
bptjm-48	220	65	system	system	NOUN
bptjm-48	220	66	,	,	PUNCT
bptjm-48	220	67	and	and	CCONJ
bptjm-48	220	68	this	this	PRON
bptjm-48	220	69	can	can	AUX
bptjm-48	220	70	be	be	AUX
bptjm-48	220	71	taken	take	VERB
bptjm-48	220	72	advantage	advantage	NOUN
bptjm-48	220	73	of	of	ADP
bptjm-48	220	74	when	when	SCONJ
bptjm-48	220	75	treating	treat	VERB
bptjm-48	220	76	patients	patient	NOUN
bptjm-48	220	77	.	.	PUNCT
bptjm-48	221	1	utilizing	utilize	VERB
bptjm-48	221	2	neoantigen	neoantigen	NOUN
bptjm-48	221	3	-	-	PUNCT
bptjm-48	221	4	based	base	VERB
bptjm-48	221	5	vaccines	vaccine	NOUN
bptjm-48	221	6	can	can	AUX
bptjm-48	221	7	prime	prime	VERB
bptjm-48	221	8	the	the	DET
bptjm-48	221	9	host	host	NOUN
bptjm-48	221	10	immune	immune	ADJ
bptjm-48	221	11	system	system	NOUN
bptjm-48	221	12	to	to	PART
bptjm-48	221	13	be	be	AUX
bptjm-48	221	14	more	more	ADV
bptjm-48	221	15	responsive	responsive	ADJ
bptjm-48	221	16	to	to	ADP
bptjm-48	221	17	subsequent	subsequent	ADJ
bptjm-48	221	18	therapies	therapy	NOUN
bptjm-48	221	19	that	that	PRON
bptjm-48	221	20	can	can	AUX
bptjm-48	221	21	enhance	enhance	VERB
bptjm-48	221	22	the	the	DET
bptjm-48	221	23	tumor	tumor	NOUN
bptjm-48	221	24	-	-	PUNCT
bptjm-48	221	25	killing	kill	VERB
bptjm-48	221	26	response	response	NOUN
bptjm-48	221	27	of	of	ADP
bptjm-48	221	28	the	the	DET
bptjm-48	221	29	host	host	NOUN
bptjm-48	221	30	immune	immune	ADJ
bptjm-48	221	31	system.48	system.48	NOUN
bptjm-48	221	32	in	in	ADP
bptjm-48	221	33	a	a	DET
bptjm-48	221	34	phase	phase	NOUN
bptjm-48	221	35	ii	ii	NOUN
bptjm-48	221	36	clinical	clinical	ADJ
bptjm-48	221	37	trial	trial	NOUN
bptjm-48	221	38	nct03047928	nct03047928	NOUN
bptjm-48	221	39	,	,	PUNCT
bptjm-48	221	40	the	the	DET
bptjm-48	221	41	programmed	program	VERB
bptjm-48	221	42	death	death	NOUN
bptjm-48	221	43	1	1	NUM
bptjm-48	221	44	(	(	PUNCT
bptjm-48	221	45	pd-1	pd-1	NOUN
bptjm-48	221	46	)	)	PUNCT
bptjm-48	221	47	regulatory	regulatory	ADJ
bptjm-48	221	48	antibody	antibody	NOUN
bptjm-48	221	49	nivolumab	nivolumab	ADV
bptjm-48	221	50	and	and	CCONJ
bptjm-48	221	51	a	a	DET
bptjm-48	221	52	peptide	peptide	ADJ
bptjm-48	221	53	vaccine	vaccine	NOUN
bptjm-48	221	54	consisting	consist	VERB
bptjm-48	221	55	of	of	ADP
bptjm-48	221	56	programmed	program	VERB
bptjm-48	221	57	death	death	NOUN
bptjm-48	221	58	ligand	ligand	NOUN
bptjm-48	221	59	1	1	NUM
bptjm-48	221	60	(	(	PUNCT
bptjm-48	221	61	pd	pd	NOUN
bptjm-48	221	62	-	-	PUNCT
bptjm-48	221	63	l1	l1	NOUN
bptjm-48	221	64	)	)	PUNCT
bptjm-48	221	65	and	and	CCONJ
bptjm-48	221	66	indoleamine	indoleamine	VERB
bptjm-48	221	67	2,3	2,3	NUM
bptjm-48	221	68	-	-	NOUN
bptjm-48	221	69	dioxygenase	dioxygenase	NOUN
bptjm-48	221	70	(	(	PUNCT
bptjm-48	221	71	ido	ido	NOUN
bptjm-48	221	72	)	)	PUNCT
bptjm-48	221	73	peptides	peptide	NOUN
bptjm-48	221	74	were	be	AUX
bptjm-48	221	75	tested	test	VERB
bptjm-48	221	76	in	in	ADP
bptjm-48	221	77	patients	patient	NOUN
bptjm-48	221	78	with	with	ADP
bptjm-48	221	79	metastatic	metastatic	ADJ
bptjm-48	221	80	melanoma.51	melanoma.51	NOUN
bptjm-48	221	81	the	the	DET
bptjm-48	221	82	primary	primary	ADJ
bptjm-48	221	83	endpoints	endpoint	NOUN
bptjm-48	221	84	for	for	ADP
bptjm-48	221	85	this	this	DET
bptjm-48	221	86	study	study	NOUN
bptjm-48	221	87	was	be	AUX
bptjm-48	221	88	feasibility	feasibility	NOUN
bptjm-48	221	89	and	and	CCONJ
bptjm-48	221	90	safety	safety	NOUN
bptjm-48	221	91	of	of	ADP
bptjm-48	221	92	the	the	DET
bptjm-48	221	93	combined	combined	ADJ
bptjm-48	221	94	treatment	treatment	NOUN
bptjm-48	221	95	.	.	PUNCT
bptjm-48	222	1	the	the	DET
bptjm-48	222	2	secondary	secondary	ADJ
bptjm-48	222	3	endpoints	endpoint	NOUN
bptjm-48	222	4	were	be	AUX
bptjm-48	222	5	e	e	NOUN
bptjm-48	222	6	�	�	NOUN
bptjm-48	222	7	cacy	cacy	NOUN
bptjm-48	222	8	and	and	CCONJ
bptjm-48	222	9	immunogenicity	immunogenicity	NOUN
bptjm-48	222	10	.	.	PUNCT
bptjm-48	223	1	overall	overall	ADV
bptjm-48	223	2	,	,	PUNCT
bptjm-48	223	3	the	the	DET
bptjm-48	223	4	study	study	NOUN
bptjm-48	223	5	revealed	reveal	VERB
bptjm-48	223	6	that	that	SCONJ
bptjm-48	223	7	the	the	DET
bptjm-48	223	8	vaccine	vaccine	NOUN
bptjm-48	223	9	-	-	PUNCT
bptjm-48	223	10	reactive	reactive	NOUN
bptjm-48	223	11	t	t	NOUN
bptjm-48	223	12	cells	cell	NOUN
bptjm-48	223	13	comprised	comprise	VERB
bptjm-48	223	14	cd4	cd4	PROPN
bptjm-48	223	15	+	+	PROPN
bptjm-48	223	16	and	and	CCONJ
bptjm-48	223	17	cd8	cd8	PROPN
bptjm-48	223	18	+	+	PROPN
bptjm-48	223	19	t	t	PROPN
bptjm-48	223	20	cells	cell	NOUN
bptjm-48	223	21	with	with	ADP
bptjm-48	223	22	activity	activity	NOUN
bptjm-48	223	23	against	against	ADP
bptjm-48	223	24	idoand	idoand	ADJ
bptjm-48	223	25	pd	pd	PROPN
bptjm-48	223	26	-	-	PUNCT
bptjm-48	223	27	l1	l1	NOUN
bptjm-48	223	28	-	-	PUNCT
bptjm-48	223	29	expressing	express	VERB
bptjm-48	223	30	cancer	cancer	NOUN
bptjm-48	223	31	and	and	CCONJ
bptjm-48	223	32	immune	immune	ADJ
bptjm-48	223	33	cells	cell	NOUN
bptjm-48	223	34	,	,	PUNCT
bptjm-48	223	35	thus	thus	ADV
bptjm-48	223	36	increasing	increase	VERB
bptjm-48	223	37	the	the	DET
bptjm-48	223	38	immunomodulatory	immunomodulatory	ADJ
bptjm-48	223	39	e	e	NOUN
bptjm-48	223	40	�	�	PROPN
bptjm-48	223	41	ect	ect	NOUN
bptjm-48	223	42	of	of	ADP
bptjm-48	223	43	the	the	DET
bptjm-48	223	44	combination	combination	NOUN
bptjm-48	223	45	therapy.51,52	therapy.51,52	NOUN
bptjm-48	223	46	berkeley	berkeley	PROPN
bptjm-48	223	47	pharma	pharma	PROPN
bptjm-48	223	48	tech	tech	NOUN
bptjm-48	223	49	journal	journal	NOUN
bptjm-48	223	50	of	of	ADP
bptjm-48	223	51	medicine	medicine	NOUN
bptjm-48	223	52	|	|	ADV
bptjm-48	223	53	55	55	NUM
bptjm-48	223	54	https://clinicaltrials.gov/ct2/show/nct03047928	https://clinicaltrials.gov/ct2/show/nct03047928	PUNCT
bptjm-48	223	55	there	there	PRON
bptjm-48	223	56	are	be	VERB
bptjm-48	223	57	many	many	ADJ
bptjm-48	223	58	other	other	ADJ
bptjm-48	223	59	clinical	clinical	ADJ
bptjm-48	223	60	trials	trial	NOUN
bptjm-48	223	61	currently	currently	ADV
bptjm-48	223	62	being	be	AUX
bptjm-48	223	63	conducted	conduct	VERB
bptjm-48	223	64	to	to	PART
bptjm-48	223	65	understand	understand	VERB
bptjm-48	223	66	the	the	DET
bptjm-48	223	67	use	use	NOUN
bptjm-48	223	68	of	of	ADP
bptjm-48	223	69	combination	combination	NOUN
bptjm-48	223	70	therapies	therapy	NOUN
bptjm-48	223	71	as	as	ADP
bptjm-48	223	72	a	a	DET
bptjm-48	223	73	treatment	treatment	NOUN
bptjm-48	223	74	method	method	NOUN
bptjm-48	223	75	for	for	ADP
bptjm-48	223	76	di	di	NOUN
bptjm-48	223	77	�	�	PROPN
bptjm-48	223	78	erent	erent	NOUN
bptjm-48	223	79	types	type	NOUN
bptjm-48	223	80	of	of	ADP
bptjm-48	223	81	cancers	cancer	NOUN
bptjm-48	223	82	including	include	VERB
bptjm-48	223	83	glioblastoma	glioblastoma	NOUN
bptjm-48	223	84	.	.	PUNCT
bptjm-48	224	1	overall	overall	ADJ
bptjm-48	224	2	,	,	PUNCT
bptjm-48	224	3	while	while	SCONJ
bptjm-48	224	4	further	further	ADJ
bptjm-48	224	5	research	research	NOUN
bptjm-48	224	6	is	be	AUX
bptjm-48	224	7	needed	need	VERB
bptjm-48	224	8	to	to	PART
bptjm-48	224	9	fully	fully	ADV
bptjm-48	224	10	understand	understand	VERB
bptjm-48	224	11	the	the	DET
bptjm-48	224	12	potential	potential	NOUN
bptjm-48	224	13	of	of	ADP
bptjm-48	224	14	neoantigen	neoantigen	NOUN
bptjm-48	224	15	vaccine	vaccine	NOUN
bptjm-48	224	16	combination	combination	VERB
bptjm-48	224	17	therapies	therapy	NOUN
bptjm-48	224	18	in	in	ADP
bptjm-48	224	19	glioblastoma	glioblastoma	NOUN
bptjm-48	224	20	,	,	PUNCT
bptjm-48	224	21	early	early	ADJ
bptjm-48	224	22	results	result	NOUN
bptjm-48	224	23	suggest	suggest	VERB
bptjm-48	224	24	that	that	SCONJ
bptjm-48	224	25	these	these	DET
bptjm-48	224	26	approaches	approach	NOUN
bptjm-48	224	27	may	may	AUX
bptjm-48	224	28	hold	hold	VERB
bptjm-48	224	29	promise	promise	NOUN
bptjm-48	224	30	as	as	ADP
bptjm-48	224	31	a	a	DET
bptjm-48	224	32	way	way	NOUN
bptjm-48	224	33	to	to	PART
bptjm-48	224	34	improve	improve	VERB
bptjm-48	224	35	outcomes	outcome	NOUN
bptjm-48	224	36	for	for	ADP
bptjm-48	224	37	patients	patient	NOUN
bptjm-48	224	38	with	with	ADP
bptjm-48	224	39	gbm	gbm	PROPN
bptjm-48	224	40	.	.	PROPN
bptjm-48	224	41	5	5	NUM
bptjm-48	224	42	.	.	NOUN
bptjm-48	224	43	practical	practical	ADJ
bptjm-48	224	44	considerations	consideration	NOUN
bptjm-48	224	45	glioblastoma	glioblastoma	NOUN
bptjm-48	224	46	is	be	AUX
bptjm-48	224	47	a	a	DET
bptjm-48	224	48	type	type	NOUN
bptjm-48	224	49	of	of	ADP
bptjm-48	224	50	brain	brain	NOUN
bptjm-48	224	51	cancer	cancer	NOUN
bptjm-48	224	52	that	that	PRON
bptjm-48	224	53	is	be	AUX
bptjm-48	224	54	di	di	NOUN
bptjm-48	224	55	�	�	PROPN
bptjm-48	224	56	cult	cult	NOUN
bptjm-48	224	57	to	to	PART
bptjm-48	224	58	treat	treat	VERB
bptjm-48	224	59	.	.	PUNCT
bptjm-48	225	1	novel	novel	PROPN
bptjm-48	225	2	neoantigen	neoantigen	NOUN
bptjm-48	225	3	-	-	PUNCT
bptjm-48	225	4	based	base	VERB
bptjm-48	225	5	treatment	treatment	NOUN
bptjm-48	225	6	methods	method	NOUN
bptjm-48	225	7	are	be	AUX
bptjm-48	225	8	being	be	AUX
bptjm-48	225	9	explored	explore	VERB
bptjm-48	225	10	as	as	ADP
bptjm-48	225	11	a	a	DET
bptjm-48	225	12	potential	potential	ADJ
bptjm-48	225	13	solution	solution	NOUN
bptjm-48	225	14	to	to	ADP
bptjm-48	225	15	this	this	DET
bptjm-48	225	16	problem	problem	NOUN
bptjm-48	225	17	.	.	PUNCT
bptjm-48	226	1	neoantigens	neoantigen	NOUN
bptjm-48	226	2	are	be	AUX
bptjm-48	226	3	unique	unique	ADJ
bptjm-48	226	4	proteins	protein	NOUN
bptjm-48	226	5	that	that	PRON
bptjm-48	226	6	are	be	AUX
bptjm-48	226	7	expressed	express	VERB
bptjm-48	226	8	on	on	ADP
bptjm-48	226	9	the	the	DET
bptjm-48	226	10	surface	surface	NOUN
bptjm-48	226	11	of	of	ADP
bptjm-48	226	12	cancer	cancer	NOUN
bptjm-48	226	13	cells	cell	NOUN
bptjm-48	226	14	,	,	PUNCT
bptjm-48	226	15	but	but	CCONJ
bptjm-48	226	16	not	not	PART
bptjm-48	226	17	on	on	ADP
bptjm-48	226	18	healthy	healthy	ADJ
bptjm-48	226	19	cells	cell	NOUN
bptjm-48	226	20	,	,	PUNCT
bptjm-48	226	21	making	make	VERB
bptjm-48	226	22	them	they	PRON
bptjm-48	226	23	a	a	DET
bptjm-48	226	24	promising	promising	ADJ
bptjm-48	226	25	target	target	NOUN
bptjm-48	226	26	for	for	ADP
bptjm-48	226	27	cancer	cancer	NOUN
bptjm-48	226	28	treatment.53	treatment.53	NOUN
bptjm-48	226	29	here	here	ADV
bptjm-48	226	30	are	be	AUX
bptjm-48	226	31	some	some	DET
bptjm-48	226	32	practical	practical	ADJ
bptjm-48	226	33	considerations	consideration	NOUN
bptjm-48	226	34	when	when	SCONJ
bptjm-48	226	35	exploring	explore	VERB
bptjm-48	226	36	novel	novel	ADJ
bptjm-48	226	37	neoantigen	neoantigen	NOUN
bptjm-48	226	38	-	-	PUNCT
bptjm-48	226	39	based	base	VERB
bptjm-48	226	40	treatment	treatment	NOUN
bptjm-48	226	41	methods	method	NOUN
bptjm-48	226	42	for	for	ADP
bptjm-48	226	43	glioblastoma	glioblastoma	NOUN
bptjm-48	226	44	:	:	PUNCT
bptjm-48	226	45	identi	identi	X
bptjm-48	226	46	�	�	PROPN
bptjm-48	226	47	cation	cation	NOUN
bptjm-48	226	48	of	of	ADP
bptjm-48	226	49	neoantigens	neoantigen	NOUN
bptjm-48	226	50	:	:	PUNCT
bptjm-48	226	51	the	the	DET
bptjm-48	226	52	�	�	PROPN
bptjm-48	226	53	rst	rst	ADJ
bptjm-48	226	54	step	step	NOUN
bptjm-48	226	55	is	be	AUX
bptjm-48	226	56	to	to	PART
bptjm-48	226	57	identify	identify	VERB
bptjm-48	226	58	the	the	DET
bptjm-48	226	59	neoantigens	neoantigen	NOUN
bptjm-48	226	60	that	that	PRON
bptjm-48	226	61	are	be	AUX
bptjm-48	226	62	present	present	ADJ
bptjm-48	226	63	in	in	ADP
bptjm-48	226	64	the	the	DET
bptjm-48	226	65	glioblastoma	glioblastoma	NOUN
bptjm-48	226	66	cells	cell	NOUN
bptjm-48	226	67	.	.	PUNCT
bptjm-48	227	1	this	this	PRON
bptjm-48	227	2	can	can	AUX
bptjm-48	227	3	be	be	AUX
bptjm-48	227	4	done	do	VERB
bptjm-48	227	5	through	through	ADP
bptjm-48	227	6	genomic	genomic	ADJ
bptjm-48	227	7	analysis	analysis	NOUN
bptjm-48	227	8	,	,	PUNCT
bptjm-48	227	9	transcriptomic	transcriptomic	ADJ
bptjm-48	227	10	analysis	analysis	NOUN
bptjm-48	227	11	,	,	PUNCT
bptjm-48	227	12	and/or	and/or	CCONJ
bptjm-48	227	13	proteomic	proteomic	ADJ
bptjm-48	227	14	analysis	analysis	NOUN
bptjm-48	227	15	.	.	PUNCT
bptjm-48	228	1	the	the	DET
bptjm-48	228	2	identi	identi	X
bptjm-48	228	3	�	�	PROPN
bptjm-48	228	4	cation	cation	NOUN
bptjm-48	228	5	of	of	ADP
bptjm-48	228	6	neoantigens	neoantigen	NOUN
bptjm-48	228	7	is	be	AUX
bptjm-48	228	8	critical	critical	ADJ
bptjm-48	228	9	for	for	ADP
bptjm-48	228	10	developing	develop	VERB
bptjm-48	228	11	a	a	DET
bptjm-48	228	12	personalized	personalized	ADJ
bptjm-48	228	13	treatment	treatment	NOUN
bptjm-48	228	14	plan	plan	NOUN
bptjm-48	228	15	.	.	PUNCT
bptjm-48	229	1	personalized	personalize	VERB
bptjm-48	229	2	treatment	treatment	NOUN
bptjm-48	229	3	plans	plan	NOUN
bptjm-48	229	4	:	:	PUNCT
bptjm-48	229	5	because	because	SCONJ
bptjm-48	229	6	each	each	DET
bptjm-48	229	7	patient	patient	NOUN
bptjm-48	229	8	's	's	PART
bptjm-48	229	9	glioblastoma	glioblastoma	NOUN
bptjm-48	229	10	is	be	AUX
bptjm-48	229	11	unique	unique	ADJ
bptjm-48	229	12	,	,	PUNCT
bptjm-48	229	13	a	a	DET
bptjm-48	229	14	personalized	personalized	ADJ
bptjm-48	229	15	treatment	treatment	NOUN
bptjm-48	229	16	plan	plan	NOUN
bptjm-48	229	17	is	be	AUX
bptjm-48	229	18	necessary	necessary	ADJ
bptjm-48	229	19	.	.	PUNCT
bptjm-48	230	1	this	this	PRON
bptjm-48	230	2	involves	involve	VERB
bptjm-48	230	3	identifying	identify	VERB
bptjm-48	230	4	the	the	DET
bptjm-48	230	5	patient	patient	NOUN
bptjm-48	230	6	's	's	PART
bptjm-48	230	7	speci	speci	NOUN
bptjm-48	230	8	�	�	PROPN
bptjm-48	230	9	c	c	PROPN
bptjm-48	230	10	neoantigens	neoantigen	NOUN
bptjm-48	230	11	and	and	CCONJ
bptjm-48	230	12	developing	develop	VERB
bptjm-48	230	13	a	a	DET
bptjm-48	230	14	treatment	treatment	NOUN
bptjm-48	230	15	plan	plan	NOUN
bptjm-48	230	16	that	that	PRON
bptjm-48	230	17	targets	target	VERB
bptjm-48	230	18	those	those	DET
bptjm-48	230	19	speci	speci	PROPN
bptjm-48	230	20	�	�	PROPN
bptjm-48	230	21	c	c	NOUN
bptjm-48	230	22	neoantigens	neoantigen	NOUN
bptjm-48	230	23	.	.	PUNCT
bptjm-48	231	1	delivery	delivery	NOUN
bptjm-48	231	2	methods	method	NOUN
bptjm-48	231	3	:	:	PUNCT
bptjm-48	231	4	one	one	NUM
bptjm-48	231	5	of	of	ADP
bptjm-48	231	6	the	the	DET
bptjm-48	231	7	challenges	challenge	NOUN
bptjm-48	231	8	of	of	ADP
bptjm-48	231	9	neoantigen	neoantigen	NOUN
bptjm-48	231	10	-	-	PUNCT
bptjm-48	231	11	based	base	VERB
bptjm-48	231	12	treatment	treatment	NOUN
bptjm-48	231	13	methods	method	NOUN
bptjm-48	231	14	is	be	AUX
bptjm-48	231	15	delivering	deliver	VERB
bptjm-48	231	16	the	the	DET
bptjm-48	231	17	treatment	treatment	NOUN
bptjm-48	231	18	to	to	ADP
bptjm-48	231	19	the	the	DET
bptjm-48	231	20	brain	brain	NOUN
bptjm-48	231	21	.	.	PUNCT
bptjm-48	232	1	traditional	traditional	ADJ
bptjm-48	232	2	delivery	delivery	NOUN
bptjm-48	232	3	methods	method	NOUN
bptjm-48	232	4	,	,	PUNCT
bptjm-48	232	5	such	such	ADJ
bptjm-48	232	6	as	as	ADP
bptjm-48	232	7	intravenous	intravenous	ADJ
bptjm-48	232	8	injections	injection	NOUN
bptjm-48	232	9	,	,	PUNCT
bptjm-48	232	10	are	be	AUX
bptjm-48	232	11	not	not	PART
bptjm-48	232	12	e	e	X
bptjm-48	232	13	�	�	NOUN
bptjm-48	232	14	ective	ective	ADJ
bptjm-48	232	15	for	for	ADP
bptjm-48	232	16	brain	brain	NOUN
bptjm-48	232	17	tumors	tumor	NOUN
bptjm-48	232	18	.	.	PUNCT
bptjm-48	233	1	therefore	therefore	ADV
bptjm-48	233	2	,	,	PUNCT
bptjm-48	233	3	new	new	ADJ
bptjm-48	233	4	delivery	delivery	NOUN
bptjm-48	233	5	methods	method	NOUN
bptjm-48	233	6	,	,	PUNCT
bptjm-48	233	7	such	such	ADJ
bptjm-48	233	8	as	as	ADP
bptjm-48	233	9	direct	direct	ADJ
bptjm-48	233	10	injection	injection	NOUN
bptjm-48	233	11	into	into	ADP
bptjm-48	233	12	the	the	DET
bptjm-48	233	13	brain	brain	NOUN
bptjm-48	233	14	,	,	PUNCT
bptjm-48	233	15	are	be	AUX
bptjm-48	233	16	being	be	AUX
bptjm-48	233	17	explored	explore	VERB
bptjm-48	233	18	.	.	PUNCT
bptjm-48	234	1	immunogenicity	immunogenicity	NOUN
bptjm-48	234	2	:	:	PUNCT
bptjm-48	234	3	it	it	PRON
bptjm-48	234	4	is	be	AUX
bptjm-48	234	5	important	important	ADJ
bptjm-48	234	6	to	to	PART
bptjm-48	234	7	ensure	ensure	VERB
bptjm-48	234	8	that	that	SCONJ
bptjm-48	234	9	the	the	DET
bptjm-48	234	10	neoantigen	neoantigen	NOUN
bptjm-48	234	11	-	-	PUNCT
bptjm-48	234	12	based	base	VERB
bptjm-48	234	13	treatment	treatment	NOUN
bptjm-48	234	14	method	method	NOUN
bptjm-48	234	15	is	be	AUX
bptjm-48	234	16	immunogenic	immunogenic	ADJ
bptjm-48	234	17	,	,	PUNCT
bptjm-48	234	18	meaning	mean	VERB
bptjm-48	234	19	that	that	SCONJ
bptjm-48	234	20	berkeley	berkeley	PROPN
bptjm-48	234	21	pharma	pharma	PROPN
bptjm-48	234	22	tech	tech	NOUN
bptjm-48	234	23	journal	journal	NOUN
bptjm-48	234	24	of	of	ADP
bptjm-48	234	25	medicine	medicine	NOUN
bptjm-48	235	1	|	|	ADV
bptjm-48	235	2	56	56	NUM
bptjm-48	235	3	it	it	PRON
bptjm-48	235	4	stimulates	stimulate	VERB
bptjm-48	235	5	an	an	DET
bptjm-48	235	6	immune	immune	ADJ
bptjm-48	235	7	response	response	NOUN
bptjm-48	235	8	.	.	PUNCT
bptjm-48	236	1	this	this	PRON
bptjm-48	236	2	is	be	AUX
bptjm-48	236	3	critical	critical	ADJ
bptjm-48	236	4	for	for	SCONJ
bptjm-48	236	5	the	the	DET
bptjm-48	236	6	treatment	treatment	NOUN
bptjm-48	236	7	to	to	PART
bptjm-48	236	8	be	be	AUX
bptjm-48	236	9	e	e	NOUN
bptjm-48	236	10	�	�	NOUN
bptjm-48	236	11	ective	ective	ADJ
bptjm-48	236	12	.	.	PUNCT
bptjm-48	237	1	combination	combination	NOUN
bptjm-48	237	2	therapies	therapy	NOUN
bptjm-48	237	3	:	:	PUNCT
bptjm-48	237	4	neoantigen	neoantigen	NOUN
bptjm-48	237	5	-	-	PUNCT
bptjm-48	237	6	based	base	VERB
bptjm-48	237	7	treatment	treatment	NOUN
bptjm-48	237	8	methods	method	NOUN
bptjm-48	237	9	may	may	AUX
bptjm-48	237	10	be	be	AUX
bptjm-48	237	11	more	more	ADJ
bptjm-48	237	12	e	e	NOUN
bptjm-48	237	13	�	�	NOUN
bptjm-48	237	14	ective	ective	ADJ
bptjm-48	237	15	when	when	SCONJ
bptjm-48	237	16	used	use	VERB
bptjm-48	237	17	in	in	ADP
bptjm-48	237	18	combination	combination	NOUN
bptjm-48	237	19	with	with	ADP
bptjm-48	237	20	other	other	ADJ
bptjm-48	237	21	therapies	therapy	NOUN
bptjm-48	237	22	,	,	PUNCT
bptjm-48	237	23	such	such	ADJ
bptjm-48	237	24	as	as	ADP
bptjm-48	237	25	chemotherapy	chemotherapy	NOUN
bptjm-48	237	26	or	or	CCONJ
bptjm-48	237	27	radiation	radiation	NOUN
bptjm-48	237	28	therapy	therapy	NOUN
bptjm-48	237	29	.	.	PUNCT
bptjm-48	238	1	therefore	therefore	ADV
bptjm-48	238	2	,	,	PUNCT
bptjm-48	238	3	the	the	DET
bptjm-48	238	4	potential	potential	NOUN
bptjm-48	238	5	for	for	ADP
bptjm-48	238	6	combination	combination	NOUN
bptjm-48	238	7	therapies	therapy	NOUN
bptjm-48	238	8	should	should	AUX
bptjm-48	238	9	be	be	AUX
bptjm-48	238	10	considered	consider	VERB
bptjm-48	238	11	.	.	PUNCT
bptjm-48	239	1	clinical	clinical	ADJ
bptjm-48	239	2	trials	trial	NOUN
bptjm-48	239	3	:	:	PUNCT
bptjm-48	239	4	clinical	clinical	ADJ
bptjm-48	239	5	trials	trial	NOUN
bptjm-48	239	6	are	be	AUX
bptjm-48	239	7	necessary	necessary	ADJ
bptjm-48	239	8	to	to	PART
bptjm-48	239	9	test	test	VERB
bptjm-48	239	10	the	the	DET
bptjm-48	239	11	safety	safety	NOUN
bptjm-48	239	12	and	and	CCONJ
bptjm-48	239	13	e	e	NOUN
bptjm-48	239	14	�	�	PROPN
bptjm-48	239	15	cacy	cacy	NOUN
bptjm-48	239	16	of	of	ADP
bptjm-48	239	17	neoantigen	neoantigen	NOUN
bptjm-48	239	18	-	-	PUNCT
bptjm-48	239	19	based	base	VERB
bptjm-48	239	20	treatment	treatment	NOUN
bptjm-48	239	21	methods	method	NOUN
bptjm-48	239	22	.	.	PUNCT
bptjm-48	240	1	these	these	DET
bptjm-48	240	2	trials	trial	NOUN
bptjm-48	240	3	should	should	AUX
bptjm-48	240	4	be	be	AUX
bptjm-48	240	5	designed	design	VERB
bptjm-48	240	6	to	to	PART
bptjm-48	240	7	address	address	VERB
bptjm-48	240	8	the	the	DET
bptjm-48	240	9	speci	speci	PROPN
bptjm-48	240	10	�	�	PROPN
bptjm-48	240	11	c	c	NOUN
bptjm-48	240	12	challenges	challenge	NOUN
bptjm-48	240	13	associated	associate	VERB
bptjm-48	240	14	with	with	ADP
bptjm-48	240	15	treating	treat	VERB
bptjm-48	240	16	glioblastoma	glioblastoma	NOUN
bptjm-48	240	17	,	,	PUNCT
bptjm-48	240	18	such	such	ADJ
bptjm-48	240	19	as	as	ADP
bptjm-48	240	20	delivery	delivery	NOUN
bptjm-48	240	21	to	to	ADP
bptjm-48	240	22	the	the	DET
bptjm-48	240	23	brain	brain	NOUN
bptjm-48	240	24	and	and	CCONJ
bptjm-48	240	25	the	the	DET
bptjm-48	240	26	development	development	NOUN
bptjm-48	240	27	of	of	ADP
bptjm-48	240	28	personalized	personalized	ADJ
bptjm-48	240	29	treatment	treatment	NOUN
bptjm-48	240	30	plans	plan	NOUN
bptjm-48	240	31	.	.	PUNCT
bptjm-48	241	1	overall	overall	ADV
bptjm-48	241	2	,	,	PUNCT
bptjm-48	241	3	exploring	explore	VERB
bptjm-48	241	4	novel	novel	ADJ
bptjm-48	241	5	neoantigen	neoantigen	NOUN
bptjm-48	241	6	-	-	PUNCT
bptjm-48	241	7	based	base	VERB
bptjm-48	241	8	treatment	treatment	NOUN
bptjm-48	241	9	methods	method	NOUN
bptjm-48	241	10	for	for	ADP
bptjm-48	241	11	glioblastoma	glioblastoma	NOUN
bptjm-48	241	12	requires	require	VERB
bptjm-48	241	13	careful	careful	ADJ
bptjm-48	241	14	consideration	consideration	NOUN
bptjm-48	241	15	of	of	ADP
bptjm-48	241	16	several	several	ADJ
bptjm-48	241	17	practical	practical	ADJ
bptjm-48	241	18	factors	factor	NOUN
bptjm-48	241	19	,	,	PUNCT
bptjm-48	241	20	including	include	VERB
bptjm-48	241	21	identi	identi	ADJ
bptjm-48	241	22	�	�	NOUN
bptjm-48	241	23	cation	cation	NOUN
bptjm-48	241	24	of	of	ADP
bptjm-48	241	25	neoantigens	neoantigen	NOUN
bptjm-48	241	26	,	,	PUNCT
bptjm-48	241	27	personalized	personalized	ADJ
bptjm-48	241	28	treatment	treatment	NOUN
bptjm-48	241	29	plans	plan	NOUN
bptjm-48	241	30	,	,	PUNCT
bptjm-48	241	31	delivery	delivery	NOUN
bptjm-48	241	32	methods	method	NOUN
bptjm-48	241	33	,	,	PUNCT
bptjm-48	241	34	immunogenicity	immunogenicity	NOUN
bptjm-48	241	35	,	,	PUNCT
bptjm-48	241	36	combination	combination	NOUN
bptjm-48	241	37	therapies	therapy	NOUN
bptjm-48	241	38	,	,	PUNCT
bptjm-48	241	39	and	and	CCONJ
bptjm-48	241	40	clinical	clinical	ADJ
bptjm-48	241	41	trials	trial	NOUN
bptjm-48	241	42	.	.	PUNCT
bptjm-48	242	1	6	6	X
bptjm-48	242	2	.	.	X
bptjm-48	242	3	conclusion	conclusion	NOUN
bptjm-48	242	4	glioblastoma	glioblastoma	NOUN
bptjm-48	242	5	remains	remain	VERB
bptjm-48	242	6	a	a	DET
bptjm-48	242	7	formidable	formidable	ADJ
bptjm-48	242	8	challenge	challenge	NOUN
bptjm-48	242	9	in	in	ADP
bptjm-48	242	10	the	the	DET
bptjm-48	242	11	�	�	PROPN
bptjm-48	242	12	eld	eld	NOUN
bptjm-48	242	13	of	of	ADP
bptjm-48	242	14	oncology	oncology	NOUN
bptjm-48	242	15	due	due	ADP
bptjm-48	242	16	to	to	ADP
bptjm-48	242	17	its	its	PRON
bptjm-48	242	18	aggressive	aggressive	ADJ
bptjm-48	242	19	nature	nature	NOUN
bptjm-48	242	20	and	and	CCONJ
bptjm-48	242	21	limited	limited	ADJ
bptjm-48	242	22	treatment	treatment	NOUN
bptjm-48	242	23	options	option	NOUN
bptjm-48	242	24	.	.	PUNCT
bptjm-48	243	1	however	however	ADV
bptjm-48	243	2	,	,	PUNCT
bptjm-48	243	3	advancements	advancement	NOUN
bptjm-48	243	4	in	in	ADP
bptjm-48	243	5	immunotherapeutic	immunotherapeutic	ADJ
bptjm-48	243	6	approaches	approach	NOUN
bptjm-48	243	7	,	,	PUNCT
bptjm-48	243	8	such	such	ADJ
bptjm-48	243	9	as	as	ADP
bptjm-48	243	10	neoantigen	neoantigen	NOUN
bptjm-48	243	11	-	-	PUNCT
bptjm-48	243	12	based	base	VERB
bptjm-48	243	13	vaccines	vaccine	NOUN
bptjm-48	243	14	,	,	PUNCT
bptjm-48	243	15	immune	immune	ADJ
bptjm-48	243	16	checkpoint	checkpoint	NOUN
bptjm-48	243	17	blockers	blocker	NOUN
bptjm-48	243	18	,	,	PUNCT
bptjm-48	243	19	and	and	CCONJ
bptjm-48	243	20	adoptive	adoptive	ADJ
bptjm-48	243	21	cellular	cellular	ADJ
bptjm-48	243	22	therapies	therapy	NOUN
bptjm-48	243	23	,	,	PUNCT
bptjm-48	243	24	have	have	AUX
bptjm-48	243	25	demonstrated	demonstrate	VERB
bptjm-48	243	26	promising	promise	VERB
bptjm-48	243	27	e	e	PROPN
bptjm-48	243	28	�	�	NOUN
bptjm-48	243	29	cacy	cacy	NOUN
bptjm-48	243	30	in	in	ADP
bptjm-48	243	31	repressing	repress	VERB
bptjm-48	243	32	glioblastoma	glioblastoma	NOUN
bptjm-48	243	33	tumor	tumor	NOUN
bptjm-48	243	34	cells	cell	NOUN
bptjm-48	243	35	.	.	PUNCT
bptjm-48	244	1	our	our	PRON
bptjm-48	244	2	comprehensive	comprehensive	ADJ
bptjm-48	244	3	review	review	NOUN
bptjm-48	244	4	of	of	ADP
bptjm-48	244	5	scienti	scienti	PROPN
bptjm-48	244	6	�	�	PROPN
bptjm-48	244	7	c	c	NOUN
bptjm-48	244	8	literature	literature	NOUN
bptjm-48	244	9	and	and	CCONJ
bptjm-48	244	10	clinical	clinical	ADJ
bptjm-48	244	11	trials	trial	NOUN
bptjm-48	244	12	has	have	AUX
bptjm-48	244	13	shed	shed	VERB
bptjm-48	244	14	light	light	NOUN
bptjm-48	244	15	on	on	ADP
bptjm-48	244	16	the	the	DET
bptjm-48	244	17	potential	potential	NOUN
bptjm-48	244	18	of	of	ADP
bptjm-48	244	19	these	these	DET
bptjm-48	244	20	treatment	treatment	NOUN
bptjm-48	244	21	methods	method	NOUN
bptjm-48	244	22	and	and	CCONJ
bptjm-48	244	23	identi	identi	NOUN
bptjm-48	244	24	�	�	PROPN
bptjm-48	244	25	ed	ed	PROPN
bptjm-48	244	26	areas	area	NOUN
bptjm-48	244	27	for	for	ADP
bptjm-48	244	28	improvement	improvement	NOUN
bptjm-48	244	29	to	to	PART
bptjm-48	244	30	further	far	ADV
bptjm-48	244	31	enhance	enhance	VERB
bptjm-48	244	32	their	their	PRON
bptjm-48	244	33	e	e	NOUN
bptjm-48	244	34	�	�	NOUN
bptjm-48	244	35	ectiveness	ectiveness	NOUN
bptjm-48	244	36	.	.	PUNCT
bptjm-48	245	1	neoantigen	neoantigen	NOUN
bptjm-48	245	2	-	-	PUNCT
bptjm-48	245	3	based	base	VERB
bptjm-48	245	4	vaccines	vaccine	NOUN
bptjm-48	245	5	have	have	AUX
bptjm-48	245	6	shown	show	VERB
bptjm-48	245	7	promise	promise	NOUN
bptjm-48	245	8	in	in	ADP
bptjm-48	245	9	priming	prime	VERB
bptjm-48	245	10	the	the	DET
bptjm-48	245	11	immune	immune	ADJ
bptjm-48	245	12	system	system	NOUN
bptjm-48	245	13	to	to	PART
bptjm-48	245	14	recognize	recognize	VERB
bptjm-48	245	15	and	and	CCONJ
bptjm-48	245	16	attack	attack	NOUN
bptjm-48	245	17	cancer	cancer	NOUN
bptjm-48	245	18	cells	cell	NOUN
bptjm-48	245	19	displaying	display	VERB
bptjm-48	245	20	unique	unique	ADJ
bptjm-48	245	21	neoantigens	neoantigen	NOUN
bptjm-48	245	22	.	.	PUNCT
bptjm-48	246	1	protein	protein	NOUN
bptjm-48	246	2	-	-	PUNCT
bptjm-48	246	3	peptide	peptide	NOUN
bptjm-48	246	4	vaccines	vaccine	NOUN
bptjm-48	246	5	have	have	AUX
bptjm-48	246	6	been	be	AUX
bptjm-48	246	7	utilized	utilize	VERB
bptjm-48	246	8	to	to	PART
bptjm-48	246	9	stimulate	stimulate	VERB
bptjm-48	246	10	a	a	DET
bptjm-48	246	11	speci	speci	ADJ
bptjm-48	246	12	�	�	PROPN
bptjm-48	246	13	c	c	PROPN
bptjm-48	246	14	cytotoxic	cytotoxic	ADJ
bptjm-48	246	15	t	t	NOUN
bptjm-48	246	16	-	-	PUNCT
bptjm-48	246	17	lymphocyte	lymphocyte	NOUN
bptjm-48	246	18	(	(	PUNCT
bptjm-48	246	19	ctl	ctl	PROPN
bptjm-48	246	20	)	)	PUNCT
bptjm-48	246	21	response	response	NOUN
bptjm-48	246	22	against	against	ADP
bptjm-48	246	23	tumor	tumor	NOUN
bptjm-48	246	24	cells	cell	NOUN
bptjm-48	246	25	expressing	express	VERB
bptjm-48	246	26	targeted	targeted	ADJ
bptjm-48	246	27	neoantigens	neoantigen	NOUN
bptjm-48	246	28	.	.	PUNCT
bptjm-48	247	1	the	the	DET
bptjm-48	247	2	clinical	clinical	ADJ
bptjm-48	247	3	trials	trial	NOUN
bptjm-48	247	4	conducted	conduct	VERB
bptjm-48	247	5	by	by	ADP
bptjm-48	247	6	hilf	hilf	PROPN
bptjm-48	247	7	et	et	PROPN
bptjm-48	247	8	al	al	PROPN
bptjm-48	247	9	.	.	PROPN
bptjm-48	247	10	and	and	CCONJ
bptjm-48	247	11	keskin	keskin	PROPN
bptjm-48	247	12	et	et	PROPN
bptjm-48	247	13	al	al	PROPN
bptjm-48	247	14	.	.	PROPN
bptjm-48	247	15	demonstrated	demonstrate	VERB
bptjm-48	247	16	increased	increase	VERB
bptjm-48	247	17	overall	overall	ADJ
bptjm-48	247	18	survival	survival	NOUN
bptjm-48	247	19	and	and	CCONJ
bptjm-48	247	20	progression	progression	NOUN
bptjm-48	247	21	-	-	PUNCT
bptjm-48	247	22	free	free	ADJ
bptjm-48	247	23	survival	survival	NOUN
bptjm-48	247	24	in	in	ADP
bptjm-48	247	25	berkeley	berkeley	PROPN
bptjm-48	247	26	pharma	pharma	PROPN
bptjm-48	247	27	tech	tech	NOUN
bptjm-48	247	28	journal	journal	NOUN
bptjm-48	247	29	of	of	ADP
bptjm-48	247	30	medicine	medicine	NOUN
bptjm-48	247	31	|	|	ADV
bptjm-48	247	32	57	57	NUM
bptjm-48	247	33	patients	patient	NOUN
bptjm-48	247	34	who	who	PRON
bptjm-48	247	35	received	receive	VERB
bptjm-48	247	36	neoantigen	neoantigen	NOUN
bptjm-48	247	37	-	-	PUNCT
bptjm-48	247	38	based	base	VERB
bptjm-48	247	39	vaccines	vaccine	NOUN
bptjm-48	247	40	,	,	PUNCT
bptjm-48	247	41	albeit	albeit	SCONJ
bptjm-48	247	42	with	with	ADP
bptjm-48	247	43	some	some	DET
bptjm-48	247	44	side	side	NOUN
bptjm-48	247	45	e	e	NOUN
bptjm-48	247	46	�	�	NOUN
bptjm-48	247	47	ects	ect	NOUN
bptjm-48	247	48	.	.	PUNCT
bptjm-48	248	1	ongoing	ongoing	ADJ
bptjm-48	248	2	trials	trial	NOUN
bptjm-48	248	3	,	,	PUNCT
bptjm-48	248	4	such	such	ADJ
bptjm-48	248	5	as	as	ADP
bptjm-48	248	6	the	the	DET
bptjm-48	248	7	reardon	reardon	PROPN
bptjm-48	248	8	et	et	PROPN
bptjm-48	248	9	al	al	PROPN
bptjm-48	248	10	.	.	PROPN
bptjm-48	248	11	trial	trial	NOUN
bptjm-48	248	12	,	,	PUNCT
bptjm-48	248	13	are	be	AUX
bptjm-48	248	14	investigating	investigate	VERB
bptjm-48	248	15	the	the	DET
bptjm-48	248	16	combination	combination	NOUN
bptjm-48	248	17	of	of	ADP
bptjm-48	248	18	neoantigen	neoantigen	NOUN
bptjm-48	248	19	-	-	PUNCT
bptjm-48	248	20	based	base	VERB
bptjm-48	248	21	vaccines	vaccine	NOUN
bptjm-48	248	22	with	with	ADP
bptjm-48	248	23	other	other	ADJ
bptjm-48	248	24	therapies	therapy	NOUN
bptjm-48	248	25	to	to	PART
bptjm-48	248	26	assess	assess	VERB
bptjm-48	248	27	their	their	PRON
bptjm-48	248	28	synergistic	synergistic	ADJ
bptjm-48	248	29	e	e	NOUN
bptjm-48	248	30	�	�	NOUN
bptjm-48	248	31	ects	ect	NOUN
bptjm-48	248	32	.	.	PUNCT
bptjm-48	249	1	nucleic	nucleic	ADJ
bptjm-48	249	2	acid	acid	NOUN
bptjm-48	249	3	vaccines	vaccine	NOUN
bptjm-48	249	4	,	,	PUNCT
bptjm-48	249	5	including	include	VERB
bptjm-48	249	6	dna	dna	PROPN
bptjm-48	249	7	and	and	CCONJ
bptjm-48	249	8	mrna	mrna	PROPN
bptjm-48	249	9	vaccines	vaccine	NOUN
bptjm-48	249	10	,	,	PUNCT
bptjm-48	249	11	have	have	AUX
bptjm-48	249	12	also	also	ADV
bptjm-48	249	13	emerged	emerge	VERB
bptjm-48	249	14	as	as	ADP
bptjm-48	249	15	potential	potential	ADJ
bptjm-48	249	16	treatment	treatment	NOUN
bptjm-48	249	17	methods	method	NOUN
bptjm-48	249	18	.	.	PUNCT
bptjm-48	250	1	dna	dna	PROPN
bptjm-48	250	2	vaccines	vaccine	NOUN
bptjm-48	250	3	introduce	introduce	VERB
bptjm-48	250	4	a	a	DET
bptjm-48	250	5	gene	gene	NOUN
bptjm-48	250	6	encoding	encode	VERB
bptjm-48	250	7	antigens	antigen	NOUN
bptjm-48	250	8	using	use	VERB
bptjm-48	250	9	bacterial	bacterial	ADJ
bptjm-48	250	10	plasmids	plasmid	NOUN
bptjm-48	250	11	as	as	ADP
bptjm-48	250	12	vectors	vector	NOUN
bptjm-48	250	13	,	,	PUNCT
bptjm-48	250	14	while	while	SCONJ
bptjm-48	250	15	mrna	mrna	PROPN
bptjm-48	250	16	vaccines	vaccine	NOUN
bptjm-48	250	17	deliver	deliver	VERB
bptjm-48	250	18	the	the	DET
bptjm-48	250	19	antigen	antigen	NOUN
bptjm-48	250	20	-	-	PUNCT
bptjm-48	250	21	encoding	encode	VERB
bptjm-48	250	22	genetic	genetic	ADJ
bptjm-48	250	23	information	information	NOUN
bptjm-48	250	24	directly	directly	ADV
bptjm-48	250	25	to	to	ADP
bptjm-48	250	26	antigen	antigen	ADV
bptjm-48	250	27	-	-	PUNCT
bptjm-48	250	28	presenting	present	VERB
bptjm-48	250	29	cells	cell	NOUN
bptjm-48	250	30	.	.	PUNCT
bptjm-48	251	1	clinical	clinical	ADJ
bptjm-48	251	2	trials	trial	NOUN
bptjm-48	251	3	led	lead	VERB
bptjm-48	251	4	by	by	ADP
bptjm-48	251	5	johanns	johanns	PROPN
bptjm-48	251	6	et	et	PROPN
bptjm-48	251	7	al	al	PROPN
bptjm-48	251	8	.	.	PROPN
bptjm-48	252	1	and	and	CCONJ
bptjm-48	252	2	sayour	sayour	VERB
bptjm-48	252	3	et	et	PROPN
bptjm-48	252	4	al	al	PROPN
bptjm-48	252	5	.	.	PROPN
bptjm-48	252	6	are	be	AUX
bptjm-48	252	7	evaluating	evaluate	VERB
bptjm-48	252	8	the	the	DET
bptjm-48	252	9	safety	safety	NOUN
bptjm-48	252	10	,	,	PUNCT
bptjm-48	252	11	feasibility	feasibility	NOUN
bptjm-48	252	12	,	,	PUNCT
bptjm-48	252	13	and	and	CCONJ
bptjm-48	252	14	immunogenicity	immunogenicity	NOUN
bptjm-48	252	15	of	of	ADP
bptjm-48	252	16	personalized	personalized	ADJ
bptjm-48	252	17	neoantigen	neoantigen	NOUN
bptjm-48	252	18	-	-	PUNCT
bptjm-48	252	19	based	base	VERB
bptjm-48	252	20	dna	dna	NOUN
bptjm-48	252	21	and	and	CCONJ
bptjm-48	252	22	mrna	mrna	PROPN
bptjm-48	252	23	vaccines	vaccine	NOUN
bptjm-48	252	24	in	in	ADP
bptjm-48	252	25	glioblastoma	glioblastoma	NOUN
bptjm-48	252	26	patients	patient	NOUN
bptjm-48	252	27	,	,	PUNCT
bptjm-48	252	28	respectively	respectively	ADV
bptjm-48	252	29	.	.	PUNCT
bptjm-48	253	1	combination	combination	NOUN
bptjm-48	253	2	therapies	therapy	NOUN
bptjm-48	253	3	with	with	ADP
bptjm-48	253	4	dna	dna	PROPN
bptjm-48	253	5	vaccines	vaccine	NOUN
bptjm-48	253	6	,	,	PUNCT
bptjm-48	253	7	such	such	ADJ
bptjm-48	253	8	as	as	ADP
bptjm-48	253	9	the	the	DET
bptjm-48	253	10	trial	trial	NOUN
bptjm-48	253	11	by	by	ADP
bptjm-48	253	12	johanns	johanns	PROPN
bptjm-48	253	13	et	et	PROPN
bptjm-48	253	14	al	al	PROPN
bptjm-48	253	15	.	.	PROPN
bptjm-48	253	16	,	,	PUNCT
bptjm-48	253	17	show	show	VERB
bptjm-48	253	18	promise	promise	NOUN
bptjm-48	253	19	in	in	ADP
bptjm-48	253	20	enhancing	enhance	VERB
bptjm-48	253	21	immunogenicity	immunogenicity	NOUN
bptjm-48	253	22	and	and	CCONJ
bptjm-48	253	23	improving	improve	VERB
bptjm-48	253	24	patient	patient	ADJ
bptjm-48	253	25	outcomes	outcome	NOUN
bptjm-48	253	26	.	.	PUNCT
bptjm-48	254	1	autologous	autologous	ADJ
bptjm-48	254	2	dendritic	dendritic	ADJ
bptjm-48	254	3	cell	cell	NOUN
bptjm-48	254	4	(	(	PUNCT
bptjm-48	254	5	dc	dc	PROPN
bptjm-48	254	6	)	)	PUNCT
bptjm-48	254	7	vaccines	vaccine	NOUN
bptjm-48	254	8	aim	aim	VERB
bptjm-48	254	9	to	to	PART
bptjm-48	254	10	stimulate	stimulate	VERB
bptjm-48	254	11	a	a	DET
bptjm-48	254	12	speci	speci	ADJ
bptjm-48	254	13	�	�	PROPN
bptjm-48	254	14	c	c	PROPN
bptjm-48	254	15	ctl	ctl	PROPN
bptjm-48	254	16	response	response	NOUN
bptjm-48	254	17	against	against	ADP
bptjm-48	254	18	cancer	cancer	NOUN
bptjm-48	254	19	cells	cell	NOUN
bptjm-48	254	20	by	by	ADP
bptjm-48	254	21	presenting	present	VERB
bptjm-48	254	22	neoantigens	neoantigen	NOUN
bptjm-48	254	23	or	or	CCONJ
bptjm-48	254	24	tumor	tumor	NOUN
bptjm-48	254	25	-	-	PUNCT
bptjm-48	254	26	associated	associate	VERB
bptjm-48	254	27	antigens	antigen	NOUN
bptjm-48	254	28	to	to	ADP
bptjm-48	254	29	the	the	DET
bptjm-48	254	30	immune	immune	ADJ
bptjm-48	254	31	system	system	NOUN
bptjm-48	254	32	.	.	PUNCT
bptjm-48	255	1	the	the	DET
bptjm-48	255	2	neo	neo	ADJ
bptjm-48	255	3	-	-	ADJ
bptjm-48	255	4	modc	modc	ADJ
bptjm-48	255	5	vaccine	vaccine	NOUN
bptjm-48	255	6	demonstrated	demonstrate	VERB
bptjm-48	255	7	immunogenicity	immunogenicity	NOUN
bptjm-48	255	8	and	and	CCONJ
bptjm-48	255	9	induced	induce	VERB
bptjm-48	255	10	tumor	tumor	NOUN
bptjm-48	255	11	regression	regression	NOUN
bptjm-48	255	12	in	in	ADP
bptjm-48	255	13	a	a	DET
bptjm-48	255	14	patient	patient	NOUN
bptjm-48	255	15	with	with	ADP
bptjm-48	255	16	advanced	advanced	ADJ
bptjm-48	255	17	metastatic	metastatic	ADJ
bptjm-48	255	18	gastric	gastric	ADJ
bptjm-48	255	19	cancer	cancer	NOUN
bptjm-48	255	20	when	when	SCONJ
bptjm-48	255	21	administered	administer	VERB
bptjm-48	255	22	alongside	alongside	ADP
bptjm-48	255	23	nivolumab	nivolumab	NOUN
bptjm-48	255	24	.	.	PUNCT
bptjm-48	256	1	the	the	DET
bptjm-48	256	2	�	�	PROPN
bptjm-48	256	3	ndings	nding	NOUN
bptjm-48	256	4	suggest	suggest	VERB
bptjm-48	256	5	the	the	DET
bptjm-48	256	6	potential	potential	NOUN
bptjm-48	256	7	of	of	ADP
bptjm-48	256	8	autologous	autologous	ADJ
bptjm-48	256	9	dc	dc	PROPN
bptjm-48	256	10	vaccines	vaccine	NOUN
bptjm-48	256	11	in	in	ADP
bptjm-48	256	12	treating	treat	VERB
bptjm-48	256	13	glioblastoma	glioblastoma	NOUN
bptjm-48	256	14	,	,	PUNCT
bptjm-48	256	15	but	but	CCONJ
bptjm-48	256	16	further	further	ADJ
bptjm-48	256	17	research	research	NOUN
bptjm-48	256	18	is	be	AUX
bptjm-48	256	19	needed	need	VERB
bptjm-48	256	20	to	to	PART
bptjm-48	256	21	optimize	optimize	VERB
bptjm-48	256	22	their	their	PRON
bptjm-48	256	23	e	e	NOUN
bptjm-48	256	24	�	�	NOUN
bptjm-48	256	25	cacy	cacy	NOUN
bptjm-48	256	26	and	and	CCONJ
bptjm-48	256	27	explore	explore	VERB
bptjm-48	256	28	combination	combination	NOUN
bptjm-48	256	29	strategies	strategy	NOUN
bptjm-48	256	30	.	.	PUNCT
bptjm-48	257	1	in	in	ADP
bptjm-48	257	2	addition	addition	NOUN
bptjm-48	257	3	to	to	ADP
bptjm-48	257	4	vaccine	vaccine	NOUN
bptjm-48	257	5	methods	method	NOUN
bptjm-48	257	6	,	,	PUNCT
bptjm-48	257	7	immune	immune	ADJ
bptjm-48	257	8	checkpoint	checkpoint	NOUN
bptjm-48	257	9	blockade	blockade	NOUN
bptjm-48	257	10	therapy	therapy	NOUN
bptjm-48	257	11	,	,	PUNCT
bptjm-48	257	12	particularly	particularly	ADV
bptjm-48	257	13	through	through	ADP
bptjm-48	257	14	the	the	DET
bptjm-48	257	15	use	use	NOUN
bptjm-48	257	16	of	of	ADP
bptjm-48	257	17	monoclonal	monoclonal	NOUN
bptjm-48	257	18	antibodies	antibody	NOUN
bptjm-48	257	19	,	,	PUNCT
bptjm-48	257	20	has	have	AUX
bptjm-48	257	21	shown	show	VERB
bptjm-48	257	22	promising	promising	ADJ
bptjm-48	257	23	results	result	NOUN
bptjm-48	257	24	in	in	ADP
bptjm-48	257	25	the	the	DET
bptjm-48	257	26	treatment	treatment	NOUN
bptjm-48	257	27	of	of	ADP
bptjm-48	257	28	glioblastoma	glioblastoma	NOUN
bptjm-48	257	29	and	and	CCONJ
bptjm-48	257	30	other	other	ADJ
bptjm-48	257	31	cancers	cancer	NOUN
bptjm-48	257	32	.	.	PUNCT
bptjm-48	258	1	by	by	ADP
bptjm-48	258	2	targeting	target	VERB
bptjm-48	258	3	key	key	ADJ
bptjm-48	258	4	signaling	signal	VERB
bptjm-48	258	5	molecules	molecule	NOUN
bptjm-48	258	6	such	such	ADJ
bptjm-48	258	7	as	as	ADP
bptjm-48	258	8	pd-1	pd-1	ADJ
bptjm-48	258	9	,	,	PUNCT
bptjm-48	258	10	pd	pd	PROPN
bptjm-48	258	11	-	-	PROPN
bptjm-48	258	12	l1	l1	PROPN
bptjm-48	258	13	,	,	PUNCT
bptjm-48	258	14	and	and	CCONJ
bptjm-48	258	15	ctla-4	ctla-4	NUM
bptjm-48	258	16	,	,	PUNCT
bptjm-48	258	17	immune	immune	ADJ
bptjm-48	258	18	checkpoint	checkpoint	NOUN
bptjm-48	258	19	inhibitors	inhibitor	NOUN
bptjm-48	258	20	can	can	AUX
bptjm-48	258	21	suppress	suppress	VERB
bptjm-48	258	22	immunosuppression	immunosuppression	NOUN
bptjm-48	258	23	and	and	CCONJ
bptjm-48	258	24	restore	restore	VERB
bptjm-48	258	25	anti	anti	ADJ
bptjm-48	258	26	-	-	ADJ
bptjm-48	258	27	tumor	tumor	ADJ
bptjm-48	258	28	responses	response	NOUN
bptjm-48	258	29	,	,	PUNCT
bptjm-48	258	30	leading	lead	VERB
bptjm-48	258	31	to	to	ADP
bptjm-48	258	32	improved	improved	ADJ
bptjm-48	258	33	outcomes	outcome	NOUN
bptjm-48	258	34	for	for	ADP
bptjm-48	258	35	patients	patient	NOUN
bptjm-48	258	36	.	.	PUNCT
bptjm-48	259	1	monoclonal	monoclonal	NOUN
bptjm-48	259	2	antibodies	antibody	NOUN
bptjm-48	259	3	provide	provide	VERB
bptjm-48	259	4	a	a	DET
bptjm-48	259	5	highly	highly	ADV
bptjm-48	259	6	speci	speci	ADJ
bptjm-48	259	7	�	�	NOUN
bptjm-48	259	8	c	c	PROPN
bptjm-48	259	9	and	and	CCONJ
bptjm-48	259	10	e	e	NOUN
bptjm-48	259	11	�	�	NOUN
bptjm-48	259	12	ective	ective	ADJ
bptjm-48	259	13	way	way	NOUN
bptjm-48	259	14	to	to	PART
bptjm-48	259	15	target	target	VERB
bptjm-48	259	16	disease	disease	NOUN
bptjm-48	259	17	-	-	PUNCT
bptjm-48	259	18	causing	cause	VERB
bptjm-48	259	19	proteins	protein	NOUN
bptjm-48	259	20	or	or	CCONJ
bptjm-48	259	21	antigens	antigen	NOUN
bptjm-48	259	22	.	.	PUNCT
bptjm-48	260	1	by	by	ADP
bptjm-48	260	2	utilizing	utilize	VERB
bptjm-48	260	3	their	their	PRON
bptjm-48	260	4	ability	ability	NOUN
bptjm-48	260	5	to	to	PART
bptjm-48	260	6	recognize	recognize	VERB
bptjm-48	260	7	and	and	CCONJ
bptjm-48	260	8	bind	bind	VERB
bptjm-48	260	9	to	to	ADP
bptjm-48	260	10	speci	speci	PROPN
bptjm-48	260	11	�	�	PROPN
bptjm-48	260	12	c	c	NOUN
bptjm-48	260	13	targets	target	NOUN
bptjm-48	260	14	,	,	PUNCT
bptjm-48	260	15	monoclonal	monoclonal	NOUN
bptjm-48	260	16	antibodies	antibody	NOUN
bptjm-48	260	17	can	can	AUX
bptjm-48	260	18	disrupt	disrupt	VERB
bptjm-48	260	19	harmful	harmful	ADJ
bptjm-48	260	20	pathways	pathway	NOUN
bptjm-48	260	21	and	and	CCONJ
bptjm-48	260	22	stimulate	stimulate	VERB
bptjm-48	260	23	the	the	DET
bptjm-48	260	24	immune	immune	ADJ
bptjm-48	260	25	response	response	NOUN
bptjm-48	260	26	against	against	ADP
bptjm-48	260	27	cancer	cancer	NOUN
bptjm-48	260	28	cells	cell	NOUN
bptjm-48	260	29	.	.	PUNCT
bptjm-48	261	1	various	various	ADJ
bptjm-48	261	2	monoclonal	monoclonal	NOUN
bptjm-48	261	3	antibodies	antibody	NOUN
bptjm-48	261	4	,	,	PUNCT
bptjm-48	261	5	including	include	VERB
bptjm-48	261	6	nivolumab	nivolumab	NOUN
bptjm-48	261	7	,	,	PUNCT
bptjm-48	261	8	ipilimumab	ipilimumab	ADJ
bptjm-48	261	9	,	,	PUNCT
bptjm-48	261	10	avelumab	avelumab	NOUN
bptjm-48	261	11	,	,	PUNCT
bptjm-48	261	12	and	and	CCONJ
bptjm-48	261	13	berkeley	berkeley	PROPN
bptjm-48	261	14	pharma	pharma	PROPN
bptjm-48	261	15	tech	tech	NOUN
bptjm-48	261	16	journal	journal	NOUN
bptjm-48	261	17	of	of	ADP
bptjm-48	261	18	medicine	medicine	NOUN
bptjm-48	261	19	|	|	ADV
bptjm-48	261	20	58	58	NUM
bptjm-48	261	21	atezolizumab	atezolizumab	NOUN
bptjm-48	261	22	,	,	PUNCT
bptjm-48	261	23	have	have	AUX
bptjm-48	261	24	shown	show	VERB
bptjm-48	261	25	e	e	NOUN
bptjm-48	261	26	�	�	NOUN
bptjm-48	261	27	cacy	cacy	NOUN
bptjm-48	261	28	in	in	ADP
bptjm-48	261	29	glioblastoma	glioblastoma	NOUN
bptjm-48	261	30	and	and	CCONJ
bptjm-48	261	31	other	other	ADJ
bptjm-48	261	32	cancer	cancer	NOUN
bptjm-48	261	33	types	type	NOUN
bptjm-48	261	34	.	.	PUNCT
bptjm-48	262	1	combination	combination	NOUN
bptjm-48	262	2	therapies	therapy	NOUN
bptjm-48	262	3	,	,	PUNCT
bptjm-48	262	4	such	such	ADJ
bptjm-48	262	5	as	as	ADP
bptjm-48	262	6	the	the	DET
bptjm-48	262	7	concurrent	concurrent	ADJ
bptjm-48	262	8	use	use	NOUN
bptjm-48	262	9	of	of	ADP
bptjm-48	262	10	nivolumab	nivolumab	NOUN
bptjm-48	262	11	and	and	CCONJ
bptjm-48	262	12	ipilimumab	ipilimumab	ADV
bptjm-48	262	13	,	,	PUNCT
bptjm-48	262	14	have	have	AUX
bptjm-48	262	15	demonstrated	demonstrate	VERB
bptjm-48	262	16	enhanced	enhance	VERB
bptjm-48	262	17	t	t	PROPN
bptjm-48	262	18	-	-	PUNCT
bptjm-48	262	19	cell	cell	NOUN
bptjm-48	262	20	function	function	NOUN
bptjm-48	262	21	and	and	CCONJ
bptjm-48	262	22	signi	signi	PROPN
bptjm-48	262	23	�	�	NOUN
bptjm-48	262	24	cant	cant	VERB
bptjm-48	262	25	antitumor	antitumor	PROPN
bptjm-48	262	26	responses	response	NOUN
bptjm-48	262	27	.	.	PUNCT
bptjm-48	263	1	these	these	DET
bptjm-48	263	2	combinations	combination	NOUN
bptjm-48	263	3	target	target	VERB
bptjm-48	263	4	multiple	multiple	ADJ
bptjm-48	263	5	checkpoints	checkpoint	NOUN
bptjm-48	263	6	simultaneously	simultaneously	ADV
bptjm-48	263	7	,	,	PUNCT
bptjm-48	263	8	leading	lead	VERB
bptjm-48	263	9	to	to	ADP
bptjm-48	263	10	more	more	ADJ
bptjm-48	263	11	e	e	NOUN
bptjm-48	263	12	�	�	NOUN
bptjm-48	263	13	ective	ective	ADJ
bptjm-48	263	14	immune	immune	ADJ
bptjm-48	263	15	responses	response	NOUN
bptjm-48	263	16	against	against	ADP
bptjm-48	263	17	cancer	cancer	NOUN
bptjm-48	263	18	cells	cell	NOUN
bptjm-48	263	19	.	.	PUNCT
bptjm-48	264	1	adoptive	adoptive	ADJ
bptjm-48	264	2	cell	cell	NOUN
bptjm-48	264	3	therapies	therapy	NOUN
bptjm-48	264	4	,	,	PUNCT
bptjm-48	264	5	such	such	ADJ
bptjm-48	264	6	as	as	ADP
bptjm-48	264	7	til	til	NOUN
bptjm-48	264	8	-	-	PUNCT
bptjm-48	264	9	based	base	VERB
bptjm-48	264	10	cell	cell	NOUN
bptjm-48	264	11	therapies	therapy	NOUN
bptjm-48	264	12	and	and	CCONJ
bptjm-48	264	13	car	car	NOUN
bptjm-48	264	14	t	t	NOUN
bptjm-48	264	15	-	-	PUNCT
bptjm-48	264	16	cell	cell	NOUN
bptjm-48	264	17	therapy	therapy	NOUN
bptjm-48	264	18	,	,	PUNCT
bptjm-48	264	19	o	o	NOUN
bptjm-48	264	20	�	�	PROPN
bptjm-48	264	21	er	er	PROPN
bptjm-48	264	22	another	another	DET
bptjm-48	264	23	avenue	avenue	NOUN
bptjm-48	264	24	for	for	ADP
bptjm-48	264	25	glioblastoma	glioblastoma	NOUN
bptjm-48	264	26	treatment	treatment	NOUN
bptjm-48	264	27	.	.	PUNCT
bptjm-48	265	1	til	til	ADJ
bptjm-48	265	2	-	-	PUNCT
bptjm-48	265	3	based	base	VERB
bptjm-48	265	4	cell	cell	NOUN
bptjm-48	265	5	therapies	therapy	NOUN
bptjm-48	265	6	can	can	AUX
bptjm-48	265	7	recognize	recognize	VERB
bptjm-48	265	8	and	and	CCONJ
bptjm-48	265	9	kill	kill	VERB
bptjm-48	265	10	tumor	tumor	NOUN
bptjm-48	265	11	cells	cell	NOUN
bptjm-48	265	12	,	,	PUNCT
bptjm-48	265	13	while	while	SCONJ
bptjm-48	265	14	car	car	NOUN
bptjm-48	265	15	t	t	NOUN
bptjm-48	265	16	-	-	PUNCT
bptjm-48	265	17	cell	cell	NOUN
bptjm-48	265	18	therapy	therapy	NOUN
bptjm-48	265	19	genetically	genetically	ADV
bptjm-48	265	20	modi	modi	PROPN
bptjm-48	265	21	�	�	PROPN
bptjm-48	265	22	es	es	ADP
bptjm-48	265	23	a	a	DET
bptjm-48	265	24	patient	patient	NOUN
bptjm-48	265	25	's	's	PART
bptjm-48	265	26	t	t	NOUN
bptjm-48	265	27	-	-	PUNCT
bptjm-48	265	28	cells	cell	NOUN
bptjm-48	265	29	to	to	PART
bptjm-48	265	30	enhance	enhance	VERB
bptjm-48	265	31	their	their	PRON
bptjm-48	265	32	ability	ability	NOUN
bptjm-48	265	33	to	to	PART
bptjm-48	265	34	target	target	VERB
bptjm-48	265	35	and	and	CCONJ
bptjm-48	265	36	attack	attack	NOUN
bptjm-48	265	37	cancer	cancer	NOUN
bptjm-48	265	38	cells	cell	NOUN
bptjm-48	265	39	.	.	PUNCT
bptjm-48	266	1	however	however	ADV
bptjm-48	266	2	,	,	PUNCT
bptjm-48	266	3	further	further	ADJ
bptjm-48	266	4	research	research	NOUN
bptjm-48	266	5	is	be	AUX
bptjm-48	266	6	needed	need	VERB
bptjm-48	266	7	to	to	PART
bptjm-48	266	8	optimize	optimize	VERB
bptjm-48	266	9	these	these	DET
bptjm-48	266	10	therapies	therapy	NOUN
bptjm-48	266	11	for	for	ADP
bptjm-48	266	12	solid	solid	ADJ
bptjm-48	266	13	tumors	tumor	NOUN
bptjm-48	266	14	like	like	ADP
bptjm-48	266	15	glioblastoma	glioblastoma	NOUN
bptjm-48	266	16	.	.	PUNCT
bptjm-48	267	1	to	to	PART
bptjm-48	267	2	further	far	ADV
bptjm-48	267	3	advance	advance	VERB
bptjm-48	267	4	glioblastoma	glioblastoma	NOUN
bptjm-48	267	5	treatment	treatment	NOUN
bptjm-48	267	6	,	,	PUNCT
bptjm-48	267	7	several	several	ADJ
bptjm-48	267	8	areas	area	NOUN
bptjm-48	267	9	of	of	ADP
bptjm-48	267	10	improvement	improvement	NOUN
bptjm-48	267	11	should	should	AUX
bptjm-48	267	12	be	be	AUX
bptjm-48	267	13	considered	consider	VERB
bptjm-48	267	14	.	.	PUNCT
bptjm-48	268	1	first	first	ADV
bptjm-48	268	2	,	,	PUNCT
bptjm-48	268	3	optimization	optimization	NOUN
bptjm-48	268	4	of	of	ADP
bptjm-48	268	5	sequencing	sequence	VERB
bptjm-48	268	6	methods	method	NOUN
bptjm-48	268	7	,	,	PUNCT
bptjm-48	268	8	such	such	ADJ
bptjm-48	268	9	as	as	ADP
bptjm-48	268	10	whole	whole	ADJ
bptjm-48	268	11	-	-	PUNCT
bptjm-48	268	12	genome	genome	NOUN
bptjm-48	268	13	sequencing	sequencing	NOUN
bptjm-48	268	14	(	(	PUNCT
bptjm-48	268	15	wgs	wgs	NOUN
bptjm-48	268	16	)	)	PUNCT
bptjm-48	268	17	,	,	PUNCT
bptjm-48	268	18	whole	whole	ADJ
bptjm-48	268	19	-	-	PUNCT
bptjm-48	268	20	exome	exome	NOUN
bptjm-48	268	21	sequencing	sequencing	NOUN
bptjm-48	268	22	(	(	PUNCT
bptjm-48	268	23	wes	wes	PROPN
bptjm-48	268	24	)	)	PUNCT
bptjm-48	268	25	,	,	PUNCT
bptjm-48	268	26	and	and	CCONJ
bptjm-48	268	27	next	next	ADJ
bptjm-48	268	28	-	-	PUNCT
bptjm-48	268	29	generation	generation	NOUN
bptjm-48	268	30	sequencing	sequencing	NOUN
bptjm-48	268	31	(	(	PUNCT
bptjm-48	268	32	ngs	ng	NOUN
bptjm-48	268	33	)	)	PUNCT
bptjm-48	268	34	,	,	PUNCT
bptjm-48	268	35	can	can	AUX
bptjm-48	268	36	enhance	enhance	VERB
bptjm-48	268	37	the	the	DET
bptjm-48	268	38	identi	identi	NOUN
bptjm-48	268	39	�	�	PROPN
bptjm-48	268	40	cation	cation	NOUN
bptjm-48	268	41	of	of	ADP
bptjm-48	268	42	neoantigens	neoantigen	NOUN
bptjm-48	268	43	and	and	CCONJ
bptjm-48	268	44	somatic	somatic	ADJ
bptjm-48	268	45	mutations	mutation	NOUN
bptjm-48	268	46	e	e	NOUN
bptjm-48	268	47	�	�	NOUN
bptjm-48	268	48	ciently	ciently	ADV
bptjm-48	268	49	in	in	ADP
bptjm-48	268	50	terms	term	NOUN
bptjm-48	268	51	of	of	ADP
bptjm-48	268	52	time	time	NOUN
bptjm-48	268	53	and	and	CCONJ
bptjm-48	268	54	cost	cost	NOUN
bptjm-48	268	55	.	.	PUNCT
bptjm-48	269	1	additionally	additionally	ADV
bptjm-48	269	2	,	,	PUNCT
bptjm-48	269	3	strategies	strategy	NOUN
bptjm-48	269	4	to	to	PART
bptjm-48	269	5	overcome	overcome	VERB
bptjm-48	269	6	immune	immune	ADJ
bptjm-48	269	7	evasion	evasion	NOUN
bptjm-48	269	8	mechanisms	mechanism	NOUN
bptjm-48	269	9	employed	employ	VERB
bptjm-48	269	10	by	by	ADP
bptjm-48	269	11	glioblastoma	glioblastoma	NOUN
bptjm-48	269	12	,	,	PUNCT
bptjm-48	269	13	such	such	ADJ
bptjm-48	269	14	as	as	ADP
bptjm-48	269	15	upregulation	upregulation	NOUN
bptjm-48	269	16	of	of	ADP
bptjm-48	269	17	immune	immune	ADJ
bptjm-48	269	18	checkpoint	checkpoint	NOUN
bptjm-48	269	19	molecules	molecule	NOUN
bptjm-48	269	20	,	,	PUNCT
bptjm-48	269	21	should	should	AUX
bptjm-48	269	22	be	be	AUX
bptjm-48	269	23	explored	explore	VERB
bptjm-48	269	24	.	.	PUNCT
bptjm-48	270	1	combination	combination	NOUN
bptjm-48	270	2	therapies	therapy	NOUN
bptjm-48	270	3	involving	involve	VERB
bptjm-48	270	4	neoantigen	neoantigen	NOUN
bptjm-48	270	5	-	-	PUNCT
bptjm-48	270	6	based	base	VERB
bptjm-48	270	7	vaccines	vaccine	NOUN
bptjm-48	270	8	,	,	PUNCT
bptjm-48	270	9	immune	immune	ADJ
bptjm-48	270	10	checkpoint	checkpoint	NOUN
bptjm-48	270	11	blockers	blocker	NOUN
bptjm-48	270	12	,	,	PUNCT
bptjm-48	270	13	and	and	CCONJ
bptjm-48	270	14	adoptive	adoptive	ADJ
bptjm-48	270	15	cellular	cellular	ADJ
bptjm-48	270	16	therapies	therapy	NOUN
bptjm-48	270	17	hold	hold	VERB
bptjm-48	270	18	promise	promise	NOUN
bptjm-48	270	19	in	in	ADP
bptjm-48	270	20	overcoming	overcome	VERB
bptjm-48	270	21	resistance	resistance	NOUN
bptjm-48	270	22	and	and	CCONJ
bptjm-48	270	23	enhancing	enhance	VERB
bptjm-48	270	24	treatment	treatment	NOUN
bptjm-48	270	25	responses	response	NOUN
bptjm-48	270	26	.	.	PUNCT
bptjm-48	271	1	in	in	ADP
bptjm-48	271	2	conclusion	conclusion	NOUN
bptjm-48	271	3	,	,	PUNCT
bptjm-48	271	4	the	the	DET
bptjm-48	271	5	development	development	NOUN
bptjm-48	271	6	and	and	CCONJ
bptjm-48	271	7	utilization	utilization	NOUN
bptjm-48	271	8	of	of	ADP
bptjm-48	271	9	neoantigen	neoantigen	NOUN
bptjm-48	271	10	-	-	PUNCT
bptjm-48	271	11	based	base	VERB
bptjm-48	271	12	vaccines	vaccine	NOUN
bptjm-48	271	13	,	,	PUNCT
bptjm-48	271	14	immune	immune	ADJ
bptjm-48	271	15	checkpoint	checkpoint	NOUN
bptjm-48	271	16	blockers	blocker	NOUN
bptjm-48	271	17	,	,	PUNCT
bptjm-48	271	18	and	and	CCONJ
bptjm-48	271	19	adoptive	adoptive	ADJ
bptjm-48	271	20	cellular	cellular	ADJ
bptjm-48	271	21	therapies	therapy	NOUN
bptjm-48	271	22	have	have	AUX
bptjm-48	271	23	opened	open	VERB
bptjm-48	271	24	new	new	ADJ
bptjm-48	271	25	avenues	avenue	NOUN
bptjm-48	271	26	for	for	ADP
bptjm-48	271	27	glioblastoma	glioblastoma	NOUN
bptjm-48	271	28	treatment	treatment	NOUN
bptjm-48	271	29	.	.	PUNCT
bptjm-48	272	1	while	while	SCONJ
bptjm-48	272	2	these	these	DET
bptjm-48	272	3	treatment	treatment	NOUN
bptjm-48	272	4	methods	method	NOUN
bptjm-48	272	5	have	have	AUX
bptjm-48	272	6	demonstrated	demonstrate	VERB
bptjm-48	272	7	e	e	PROPN
bptjm-48	272	8	�	�	NOUN
bptjm-48	272	9	cacy	cacy	NOUN
bptjm-48	272	10	,	,	PUNCT
bptjm-48	272	11	ongoing	ongoing	ADJ
bptjm-48	272	12	research	research	NOUN
bptjm-48	272	13	and	and	CCONJ
bptjm-48	272	14	improvements	improvement	NOUN
bptjm-48	272	15	in	in	ADP
bptjm-48	272	16	sequencing	sequence	VERB
bptjm-48	272	17	techniques	technique	NOUN
bptjm-48	272	18	,	,	PUNCT
bptjm-48	272	19	combination	combination	NOUN
bptjm-48	272	20	therapies	therapy	NOUN
bptjm-48	272	21	,	,	PUNCT
bptjm-48	272	22	and	and	CCONJ
bptjm-48	272	23	immunomodulatory	immunomodulatory	ADJ
bptjm-48	272	24	strategies	strategy	NOUN
bptjm-48	272	25	are	be	AUX
bptjm-48	272	26	crucial	crucial	ADJ
bptjm-48	272	27	for	for	ADP
bptjm-48	272	28	achieving	achieve	VERB
bptjm-48	272	29	further	further	ADJ
bptjm-48	272	30	breakthroughs	breakthrough	NOUN
bptjm-48	272	31	.	.	PUNCT
bptjm-48	273	1	the	the	DET
bptjm-48	273	2	integration	integration	NOUN
bptjm-48	273	3	of	of	ADP
bptjm-48	273	4	personalized	personalized	ADJ
bptjm-48	273	5	medicine	medicine	NOUN
bptjm-48	273	6	approaches	approach	NOUN
bptjm-48	273	7	and	and	CCONJ
bptjm-48	273	8	a	a	DET
bptjm-48	273	9	deeper	deep	ADJ
bptjm-48	273	10	understanding	understanding	NOUN
bptjm-48	273	11	of	of	ADP
bptjm-48	273	12	the	the	DET
bptjm-48	273	13	complex	complex	ADJ
bptjm-48	273	14	interplay	interplay	NOUN
bptjm-48	273	15	between	between	ADP
bptjm-48	273	16	the	the	DET
bptjm-48	273	17	tumor	tumor	NOUN
bptjm-48	273	18	microenvironment	microenvironment	NOUN
bptjm-48	273	19	and	and	CCONJ
bptjm-48	273	20	the	the	DET
bptjm-48	273	21	immune	immune	ADJ
bptjm-48	273	22	system	system	NOUN
bptjm-48	273	23	will	will	AUX
bptjm-48	273	24	contribute	contribute	VERB
bptjm-48	273	25	to	to	ADP
bptjm-48	273	26	the	the	DET
bptjm-48	273	27	development	development	NOUN
bptjm-48	273	28	of	of	ADP
bptjm-48	273	29	more	more	ADJ
bptjm-48	273	30	e	e	NOUN
bptjm-48	273	31	�	�	NOUN
bptjm-48	273	32	ective	ective	ADJ
bptjm-48	273	33	and	and	CCONJ
bptjm-48	273	34	targeted	target	VERB
bptjm-48	273	35	therapies	therapy	NOUN
bptjm-48	273	36	for	for	ADP
bptjm-48	273	37	glioblastoma	glioblastoma	NOUN
bptjm-48	273	38	patients	patient	NOUN
bptjm-48	273	39	,	,	PUNCT
bptjm-48	273	40	ultimately	ultimately	ADV
bptjm-48	273	41	improving	improve	VERB
bptjm-48	273	42	their	their	PRON
bptjm-48	273	43	prognosis	prognosis	NOUN
bptjm-48	273	44	and	and	CCONJ
bptjm-48	273	45	quality	quality	NOUN
bptjm-48	273	46	of	of	ADP
bptjm-48	273	47	life	life	NOUN
bptjm-48	273	48	.	.	PUNCT
bptjm-48	274	1	berkeley	berkeley	PROPN
bptjm-48	274	2	pharma	pharma	PROPN
bptjm-48	274	3	tech	tech	PROPN
bptjm-48	274	4	journal	journal	NOUN
bptjm-48	274	5	of	of	ADP
bptjm-48	274	6	medicine	medicine	NOUN
bptjm-48	274	7	|	|	ADV
bptjm-48	274	8	59	59	NUM
bptjm-48	274	9	references	reference	NOUN
bptjm-48	274	10	1	1	NUM
bptjm-48	274	11	.	.	PUNCT
bptjm-48	275	1	wirsching	wirsche	VERB
bptjm-48	275	2	hg	hg	NOUN
bptjm-48	275	3	,	,	PUNCT
bptjm-48	275	4	galanis	galanis	PROPN
bptjm-48	275	5	e	e	PROPN
bptjm-48	275	6	,	,	PUNCT
bptjm-48	275	7	weller	weller	NOUN
bptjm-48	275	8	m.	m.	NOUN
bptjm-48	275	9	glioblastoma.handb	glioblastoma.handb	NOUN
bptjm-48	275	10	clin	clin	PROPN
bptjm-48	275	11	neurol	neurol	PROPN
bptjm-48	275	12	.	.	PUNCT
bptjm-48	276	1	2016;134:381	2016;134:381	NUM
bptjm-48	276	2	-	-	SYM
bptjm-48	276	3	397	397	NUM
bptjm-48	276	4	.	.	PUNCT
bptjm-48	277	1	doi:10.1016	doi:10.1016	PROPN
bptjm-48	277	2	/	/	SYM
bptjm-48	277	3	b978	b978	PROPN
bptjm-48	277	4	-	-	PUNCT
bptjm-48	277	5	0	0	NUM
bptjm-48	277	6	-	-	PUNCT
bptjm-48	277	7	12	12	NUM
bptjm-48	277	8	-	-	PUNCT
bptjm-48	277	9	802997	802997	NUM
bptjm-48	277	10	-	-	PUNCT
bptjm-48	277	11	8.00023	8.00023	NUM
bptjm-48	277	12	-	-	SYM
bptjm-48	277	13	2	2	NUM
bptjm-48	277	14	2	2	NUM
bptjm-48	277	15	.	.	PUNCT
bptjm-48	277	16	glioblastoma	glioblastoma	NOUN
bptjm-48	277	17	(	(	PUNCT
bptjm-48	277	18	gbm	gbm	PROPN
bptjm-48	277	19	)	)	PUNCT
bptjm-48	277	20	american	american	ADJ
bptjm-48	277	21	brain	brain	PROPN
bptjm-48	277	22	tumor	tumor	PROPN
bptjm-48	277	23	association	association	PROPN
bptjm-48	277	24	|	|	ADV
bptjm-48	277	25	learnmore	learnmore	NOUN
bptjm-48	277	26	.	.	PUNCT
bptjm-48	278	1	published	publish	VERB
bptjm-48	278	2	august	august	PROPN
bptjm-48	278	3	22	22	NUM
bptjm-48	278	4	,	,	PUNCT
bptjm-48	278	5	2022	2022	NUM
bptjm-48	278	6	.	.	PUNCT
bptjm-48	279	1	accessed	access	VERB
bptjm-48	279	2	february	february	PROPN
bptjm-48	279	3	16	16	NUM
bptjm-48	279	4	,	,	PUNCT
bptjm-48	279	5	2023	2023	NUM
bptjm-48	279	6	.	.	PUNCT
bptjm-48	280	1	https://www.abta.org/tumor_types/glioblasto	https://www.abta.org/tumor_types/glioblasto	VERB
bptjm-48	280	2	ma	ma	NOUN
bptjm-48	280	3	-	-	PUNCT
bptjm-48	280	4	gbm/	gbm/	NOUN
bptjm-48	280	5	3	3	NUM
bptjm-48	280	6	.	.	PUNCT
bptjm-48	280	7	stoyanov	stoyanov	PROPN
bptjm-48	280	8	gs	gs	PROPN
bptjm-48	280	9	,	,	PUNCT
bptjm-48	280	10	dzhenkov	dzhenkov	PROPN
bptjm-48	280	11	d	d	X
bptjm-48	280	12	,	,	PUNCT
bptjm-48	280	13	ghenev	ghenev	PROPN
bptjm-48	280	14	p	p	PRON
bptjm-48	280	15	,	,	PUNCT
bptjm-48	280	16	iliev	iliev	ADP
bptjm-48	280	17	b	b	PROPN
bptjm-48	280	18	,	,	PUNCT
bptjm-48	280	19	enchev	enchev	PROPN
bptjm-48	280	20	y	y	PROPN
bptjm-48	280	21	,	,	PUNCT
bptjm-48	280	22	tonchev	tonchev	PROPN
bptjm-48	280	23	ab	ab	PROPN
bptjm-48	280	24	.	.	PROPN
bptjm-48	280	25	cell	cell	NOUN
bptjm-48	280	26	biology	biology	NOUN
bptjm-48	280	27	of	of	ADP
bptjm-48	280	28	glioblastoma	glioblastoma	NOUN
bptjm-48	280	29	multiforme	multiforme	NOUN
bptjm-48	280	30	:	:	PUNCT
bptjm-48	280	31	from	from	ADP
bptjm-48	280	32	basic	basic	ADJ
bptjm-48	280	33	science	science	NOUN
bptjm-48	280	34	to	to	ADP
bptjm-48	280	35	diagnosis	diagnosis	NOUN
bptjm-48	280	36	and	and	CCONJ
bptjm-48	280	37	treatment	treatment	NOUN
bptjm-48	280	38	.	.	PUNCT
bptjm-48	281	1	med	med	PROPN
bptjm-48	281	2	oncol	oncol	ADJ
bptjm-48	281	3	.	.	PUNCT
bptjm-48	282	1	2018;35(3):27	2018;35(3):27	X
bptjm-48	282	2	.	.	PUNCT
bptjm-48	282	3	doi:10.1007	doi:10.1007	PROPN
bptjm-48	282	4	/	/	SYM
bptjm-48	282	5	s12032	s12032	NUM
bptjm-48	282	6	-	-	PUNCT
bptjm-48	282	7	018	018	NUM
bptjm-48	282	8	-	-	PUNCT
bptjm-48	282	9	1083	1083	NUM
bptjm-48	282	10	-	-	SYM
bptjm-48	282	11	x	x	SYM
bptjm-48	282	12	4	4	PROPN
bptjm-48	282	13	.	.	NOUN
bptjm-48	282	14	tamimi	tamimi	PROPN
bptjm-48	282	15	af	af	PROPN
bptjm-48	282	16	,	,	PUNCT
bptjm-48	282	17	juweidm	juweidm	NOUN
bptjm-48	282	18	.	.	PUNCT
bptjm-48	283	1	epidemiology	epidemiology	NOUN
bptjm-48	283	2	and	and	CCONJ
bptjm-48	283	3	outcome	outcome	NOUN
bptjm-48	283	4	of	of	ADP
bptjm-48	283	5	glioblastoma	glioblastoma	NOUN
bptjm-48	283	6	.	.	PUNCT
bptjm-48	284	1	in	in	ADP
bptjm-48	284	2	:	:	PUNCT
bptjm-48	284	3	de	de	X
bptjm-48	284	4	vleeschouwer	vleeschouwer	X
bptjm-48	284	5	s	s	PROPN
bptjm-48	284	6	,	,	PUNCT
bptjm-48	284	7	ed	ed	NOUN
bptjm-48	284	8	.	.	PUNCT
bptjm-48	284	9	glioblastoma	glioblastoma	NOUN
bptjm-48	284	10	.	.	PUNCT
bptjm-48	285	1	codon	codon	NOUN
bptjm-48	285	2	publications	publication	NOUN
bptjm-48	285	3	;	;	PUNCT
bptjm-48	285	4	2017	2017	NUM
bptjm-48	285	5	.	.	PUNCT
bptjm-48	286	1	accessedmay	accessedmay	VERB
bptjm-48	286	2	3	3	NUM
bptjm-48	286	3	,	,	PUNCT
bptjm-48	286	4	2023	2023	NUM
bptjm-48	286	5	.	.	PUNCT
bptjm-48	287	1	http://www.ncbi.nlm.nih.gov/books/nbk47	http://www.ncbi.nlm.nih.gov/books/nbk47	NUM
bptjm-48	287	2	0003/	0003/	NOUN
bptjm-48	287	3	5	5	NUM
bptjm-48	287	4	.	.	NUM
bptjm-48	287	5	glioblastomamultiforme	glioblastomamultiforme	PROPN
bptjm-48	287	6	–	–	PUNCT
bptjm-48	287	7	symptoms	symptom	NOUN
bptjm-48	287	8	,	,	PUNCT
bptjm-48	287	9	diagnosis	diagnosis	NOUN
bptjm-48	287	10	and	and	CCONJ
bptjm-48	287	11	treatment	treatment	NOUN
bptjm-48	287	12	options	option	NOUN
bptjm-48	287	13	.	.	PUNCT
bptjm-48	288	1	accessed	access	VERB
bptjm-48	288	2	february	february	PROPN
bptjm-48	288	3	16	16	NUM
bptjm-48	288	4	,	,	PUNCT
bptjm-48	288	5	2023	2023	NUM
bptjm-48	288	6	.	.	PUNCT
bptjm-48	288	7	https://www.aans.org/	https://www.aans.org/	NOUN
bptjm-48	289	1	6	6	NUM
bptjm-48	289	2	.	.	PUNCT
bptjm-48	290	1	davis	davis	PROPN
bptjm-48	290	2	me	i	PRON
bptjm-48	290	3	.	.	PUNCT
bptjm-48	291	1	glioblastoma	glioblastoma	NOUN
bptjm-48	291	2	:	:	PUNCT
bptjm-48	291	3	overview	overview	NOUN
bptjm-48	291	4	of	of	ADP
bptjm-48	291	5	disease	disease	NOUN
bptjm-48	291	6	and	and	CCONJ
bptjm-48	291	7	treatment	treatment	NOUN
bptjm-48	291	8	.	.	PUNCT
bptjm-48	292	1	clin	clin	PROPN
bptjm-48	292	2	j	j	PROPN
bptjm-48	292	3	oncol	oncol	PROPN
bptjm-48	292	4	nurs	nur	VERB
bptjm-48	292	5	.	.	PUNCT
bptjm-48	293	1	2016;20(5):s2	2016;20(5):s2	NOUN
bptjm-48	293	2	-	-	PUNCT
bptjm-48	293	3	s8	s8	NOUN
bptjm-48	293	4	.	.	PUNCT
bptjm-48	294	1	doi:10.1188/16.cjon.s1.2	doi:10.1188/16.cjon.s1.2	NOUN
bptjm-48	294	2	-	-	NOUN
bptjm-48	294	3	8	8	NUM
bptjm-48	294	4	7	7	NUM
bptjm-48	294	5	.	.	PUNCT
bptjm-48	295	1	wang	wang	PROPN
bptjm-48	295	2	z	z	PROPN
bptjm-48	295	3	,	,	PUNCT
bptjm-48	295	4	peet	peet	PROPN
bptjm-48	295	5	np	np	PROPN
bptjm-48	295	6	,	,	PUNCT
bptjm-48	295	7	zhang	zhang	PROPN
bptjm-48	295	8	p	p	PROPN
bptjm-48	295	9	,	,	PUNCT
bptjm-48	295	10	jiang	jiang	PROPN
bptjm-48	295	11	y	y	PROPN
bptjm-48	295	12	,	,	PUNCT
bptjm-48	295	13	rong	rong	PROPN
bptjm-48	295	14	l.	l.	PROPN
bptjm-48	295	15	current	current	PROPN
bptjm-48	295	16	development	development	NOUN
bptjm-48	295	17	of	of	ADP
bptjm-48	295	18	glioblastoma	glioblastoma	NOUN
bptjm-48	295	19	therapeutic	therapeutic	ADJ
bptjm-48	295	20	agents	agent	NOUN
bptjm-48	295	21	.	.	PUNCT
bptjm-48	296	1	molecular	molecular	ADJ
bptjm-48	296	2	cancer	cancer	NOUN
bptjm-48	296	3	therapeutics	therapeutic	NOUN
bptjm-48	296	4	.	.	PUNCT
bptjm-48	297	1	2021;20(9):1521	2021;20(9):1521	NUM
bptjm-48	297	2	-	-	SYM
bptjm-48	297	3	1532	1532	NUM
bptjm-48	297	4	.	.	PUNCT
bptjm-48	298	1	doi:10.1158/1535	doi:10.1158/1535	NOUN
bptjm-48	298	2	-	-	PUNCT
bptjm-48	298	3	7163.mct-21	7163.mct-21	PROPN
bptjm-48	298	4	-	-	PUNCT
bptjm-48	298	5	0159	0159	NUM
bptjm-48	298	6	8	8	NUM
bptjm-48	298	7	.	.	PUNCT
bptjm-48	298	8	md	md	PROPN
bptjm-48	298	9	pyw	pyw	PROPN
bptjm-48	298	10	.	.	PUNCT
bptjm-48	299	1	individualized	individualized	ADJ
bptjm-48	299	2	screening	screening	NOUN
bptjm-48	299	3	trial	trial	NOUN
bptjm-48	299	4	of	of	ADP
bptjm-48	299	5	innovative	innovative	ADJ
bptjm-48	299	6	glioblastoma	glioblastoma	NOUN
bptjm-48	299	7	therapy	therapy	NOUN
bptjm-48	299	8	(	(	PUNCT
bptjm-48	299	9	insight	insight	NOUN
bptjm-48	299	10	)	)	PUNCT
bptjm-48	299	11	.	.	PUNCT
bptjm-48	300	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	300	2	;	;	PUNCT
bptjm-48	300	3	2022	2022	NUM
bptjm-48	300	4	.	.	PUNCT
bptjm-48	301	1	accessedmay	accessedmay	VERB
bptjm-48	301	2	5	5	NUM
bptjm-48	301	3	,	,	PUNCT
bptjm-48	301	4	2023	2023	NUM
bptjm-48	301	5	.	.	PUNCT
bptjm-48	302	1	https://clinicaltrials.gov/ct2/show/nct02977780	https://clinicaltrials.gov/ct2/show/nct02977780	PROPN
bptjm-48	302	2	9	9	NUM
bptjm-48	302	3	.	.	X
bptjm-48	302	4	de	de	PROPN
bptjm-48	302	5	plaen	plaen	PROPN
bptjm-48	302	6	e	e	PROPN
bptjm-48	302	7	,	,	PUNCT
bptjm-48	302	8	lurquin	lurquin	PROPN
bptjm-48	302	9	c	c	NOUN
bptjm-48	302	10	,	,	PUNCT
bptjm-48	302	11	van	van	PROPN
bptjm-48	302	12	pel	pel	PROPN
bptjm-48	302	13	a	a	PROPN
bptjm-48	302	14	,	,	PUNCT
bptjm-48	302	15	et	et	PROPN
bptjm-48	302	16	al	al	PROPN
bptjm-48	302	17	.	.	PROPN
bptjm-48	302	18	immunogenic	immunogenic	ADJ
bptjm-48	302	19	(	(	PUNCT
bptjm-48	302	20	tum-	tum-	NOUN
bptjm-48	302	21	)	)	PUNCT
bptjm-48	302	22	variants	variant	NOUN
bptjm-48	302	23	of	of	ADP
bptjm-48	302	24	mouse	mouse	NOUN
bptjm-48	302	25	tumor	tumor	NOUN
bptjm-48	302	26	p815	p815	NOUN
bptjm-48	302	27	:	:	PUNCT
bptjm-48	302	28	cloning	cloning	NOUN
bptjm-48	302	29	of	of	ADP
bptjm-48	302	30	the	the	DET
bptjm-48	302	31	gene	gene	NOUN
bptjm-48	302	32	of	of	ADP
bptjm-48	302	33	tumantigen	tumantigen	PROPN
bptjm-48	302	34	p91a	p91a	PROPN
bptjm-48	302	35	and	and	CCONJ
bptjm-48	302	36	identi	identi	PROPN
bptjm-48	302	37	�	�	PROPN
bptjm-48	302	38	cation	cation	NOUN
bptjm-48	302	39	of	of	ADP
bptjm-48	302	40	the	the	DET
bptjm-48	302	41	tummutation	tummutation	NOUN
bptjm-48	302	42	.	.	PUNCT
bptjm-48	303	1	proc	proc	PROPN
bptjm-48	303	2	natl	natl	PROPN
bptjm-48	303	3	acad	acad	PROPN
bptjm-48	303	4	sci	sci	PROPN
bptjm-48	303	5	u	u	PROPN
bptjm-48	303	6	s	s	NOUN
bptjm-48	303	7	a.	a.	NOUN
bptjm-48	303	8	1988;85(7):2274	1988;85(7):2274	NUM
bptjm-48	303	9	-	-	PUNCT
bptjm-48	303	10	2278	2278	NUM
bptjm-48	303	11	.	.	PUNCT
bptjm-48	304	1	doi:10.1073	doi:10.1073	NOUN
bptjm-48	304	2	/	/	SYM
bptjm-48	304	3	pnas.85.7.2274	pnas.85.7.2274	PROPN
bptjm-48	304	4	10	10	NUM
bptjm-48	304	5	.	.	PUNCT
bptjm-48	305	1	uebel	uebel	PROPN
bptjm-48	305	2	s	s	PROPN
bptjm-48	305	3	,	,	PUNCT
bptjm-48	305	4	tampé	tampé	PROPN
bptjm-48	305	5	r.	r.	PROPN
bptjm-48	305	6	speci	speci	PROPN
bptjm-48	305	7	�	�	PROPN
bptjm-48	305	8	city	city	NOUN
bptjm-48	305	9	of	of	ADP
bptjm-48	305	10	the	the	DET
bptjm-48	305	11	proteasome	proteasome	NOUN
bptjm-48	305	12	and	and	CCONJ
bptjm-48	305	13	the	the	DET
bptjm-48	305	14	tap	tap	NOUN
bptjm-48	305	15	transporter	transporter	NOUN
bptjm-48	305	16	.	.	PUNCT
bptjm-48	306	1	curr	curr	PROPN
bptjm-48	306	2	opin	opin	PROPN
bptjm-48	306	3	immunol	immunol	NOUN
bptjm-48	306	4	.	.	PUNCT
bptjm-48	307	1	1999;11(2):203	1999;11(2):203	NUM
bptjm-48	307	2	-	-	PUNCT
bptjm-48	307	3	208	208	NUM
bptjm-48	307	4	.	.	PUNCT
bptjm-48	307	5	doi:10.1016	doi:10.1016	PROPN
bptjm-48	307	6	/	/	SYM
bptjm-48	307	7	s0952	s0952	PROPN
bptjm-48	307	8	-	-	PUNCT
bptjm-48	307	9	7915(99)80034	7915(99)80034	NOUN
bptjm-48	307	10	-	-	PUNCT
bptjm-48	307	11	x	x	SYM
bptjm-48	307	12	11	11	NUM
bptjm-48	307	13	.	.	PUNCT
bptjm-48	308	1	hutchison	hutchison	PROPN
bptjm-48	308	2	s	s	PROPN
bptjm-48	308	3	,	,	PUNCT
bptjm-48	308	4	pritchard	pritchard	PROPN
bptjm-48	308	5	al	al	PROPN
bptjm-48	308	6	.	.	PROPN
bptjm-48	309	1	identifying	identify	VERB
bptjm-48	309	2	neoantigens	neoantigen	NOUN
bptjm-48	309	3	for	for	ADP
bptjm-48	309	4	use	use	NOUN
bptjm-48	309	5	in	in	ADP
bptjm-48	309	6	immunotherapy	immunotherapy	NOUN
bptjm-48	309	7	.	.	PUNCT
bptjm-48	310	1	mammgenome	mammgenome	NOUN
bptjm-48	310	2	.	.	PUNCT
bptjm-48	311	1	2018;29(11	2018;29(11	NUM
bptjm-48	311	2	-	-	PUNCT
bptjm-48	311	3	12):714	12):714	NUM
bptjm-48	311	4	-	-	PUNCT
bptjm-48	311	5	730	730	NUM
bptjm-48	311	6	.	.	PUNCT
bptjm-48	311	7	doi:10.1007	doi:10.1007	PROPN
bptjm-48	311	8	/	/	SYM
bptjm-48	311	9	s00335	s00335	NOUN
bptjm-48	311	10	-	-	PUNCT
bptjm-48	311	11	018	018	NUM
bptjm-48	311	12	-	-	PUNCT
bptjm-48	311	13	9771	9771	NUM
bptjm-48	311	14	-	-	SYM
bptjm-48	311	15	6	6	NUM
bptjm-48	311	16	12	12	NUM
bptjm-48	311	17	.	.	PUNCT
bptjm-48	312	1	efremovam	efremovam	PROPN
bptjm-48	312	2	,	,	PUNCT
bptjm-48	312	3	finotello	finotello	PROPN
bptjm-48	312	4	f	f	X
bptjm-48	312	5	,	,	PUNCT
bptjm-48	312	6	rieder	rieder	NOUN
bptjm-48	312	7	d	d	PROPN
bptjm-48	312	8	,	,	PUNCT
bptjm-48	312	9	trajanoski	trajanoski	PROPN
bptjm-48	312	10	z.	z.	PROPN
bptjm-48	312	11	neoantigens	neoantigens	PROPN
bptjm-48	312	12	generated	generate	VERB
bptjm-48	312	13	by	by	ADP
bptjm-48	312	14	individual	individual	ADJ
bptjm-48	312	15	mutations	mutation	NOUN
bptjm-48	312	16	and	and	CCONJ
bptjm-48	312	17	their	their	PRON
bptjm-48	312	18	role	role	NOUN
bptjm-48	312	19	in	in	ADP
bptjm-48	312	20	cancer	cancer	NOUN
bptjm-48	312	21	immunity	immunity	NOUN
bptjm-48	312	22	and	and	CCONJ
bptjm-48	312	23	immunotherapy	immunotherapy	NOUN
bptjm-48	312	24	.	.	PUNCT
bptjm-48	313	1	front	front	ADJ
bptjm-48	313	2	immunol	immunol	NOUN
bptjm-48	313	3	.	.	PUNCT
bptjm-48	314	1	2017;8:1679	2017;8:1679	PROPN
bptjm-48	314	2	.	.	PUNCT
bptjm-48	315	1	published	publish	VERB
bptjm-48	315	2	2017	2017	NUM
bptjm-48	315	3	nov	nov	PROPN
bptjm-48	315	4	28	28	NUM
bptjm-48	315	5	.	.	PUNCT
bptjm-48	316	1	doi:10.3389/	doi:10.3389/	NUM
bptjm-48	316	2	�	�	PROPN
bptjm-48	316	3	mmu.2017.01679	mmu.2017.01679	PROPN
bptjm-48	316	4	13	13	NUM
bptjm-48	316	5	.	.	PUNCT
bptjm-48	317	1	correale	correale	PROPN
bptjm-48	317	2	p	p	PROPN
bptjm-48	317	3	,	,	PUNCT
bptjm-48	317	4	walmsley	walmsley	PROPN
bptjm-48	317	5	k	k	PROPN
bptjm-48	317	6	,	,	PUNCT
bptjm-48	317	7	nieroda	nieroda	NOUN
bptjm-48	317	8	c	c	NOUN
bptjm-48	317	9	,	,	PUNCT
bptjm-48	317	10	et	et	PROPN
bptjm-48	317	11	al	al	PROPN
bptjm-48	317	12	.	.	PROPN
bptjm-48	318	1	in	in	ADP
bptjm-48	318	2	vitro	vitro	X
bptjm-48	318	3	generation	generation	NOUN
bptjm-48	318	4	of	of	ADP
bptjm-48	318	5	human	human	ADJ
bptjm-48	318	6	cytotoxic	cytotoxic	ADJ
bptjm-48	318	7	t	t	NOUN
bptjm-48	318	8	lymphocytes	lymphocyte	VERB
bptjm-48	318	9	speci	speci	PROPN
bptjm-48	318	10	�	�	PROPN
bptjm-48	318	11	c	c	NOUN
bptjm-48	318	12	for	for	ADP
bptjm-48	318	13	peptides	peptide	NOUN
bptjm-48	318	14	derived	derive	VERB
bptjm-48	318	15	from	from	ADP
bptjm-48	318	16	prostate	prostate	NOUN
bptjm-48	318	17	-	-	PUNCT
bptjm-48	318	18	speci	speci	NOUN
bptjm-48	318	19	�	�	PROPN
bptjm-48	318	20	c	c	NOUN
bptjm-48	318	21	antigen	antigen	NOUN
bptjm-48	318	22	.	.	PUNCT
bptjm-48	319	1	j	j	PROPN
bptjm-48	319	2	natl	natl	PROPN
bptjm-48	319	3	cancer	cancer	PROPN
bptjm-48	319	4	inst	inst	PROPN
bptjm-48	319	5	.	.	PUNCT
bptjm-48	320	1	1997;89(4):293	1997;89(4):293	NUM
bptjm-48	320	2	-	-	PUNCT
bptjm-48	320	3	300	300	NUM
bptjm-48	320	4	.	.	PUNCT
bptjm-48	320	5	doi:10.1093	doi:10.1093	NOUN
bptjm-48	320	6	/	/	SYM
bptjm-48	320	7	jnci/89.4.293	jnci/89.4.293	PROPN
bptjm-48	320	8	14	14	NUM
bptjm-48	320	9	.	.	PUNCT
bptjm-48	321	1	guo	guo	PROPN
bptjm-48	321	2	z	z	PROPN
bptjm-48	321	3	,	,	PUNCT
bptjm-48	321	4	yuan	yuan	PROPN
bptjm-48	321	5	y	y	PROPN
bptjm-48	321	6	,	,	PUNCT
bptjm-48	321	7	chen	chen	PROPN
bptjm-48	321	8	c	c	PROPN
bptjm-48	321	9	,	,	PUNCT
bptjm-48	321	10	et	et	PROPN
bptjm-48	321	11	al	al	PROPN
bptjm-48	321	12	.	.	PUNCT
bptjm-48	322	1	durable	durable	ADJ
bptjm-48	322	2	complete	complete	ADJ
bptjm-48	322	3	response	response	NOUN
bptjm-48	322	4	to	to	ADP
bptjm-48	322	5	neoantigen	neoantigen	ADV
bptjm-48	322	6	-	-	PUNCT
bptjm-48	322	7	loaded	load	VERB
bptjm-48	322	8	dendritic	dendritic	ADJ
bptjm-48	322	9	-	-	PUNCT
bptjm-48	322	10	cell	cell	NOUN
bptjm-48	322	11	vaccine	vaccine	NOUN
bptjm-48	322	12	following	follow	VERB
bptjm-48	322	13	anti	anti	ADJ
bptjm-48	322	14	-	-	ADJ
bptjm-48	322	15	pd-1	pd-1	ADJ
bptjm-48	322	16	therapy	therapy	NOUN
bptjm-48	322	17	in	in	ADP
bptjm-48	322	18	metastatic	metastatic	ADJ
bptjm-48	322	19	gastric	gastric	ADJ
bptjm-48	322	20	cancer	cancer	NOUN
bptjm-48	322	21	.	.	PUNCT
bptjm-48	323	1	npj	npj	PROPN
bptjm-48	323	2	precis	precis	PROPN
bptjm-48	323	3	onc	onc	PROPN
bptjm-48	323	4	.	.	PUNCT
bptjm-48	324	1	2022;6(1):1	2022;6(1):1	NOUN
bptjm-48	324	2	-	-	PUNCT
bptjm-48	324	3	7	7	NUM
bptjm-48	324	4	.	.	PUNCT
bptjm-48	324	5	doi:10.1038	doi:10.1038	NOUN
bptjm-48	324	6	/	/	SYM
bptjm-48	324	7	s41698	s41698	NOUN
bptjm-48	324	8	-	-	PUNCT
bptjm-48	324	9	022	022	NUM
bptjm-48	324	10	-	-	PUNCT
bptjm-48	324	11	00279	00279	NUM
bptjm-48	324	12	-	-	SYM
bptjm-48	324	13	3	3	NUM
bptjm-48	324	14	berkeley	berkeley	PROPN
bptjm-48	324	15	pharma	pharma	PROPN
bptjm-48	324	16	tech	tech	NOUN
bptjm-48	324	17	journal	journal	NOUN
bptjm-48	324	18	of	of	ADP
bptjm-48	324	19	medicine	medicine	NOUN
bptjm-48	325	1	|	|	ADV
bptjm-48	325	2	60	60	NUM
bptjm-48	326	1	https://doi.org/10.1016/b978-0-12-802997-8.00023-2	https://doi.org/10.1016/b978-0-12-802997-8.00023-2	PROPN
bptjm-48	326	2	https://www.abta.org/tumor_types/glioblastoma-gbm/	https://www.abta.org/tumor_types/glioblastoma-gbm/	NOUN
bptjm-48	326	3	https://www.abta.org/tumor_types/glioblastoma-gbm/	https://www.abta.org/tumor_types/glioblastoma-gbm/	NOUN
bptjm-48	326	4	https://www.abta.org/tumor_types/glioblastoma-gbm/	https://www.abta.org/tumor_types/glioblastoma-gbm/	NOUN
bptjm-48	326	5	http://www.ncbi.nlm.nih.gov/books/nbk470003/	http://www.ncbi.nlm.nih.gov/books/nbk470003/	ADJ
bptjm-48	326	6	http://www.ncbi.nlm.nih.gov/books/nbk470003/	http://www.ncbi.nlm.nih.gov/books/nbk470003/	ADJ
bptjm-48	326	7	http://www.ncbi.nlm.nih.gov/books/nbk470003/	http://www.ncbi.nlm.nih.gov/books/nbk470003/	ADJ
bptjm-48	326	8	https://www.aans.org/	https://www.aans.org/	ADJ
bptjm-48	326	9	https://doi.org/10.1188/16.cjon.s1.2-8	https://doi.org/10.1188/16.cjon.s1.2-8	NOUN
bptjm-48	326	10	https://doi.org/10.1158/1535-7163.mct-21-0159	https://doi.org/10.1158/1535-7163.mct-21-0159	PRON
bptjm-48	326	11	https://clinicaltrials.gov/ct2/show/nct02977780	https://clinicaltrials.gov/ct2/show/nct02977780	X
bptjm-48	326	12	https://clinicaltrials.gov/ct2/show/nct02977780	https://clinicaltrials.gov/ct2/show/nct02977780	PROPN
bptjm-48	326	13	15	15	NUM
bptjm-48	326	14	.	.	PUNCT
bptjm-48	326	15	malonis	malonis	PROPN
bptjm-48	326	16	rj	rj	PROPN
bptjm-48	326	17	,	,	PUNCT
bptjm-48	326	18	lai	lai	PROPN
bptjm-48	326	19	jr	jr	PROPN
bptjm-48	326	20	,	,	PUNCT
bptjm-48	326	21	vergnolle	vergnolle	PROPN
bptjm-48	326	22	o.	o.	PROPN
bptjm-48	326	23	peptide	peptide	NOUN
bptjm-48	326	24	-	-	PUNCT
bptjm-48	326	25	based	base	VERB
bptjm-48	326	26	vaccines	vaccine	NOUN
bptjm-48	326	27	:	:	PUNCT
bptjm-48	326	28	current	current	ADJ
bptjm-48	326	29	progress	progress	NOUN
bptjm-48	326	30	and	and	CCONJ
bptjm-48	326	31	future	future	ADJ
bptjm-48	326	32	challenges	challenge	NOUN
bptjm-48	326	33	.	.	PUNCT
bptjm-48	327	1	chem	chem	PROPN
bptjm-48	327	2	rev	rev	VERB
bptjm-48	327	3	.	.	PUNCT
bptjm-48	328	1	2020;120(6):3210	2020;120(6):3210	NUM
bptjm-48	328	2	-	-	SYM
bptjm-48	328	3	3229	3229	NUM
bptjm-48	328	4	.	.	PUNCT
bptjm-48	329	1	doi:10.1021	doi:10.1021	ADJ
bptjm-48	329	2	/	/	SYM
bptjm-48	329	3	acs.chemrev.9b00472	acs.chemrev.9b00472	PROPN
bptjm-48	329	4	16	16	NUM
bptjm-48	329	5	.	.	PUNCT
bptjm-48	330	1	li	li	PROPN
bptjm-48	330	2	w	w	PROPN
bptjm-48	330	3	,	,	PUNCT
bptjm-48	330	4	joshi	joshi	PROPN
bptjm-48	330	5	md	md	PROPN
bptjm-48	330	6	,	,	PUNCT
bptjm-48	330	7	singhania	singhania	PROPN
bptjm-48	330	8	s	s	PROPN
bptjm-48	330	9	,	,	PUNCT
bptjm-48	330	10	ramsey	ramsey	PROPN
bptjm-48	330	11	kh	kh	PROPN
bptjm-48	330	12	,	,	PUNCT
bptjm-48	330	13	murthy	murthy	PROPN
bptjm-48	330	14	ak	ak	PROPN
bptjm-48	330	15	.	.	PROPN
bptjm-48	330	16	peptide	peptide	PROPN
bptjm-48	330	17	vaccine	vaccine	NOUN
bptjm-48	330	18	:	:	PUNCT
bptjm-48	330	19	progress	progress	NOUN
bptjm-48	330	20	and	and	CCONJ
bptjm-48	330	21	challenges.vaccines	challenges.vaccine	NOUN
bptjm-48	330	22	(	(	PUNCT
bptjm-48	330	23	basel	basel	PROPN
bptjm-48	330	24	)	)	PUNCT
bptjm-48	330	25	.	.	PUNCT
bptjm-48	331	1	2014;2(3):515	2014;2(3):515	NUM
bptjm-48	331	2	-	-	SYM
bptjm-48	331	3	536	536	NUM
bptjm-48	331	4	.	.	PUNCT
bptjm-48	332	1	doi:10.3390	doi:10.3390	NOUN
bptjm-48	332	2	/	/	SYM
bptjm-48	332	3	vaccines2030515	vaccines2030515	PROPN
bptjm-48	332	4	17	17	NUM
bptjm-48	332	5	.	.	PUNCT
bptjm-48	333	1	wang	wang	PROPN
bptjm-48	333	2	c	c	PROPN
bptjm-48	333	3	,	,	PUNCT
bptjm-48	333	4	yum	yum	INTJ
bptjm-48	333	5	,	,	PUNCT
bptjm-48	333	6	zhangw	zhangw	NOUN
bptjm-48	333	7	.	.	PUNCT
bptjm-48	334	1	neoantigen	neoantigen	PROPN
bptjm-48	334	2	discovery	discovery	PROPN
bptjm-48	334	3	and	and	CCONJ
bptjm-48	334	4	applications	application	NOUN
bptjm-48	334	5	in	in	ADP
bptjm-48	334	6	glioblastoma	glioblastoma	NOUN
bptjm-48	334	7	:	:	PUNCT
bptjm-48	334	8	an	an	DET
bptjm-48	334	9	immunotherapy	immunotherapy	NOUN
bptjm-48	334	10	perspective	perspective	NOUN
bptjm-48	334	11	.	.	PUNCT
bptjm-48	335	1	cancer	cancer	NOUN
bptjm-48	335	2	letters	letter	NOUN
bptjm-48	335	3	.	.	PUNCT
bptjm-48	336	1	2022;550:215945	2022;550:215945	X
bptjm-48	336	2	.	.	PUNCT
bptjm-48	337	1	doi:10.1016	doi:10.1016	PROPN
bptjm-48	337	2	/	/	SYM
bptjm-48	337	3	j.canlet.2022.215945	j.canlet.2022.215945	PROPN
bptjm-48	337	4	18	18	NUM
bptjm-48	337	5	.	.	PUNCT
bptjm-48	338	1	3wes	3wes	NUM
bptjm-48	338	2	vs	vs	ADP
bptjm-48	338	3	wgs	wgs	NOUN
bptjm-48	338	4	vs	vs	ADP
bptjm-48	338	5	custom	custom	NOUN
bptjm-48	338	6	panels	panel	NOUN
bptjm-48	338	7	.	.	PUNCT
bptjm-48	339	1	sequencing	sequence	VERB
bptjm-48	339	2	.	.	PUNCT
bptjm-48	340	1	accessedmarch	accessedmarch	PROPN
bptjm-48	340	2	23	23	NUM
bptjm-48	340	3	,	,	PUNCT
bptjm-48	340	4	2023	2023	NUM
bptjm-48	340	5	.	.	PUNCT
bptjm-48	341	1	https://sequencing.roche.com/us/en/article-listing/weswgs-custom.html	https://sequencing.roche.com/us/en/article-listing/weswgs-custom.html	PROPN
bptjm-48	341	2	19	19	NUM
bptjm-48	341	3	.	.	PUNCT
bptjm-48	341	4	behjati	behjati	PROPN
bptjm-48	341	5	s	s	PROPN
bptjm-48	341	6	,	,	PUNCT
bptjm-48	341	7	tarpey	tarpey	NOUN
bptjm-48	341	8	ps	ps	NOUN
bptjm-48	341	9	.	.	PUNCT
bptjm-48	342	1	what	what	PRON
bptjm-48	342	2	is	be	AUX
bptjm-48	342	3	next	next	ADJ
bptjm-48	342	4	generation	generation	NOUN
bptjm-48	342	5	sequencing	sequence	VERB
bptjm-48	342	6	?	?	PUNCT
bptjm-48	343	1	arch	arch	NOUN
bptjm-48	343	2	dis	dis	PROPN
bptjm-48	343	3	child	child	PROPN
bptjm-48	343	4	educ	educ	VERB
bptjm-48	343	5	pract	pract	PROPN
bptjm-48	343	6	ed	ed	NOUN
bptjm-48	343	7	.	.	PUNCT
bptjm-48	344	1	2013;98(6):236	2013;98(6):236	NUM
bptjm-48	344	2	-	-	SYM
bptjm-48	344	3	238	238	NUM
bptjm-48	344	4	.	.	PUNCT
bptjm-48	345	1	doi:10.1136	doi:10.1136	NOUN
bptjm-48	345	2	/	/	SYM
bptjm-48	345	3	archdischild-2013	archdischild-2013	NOUN
bptjm-48	345	4	-	-	PUNCT
bptjm-48	345	5	304340	304340	NUM
bptjm-48	345	6	20	20	NUM
bptjm-48	345	7	.	.	PUNCT
bptjm-48	346	1	hilf	hilf	PROPN
bptjm-48	346	2	n	n	CCONJ
bptjm-48	346	3	,	,	PUNCT
bptjm-48	346	4	kuttru	kuttru	PROPN
bptjm-48	346	5	�	�	PROPN
bptjm-48	346	6	-coqui	-coqui	NOUN
bptjm-48	346	7	s	s	PART
bptjm-48	346	8	,	,	PUNCT
bptjm-48	346	9	frenzel	frenzel	ADJ
bptjm-48	346	10	k	k	PROPN
bptjm-48	346	11	,	,	PUNCT
bptjm-48	346	12	et	et	PROPN
bptjm-48	346	13	al	al	PROPN
bptjm-48	346	14	.	.	PROPN
bptjm-48	347	1	actively	actively	ADV
bptjm-48	347	2	personalized	personalize	VERB
bptjm-48	347	3	vaccination	vaccination	NOUN
bptjm-48	347	4	trial	trial	NOUN
bptjm-48	347	5	for	for	ADP
bptjm-48	347	6	newly	newly	ADV
bptjm-48	347	7	diagnosed	diagnose	VERB
bptjm-48	347	8	glioblastoma.nature	glioblastoma.nature	NOUN
bptjm-48	347	9	.	.	PUNCT
bptjm-48	348	1	2019;565(7738):240	2019;565(7738):240	NUM
bptjm-48	348	2	-	-	SYM
bptjm-48	348	3	245	245	NUM
bptjm-48	348	4	.	.	PUNCT
bptjm-48	349	1	doi:10.1038	doi:10.1038	NOUN
bptjm-48	349	2	/	/	SYM
bptjm-48	349	3	s41586	s41586	PROPN
bptjm-48	349	4	-	-	PUNCT
bptjm-48	349	5	018	018	NUM
bptjm-48	349	6	-	-	PUNCT
bptjm-48	349	7	0810	0810	NUM
bptjm-48	349	8	-	-	SYM
bptjm-48	349	9	y	y	PROPN
bptjm-48	349	10	21	21	NUM
bptjm-48	349	11	.	.	PUNCT
bptjm-48	350	1	keskin	keskin	PROPN
bptjm-48	350	2	db	db	PROPN
bptjm-48	350	3	,	,	PUNCT
bptjm-48	350	4	anandappa	anandappa	PROPN
bptjm-48	350	5	aj	aj	PROPN
bptjm-48	350	6	,	,	PUNCT
bptjm-48	350	7	sun	sun	PROPN
bptjm-48	350	8	j	j	PROPN
bptjm-48	350	9	,	,	PUNCT
bptjm-48	350	10	et	et	PROPN
bptjm-48	350	11	al	al	PROPN
bptjm-48	350	12	.	.	PUNCT
bptjm-48	351	1	neoantigen	neoantigen	PROPN
bptjm-48	351	2	vaccine	vaccine	NOUN
bptjm-48	351	3	generates	generate	VERB
bptjm-48	351	4	intratumoral	intratumoral	ADJ
bptjm-48	351	5	t	t	PROPN
bptjm-48	351	6	cell	cell	NOUN
bptjm-48	351	7	responses	response	NOUN
bptjm-48	351	8	in	in	ADP
bptjm-48	351	9	phase	phase	NOUN
bptjm-48	351	10	ib	ib	NOUN
bptjm-48	351	11	glioblastoma	glioblastoma	NOUN
bptjm-48	351	12	trial.nature	trial.nature	NOUN
bptjm-48	351	13	.	.	PUNCT
bptjm-48	352	1	2019;565(7738):234	2019;565(7738):234	NUM
bptjm-48	352	2	-	-	SYM
bptjm-48	352	3	239	239	NUM
bptjm-48	352	4	.	.	PUNCT
bptjm-48	352	5	doi:10.1038	doi:10.1038	NOUN
bptjm-48	352	6	/	/	SYM
bptjm-48	352	7	s41586	s41586	PROPN
bptjm-48	352	8	-	-	PUNCT
bptjm-48	352	9	018	018	NUM
bptjm-48	352	10	-	-	PUNCT
bptjm-48	352	11	0792	0792	NUM
bptjm-48	352	12	-	-	SYM
bptjm-48	352	13	9	9	NUM
bptjm-48	352	14	22	22	NUM
bptjm-48	352	15	.	.	PUNCT
bptjm-48	353	1	mddr	mddr	PROPN
bptjm-48	353	2	.	.	PUNCT
bptjm-48	354	1	a	a	DET
bptjm-48	354	2	phase	phase	NOUN
bptjm-48	354	3	i	i	PRON
bptjm-48	354	4	study	study	VERB
bptjm-48	354	5	of	of	ADP
bptjm-48	354	6	a	a	DET
bptjm-48	354	7	personalized	personalized	ADJ
bptjm-48	354	8	neoantigen	neoantigen	NOUN
bptjm-48	354	9	cancer	cancer	NOUN
bptjm-48	354	10	vaccinewith	vaccinewith	PROPN
bptjm-48	354	11	radiotherapy	radiotherapy	PROPN
bptjm-48	354	12	plus	plus	CCONJ
bptjm-48	354	13	pembrolizumab	pembrolizumab	NOUN
bptjm-48	354	14	/	/	SYM
bptjm-48	354	15	mk-3475	mk-3475	PROPN
bptjm-48	354	16	among	among	ADP
bptjm-48	354	17	newly	newly	ADV
bptjm-48	354	18	diagnosed	diagnose	VERB
bptjm-48	354	19	glioblastoma	glioblastoma	NOUN
bptjm-48	354	20	patients	patient	NOUN
bptjm-48	354	21	.	.	PUNCT
bptjm-48	355	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	355	2	;	;	PUNCT
bptjm-48	355	3	2022	2022	NUM
bptjm-48	355	4	.	.	PUNCT
bptjm-48	356	1	accessed	access	VERB
bptjm-48	356	2	may	may	PROPN
bptjm-48	356	3	2	2	NUM
bptjm-48	356	4	,	,	PUNCT
bptjm-48	356	5	2023	2023	NUM
bptjm-48	356	6	.	.	PUNCT
bptjm-48	357	1	https://clinicaltrials.gov/ct2/show/nct02287428	https://clinicaltrials.gov/ct2/show/nct02287428	ADP
bptjm-48	357	2	23	23	NUM
bptjm-48	357	3	.	.	PUNCT
bptjm-48	358	1	qin	qin	PROPN
bptjm-48	359	1	f	f	PROPN
bptjm-48	359	2	,	,	PUNCT
bptjm-48	359	3	xia	xia	PROPN
bptjm-48	359	4	f	f	PROPN
bptjm-48	359	5	,	,	PUNCT
bptjm-48	359	6	chen	chen	PROPN
bptjm-48	359	7	h	h	PROPN
bptjm-48	359	8	,	,	PUNCT
bptjm-48	359	9	et	et	PROPN
bptjm-48	359	10	al	al	PROPN
bptjm-48	359	11	.	.	PUNCT
bptjm-48	360	1	a	a	DET
bptjm-48	360	2	guide	guide	NOUN
bptjm-48	360	3	to	to	ADP
bptjm-48	360	4	nucleic	nucleic	ADJ
bptjm-48	360	5	acid	acid	NOUN
bptjm-48	360	6	vaccines	vaccine	NOUN
bptjm-48	360	7	in	in	ADP
bptjm-48	360	8	the	the	DET
bptjm-48	360	9	prevention	prevention	NOUN
bptjm-48	360	10	and	and	CCONJ
bptjm-48	360	11	treatment	treatment	NOUN
bptjm-48	360	12	of	of	ADP
bptjm-48	360	13	infectious	infectious	ADJ
bptjm-48	360	14	diseases	disease	NOUN
bptjm-48	360	15	and	and	CCONJ
bptjm-48	360	16	cancers	cancer	NOUN
bptjm-48	360	17	:	:	PUNCT
bptjm-48	360	18	from	from	ADP
bptjm-48	360	19	basic	basic	ADJ
bptjm-48	360	20	principles	principle	NOUN
bptjm-48	360	21	to	to	ADP
bptjm-48	360	22	current	current	ADJ
bptjm-48	360	23	applications	application	NOUN
bptjm-48	360	24	.	.	PUNCT
bptjm-48	361	1	front	front	ADJ
bptjm-48	361	2	cell	cell	NOUN
bptjm-48	361	3	dev	dev	PROPN
bptjm-48	361	4	biol	biol	PROPN
bptjm-48	361	5	.	.	PUNCT
bptjm-48	362	1	2021;9:633776	2021;9:633776	PROPN
bptjm-48	362	2	.	.	PUNCT
bptjm-48	363	1	published	publish	VERB
bptjm-48	363	2	2021may	2021may	NUM
bptjm-48	363	3	25	25	NUM
bptjm-48	363	4	.	.	PUNCT
bptjm-48	363	5	doi:10.3389	doi:10.3389	PROPN
bptjm-48	363	6	/	/	SYM
bptjm-48	363	7	fcell.2021.633776	fcell.2021.633776	PROPN
bptjm-48	363	8	24	24	NUM
bptjm-48	363	9	.	.	PUNCT
bptjm-48	364	1	bai	bai	PROPN
bptjm-48	364	2	h	h	PROPN
bptjm-48	364	3	,	,	PUNCT
bptjm-48	364	4	lester	lester	PROPN
bptjm-48	364	5	gms	gms	PROPN
bptjm-48	364	6	,	,	PUNCT
bptjm-48	364	7	petishnok	petishnok	NOUN
bptjm-48	364	8	lc	lc	PROPN
bptjm-48	364	9	,	,	PUNCT
bptjm-48	364	10	dean	dean	PROPN
bptjm-48	364	11	da	da	PROPN
bptjm-48	364	12	.	.	PUNCT
bptjm-48	364	13	cytoplasmic	cytoplasmic	ADJ
bptjm-48	364	14	transport	transport	NOUN
bptjm-48	364	15	and	and	CCONJ
bptjm-48	364	16	nuclear	nuclear	ADJ
bptjm-48	364	17	import	import	NOUN
bptjm-48	364	18	of	of	ADP
bptjm-48	364	19	plasmid	plasmid	PROPN
bptjm-48	364	20	dna	dna	PROPN
bptjm-48	364	21	.	.	PUNCT
bptjm-48	365	1	biosci	biosci	PROPN
bptjm-48	365	2	rep	rep	PROPN
bptjm-48	365	3	.	.	PROPN
bptjm-48	365	4	2017;37(6):bsr20160616	2017;37(6):bsr20160616	PUNCT
bptjm-48	365	5	.	.	PUNCT
bptjm-48	366	1	published	publish	VERB
bptjm-48	366	2	2017	2017	NUM
bptjm-48	366	3	nov	nov	PROPN
bptjm-48	366	4	29	29	NUM
bptjm-48	366	5	.	.	PUNCT
bptjm-48	367	1	doi:10.1042	doi:10.1042	PROPN
bptjm-48	367	2	/	/	SYM
bptjm-48	367	3	bsr20160616	bsr20160616	PROPN
bptjm-48	367	4	25	25	NUM
bptjm-48	367	5	.	.	PUNCT
bptjm-48	368	1	washington	washington	PROPN
bptjm-48	368	2	university	university	PROPN
bptjm-48	368	3	school	school	NOUN
bptjm-48	368	4	of	of	ADP
bptjm-48	368	5	medicine	medicine	NOUN
bptjm-48	368	6	.	.	PUNCT
bptjm-48	369	1	a	a	DET
bptjm-48	369	2	pilot	pilot	NOUN
bptjm-48	369	3	study	study	NOUN
bptjm-48	369	4	to	to	PART
bptjm-48	369	5	assess	assess	VERB
bptjm-48	369	6	the	the	DET
bptjm-48	369	7	safety	safety	NOUN
bptjm-48	369	8	,	,	PUNCT
bptjm-48	369	9	feasibility	feasibility	NOUN
bptjm-48	369	10	,	,	PUNCT
bptjm-48	369	11	and	and	CCONJ
bptjm-48	369	12	immunogenicity	immunogenicity	NOUN
bptjm-48	369	13	of	of	ADP
bptjm-48	369	14	a	a	DET
bptjm-48	369	15	neoantigen	neoantigen	NOUN
bptjm-48	369	16	-	-	PUNCT
bptjm-48	369	17	based	base	VERB
bptjm-48	369	18	personalized	personalize	VERB
bptjm-48	369	19	in	in	ADP
bptjm-48	369	20	patients	patient	NOUN
bptjm-48	369	21	with	with	ADP
bptjm-48	369	22	newly	newly	ADV
bptjm-48	369	23	diagnosed	diagnose	VERB
bptjm-48	369	24	,	,	PUNCT
bptjm-48	369	25	unmethylated	unmethylated	ADJ
bptjm-48	369	26	glioblastoma	glioblastoma	NOUN
bptjm-48	369	27	.	.	PUNCT
bptjm-48	370	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	370	2	;	;	PUNCT
bptjm-48	370	3	2023	2023	NUM
bptjm-48	370	4	.	.	PUNCT
bptjm-48	371	1	accessedmay	accessedmay	VERB
bptjm-48	371	2	5	5	NUM
bptjm-48	371	3	,	,	PUNCT
bptjm-48	371	4	2023	2023	NUM
bptjm-48	371	5	.	.	PUNCT
bptjm-48	372	1	https://clinicaltrials.gov/ct2/show/nct04015700	https://clinicaltrials.gov/ct2/show/nct04015700	NUM
bptjm-48	372	2	26	26	NUM
bptjm-48	372	3	.	.	PUNCT
bptjm-48	373	1	washington	washington	PROPN
bptjm-48	373	2	university	university	PROPN
bptjm-48	373	3	school	school	NOUN
bptjm-48	373	4	of	of	ADP
bptjm-48	373	5	medicine	medicine	NOUN
bptjm-48	373	6	.	.	PUNCT
bptjm-48	374	1	a	a	DET
bptjm-48	374	2	pilot	pilot	NOUN
bptjm-48	374	3	study	study	NOUN
bptjm-48	374	4	to	to	PART
bptjm-48	374	5	assess	assess	VERB
bptjm-48	374	6	the	the	DET
bptjm-48	374	7	safety	safety	NOUN
bptjm-48	374	8	and	and	CCONJ
bptjm-48	374	9	immunogenicity	immunogenicity	NOUN
bptjm-48	374	10	of	of	ADP
bptjm-48	374	11	a	a	DET
bptjm-48	374	12	neoantigen	neoantigen	NOUN
bptjm-48	374	13	-	-	PUNCT
bptjm-48	374	14	based	base	VERB
bptjm-48	374	15	personalized	personalized	ADJ
bptjm-48	374	16	dnavaccine	dnavaccine	NOUN
bptjm-48	374	17	with	with	ADP
bptjm-48	374	18	retifanlimab	retifanlimab	NOUN
bptjm-48	374	19	pd-1	pd-1	ADP
bptjm-48	374	20	blockade	blockade	NOUN
bptjm-48	374	21	therapy	therapy	NOUN
bptjm-48	374	22	in	in	ADP
bptjm-48	374	23	patients	patient	NOUN
bptjm-48	374	24	with	with	ADP
bptjm-48	374	25	newly	newly	ADV
bptjm-48	374	26	diagnosed	diagnose	VERB
bptjm-48	374	27	,	,	PUNCT
bptjm-48	374	28	unmethylated	unmethylated	ADJ
bptjm-48	374	29	glioblastoma	glioblastoma	NOUN
bptjm-48	374	30	.	.	PUNCT
bptjm-48	375	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	375	2	;	;	PUNCT
bptjm-48	375	3	2023	2023	NUM
bptjm-48	375	4	.	.	PUNCT
bptjm-48	376	1	accessedmay	accessedmay	VERB
bptjm-48	376	2	5	5	NUM
bptjm-48	376	3	,	,	PUNCT
bptjm-48	376	4	2023	2023	NUM
bptjm-48	376	5	.	.	PUNCT
bptjm-48	377	1	https://clinicaltrials.gov/ct2/show/nct05743595	https://clinicaltrials.gov/ct2/show/nct05743595	X
bptjm-48	377	2	27	27	NUM
bptjm-48	377	3	.	.	PUNCT
bptjm-48	378	1	washington	washington	PROPN
bptjm-48	378	2	university	university	PROPN
bptjm-48	378	3	school	school	NOUN
bptjm-48	378	4	of	of	ADP
bptjm-48	378	5	medicine	medicine	NOUN
bptjm-48	378	6	.	.	PUNCT
bptjm-48	379	1	a	a	DET
bptjm-48	379	2	randomized	randomized	ADJ
bptjm-48	379	3	phase	phase	NOUN
bptjm-48	379	4	1	1	NUM
bptjm-48	379	5	trial	trial	NOUN
bptjm-48	379	6	of	of	ADP
bptjm-48	379	7	neoantigen	neoantigen	PROPN
bptjm-48	379	8	dnavaccine	dnavaccine	NOUN
bptjm-48	379	9	alone	alone	ADV
bptjm-48	379	10	vs.	vs.	X
bptjm-48	379	11	neoantigen	neoantigen	X
bptjm-48	379	12	dnavaccine	dnavaccine	NOUN
bptjm-48	379	13	plus	plus	CCONJ
bptjm-48	379	14	durvalumab	durvalumab	NOUN
bptjm-48	379	15	in	in	ADP
bptjm-48	379	16	triple	triple	ADJ
bptjm-48	379	17	negative	negative	ADJ
bptjm-48	379	18	breast	breast	NOUN
bptjm-48	379	19	cancer	cancer	NOUN
bptjm-48	379	20	patients	patient	NOUN
bptjm-48	379	21	following	follow	VERB
bptjm-48	379	22	standard	standard	NOUN
bptjm-48	379	23	of	of	ADP
bptjm-48	379	24	care	care	NOUN
bptjm-48	379	25	therapy	therapy	NOUN
bptjm-48	379	26	.	.	PUNCT
bptjm-48	380	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	380	2	;	;	PUNCT
bptjm-48	380	3	2023	2023	NUM
bptjm-48	380	4	.	.	PUNCT
bptjm-48	381	1	accessedmay	accessedmay	VERB
bptjm-48	381	2	5	5	NUM
bptjm-48	381	3	,	,	PUNCT
bptjm-48	381	4	2023	2023	NUM
bptjm-48	381	5	.	.	PUNCT
bptjm-48	382	1	https://clinicaltrials.gov/ct2/show/nct03199040	https://clinicaltrials.gov/ct2/show/nct03199040	NOUN
bptjm-48	382	2	28	28	NUM
bptjm-48	382	3	.	.	PUNCT
bptjm-48	383	1	university	university	PROPN
bptjm-48	383	2	of	of	ADP
bptjm-48	383	3	florida	florida	PROPN
bptjm-48	383	4	.	.	PUNCT
bptjm-48	384	1	a	a	DET
bptjm-48	384	2	study	study	NOUN
bptjm-48	384	3	of	of	ADP
bptjm-48	384	4	rna	rna	NOUN
bptjm-48	384	5	-	-	PUNCT
bptjm-48	384	6	lipid	lipid	NOUN
bptjm-48	384	7	particle	particle	NOUN
bptjm-48	384	8	(	(	PUNCT
bptjm-48	384	9	rna	rna	NOUN
bptjm-48	384	10	-	-	PUNCT
bptjm-48	384	11	lp	lp	NOUN
bptjm-48	384	12	)	)	PUNCT
bptjm-48	384	13	vaccines	vaccine	NOUN
bptjm-48	384	14	for	for	ADP
bptjm-48	384	15	newly	newly	ADV
bptjm-48	384	16	diagnosed	diagnose	VERB
bptjm-48	384	17	berkeley	berkeley	PROPN
bptjm-48	384	18	pharma	pharma	PROPN
bptjm-48	384	19	tech	tech	NOUN
bptjm-48	384	20	journal	journal	NOUN
bptjm-48	384	21	of	of	ADP
bptjm-48	384	22	medicine	medicine	NOUN
bptjm-48	384	23	|	|	ADV
bptjm-48	384	24	61	61	NUM
bptjm-48	384	25	https://doi.org/10.1021/acs.chemrev.9b00472	https://doi.org/10.1021/acs.chemrev.9b00472	NOUN
bptjm-48	384	26	https://doi.org/10.3390/vaccines2030515	https://doi.org/10.3390/vaccines2030515	VERB
bptjm-48	384	27	https://doi.org/10.1016/j.canlet.2022.215945	https://doi.org/10.1016/j.canlet.2022.215945	ADJ
bptjm-48	384	28	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	PRON
bptjm-48	384	29	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	NOUN
bptjm-48	385	1	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	https://sequencing.roche.com/us/en/article-listing/wes-wgs-custom.html	X
bptjm-48	386	1	https://doi.org/10.1136/archdischild-2013-304340	https://doi.org/10.1136/archdischild-2013-304340	PROPN
bptjm-48	386	2	https://doi.org/10.1038/s41586-018-0810-y	https://doi.org/10.1038/s41586-018-0810-y	ADJ
bptjm-48	386	3	https://doi.org/10.1038/s41586-018-0792-9	https://doi.org/10.1038/s41586-018-0792-9	NOUN
bptjm-48	386	4	https://clinicaltrials.gov/ct2/show/nct02287428	https://clinicaltrials.gov/ct2/show/nct02287428	ADP
bptjm-48	386	5	https://clinicaltrials.gov/ct2/show/nct02287428	https://clinicaltrials.gov/ct2/show/nct02287428	X
bptjm-48	386	6	https://clinicaltrials.gov/ct2/show/nct04015700	https://clinicaltrials.gov/ct2/show/nct04015700	X
bptjm-48	386	7	https://clinicaltrials.gov/ct2/show/nct05743595	https://clinicaltrials.gov/ct2/show/nct05743595	X
bptjm-48	386	8	https://clinicaltrials.gov/ct2/show/nct05743595	https://clinicaltrials.gov/ct2/show/nct05743595	X
bptjm-48	386	9	https://clinicaltrials.gov/ct2/show/nct03199040	https://clinicaltrials.gov/ct2/show/nct03199040	PART
bptjm-48	386	10	https://clinicaltrials.gov/ct2/show/nct03199040	https://clinicaltrials.gov/ct2/show/nct03199040	PART
bptjm-48	386	11	pediatric	pediatric	ADJ
bptjm-48	386	12	high	high	ADJ
bptjm-48	386	13	-	-	PUNCT
bptjm-48	386	14	grade	grade	NOUN
bptjm-48	386	15	gliomas	glioma	NOUN
bptjm-48	386	16	(	(	PUNCT
bptjm-48	386	17	phgg	phgg	NOUN
bptjm-48	386	18	)	)	PUNCT
bptjm-48	386	19	and	and	CCONJ
bptjm-48	386	20	adult	adult	NOUN
bptjm-48	386	21	glioblastoma	glioblastoma	NOUN
bptjm-48	386	22	(	(	PUNCT
bptjm-48	386	23	gbm	gbm	PROPN
bptjm-48	386	24	)	)	PUNCT
bptjm-48	386	25	.	.	PUNCT
bptjm-48	387	1	clinicaltrials.gov	clinicaltrials.gov	X
bptjm-48	387	2	;	;	PUNCT
bptjm-48	387	3	2023	2023	NUM
bptjm-48	387	4	.	.	PUNCT
bptjm-48	388	1	accessed	access	VERB
bptjm-48	388	2	may	may	PROPN
bptjm-48	388	3	5	5	NUM
bptjm-48	388	4	,	,	PUNCT
bptjm-48	388	5	2023	2023	NUM
bptjm-48	388	6	.	.	PUNCT
bptjm-48	389	1	https://clinicaltrials.gov/ct2/show/nct04573140	https://clinicaltrials.gov/ct2/show/nct04573140	NUM
bptjm-48	389	2	29	29	NUM
bptjm-48	389	3	.	.	PUNCT
bptjm-48	390	1	ph.d	ph.d	PROPN
bptjm-48	390	2	ga	ga	PROPN
bptjm-48	390	3	.	.	PUNCT
bptjm-48	390	4	evaluation	evaluation	NOUN
bptjm-48	390	5	of	of	ADP
bptjm-48	390	6	overcoming	overcome	VERB
bptjm-48	390	7	limited	limited	ADJ
bptjm-48	390	8	migration	migration	NOUN
bptjm-48	390	9	and	and	CCONJ
bptjm-48	390	10	enhancing	enhance	VERB
bptjm-48	390	11	cytomegalovirus	cytomegalovirus	NOUN
bptjm-48	390	12	-	-	PUNCT
bptjm-48	390	13	speci	speci	NOUN
bptjm-48	390	14	�	�	PROPN
bptjm-48	390	15	c	c	NOUN
bptjm-48	390	16	dendritic	dendritic	ADJ
bptjm-48	390	17	cell	cell	NOUN
bptjm-48	390	18	vaccines	vaccine	NOUN
bptjm-48	390	19	with	with	ADP
bptjm-48	390	20	adjuvant	adjuvant	ADJ
bptjm-48	390	21	tetanus	tetanus	PROPN
bptjm-48	390	22	pre	pre	ADJ
bptjm-48	390	23	-	-	NOUN
bptjm-48	390	24	conditioning	condition	VERB
bptjm-48	390	25	in	in	ADP
bptjm-48	390	26	patients	patient	NOUN
bptjm-48	390	27	with	with	ADP
bptjm-48	390	28	newly	newly	ADV
bptjm-48	390	29	-	-	PUNCT
bptjm-48	390	30	diagnosed	diagnose	VERB
bptjm-48	390	31	glioblastoma	glioblastoma	NOUN
bptjm-48	390	32	.	.	PUNCT
bptjm-48	391	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	391	2	;	;	PUNCT
bptjm-48	391	3	2022	2022	NUM
bptjm-48	391	4	.	.	PUNCT
bptjm-48	392	1	accessedmay	accessedmay	VERB
bptjm-48	392	2	5	5	NUM
bptjm-48	392	3	,	,	PUNCT
bptjm-48	392	4	2023	2023	NUM
bptjm-48	392	5	.	.	PUNCT
bptjm-48	393	1	https://clinicaltrials.gov/ct2/show/nct02366728	https://clinicaltrials.gov/ct2/show/nct02366728	NOUN
bptjm-48	393	2	30	30	NUM
bptjm-48	393	3	.	.	PUNCT
bptjm-48	394	1	saadeldin	saadeldin	VERB
bptjm-48	394	2	mk	mk	PROPN
bptjm-48	394	3	,	,	PUNCT
bptjm-48	394	4	abdel	abdel	PROPN
bptjm-48	394	5	-	-	PUNCT
bptjm-48	394	6	aziz	aziz	PROPN
bptjm-48	394	7	ak	ak	PROPN
bptjm-48	394	8	,	,	PUNCT
bptjm-48	394	9	abdellatif	abdellatif	NOUN
bptjm-48	394	10	a.	a.	NOUN
bptjm-48	394	11	dendritic	dendritic	ADJ
bptjm-48	394	12	cell	cell	NOUN
bptjm-48	394	13	vaccine	vaccine	NOUN
bptjm-48	394	14	immunotherapy	immunotherapy	NOUN
bptjm-48	394	15	;	;	PUNCT
bptjm-48	394	16	the	the	DET
bptjm-48	394	17	beginning	beginning	NOUN
bptjm-48	394	18	of	of	ADP
bptjm-48	394	19	the	the	DET
bptjm-48	394	20	end	end	NOUN
bptjm-48	394	21	of	of	ADP
bptjm-48	394	22	cancer	cancer	NOUN
bptjm-48	394	23	and	and	CCONJ
bptjm-48	394	24	covid-19	covid-19	PROPN
bptjm-48	394	25	.	.	PUNCT
bptjm-48	395	1	a	a	DET
bptjm-48	395	2	hypothesis	hypothesis	NOUN
bptjm-48	395	3	.	.	PUNCT
bptjm-48	396	1	medhypotheses	medhypothese	NOUN
bptjm-48	396	2	.	.	PUNCT
bptjm-48	397	1	2021;146:110365	2021;146:110365	X
bptjm-48	397	2	.	.	PUNCT
bptjm-48	397	3	doi:10.1016	doi:10.1016	PROPN
bptjm-48	397	4	/	/	SYM
bptjm-48	397	5	j.mehy.2020.110365	j.mehy.2020.110365	PROPN
bptjm-48	397	6	31	31	NUM
bptjm-48	397	7	.	.	PUNCT
bptjm-48	398	1	datsi	datsi	PROPN
bptjm-48	398	2	a	a	DET
bptjm-48	398	3	,	,	PUNCT
bptjm-48	398	4	sorg	sorg	PROPN
bptjm-48	398	5	rv	rv	PROPN
bptjm-48	398	6	.	.	PUNCT
bptjm-48	398	7	dendritic	dendritic	ADJ
bptjm-48	398	8	cell	cell	NOUN
bptjm-48	398	9	vaccination	vaccination	NOUN
bptjm-48	398	10	of	of	ADP
bptjm-48	398	11	glioblastoma	glioblastoma	NOUN
bptjm-48	398	12	:	:	PUNCT
bptjm-48	398	13	road	road	NOUN
bptjm-48	398	14	to	to	ADP
bptjm-48	398	15	success	success	NOUN
bptjm-48	398	16	or	or	CCONJ
bptjm-48	398	17	dead	dead	ADJ
bptjm-48	398	18	end	end	NOUN
bptjm-48	398	19	.	.	PUNCT
bptjm-48	399	1	frontiers	frontier	NOUN
bptjm-48	399	2	in	in	ADP
bptjm-48	399	3	immunology	immunology	NOUN
bptjm-48	399	4	.	.	PUNCT
bptjm-48	400	1	2021;12	2021;12	X
bptjm-48	400	2	.	.	PUNCT
bptjm-48	401	1	accessedmarch	accessedmarch	PROPN
bptjm-48	401	2	23	23	NUM
bptjm-48	401	3	,	,	PUNCT
bptjm-48	401	4	2023	2023	NUM
bptjm-48	401	5	.	.	PUNCT
bptjm-48	402	1	https://www.frontiersin.org/articles/10.3389/�mmu.2	https://www.frontiersin.org/articles/10.3389/�mmu.2	PRON
bptjm-48	403	1	021.770390	021.770390	NUM
bptjm-48	403	2	32	32	NUM
bptjm-48	403	3	.	.	PUNCT
bptjm-48	404	1	isaacsson	isaacsson	PROPN
bptjm-48	404	2	velho	velho	PROPN
bptjm-48	404	3	p	p	NOUN
bptjm-48	404	4	,	,	PUNCT
bptjm-48	404	5	antonarakis	antonarakis	PROPN
bptjm-48	404	6	es	es	NOUN
bptjm-48	404	7	.	.	PUNCT
bptjm-48	405	1	pd-1	pd-1	ADP
bptjm-48	405	2	/	/	SYM
bptjm-48	405	3	pd	pd	ADJ
bptjm-48	405	4	-	-	PUNCT
bptjm-48	405	5	l1	l1	PROPN
bptjm-48	405	6	pathway	pathway	NOUN
bptjm-48	405	7	inhibitors	inhibitor	NOUN
bptjm-48	405	8	in	in	ADP
bptjm-48	405	9	advanced	advanced	ADJ
bptjm-48	405	10	prostate	prostate	NOUN
bptjm-48	405	11	cancer	cancer	NOUN
bptjm-48	405	12	.	.	PUNCT
bptjm-48	406	1	expert	expert	NOUN
bptjm-48	406	2	rev	rev	PROPN
bptjm-48	406	3	clin	clin	PROPN
bptjm-48	406	4	pharmacol	pharmacol	PROPN
bptjm-48	406	5	.	.	PUNCT
bptjm-48	407	1	2018;11(5):475	2018;11(5):475	NOUN
bptjm-48	407	2	-	-	SYM
bptjm-48	407	3	486	486	NUM
bptjm-48	407	4	.	.	PUNCT
bptjm-48	408	1	doi:10.1080/17512433.2018.1464388	doi:10.1080/17512433.2018.1464388	NOUN
bptjm-48	408	2	.	.	PROPN
bptjm-48	408	3	33	33	NUM
bptjm-48	408	4	.	.	PUNCT
bptjm-48	409	1	coxon	coxon	PROPN
bptjm-48	409	2	at	at	ADP
bptjm-48	409	3	,	,	PUNCT
bptjm-48	409	4	johanns	johanns	PROPN
bptjm-48	409	5	tm	tm	PROPN
bptjm-48	409	6	,	,	PUNCT
bptjm-48	409	7	dunn	dunn	PROPN
bptjm-48	409	8	gp	gp	NOUN
bptjm-48	409	9	.	.	PUNCT
bptjm-48	410	1	an	an	DET
bptjm-48	410	2	innovative	innovative	ADJ
bptjm-48	410	3	immunotherapy	immunotherapy	NOUN
bptjm-48	410	4	vaccine	vaccine	NOUN
bptjm-48	410	5	with	with	ADP
bptjm-48	410	6	combination	combination	NOUN
bptjm-48	410	7	checkpoint	checkpoint	NOUN
bptjm-48	410	8	blockade	blockade	NOUN
bptjm-48	410	9	as	as	ADP
bptjm-48	410	10	a	a	DET
bptjm-48	410	11	first	first	ADJ
bptjm-48	410	12	line	line	NOUN
bptjm-48	410	13	treatment	treatment	NOUN
bptjm-48	410	14	for	for	ADP
bptjm-48	410	15	glioblastoma	glioblastoma	NOUN
bptjm-48	410	16	in	in	ADP
bptjm-48	410	17	the	the	DET
bptjm-48	410	18	context	context	NOUN
bptjm-48	410	19	of	of	ADP
bptjm-48	410	20	current	current	ADJ
bptjm-48	410	21	treatments	treatment	NOUN
bptjm-48	410	22	.	.	PUNCT
bptjm-48	411	1	momed	mome	VERB
bptjm-48	411	2	.	.	PUNCT
bptjm-48	412	1	2020;117(1):45	2020;117(1):45	NUM
bptjm-48	412	2	-	-	SYM
bptjm-48	412	3	49	49	NUM
bptjm-48	412	4	.	.	PUNCT
bptjm-48	413	1	34	34	NUM
bptjm-48	413	2	.	.	PUNCT
bptjm-48	414	1	malik	malik	PROPN
bptjm-48	414	2	b	b	PROPN
bptjm-48	414	3	,	,	PUNCT
bptjm-48	414	4	ghatol	ghatol	NOUN
bptjm-48	414	5	a.	a.	NOUN
bptjm-48	414	6	understanding	understanding	NOUN
bptjm-48	414	7	how	how	SCONJ
bptjm-48	414	8	monoclonal	monoclonal	NOUN
bptjm-48	414	9	antibodies	antibodie	VERB
bptjm-48	414	10	work	work	NOUN
bptjm-48	414	11	.	.	PUNCT
bptjm-48	415	1	in	in	ADP
bptjm-48	415	2	:	:	PUNCT
bptjm-48	415	3	statpearls	statpearl	NOUN
bptjm-48	415	4	.	.	PUNCT
bptjm-48	416	1	statpearls	statpearl	NOUN
bptjm-48	416	2	publishing	publishing	NOUN
bptjm-48	416	3	;	;	PUNCT
bptjm-48	416	4	2023	2023	NUM
bptjm-48	416	5	.	.	PUNCT
bptjm-48	417	1	accessed	access	VERB
bptjm-48	417	2	april	april	PROPN
bptjm-48	417	3	8	8	NUM
bptjm-48	417	4	,	,	PUNCT
bptjm-48	417	5	2023	2023	NUM
bptjm-48	417	6	.	.	PUNCT
bptjm-48	418	1	http://www.ncbi.nlm.nih.gov/books/nbk572118/	http://www.ncbi.nlm.nih.gov/books/nbk572118/	PROPN
bptjm-48	418	2	35	35	NUM
bptjm-48	418	3	.	.	PUNCT
bptjm-48	419	1	aziz	aziz	PROPN
bptjm-48	419	2	m	m	PROPN
bptjm-48	419	3	,	,	PUNCT
bptjm-48	419	4	iheanacho	iheanacho	PROPN
bptjm-48	419	5	f	f	PROPN
bptjm-48	419	6	,	,	PUNCT
bptjm-48	419	7	hashmimf	hashmimf	PROPN
bptjm-48	419	8	.	.	PUNCT
bptjm-48	420	1	physiology	physiology	NOUN
bptjm-48	420	2	,	,	PUNCT
bptjm-48	420	3	antibody	antibody	NOUN
bptjm-48	420	4	.	.	PUNCT
bptjm-48	421	1	in	in	ADP
bptjm-48	421	2	:	:	PUNCT
bptjm-48	421	3	statpearls	statpearl	NOUN
bptjm-48	421	4	.	.	PUNCT
bptjm-48	422	1	statpearls	statpearl	NOUN
bptjm-48	422	2	publishing	publishing	NOUN
bptjm-48	422	3	;	;	PUNCT
bptjm-48	422	4	2023	2023	NUM
bptjm-48	422	5	.	.	PUNCT
bptjm-48	423	1	accessed	access	VERB
bptjm-48	423	2	april	april	PROPN
bptjm-48	423	3	8	8	NUM
bptjm-48	423	4	,	,	PUNCT
bptjm-48	423	5	2023	2023	NUM
bptjm-48	423	6	.	.	PUNCT
bptjm-48	424	1	http://www.ncbi.nlm.nih.gov/books/nbk546670/	http://www.ncbi.nlm.nih.gov/books/nbk546670/	NOUN
bptjm-48	424	2	36	36	NUM
bptjm-48	424	3	.	.	PUNCT
bptjm-48	425	1	clinica	clinica	PROPN
bptjm-48	425	2	universidad	universidad	PROPN
bptjm-48	425	3	de	de	PROPN
bptjm-48	425	4	navarra	navarra	PROPN
bptjm-48	425	5	,	,	PUNCT
bptjm-48	425	6	universidad	universidad	PROPN
bptjm-48	425	7	de	de	PROPN
bptjm-48	425	8	navarra	navarra	PROPN
bptjm-48	425	9	.	.	PROPN
bptjm-48	425	10	phase	phase	PROPN
bptjm-48	425	11	ii	ii	PROPN
bptjm-48	425	12	study	study	NOUN
bptjm-48	425	13	of	of	ADP
bptjm-48	425	14	neoadjuvant	neoadjuvant	ADJ
bptjm-48	425	15	nivolumab	nivolumab	NOUN
bptjm-48	425	16	in	in	ADP
bptjm-48	425	17	patientswith	patientswith	NOUN
bptjm-48	425	18	glioblastomamultiforme	glioblastomamultiforme	NOUN
bptjm-48	425	19	.	.	PUNCT
bptjm-48	426	1	clinicaltrials.gov	clinicaltrials.gov	X
bptjm-48	426	2	;	;	PUNCT
bptjm-48	426	3	2017	2017	NUM
bptjm-48	426	4	.	.	PUNCT
bptjm-48	427	1	accessedmay	accessedmay	VERB
bptjm-48	427	2	5	5	NUM
bptjm-48	427	3	,	,	PUNCT
bptjm-48	427	4	2023	2023	NUM
bptjm-48	427	5	.	.	PUNCT
bptjm-48	428	1	https://clinicaltrials.gov/ct2/show/nct02550249	https://clinicaltrials.gov/ct2/show/nct02550249	PROPN
bptjm-48	429	1	37	37	NUM
bptjm-48	429	2	.	.	PUNCT
bptjm-48	429	3	national	national	PROPN
bptjm-48	429	4	cancer	cancer	PROPN
bptjm-48	429	5	institute	institute	PROPN
bptjm-48	429	6	(	(	PUNCT
bptjm-48	429	7	nci	nci	PROPN
bptjm-48	429	8	)	)	PUNCT
bptjm-48	429	9	.	.	PUNCT
bptjm-48	430	1	phase	phase	NOUN
bptjm-48	430	2	ii	ii	NOUN
bptjm-48	430	3	trial	trial	NOUN
bptjm-48	430	4	evaluating	evaluate	VERB
bptjm-48	430	5	nivolumab	nivolumab	NOUN
bptjm-48	430	6	in	in	ADP
bptjm-48	430	7	patientswith	patientswith	NOUN
bptjm-48	430	8	idh	idh	NOUN
bptjm-48	430	9	-	-	PUNCT
bptjm-48	430	10	mutant	mutant	NOUN
bptjm-48	430	11	gliomaswith	gliomaswith	NOUN
bptjm-48	430	12	andwithout	andwithout	NOUN
bptjm-48	430	13	hypermutator	hypermutator	NOUN
bptjm-48	430	14	phenotype	phenotype	NOUN
bptjm-48	430	15	.	.	PUNCT
bptjm-48	431	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	431	2	;	;	PUNCT
bptjm-48	431	3	2023	2023	NUM
bptjm-48	431	4	.	.	PUNCT
bptjm-48	432	1	accessedmay	accessedmay	VERB
bptjm-48	432	2	5	5	NUM
bptjm-48	432	3	,	,	PUNCT
bptjm-48	432	4	2023	2023	NUM
bptjm-48	432	5	.	.	PUNCT
bptjm-48	433	1	https://clinicaltrials.gov/ct2/show/nct03718767	https://clinicaltrials.gov/ct2/show/nct03718767	PROPN
bptjm-48	433	2	38	38	NUM
bptjm-48	433	3	.	.	PUNCT
bptjm-48	434	1	nyu	nyu	PROPN
bptjm-48	434	2	langone	langone	NOUN
bptjm-48	434	3	health.a	health.a	PROPN
bptjm-48	434	4	phase	phase	NOUN
bptjm-48	434	5	ii	ii	NOUN
bptjm-48	434	6	,	,	PUNCT
bptjm-48	434	7	open	open	ADJ
bptjm-48	434	8	-	-	PUNCT
bptjm-48	434	9	label	label	NOUN
bptjm-48	434	10	,	,	PUNCT
bptjm-48	434	11	single	single	ADJ
bptjm-48	434	12	arm	arm	NOUN
bptjm-48	434	13	trial	trial	NOUN
bptjm-48	434	14	of	of	ADP
bptjm-48	434	15	nivolumab	nivolumab	NOUN
bptjm-48	434	16	,	,	PUNCT
bptjm-48	434	17	ipilimumab	ipilimumab	ADV
bptjm-48	434	18	,	,	PUNCT
bptjm-48	434	19	and	and	CCONJ
bptjm-48	434	20	short	short	ADJ
bptjm-48	434	21	-	-	PUNCT
bptjm-48	434	22	course	course	NOUN
bptjm-48	434	23	radiotherapy	radiotherapy	NOUN
bptjm-48	434	24	in	in	ADP
bptjm-48	434	25	adultswith	adultswith	ADV
bptjm-48	434	26	newly	newly	ADV
bptjm-48	434	27	diagnosed	diagnose	VERB
bptjm-48	434	28	,	,	PUNCT
bptjm-48	434	29	mgmtunmethylated	mgmtunmethylated	ADJ
bptjm-48	434	30	glioblastoma	glioblastoma	NOUN
bptjm-48	434	31	.	.	PUNCT
bptjm-48	435	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	435	2	;	;	PUNCT
bptjm-48	435	3	2022	2022	NUM
bptjm-48	435	4	.	.	PUNCT
bptjm-48	436	1	accessedmay	accessedmay	VERB
bptjm-48	436	2	5	5	NUM
bptjm-48	436	3	,	,	PUNCT
bptjm-48	436	4	2023	2023	NUM
bptjm-48	436	5	.	.	PUNCT
bptjm-48	437	1	https://clinicaltrials.gov/ct2/show/nct03367715	https://clinicaltrials.gov/ct2/show/nct03367715	NOUN
bptjm-48	437	2	39	39	NUM
bptjm-48	437	3	.	.	PUNCT
bptjm-48	438	1	yamamoto	yamamoto	PROPN
bptjm-48	438	2	tn	tn	PROPN
bptjm-48	438	3	,	,	PUNCT
bptjm-48	438	4	kishton	kishton	PROPN
bptjm-48	438	5	rj	rj	PROPN
bptjm-48	438	6	,	,	PUNCT
bptjm-48	438	7	restifo	restifo	ADJ
bptjm-48	438	8	np	np	INTJ
bptjm-48	438	9	.	.	PUNCT
bptjm-48	438	10	developing	develop	VERB
bptjm-48	438	11	neoantigen	neoantigen	NOUN
bptjm-48	438	12	-	-	PUNCT
bptjm-48	438	13	targeted	target	VERB
bptjm-48	438	14	t	t	NOUN
bptjm-48	438	15	cell	cell	NOUN
bptjm-48	438	16	–	–	PUNCT
bptjm-48	438	17	based	base	VERB
bptjm-48	438	18	treatments	treatment	NOUN
bptjm-48	438	19	for	for	ADP
bptjm-48	438	20	solid	solid	ADJ
bptjm-48	438	21	tumors.natmed	tumors.natme	VERB
bptjm-48	438	22	.	.	PUNCT
bptjm-48	439	1	2019;25(10):1488	2019;25(10):1488	NUM
bptjm-48	439	2	-	-	SYM
bptjm-48	439	3	1499	1499	NUM
bptjm-48	439	4	.	.	PUNCT
bptjm-48	440	1	doi:10.1038	doi:10.1038	NOUN
bptjm-48	440	2	/	/	SYM
bptjm-48	440	3	s41591	s41591	NOUN
bptjm-48	440	4	-	-	PUNCT
bptjm-48	440	5	019	019	NUM
bptjm-48	440	6	-	-	PUNCT
bptjm-48	440	7	0596	0596	NUM
bptjm-48	440	8	-	-	PUNCT
bptjm-48	440	9	y	y	PROPN
bptjm-48	440	10	40	40	NUM
bptjm-48	440	11	.	.	PUNCT
bptjm-48	441	1	yoonws	yoonws	PROPN
bptjm-48	441	2	,	,	PUNCT
bptjm-48	441	3	chung	chung	PROPN
bptjm-48	441	4	ds	ds	PROPN
bptjm-48	441	5	.	.	PROPN
bptjm-48	441	6	advanced	advanced	PROPN
bptjm-48	441	7	t	t	PROPN
bptjm-48	441	8	and	and	CCONJ
bptjm-48	441	9	nkcell	nkcell	VERB
bptjm-48	441	10	therapy	therapy	NOUN
bptjm-48	441	11	for	for	ADP
bptjm-48	441	12	glioblastoma	glioblastoma	NOUN
bptjm-48	441	13	.	.	PUNCT
bptjm-48	442	1	journal	journal	NOUN
bptjm-48	442	2	of	of	ADP
bptjm-48	442	3	korean	korean	ADJ
bptjm-48	442	4	neurosurgical	neurosurgical	ADJ
bptjm-48	442	5	society	society	NOUN
bptjm-48	442	6	.	.	PUNCT
bptjm-48	443	1	published	publish	VERB
bptjm-48	443	2	online	online	ADJ
bptjm-48	443	3	january	january	PROPN
bptjm-48	443	4	2	2	NUM
bptjm-48	443	5	,	,	PUNCT
bptjm-48	443	6	2023	2023	NUM
bptjm-48	443	7	.	.	PUNCT
bptjm-48	444	1	accessed	access	VERB
bptjm-48	444	2	january	january	PROPN
bptjm-48	444	3	30	30	NUM
bptjm-48	444	4	,	,	PUNCT
bptjm-48	444	5	2023	2023	NUM
bptjm-48	444	6	.	.	PUNCT
bptjm-48	445	1	https://www.jkns.or.kr/journal/view.php?number=75	https://www.jkns.or.kr/journal/view.php?number=75	PROPN
bptjm-48	445	2	berkeley	berkeley	PROPN
bptjm-48	445	3	pharma	pharma	PROPN
bptjm-48	445	4	tech	tech	NOUN
bptjm-48	445	5	journal	journal	NOUN
bptjm-48	445	6	of	of	ADP
bptjm-48	445	7	medicine	medicine	NOUN
bptjm-48	445	8	|	|	ADV
bptjm-48	445	9	62	62	NUM
bptjm-48	445	10	https://clinicaltrials.gov/ct2/show/nct04573140	https://clinicaltrials.gov/ct2/show/nct04573140	NOUN
bptjm-48	445	11	https://clinicaltrials.gov/ct2/show/nct04573140	https://clinicaltrials.gov/ct2/show/nct04573140	NOUN
bptjm-48	445	12	https://clinicaltrials.gov/ct2/show/nct02366728	https://clinicaltrials.gov/ct2/show/nct02366728	PROPN
bptjm-48	445	13	https://doi.org/10.1016/j.mehy.2020.110365	https://doi.org/10.1016/j.mehy.2020.110365	VERB
bptjm-48	445	14	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	INTJ
bptjm-48	445	15	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	INTJ
bptjm-48	445	16	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	INTJ
bptjm-48	446	1	https://doi.org/10.1080/17512433.2018.1464388	https://doi.org/10.1080/17512433.2018.1464388	NUM
bptjm-48	446	2	http://www.ncbi.nlm.nih.gov/books/nbk572118/	http://www.ncbi.nlm.nih.gov/books/nbk572118/	ADJ
bptjm-48	446	3	http://www.ncbi.nlm.nih.gov/books/nbk572118/	http://www.ncbi.nlm.nih.gov/books/nbk572118/	PROPN
bptjm-48	446	4	http://www.ncbi.nlm.nih.gov/books/nbk546670/	http://www.ncbi.nlm.nih.gov/books/nbk546670/	PROPN
bptjm-48	446	5	http://www.ncbi.nlm.nih.gov/books/nbk546670/	http://www.ncbi.nlm.nih.gov/books/nbk546670/	PROPN
bptjm-48	446	6	https://clinicaltrials.gov/ct2/show/nct02550249	https://clinicaltrials.gov/ct2/show/nct02550249	X
bptjm-48	447	1	https://clinicaltrials.gov/ct2/show/nct02550249	https://clinicaltrials.gov/ct2/show/nct02550249	PROPN
bptjm-48	447	2	https://clinicaltrials.gov/ct2/show/nct03718767	https://clinicaltrials.gov/ct2/show/nct03718767	PROPN
bptjm-48	447	3	https://clinicaltrials.gov/ct2/show/nct03718767	https://clinicaltrials.gov/ct2/show/nct03718767	NUM
bptjm-48	447	4	https://clinicaltrials.gov/ct2/show/nct03367715	https://clinicaltrials.gov/ct2/show/nct03367715	NOUN
bptjm-48	447	5	https://clinicaltrials.gov/ct2/show/nct03367715	https://clinicaltrials.gov/ct2/show/nct03367715	NOUN
bptjm-48	447	6	https://doi.org/10.1038/s41591-019-0596-y	https://doi.org/10.1038/s41591-019-0596-y	PROPN
bptjm-48	447	7	https://www.jkns.or.kr/journal/view.php?number=7591	https://www.jkns.or.kr/journal/view.php?number=7591	PROPN
bptjm-48	447	8	https://www.jkns.or.kr/journal/view.php?number=7591	https://www.jkns.or.kr/journal/view.php?number=7591	PROPN
bptjm-48	447	9	91	91	NUM
bptjm-48	447	10	41	41	NUM
bptjm-48	447	11	.	.	PUNCT
bptjm-48	448	1	sterner	sterner	PROPN
bptjm-48	448	2	rc	rc	PROPN
bptjm-48	448	3	,	,	PUNCT
bptjm-48	448	4	sterner	sterner	PROPN
bptjm-48	448	5	rm	rm	PROPN
bptjm-48	448	6	.	.	PUNCT
bptjm-48	448	7	car	car	PROPN
bptjm-48	448	8	-	-	PUNCT
bptjm-48	448	9	t	t	PROPN
bptjm-48	448	10	cell	cell	NOUN
bptjm-48	448	11	therapy	therapy	NOUN
bptjm-48	448	12	:	:	PUNCT
bptjm-48	448	13	current	current	ADJ
bptjm-48	448	14	limitations	limitation	NOUN
bptjm-48	448	15	and	and	CCONJ
bptjm-48	448	16	potential	potential	ADJ
bptjm-48	448	17	strategies	strategy	NOUN
bptjm-48	448	18	.	.	PUNCT
bptjm-48	449	1	blood	blood	NOUN
bptjm-48	449	2	cancer	cancer	NOUN
bptjm-48	449	3	j.	j.	PROPN
bptjm-48	449	4	2021;11(4):1	2021;11(4):1	PROPN
bptjm-48	449	5	-	-	PUNCT
bptjm-48	449	6	11	11	NUM
bptjm-48	449	7	.	.	PUNCT
bptjm-48	450	1	doi:10.1038	doi:10.1038	NOUN
bptjm-48	450	2	/	/	SYM
bptjm-48	450	3	s41408	s41408	NUM
bptjm-48	450	4	-	-	PUNCT
bptjm-48	450	5	021	021	NUM
bptjm-48	450	6	-	-	PUNCT
bptjm-48	450	7	00459	00459	NUM
bptjm-48	450	8	-	-	SYM
bptjm-48	450	9	7	7	NUM
bptjm-48	450	10	42	42	NUM
bptjm-48	450	11	.	.	PUNCT
bptjm-48	451	1	fang	fang	PROPN
bptjm-48	451	2	x	x	PROPN
bptjm-48	451	3	,	,	PUNCT
bptjm-48	451	4	guo	guo	PROPN
bptjm-48	451	5	z	z	PROPN
bptjm-48	451	6	,	,	PUNCT
bptjm-48	451	7	liang	liang	PROPN
bptjm-48	451	8	j	j	PROPN
bptjm-48	451	9	,	,	PUNCT
bptjm-48	451	10	et	et	PROPN
bptjm-48	451	11	al	al	PROPN
bptjm-48	451	12	.	.	PUNCT
bptjm-48	451	13	neoantigens	neoantigens	PROPN
bptjm-48	451	14	and	and	CCONJ
bptjm-48	451	15	their	their	PRON
bptjm-48	451	16	potential	potential	ADJ
bptjm-48	451	17	applications	application	NOUN
bptjm-48	451	18	in	in	ADP
bptjm-48	451	19	tumor	tumor	NOUN
bptjm-48	451	20	immunotherapy.oncol	immunotherapy.oncol	PROPN
bptjm-48	451	21	lett	lett	NOUN
bptjm-48	451	22	.	.	PUNCT
bptjm-48	452	1	2022;23(3):88	2022;23(3):88	X
bptjm-48	452	2	.	.	PUNCT
bptjm-48	453	1	doi:10.3892	doi:10.3892	NOUN
bptjm-48	453	2	/	/	SYM
bptjm-48	453	3	ol.2022.13208	ol.2022.13208	ADJ
bptjm-48	453	4	43	43	NUM
bptjm-48	453	5	.	.	PUNCT
bptjm-48	454	1	zhao	zhao	PROPN
bptjm-48	454	2	y	y	PROPN
bptjm-48	454	3	,	,	PUNCT
bptjm-48	454	4	deng	deng	PROPN
bptjm-48	454	5	j	j	PROPN
bptjm-48	454	6	,	,	PUNCT
bptjm-48	454	7	rao	rao	PROPN
bptjm-48	454	8	s	s	PROPN
bptjm-48	454	9	,	,	PUNCT
bptjm-48	454	10	et	et	PROPN
bptjm-48	454	11	al	al	PROPN
bptjm-48	454	12	.	.	PROPN
bptjm-48	454	13	tumor	tumor	PROPN
bptjm-48	454	14	in	in	ADP
bptjm-48	454	15	�	�	PROPN
bptjm-48	454	16	ltrating	ltrate	VERB
bptjm-48	454	17	lymphocyte	lymphocyte	NOUN
bptjm-48	454	18	(	(	PUNCT
bptjm-48	454	19	til	til	ADJ
bptjm-48	454	20	)	)	PUNCT
bptjm-48	454	21	therapy	therapy	NOUN
bptjm-48	454	22	for	for	ADP
bptjm-48	454	23	solid	solid	ADJ
bptjm-48	454	24	tumor	tumor	NOUN
bptjm-48	454	25	treatment	treatment	NOUN
bptjm-48	454	26	:	:	PUNCT
bptjm-48	454	27	progressions	progression	NOUN
bptjm-48	454	28	and	and	CCONJ
bptjm-48	454	29	challenges	challenge	NOUN
bptjm-48	454	30	.	.	PUNCT
bptjm-48	455	1	cancers	cancer	NOUN
bptjm-48	455	2	(	(	PUNCT
bptjm-48	455	3	basel	basel	PROPN
bptjm-48	455	4	)	)	PUNCT
bptjm-48	455	5	.	.	PUNCT
bptjm-48	456	1	2022;14(17):4160	2022;14(17):4160	X
bptjm-48	456	2	.	.	NOUN
bptjm-48	456	3	doi:10.3390	doi:10.3390	NOUN
bptjm-48	456	4	/	/	SYM
bptjm-48	456	5	cancers14174160	cancers14174160	PROPN
bptjm-48	456	6	44	44	NUM
bptjm-48	456	7	.	.	PUNCT
bptjm-48	457	1	tvax	tvax	PROPN
bptjm-48	457	2	biomedical.randomized	biomedical.randomize	VERB
bptjm-48	457	3	phase	phase	NOUN
bptjm-48	457	4	2b	2b	NUM
bptjm-48	457	5	study	study	NOUN
bptjm-48	457	6	to	to	PART
bptjm-48	457	7	evaluate	evaluate	VERB
bptjm-48	457	8	safety	safety	NOUN
bptjm-48	457	9	and	and	CCONJ
bptjm-48	457	10	efficacy	efficacy	NOUN
bptjm-48	457	11	of	of	ADP
bptjm-48	457	12	(	(	PUNCT
bptjm-48	457	13	tvax	tvax	PROPN
bptjm-48	457	14	biomedical	biomedical	PROPN
bptjm-48	457	15	,	,	PUNCT
bptjm-48	457	16	inc	inc	PROPN
bptjm-48	457	17	’s	’s	PART
bptjm-48	457	18	)	)	PUNCT
bptjm-48	457	19	tvi	tvi	PROPN
bptjm-48	457	20	-	-	PUNCT
bptjm-48	457	21	brain-1	brain-1	PROPN
bptjm-48	457	22	combinedwith	combinedwith	NOUN
bptjm-48	457	23	conformal	conformal	NOUN
bptjm-48	457	24	radiotherapy	radiotherapy	NOUN
bptjm-48	457	25	and	and	CCONJ
bptjm-48	457	26	temozolomide	temozolomide	NOUN
bptjm-48	457	27	compared	compare	VERB
bptjm-48	457	28	to	to	ADP
bptjm-48	457	29	standard	standard	ADJ
bptjm-48	457	30	therapy	therapy	NOUN
bptjm-48	457	31	in	in	ADP
bptjm-48	457	32	newly	newly	ADV
bptjm-48	457	33	diagnosed	diagnose	VERB
bptjm-48	457	34	o6	o6	NOUN
bptjm-48	457	35	-	-	PUNCT
bptjm-48	457	36	methylguanine	methylguanine	NOUN
bptjm-48	457	37	-	-	PUNCT
bptjm-48	457	38	dna	dna	NOUN
bptjm-48	457	39	-	-	PUNCT
bptjm-48	457	40	methyltransferase	methyltransferase	NOUN
bptjm-48	457	41	(	(	PUNCT
bptjm-48	457	42	mgmt	mgmt	NOUN
bptjm-48	457	43	)	)	PUNCT
bptjm-48	457	44	negative	negative	ADJ
bptjm-48	457	45	glioblastomamultiforme	glioblastomamultiforme	NOUN
bptjm-48	457	46	(	(	PUNCT
bptjm-48	457	47	gbm	gbm	NOUN
bptjm-48	457	48	)	)	PUNCT
bptjm-48	457	49	.	.	PUNCT
bptjm-48	458	1	clinicaltrials.gov	clinicaltrials.gov	X
bptjm-48	458	2	;	;	PUNCT
bptjm-48	458	3	2023	2023	NUM
bptjm-48	458	4	.	.	PUNCT
bptjm-48	459	1	accessedmay	accessedmay	VERB
bptjm-48	459	2	5	5	NUM
bptjm-48	459	3	,	,	PUNCT
bptjm-48	459	4	2023	2023	NUM
bptjm-48	459	5	.	.	PUNCT
bptjm-48	460	1	https://clinicaltrials.gov/ct2/show/nct05685004	https://clinicaltrials.gov/ct2/show/nct05685004	PROPN
bptjm-48	460	2	45	45	NUM
bptjm-48	460	3	.	.	PUNCT
bptjm-48	461	1	feldheim	feldheim	PROPN
bptjm-48	461	2	j	j	PROPN
bptjm-48	461	3	,	,	PUNCT
bptjm-48	461	4	kessler	kessler	PROPN
bptjm-48	461	5	af	af	PROPN
bptjm-48	461	6	,	,	PUNCT
bptjm-48	461	7	monoranu	monoranu	PROPN
bptjm-48	461	8	cm	cm	NOUN
bptjm-48	461	9	,	,	PUNCT
bptjm-48	461	10	ernestus	ernestus	NOUN
bptjm-48	461	11	ri	ri	PROPN
bptjm-48	461	12	,	,	PUNCT
bptjm-48	461	13	löhr	löhr	VERB
bptjm-48	461	14	m	m	PROPN
bptjm-48	461	15	,	,	PUNCT
bptjm-48	461	16	hagemann	hagemann	PROPN
bptjm-48	461	17	c.	c.	PROPN
bptjm-48	461	18	changes	change	NOUN
bptjm-48	461	19	of	of	ADP
bptjm-48	461	20	o6	o6	NOUN
bptjm-48	461	21	-	-	PUNCT
bptjm-48	461	22	methylguanine	methylguanine	NOUN
bptjm-48	461	23	dnamethyltransferase	dnamethyltransferase	NOUN
bptjm-48	461	24	(	(	PUNCT
bptjm-48	461	25	mgmt	mgmt	NOUN
bptjm-48	461	26	)	)	PUNCT
bptjm-48	461	27	promoter	promoter	NOUN
bptjm-48	461	28	methylation	methylation	NOUN
bptjm-48	461	29	in	in	ADP
bptjm-48	461	30	glioblastoma	glioblastoma	NOUN
bptjm-48	461	31	relapse	relapse	NOUN
bptjm-48	461	32	—	—	PUNCT
bptjm-48	461	33	a	a	DET
bptjm-48	461	34	meta	meta	ADJ
bptjm-48	461	35	-	-	PUNCT
bptjm-48	461	36	analysis	analysis	NOUN
bptjm-48	461	37	type	type	NOUN
bptjm-48	461	38	literature	literature	NOUN
bptjm-48	461	39	review	review	NOUN
bptjm-48	461	40	.	.	PUNCT
bptjm-48	462	1	cancers	cancer	NOUN
bptjm-48	462	2	(	(	PUNCT
bptjm-48	462	3	basel	basel	PROPN
bptjm-48	462	4	)	)	PUNCT
bptjm-48	462	5	.	.	PUNCT
bptjm-48	463	1	2019;11(12):1837	2019;11(12):1837	X
bptjm-48	463	2	.	.	PUNCT
bptjm-48	463	3	doi:10.3390	doi:10.3390	PROPN
bptjm-48	463	4	/	/	SYM
bptjm-48	463	5	cancers11121837	cancers11121837	PROPN
bptjm-48	463	6	46	46	NUM
bptjm-48	463	7	.	.	PUNCT
bptjm-48	464	1	alnefaie	alnefaie	PROPN
bptjm-48	464	2	a	a	PRON
bptjm-48	464	3	,	,	PUNCT
bptjm-48	464	4	albogami	albogami	ADJ
bptjm-48	464	5	s	s	NOUN
bptjm-48	464	6	,	,	PUNCT
bptjm-48	464	7	asiri	asiri	PROPN
bptjm-48	464	8	y	y	PROPN
bptjm-48	464	9	,	,	PUNCT
bptjm-48	464	10	et	et	PROPN
bptjm-48	464	11	al	al	PROPN
bptjm-48	464	12	.	.	PROPN
bptjm-48	464	13	chimeric	chimeric	ADJ
bptjm-48	464	14	antigen	antigen	ADJ
bptjm-48	464	15	receptor	receptor	NOUN
bptjm-48	464	16	t	t	PROPN
bptjm-48	464	17	-	-	PUNCT
bptjm-48	464	18	cells	cell	NOUN
bptjm-48	464	19	:	:	PUNCT
bptjm-48	464	20	an	an	DET
bptjm-48	464	21	overview	overview	NOUN
bptjm-48	464	22	of	of	ADP
bptjm-48	464	23	concepts	concept	NOUN
bptjm-48	464	24	,	,	PUNCT
bptjm-48	464	25	applications	application	NOUN
bptjm-48	464	26	,	,	PUNCT
bptjm-48	464	27	limitations	limitation	NOUN
bptjm-48	464	28	,	,	PUNCT
bptjm-48	464	29	and	and	CCONJ
bptjm-48	464	30	proposed	propose	VERB
bptjm-48	464	31	solutions	solution	NOUN
bptjm-48	464	32	.	.	PUNCT
bptjm-48	465	1	frontiers	frontier	NOUN
bptjm-48	465	2	in	in	ADP
bptjm-48	465	3	bioengineering	bioengineering	NOUN
bptjm-48	465	4	and	and	CCONJ
bptjm-48	465	5	biotechnology	biotechnology	NOUN
bptjm-48	465	6	.	.	PUNCT
bptjm-48	466	1	2022;10	2022;10	NUM
bptjm-48	466	2	.	.	PUNCT
bptjm-48	466	3	accessed	access	VERB
bptjm-48	466	4	april	april	PROPN
bptjm-48	466	5	8	8	NUM
bptjm-48	466	6	,	,	PUNCT
bptjm-48	466	7	2023	2023	NUM
bptjm-48	466	8	.	.	PUNCT
bptjm-48	467	1	https://www.frontiersin.org/articles/10.3389/fbioe.20	https://www.frontiersin.org/articles/10.3389/fbioe.20	X
bptjm-48	467	2	22.797440	22.797440	NUM
bptjm-48	467	3	47	47	NUM
bptjm-48	467	4	.	.	PUNCT
bptjm-48	468	1	brown	brown	PROPN
bptjm-48	468	2	ce	ce	PROPN
bptjm-48	468	3	,	,	PUNCT
bptjm-48	468	4	aguilar	aguilar	PROPN
bptjm-48	468	5	b	b	PROPN
bptjm-48	468	6	,	,	PUNCT
bptjm-48	468	7	starr	starr	PROPN
bptjm-48	468	8	r	r	PROPN
bptjm-48	468	9	,	,	PUNCT
bptjm-48	468	10	et	et	PROPN
bptjm-48	468	11	al	al	PROPN
bptjm-48	468	12	.	.	PUNCT
bptjm-48	468	13	optimization	optimization	NOUN
bptjm-48	468	14	of	of	ADP
bptjm-48	468	15	il13rα2	il13rα2	PROPN
bptjm-48	468	16	-	-	PUNCT
bptjm-48	468	17	targeted	target	VERB
bptjm-48	468	18	chimeric	chimeric	ADJ
bptjm-48	468	19	antigen	antigen	ADJ
bptjm-48	468	20	receptor	receptor	NOUN
bptjm-48	468	21	t	t	NOUN
bptjm-48	468	22	cells	cell	NOUN
bptjm-48	468	23	for	for	ADP
bptjm-48	468	24	improved	improve	VERB
bptjm-48	468	25	anti	anti	ADJ
bptjm-48	468	26	-	-	ADJ
bptjm-48	468	27	tumor	tumor	ADJ
bptjm-48	468	28	e	e	NOUN
bptjm-48	468	29	�	�	NOUN
bptjm-48	468	30	cacy	cacy	NOUN
bptjm-48	468	31	against	against	ADP
bptjm-48	468	32	glioblastoma.mol	glioblastoma.mol	X
bptjm-48	468	33	ther	ther	ADV
bptjm-48	468	34	.	.	PUNCT
bptjm-48	469	1	2018;26(1):31	2018;26(1):31	NUM
bptjm-48	469	2	-	-	SYM
bptjm-48	469	3	44	44	NUM
bptjm-48	469	4	.	.	PUNCT
bptjm-48	470	1	doi:10.1016	doi:10.1016	PROPN
bptjm-48	470	2	/	/	SYM
bptjm-48	470	3	j.ymthe.2017.10.002	j.ymthe.2017.10.002	PROPN
bptjm-48	470	4	48	48	NUM
bptjm-48	470	5	.	.	PUNCT
bptjm-48	471	1	hodge	hodge	PROPN
bptjm-48	471	2	jw	jw	PROPN
bptjm-48	471	3	,	,	PUNCT
bptjm-48	471	4	ardiani	ardiani	PROPN
bptjm-48	471	5	a	a	PRON
bptjm-48	471	6	,	,	PUNCT
bptjm-48	471	7	farsaci	farsaci	PROPN
bptjm-48	471	8	b	b	PROPN
bptjm-48	471	9	,	,	PUNCT
bptjm-48	471	10	kwilas	kwilas	PROPN
bptjm-48	471	11	ar	ar	PROPN
bptjm-48	471	12	,	,	PUNCT
bptjm-48	471	13	gameiro	gameiro	PROPN
bptjm-48	471	14	s.	s.	PROPN
bptjm-48	471	15	the	the	DET
bptjm-48	471	16	tipping	tipping	NOUN
bptjm-48	471	17	point	point	NOUN
bptjm-48	471	18	for	for	ADP
bptjm-48	471	19	combination	combination	NOUN
bptjm-48	471	20	therapy	therapy	NOUN
bptjm-48	471	21	:	:	PUNCT
bptjm-48	471	22	cancer	cancer	NOUN
bptjm-48	471	23	vaccines	vaccine	NOUN
bptjm-48	471	24	with	with	ADP
bptjm-48	471	25	radiation	radiation	NOUN
bptjm-48	471	26	,	,	PUNCT
bptjm-48	471	27	chemotherapy	chemotherapy	NOUN
bptjm-48	471	28	,	,	PUNCT
bptjm-48	471	29	or	or	CCONJ
bptjm-48	471	30	targeted	target	VERB
bptjm-48	471	31	small	small	ADJ
bptjm-48	471	32	molecule	molecule	NOUN
bptjm-48	471	33	inhibitors	inhibitor	NOUN
bptjm-48	471	34	.	.	PUNCT
bptjm-48	472	1	semin	semin	PROPN
bptjm-48	472	2	oncol	oncol	PROPN
bptjm-48	472	3	.	.	PUNCT
bptjm-48	473	1	2012;39(3):323	2012;39(3):323	NUM
bptjm-48	473	2	-	-	PUNCT
bptjm-48	473	3	339	339	NUM
bptjm-48	473	4	.	.	PUNCT
bptjm-48	474	1	doi:10.1053	doi:10.1053	NOUN
bptjm-48	474	2	/	/	SYM
bptjm-48	474	3	j.seminoncol.2012.02.006	j.seminoncol.2012.02.006	PRON
bptjm-48	474	4	49	49	NUM
bptjm-48	474	5	.	.	PUNCT
bptjm-48	475	1	liu	liu	PROPN
bptjm-48	475	2	cj	cj	PROPN
bptjm-48	475	3	,	,	PUNCT
bptjm-48	475	4	schaettler	schaettler	NOUN
bptjm-48	475	5	m	m	PROPN
bptjm-48	475	6	,	,	PUNCT
bptjm-48	475	7	blaha	blaha	PROPN
bptjm-48	475	8	dt	dt	X
bptjm-48	475	9	,	,	PUNCT
bptjm-48	475	10	et	et	PROPN
bptjm-48	475	11	al	al	PROPN
bptjm-48	475	12	.	.	PROPN
bptjm-48	476	1	treatment	treatment	NOUN
bptjm-48	476	2	of	of	ADP
bptjm-48	476	3	an	an	DET
bptjm-48	476	4	aggressive	aggressive	ADJ
bptjm-48	476	5	orthotopic	orthotopic	ADJ
bptjm-48	476	6	murine	murine	ADJ
bptjm-48	476	7	glioblastoma	glioblastoma	NOUN
bptjm-48	476	8	model	model	NOUN
bptjm-48	476	9	with	with	ADP
bptjm-48	476	10	combination	combination	NOUN
bptjm-48	476	11	checkpoint	checkpoint	NOUN
bptjm-48	476	12	blockade	blockade	NOUN
bptjm-48	476	13	and	and	CCONJ
bptjm-48	476	14	a	a	DET
bptjm-48	476	15	multivalent	multivalent	NOUN
bptjm-48	476	16	neoantigen	neoantigen	PROPN
bptjm-48	476	17	vaccine.neuro	vaccine.neuro	PROPN
bptjm-48	476	18	oncol	oncol	ADJ
bptjm-48	476	19	.	.	PUNCT
bptjm-48	477	1	2020;22(9):1276	2020;22(9):1276	NUM
bptjm-48	477	2	-	-	SYM
bptjm-48	477	3	1288	1288	NUM
bptjm-48	477	4	.	.	PUNCT
bptjm-48	478	1	doi:10.1093	doi:10.1093	NOUN
bptjm-48	478	2	/	/	SYM
bptjm-48	478	3	neuonc	neuonc	VERB
bptjm-48	478	4	/	/	SYM
bptjm-48	478	5	noaa050	noaa050	PROPN
bptjm-48	478	6	50	50	NUM
bptjm-48	478	7	.	.	PUNCT
bptjm-48	479	1	rosenberg	rosenberg	PROPN
bptjm-48	479	2	sa	sa	PROPN
bptjm-48	479	3	,	,	PUNCT
bptjm-48	479	4	yang	yang	PROPN
bptjm-48	479	5	jc	jc	PROPN
bptjm-48	479	6	,	,	PUNCT
bptjm-48	479	7	restifo	restifo	ADJ
bptjm-48	479	8	np	np	INTJ
bptjm-48	479	9	.	.	PUNCT
bptjm-48	479	10	cancer	cancer	NOUN
bptjm-48	479	11	immunotherapy	immunotherapy	NOUN
bptjm-48	479	12	:	:	PUNCT
bptjm-48	479	13	moving	move	VERB
bptjm-48	479	14	beyond	beyond	ADP
bptjm-48	479	15	current	current	ADJ
bptjm-48	479	16	vaccines.nat	vaccines.nat	NOUN
bptjm-48	479	17	med	me	VERB
bptjm-48	479	18	.	.	PUNCT
bptjm-48	480	1	2004;10(9):909	2004;10(9):909	NUM
bptjm-48	480	2	-	-	SYM
bptjm-48	480	3	915	915	NUM
bptjm-48	480	4	.	.	PUNCT
bptjm-48	481	1	doi:10.1038	doi:10.1038	NOUN
bptjm-48	481	2	/	/	SYM
bptjm-48	481	3	nm1100	nm1100	PROPN
bptjm-48	481	4	51	51	NUM
bptjm-48	481	5	.	.	PUNCT
bptjm-48	482	1	kjeldsen	kjeldsen	PROPN
bptjm-48	482	2	jw	jw	PROPN
bptjm-48	482	3	,	,	PUNCT
bptjm-48	482	4	lorentzen	lorentzen	PROPN
bptjm-48	482	5	cl	cl	NOUN
bptjm-48	482	6	,	,	PUNCT
bptjm-48	482	7	martinenaite	martinenaite	NOUN
bptjm-48	482	8	e	e	NOUN
bptjm-48	482	9	,	,	PUNCT
bptjm-48	482	10	et	et	PROPN
bptjm-48	482	11	al	al	PROPN
bptjm-48	482	12	.	.	PUNCT
bptjm-48	483	1	a	a	DET
bptjm-48	483	2	phase	phase	NOUN
bptjm-48	483	3	1/2	1/2	NUM
bptjm-48	483	4	trial	trial	NOUN
bptjm-48	483	5	of	of	ADP
bptjm-48	483	6	an	an	DET
bptjm-48	483	7	immune	immune	ADJ
bptjm-48	483	8	-	-	PUNCT
bptjm-48	483	9	modulatory	modulatory	NOUN
bptjm-48	483	10	vaccine	vaccine	NOUN
bptjm-48	483	11	against	against	ADP
bptjm-48	483	12	ido	ido	PROPN
bptjm-48	483	13	/	/	SYM
bptjm-48	483	14	pd	pd	PROPN
bptjm-48	483	15	-	-	PROPN
bptjm-48	483	16	l1	l1	PROPN
bptjm-48	483	17	in	in	ADP
bptjm-48	483	18	combination	combination	NOUN
bptjm-48	483	19	with	with	ADP
bptjm-48	483	20	nivolumab	nivolumab	NOUN
bptjm-48	483	21	in	in	ADP
bptjm-48	483	22	metastatic	metastatic	ADJ
bptjm-48	483	23	melanoma.natmed	melanoma.natmed	NUM
bptjm-48	483	24	.	.	PUNCT
bptjm-48	484	1	2021;27(12):2212	2021;27(12):2212	NUM
bptjm-48	484	2	-	-	SYM
bptjm-48	484	3	2223	2223	NUM
bptjm-48	484	4	.	.	PUNCT
bptjm-48	485	1	doi:10.1038	doi:10.1038	NOUN
bptjm-48	485	2	/	/	SYM
bptjm-48	485	3	s41591	s41591	NOUN
bptjm-48	485	4	-	-	PUNCT
bptjm-48	485	5	021	021	NUM
bptjm-48	485	6	-	-	PUNCT
bptjm-48	485	7	01544	01544	NUM
bptjm-48	485	8	-	-	PUNCT
bptjm-48	485	9	x	x	SYM
bptjm-48	485	10	52	52	NUM
bptjm-48	485	11	.	.	PUNCT
bptjm-48	486	1	svane	svane	NOUN
bptjm-48	486	2	i	i	PROPN
bptjm-48	486	3	m.	m.	NOUN
bptjm-48	486	4	combination	combination	NOUN
bptjm-48	486	5	therapywith	therapywith	NOUN
bptjm-48	486	6	nivolumab	nivolumab	NOUN
bptjm-48	486	7	and	and	CCONJ
bptjm-48	486	8	pd	pd	PROPN
bptjm-48	486	9	-	-	PUNCT
bptjm-48	486	10	l1	l1	PROPN
bptjm-48	486	11	/	/	SYM
bptjm-48	486	12	ido	ido	PROPN
bptjm-48	486	13	peptide	peptide	NOUN
bptjm-48	486	14	vaccine	vaccine	NOUN
bptjm-48	486	15	to	to	ADP
bptjm-48	486	16	patientswith	patientswith	PROPN
bptjm-48	486	17	berkeley	berkeley	PROPN
bptjm-48	486	18	pharma	pharma	PROPN
bptjm-48	486	19	tech	tech	NOUN
bptjm-48	486	20	journal	journal	NOUN
bptjm-48	486	21	of	of	ADP
bptjm-48	486	22	medicine	medicine	NOUN
bptjm-48	486	23	|	|	ADV
bptjm-48	486	24	63	63	NUM
bptjm-48	486	25	https://www.jkns.or.kr/journal/view.php?number=7591	https://www.jkns.or.kr/journal/view.php?number=7591	PROPN
bptjm-48	486	26	https://doi.org/10.1038/s41408-021-00459-7	https://doi.org/10.1038/s41408-021-00459-7	NUM
bptjm-48	486	27	https://doi.org/10.3892/ol.2022.13208	https://doi.org/10.3892/ol.2022.13208	ADJ
bptjm-48	486	28	https://doi.org/10.3390/cancers14174160	https://doi.org/10.3390/cancers14174160	NOUN
bptjm-48	486	29	https://clinicaltrials.gov/ct2/show/nct05685004	https://clinicaltrials.gov/ct2/show/nct05685004	PROPN
bptjm-48	486	30	https://clinicaltrials.gov/ct2/show/nct05685004	https://clinicaltrials.gov/ct2/show/nct05685004	VERB
bptjm-48	487	1	https://doi.org/10.3390/cancers11121837	https://doi.org/10.3390/cancers11121837	NOUN
bptjm-48	487	2	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	ADJ
bptjm-48	487	3	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	PROPN
bptjm-48	487	4	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	PROPN
bptjm-48	487	5	https://doi.org/10.1016/j.ymthe.2017.10.002	https://doi.org/10.1016/j.ymthe.2017.10.002	NOUN
bptjm-48	487	6	https://doi.org/10.1053/j.seminoncol.2012.02.006	https://doi.org/10.1053/j.seminoncol.2012.02.006	ADJ
bptjm-48	487	7	https://doi.org/10.1093/neuonc/noaa050	https://doi.org/10.1093/neuonc/noaa050	NOUN
bptjm-48	487	8	https://doi.org/10.1038/nm1100	https://doi.org/10.1038/nm1100	PUNCT
bptjm-48	487	9	https://doi.org/10.1038/s41591-021-01544-x	https://doi.org/10.1038/s41591-021-01544-x	PROPN
bptjm-48	487	10	metastatic	metastatic	ADJ
bptjm-48	487	11	melanoma	melanoma	NOUN
bptjm-48	487	12	.	.	PUNCT
bptjm-48	488	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
bptjm-48	488	2	;	;	PUNCT
bptjm-48	488	3	2022	2022	NUM
bptjm-48	488	4	.	.	PUNCT
bptjm-48	489	1	accessedmay	accessedmay	VERB
bptjm-48	489	2	5	5	NUM
bptjm-48	489	3	,	,	PUNCT
bptjm-48	489	4	2023	2023	NUM
bptjm-48	489	5	.	.	PUNCT
bptjm-48	489	6	https://clinicaltrials.gov/ct2/show/nct03047928	https://clinicaltrials.gov/ct2/show/nct03047928	X
bptjm-48	490	1	53	53	NUM
bptjm-48	490	2	.	.	PUNCT
bptjm-48	491	1	chen	chen	PROPN
bptjm-48	491	2	i	i	PRON
bptjm-48	491	3	,	,	PUNCT
bptjm-48	491	4	chenmy	chenmy	PROPN
bptjm-48	491	5	,	,	PUNCT
bptjm-48	491	6	goedegebuure	goedegebuure	NOUN
bptjm-48	491	7	sp	sp	NOUN
bptjm-48	491	8	,	,	PUNCT
bptjm-48	491	9	gillanders	gillander	NOUN
bptjm-48	491	10	we	we	PRON
bptjm-48	491	11	.	.	PUNCT
bptjm-48	492	1	challenges	challenge	NOUN
bptjm-48	492	2	targeting	target	VERB
bptjm-48	492	3	cancer	cancer	NOUN
bptjm-48	492	4	neoantigens	neoantigen	NOUN
bptjm-48	492	5	in	in	ADP
bptjm-48	492	6	2021	2021	NUM
bptjm-48	492	7	:	:	PUNCT
bptjm-48	492	8	a	a	DET
bptjm-48	492	9	systematic	systematic	ADJ
bptjm-48	492	10	literature	literature	NOUN
bptjm-48	492	11	review	review	NOUN
bptjm-48	492	12	.	.	PUNCT
bptjm-48	493	1	expert	expert	NOUN
bptjm-48	493	2	rev	rev	VERB
bptjm-48	493	3	vaccines	vaccine	NOUN
bptjm-48	493	4	.	.	PUNCT
bptjm-48	494	1	2021;20(7):827	2021;20(7):827	NUM
bptjm-48	494	2	-	-	SYM
bptjm-48	494	3	837	837	NUM
bptjm-48	494	4	.	.	PUNCT
bptjm-48	495	1	doi:10.1080/14760584.2021.1935248	doi:10.1080/14760584.2021.1935248	PROPN
bptjm-48	495	2	berkeley	berkeley	PROPN
bptjm-48	495	3	pharma	pharma	PROPN
bptjm-48	495	4	tech	tech	NOUN
bptjm-48	495	5	journal	journal	NOUN
bptjm-48	495	6	of	of	ADP
bptjm-48	495	7	medicine	medicine	NOUN
bptjm-48	495	8	|	|	ADV
bptjm-48	495	9	64	64	NUM
bptjm-48	495	10	https://clinicaltrials.gov/ct2/show/nct03047928	https://clinicaltrials.gov/ct2/show/nct03047928	NUM
bptjm-48	495	11	https://clinicaltrials.gov/ct2/show/nct03047928	https://clinicaltrials.gov/ct2/show/nct03047928	PUNCT
bptjm-48	495	12	https://doi.org/10.1080/14760584.2021.1935248	https://doi.org/10.1080/14760584.2021.1935248	PUNCT